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Study	Abstract:		
Context:	 The	 UK	 Nepali	 community	 is	 a	 unique	 migrant	 population,	 with	 recent	 expansion	 and	
presence	 in	 the	 UK	 following	 the	 approval	 of	 settlement	 rights	 to	 Gurkha	 veterans	 and	 their	
dependents	granted	from	2004	to	2008.	 	The	community	is	heterogeneous	in	relation	to	caste	and	
religion,	with	Ghurkha	military	ties	the	principal	denominator	to	bind	this	newly	arrived	population.			
Many	in	the	community	have	settled	close	to	military	institutions,	with	a	new	migrant	population	that	
has	emerged	as	a	result	around	the	Aldershot	area	in	Hampshire	and	Surrey.		
The	 health	 awareness	 and	 needs	 of	 the	 UK	 Nepali	 community	 is	 poorly	 understood,	 including	 in	
chronic	 viral	 hepatitis	 (CVH),	 with	 increased	 hepatitis	 B	 and	 C	 (HBV	 and	 HCV)	 risks	 that	 are	 well	
described	in	migrant	groups	from	the	neighbouring	countries	of	India	and	China,	but	with	no	previous	
studies	in	the	UK	Nepali	population.		
HBV	and	HCV	is	a	global	disease,	and	carries	a	higher	death	toll	than	that	seen	in	comparison	to	HIV	
or	tuberculosis.	CVH	disproportionately	affects	some	migrant	groups,	with	case-finding	to	test	at-risk	
groups	part	of	national	guidance	by	the	National	Institute	of	Health	and	Care	Excellence	(NICE),	as	well	
as	 the	World	Health	Organisation	 (WHO),	with	WHO	goals	 that	 look	 to	eradicate	HBV	and	HCV	by	
2030.		
At	the	same	time,	migrant	groups	such	as	the	recently	arrived	Nepali	community	face	growing	political	
and	social	pressures,	with	rising	nationalism	and	anti-migrant	sentiment	seen	across	Europe,	and	with	
blood	borne	virus	rates	that	have	been	specifically	targeted	by	right-wing	political	groups	in	the	UK.		
CVH	 is	 typically	 asymptomatic	 until	 advanced	 and	 severe	 complications	 develop;	 but	 with	 highly	
effective	and	well-tolerated	 treatments	available	 if	disease	 is	 identified	at	 the	 right	 time.	Effective	
case-finding	to	identify	CVH	in	at-risk	groups	is	therefore	a	priority,	and	a	key	aim	of	national	(NICE)	
CVH	testing	guidance.	The	awareness	and	implementation	of	this	policy	is	however	largely	unknown,	
with	particular	deficits	in	our	understanding	of	testing	activity	in	primary	care,	which	remains	crucial	
to	delivering	CVH	testing	in	migrant	communities	nationally.	
The	 following	 study	 therefore	presents	 a	 comprehensive	 exploration	of	 the	potential	 barriers	 and	
facilitators	that	exist	towards	CVH	testing	in	migrant	groups,	taking	the	Nepali	community	as	the	focus	
of	this	thesis.	It	explores	the	factors	that	exist	at	the	policy	level	towards	effective	testing	delivery	in	
migrant	groups,	and	at	the	local	(community)	level	towards	CVH	testing	in	primary	care,	and	compares	
the	understanding	and	perception	of	the	newly	arrived	Nepali	community	towards	liver	disease,	and	
the	development	of	a	community	based	study	to	identify	the	CVH	risks	in	the	local	Nepali	population.		
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Intervention:		At	the	macro-level	a	policy	prioritisation	framework	was	utilised	to	look	at	the	factors	
that	 influence	 how	 CVH	 testing	 policy	 can	 achieve	 political	 attention	 and	 resources	 for	 its	
implementation.	At	the	community	(micro)	level,	focus	group	studies	were	undertaken	with	members	
of	the	Nepali	population	to	explore	the	awareness,	knowledge	and	perception	of	liver	disease,	as	well	
as	the	potential	risks	and	barriers	that	may	exist	towards	health	engagement	strategies.	Qualitative	
focus	 studies	were	also	 conducted	with	General	Practitioners	 (GPs)	 from	3	 local	GP	practices	who	
serve	 the	 recently	 arrived	 Nepali	 community,	 to	 understand	 the	 awareness,	 knowledge	 and	
perception	of	CVH	testing	in	migrant	groups.	A	dedicated	community-based	testing	intervention	was	
then	developed	to	directly	assess	HBV	and	HCV	prevalence	in	the	local	Nepali	community,	building	on	
the	findings	from	local	focus	group	studies.		
Outcome:	At	the	policy	level,	the	National	Institute	for	Health	and	Care	Excellence	has	produced	CVH	
testing	recommendations	that	are	far-reaching,	and	would	have	a	positive	impact	on	CVH	testing	in	
migrant	communities,	including	the	UK	Nepali	population.	However,	policy	has	been	developed	in	a	
top-down	approach,	without	clear	leadership	to	coordinate	testing	activity,	and	without	community	
level	 cohesion	 that	 is	 evident	 at	 the	 Local	 Authority,	 local	 health	 service	 (currently	 Clinical	
Commissioning	Groups	(CCG))	or	primary	care	level.		
At	the	micro-level,	focus	group	studies	in	the	Nepali	community	identified	high-levels	of	awareness	of	
liver	disease,	and	although	understood	principally	as	“jaundice”,	liver	disease	is	viewed	as	a	disease	
to	be	feared.	Whilst	perceptions	of	stigma	are	evident,	with	associations	to	extrinsic	agents	such	as	
Spirits	and	Witch	Doctors	in	disease	and	cure,	there	is	an	overwhelming	desire	to	engage	with	modern	
healthcare	approaches	in	the	UK,	with	primary	care	a	trusted	and	well	sought	counsel	to	learn	about	
liver	disease.	Focus	group	studies	in	primary	care	though	suggest	significant	barriers	to	CVH	testing	in	
migrant	groups,	with	low	levels	of	awareness	and	knowledge	towards	existing	policy,	and	with	active	
perceptions	 of	 prejudice	 and	 harm	 if	 they	 were	 to	 engage	 in	 CVH	 testing	 activity	 in	 migrant	
communities.		
As	part	of	a	dedicated	testing	study,	HBV	and	HCV	testing	was	undertaken	in	1005	participants	(984	
unique	 individuals)	 from	 the	 local	Nepali	 population,	with	 the	 close	and	 integral	 involvement	of	 a	
specially	 developed	 Nepali	 research	 committee.	 DBS	 (Dry-blood	 spot)	 testing	was	 used	 to	 deliver	
testing	at	centrally	located	community	sites.	Significant	anti-migrant	sentiment	was	expressed	during	
the	study,	 limiting	the	ability	 for	 formal	study	advertising	through	written	or	visual	media.	Despite	
this,	we	were	able	to	recruit	close	to	1000	members	of	the	local	community,	with	word-of-mouth	a	
powerful	route	to	disseminate	testing	information	in	the	Nepali	community.	Absolute	rates	of	active	
CVH	were	low,	with	HBsAg	detected	in	just	3	(0.3%)	of	individuals	and	HCV	Ab	detected	in	4	individuals	
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(0.4%),	 although	 none	 of	 these	 participants	 had	 detectable	 RNA	 levels	 on	 subsequent	 testing.	
Evidence	 of	 previous	 HBV	 exposure	 was	 however	 raised,	 with	 9.25%	 (91)	 of	 participants	
demonstrating	HBcAb	positivity.	Associated	risk	factors	for	HBcAb	positivity	were	lower	educational	
status	and	male	gender.	
Conclusion:	Overall,	the	absolute	rates	of	active	CVH	appear	low	in	Nepali	community,	but	with	higher	
rates	of	previous	hepatitis	B	exposure	that	warrant	the	need	to	understand	disease	risks	in	the	wider	
Nepali	community.	At	the	policy	level,	there	are	gaps	in	the	effectiveness	of	policy	across	the	policy	
prioritisation	framework,	with	a	lack	of	leadership	and	direction	to	facilitate	testing	at	the	community	
level.	Members	of	the	Nepali	community	view	CVH	as	a	disease	to	be	feared,	and	whilst	stigma	arises	
as	a	perception	towards	liver	disease,	the	overwhelming	emphasis	is	a	wish	to	engage	with	health	care	
professionals,	with	good	 levels	of	engagement	demonstrated	 in	our	 subsequent	community-based	
testing	studies.	The	perceptions	raised	in	primary	care	though	demonstrate	a	reluctance	to	engage	in	
CVH	 testing	 activity	 in	 migrant	 groups,	 with	 the	 need	 for	 further	 interventions	 to	modify	 testing	
behaviour	if	we	are	to	reach	global	and	national	CVH	eradication	goals.		
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From	policy	to	practice:	Hepatitis	B	&	C	risks	in	the	UK	Nepali	community,	and	the	barriers	to	migrant	testing	across	the	health	system	
Introduction:	
This	 thesis	 takes	 a	 view	 across	 the	macro	 and	micro	 levels	 to	 explore	 the	 potential	 barriers	 and	
facilitators	that	exist	towards	chronic	viral	hepatitis	(CVH)	testing	in	migrant	communities,	focusing	on	
the	UK	Nepali	population;	a	new	and	unique	migrant	community.	It	explores	the	levers	that	exist	for	
action	 at	 the	 national	 policy	 level,	 and	 the	 community	 (primary	 care)	 level,	 and	 develops	 a	
comprehensive	strategy	through	a	mixed-methods	approach	to	understand	and	directly	assess	CVH	
risks	in	the	newly	arrived	Nepali	community.		
Chronic	viral	hepatitis	(CVH)	due	to	hepatitis	B	and	C	(HBV	and	HCV)	are	blood	borne	viral	infections	
that	affect	 the	 liver,	 and	are	 the	 leading	cause	of	 cirrhosis	 (end-stage	 scarring)	and	hepatocellular	
carcinoma	(HCC,	primary	liver	cancer)	worldwide.	The	global	death	toll	seen	due	to	CVH	is	rising,	and	
is	higher	than	that	reported	with	HIV,	and	comparable	to	that	seen	for	tuberculosis;	with	CVH	the	only	
one	of	these	conditions	with	a	mortality	rate	that	continues	to	rise	[WHO	2017,	WHO	May	2016].	
The	baseline	prevalence	of	CVH	is	low	in	the	UK,	but	liver	disease	is	the	5th	biggest	killer,	with	CVH	
being	among	the	 leading	causes	for	this	excess	mortality	 [CMO	2012].	There	 is	marked	geographic	
variation	in	the	prevalence	of	CVH,	with	a	disproportionate	burden	of	disease	that	 is	seen	in	many	
parts	of	the	world	[Hahne	SJ	2013].	Globally,	only	around	9%	(22	millions)	of	all	HBV	patients,	and	22%	
(14	millions)	of	HCV	patients	are	estimated	to	have	been	diagnosed	and	aware	of	their	disease	state,	
and	even	by	2015,	only	around	8%	of	these	HBV	patients	and	7.4%	of	HCV	patients	had	received	or	
commenced	treatment	[WHO	Global	Hepatitis	Report	2017].	
HBV	and	HCV	can	be	 transmitted	 from	person	 to	person,	with	blood	borne	exposure	 the	principal	
route.	Risk	factors	for	acquisition	include	iatrogenic	exposure	and	risk	activities,	such	as	injecting	drug	
use,	as	well	as	mother-to-child	(vertical)	transmission,	or	infection	in	the	first	few	years	of	life,	with	
these	vertical	and	childhood	risks	accountable	for	the	endemicity	of	HBV	worldwide	[WHO	July	2017].		
Not	all	patients	 infected	with	HBV	and	HCV	will	develop	chronic	(long-term)	 infection,	and	there	 is	
variation	in	this	chronicity	based	on	the	age	at	acquisition	[Hyams	KC	1995].	Importantly	though,	both	
acute	and	chronic	infection	may	cause	few	symptoms,	and	infection	therefore	goes	unrecognised	by	
patient	and	clinician	alike	until	end-stage	complications	develop	(70%	of	adults	and	90%	of	children	
may	 not	 develop	 symptoms	 of	 acute	 hepatitis	 B	 infection	 [Foundation	 for	 Liver	 Research	 2004]).	
Testing	is	therefore	the	only	way	to	identify	infection,	with	effective	and	accurate	testing	strategies	
that	are	available.		
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Training	and	working	as	a	NHS	specialty	doctor	in	hepatology,	I	have	seen	many	patients	who	present	
with	 the	 complications	 of	 CVH	 through	 delayed	 diagnosis,	with	 disease	 that	was	 not	 identified	 or	
treated	earlier.	 These	patients	have	often	developed	many	of	 the	advanced	 complications	of	 liver	
disease	and	portal	hypertension	(figure	1),	with	significant	morbidity	and	mortality	risks,	and	with	the	
drastic	interventions	of	liver	transplantation	that	may	be	their	only	treatment	option.		
	
	
	
Figure	1:	Summary	of	complications	seen	in	end-stage	liver	disease	(cirrhosis)	(Dooley	J,	12	edition),	with	
factors	that	can	individually	or	cumulatively	increase	morbidity	and	mortality	in	effected	individuals		
The	tragedy	in	these	individual	cases	and	in	undiagnosed	infection	is	that	early	identification	facilitates	
treatment	to	prevent	liver	disease	progression	and	the	development	of	thes	systemic	complications.		
Testing	is	straightforward	and	can	be	delivered	by	a	blood	or	saliva	tests,	which	will	identify	current	
infection	and	previous	exposure.	Highly	effective	treatment	now	exists	for	viral	hepatitis,	and	huge	
scientific	advances	have	been	made	over	the	last	few	years	to	revolutionise	the	treatment	of	Hepatitis	
C,	 such	 that	 treatment	 for	 HBV	 and	 HCV	 is	 now	 close	 to	 100%	 effective	 in	 preventing	 disease	
progression	 if	 it	 can	be	 identified	 at	 the	 right	 time,	 and	with	 globally	 driven	 initiatives	 in	place	 to	
eliminate	CVH	by	2030	[Lawitz	E	2015,	Sulkowski	M	2014,	EASL	recommendations	2015,	Williams	R	
2014,	WHO	May	2016].		
CVH	has	a	global	distribution,	with	HBV	endemic	in	some	parts	of	the	world	[WHO	May	2016,	WHO	
July	2017].	Migrant	groups	in	the	UK	are	thought	to	be	at	increased	risks	of	CVH,	with	up	to	95%	of	
newly	identified	chronic	HBV	cases	that	are	seen	in	migrant	individuals	[NICE	2012],	and	with	higher	
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rates	of	HCV	reported	in	the	sentinel	surveillance	programmes	undertaken	by	Public	Health	England,	
with	prevalence	rates	between	2	to	6%	in	some	communities,	in	comparison	to	baseline	prevalence	
estimates	of	0.4%	in	the	UK	community	[PHE	2013,	PHE	2017].		
CVH	testing	 in	migrant	communities	 is	 therefore	supported	 in	national	and	 international	guidance,	
with	case-finding	objectives	to	identify	and	engage	with	at-risk	groups	for	treatment	(figure	2).	In	the	
UK,	the	National	 Institute	of	Health	and	Care	Excellence	(NICE)	released	updated	guidance	 in	2012	
recommending	CVH	testing	in	at-risk	groups,	with	specific	focus	on	migrant	communities	(figure	3).		
	
	
	
	
	
	
	
	
	
	
Figure	2:	case-finding	process	in	at-risk	groups	
	
Figure	3:Principal	at-risk	groups	to	approach	and	offer	HBV	and	HCV	testing	in	England	[NICE	2012]	
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Migrant	 groups	 do	 however	 face	 inequalities	 in	 healthcare	 access	 in	 the	 host	 country,	 as	 well	 as	
altered	patterns	of	healthcare	engagement	that	can	leave	this	community	vulnerable	[WHO	2010],	in	
addition	 to	 a	 higher	 burden	 of	 disease	 risk	 that	 may	 exist	 from	 their	 native	 environment.	 First	
generation	migrants,	and	new	migrant	communities	may	be	at	even	greater	need	with	regard	to	(an	
unknown)	disease	burden	[Uddin	G	2010],	as	well	as	uncertainties	in	how	to	reach-out	to	this	new	
community	for	health	engagement.		
The	UK	Nepali	community	is	a	unique	migrant	population	in	need	of	study,	with	a	rapid	and	significant	
rise	in	population	numbers	following	the	widely	celebrated	approval	of	UK	settlement	rights	to	ex-
Gurkha	servicemen	and	their	dependents	in	2004	and	2009	[Home	Office	2017].	This	new	community	
has	settled	close	to	established	military	links,	with	a	large	population	that	has	based	itself	around	the	
Aldershot	garrison	in	Surrey	and	Hampshire.	Indeed,	estimates	suggest	that	the	Rushmoor	district	now	
has	the	largest	population	of	Nepali	in	the	UK,	with	an	estimated	6-10%	of	the	local	population	who	
are	now	Nepalese	[CNSUK	2013,	Telegraph	February	2011].		
The	health	needs	of	the	newly	arrived	Nepali	community	is	unknown,	including	in	the	context	of	CVH,	
with	a	higher	burden	of	CVH	that	is	well	documented	in	the	neighbouring	countries	of	India	and	China	
[Sharma	 S	 2015],	 and	 a	 unique	 geographic	 population	 extraction	 (in	 view	 of	 Gurkha	 recruitment	
practices)	that	new	resides	in	the	UK.		
The	Need	for	Study	–	exploring	CVH	risks	in	the	newly	arrived	Nepali	community:	
Little	is	known	about	the	CVH	risks	in	the	newly	arrived	Nepali	community,	or	the	health	awareness	
and	perception	in	this	population.	Many	in	the	community	are	likely	to	be	older,	given	the	extension	
of	 settlement	 rights	 in	 2009	 to	 allow	 older	 ex-servicemen	 and	 their	 dependents	 to	 settle;	 with	
undiagnosed	CVH	in	these	individuals	that	may	be	at	a	more	advanced	stage.		
There	is	heterogeneity	in	documented	CVH	rates	within	and	between	migrant	groups,	with	difficulties	
therefore	in	understanding	and	extrapolating	HBV	and	HCV	risks	amongst	diverse	population	groups.	
CVH	risks	may	also	be	higher	in	recently	arrived	migrants	[Uddin	G	2010],	with	the	need	therefore	to	
explore	chronic	hepatitis	B	and	C	(CVH)	risks	in	the	newly	arrived	UK	Nepali	community.	
There	 is	a	higher	CVH	burden	suggested	 in	members	of	 the	UK	South	Asian	community,	 identified	
through	PHE	(Public	Health	England)	sentinel	surveillance	data	and	community-based	research	studies	
[PHE	2017,	Uddin	G	2010,	Sharma	S	2015,	Vedio	A	2013].	Hepatitis	B	prevalence	is	estimated	to	be	
around	2%	in	the	South	East	Asian	region	overall	[WHO	July	2018],	with	reported	HCV	rates	in	the	UK	
South	 Asian	 population	 of	 2.7%	 [Sharma	 S	 2015],	 although	more	 recent	 studies	 suggest	 that	 the	
prevalence	 rates	 of	 CVH	 (HBV	 and	 HCV)	 may	 be	 somewhat	 lower	 at	 2%	 (1.1%	 HBV,	 0.9%	 HCV)	
	 17	
[Flanagan	 S	 et	 al.	 2019].	 Initial	 case-finding	 initiatives	 in	migrant	 groups	were	 conducted	with	 an	
estimated	threshold	of	2%	prevalence	for	CVH	in	these	groups,	with	cost-effectiveness	analysis	based	
on	these	risk-estimates,	as	detailed	in	initial	NICE	(National	Institute	of	Health	and	Care	Excellence)	
CVH	testing	guidance	[NICE	2012].	The	heterogeneity	amongst	published	studies	suggests	firstly	that	
this	threshold	may	still	exist,	but	even	with	the	 lower	estimates	of	CVH	prevalence	from	the	 latest	
HepFree	study	in	the	UK,		the	cost-effectiveness	of	testing	migrant	groups	is	still	met	at	an	estimated	
£8540	per	QALY	[Flanagan	S	et	al.	2019],	with	growing	cost-effectiveness	support	for	migrant	case-
finding	 initiatives	 in	 other	 European	 countries,	 with	 cost-effectiveness	 demonstrated	 even	 at	
estimated	 seroprevalence	 rates	 of	 0.41%	 for	 HBsAg	 and	 HCV	 RNA	 at	 0.22%	 in	 the	 Netherlands	
[Suijkerbuijik	AWM	2018].		
CVH	testing	 in	migrant	communities	 is	 recommended	as	part	of	national	policy,	with	updated	CVH	
testing	recommendations	issued	by	NICE	in	2012	[NICE	2012].	National	policy	has	an	important	role	in	
coordinating	and	delivering	testing	through	(existing)	health	facility-based	testing,	with	primary	care	
the	principal	agent	tasked	to	deliver	testing	to	a	wide	and	heterogeneous	migrant	population,	and	to	
facilitate	 linkage	 to	 health	 services	 [WHO	May	 2016].	 The	 awareness	 and	 uptake	 of	 current	 CVH	
testing	policy	 is	 however	 largely	 unknown,	with	policy	 endeavours	 over	 the	past	 10-14	 years	 that	
produced	low	levels	of	awareness	and	confidence	in	managing	CVH,	particularly	in	primary	care	[NICE	
2012,	DH	2004,	DH	2009,	De	Souza	2005,	RCGP	2007,	APPHG	2011].	
The	awareness	of	policy,	as	well	as	the	practice	and	perception	of	testing	in	primary	care	is	therefore	
important	in	understanding	the	potential	barriers	that	exist	at	the	micro-level	towards	testing	in	the	
newly	arrived	Nepali	population,	as	well	as	migrant	testing	more	broadly	across	the	health	system.		
At	the	same	time,	it	is	important	to	have	a	direct	assessment	of	the	CVH	risks	that	exist	in	the	local	
Nepali	 population,	 with	 uncertainties	 that	 exist	 in	 the	 awareness,	 knowledge	 and	 perception	 of	
disease	in	the	newly	arrived	community,	and	how	these	sensitivities	may	affect	health	engagement	
practices	[Norredam	M	2010,	Kessing	L	2013].		
	
Research	Aims	and	Objectives:			
The	aim	of	this	thesis	is	therefore	to	explore	the	chronic	hepatitis	B	and	C	(CVH)	risks	that	exist	in	the	
UK	Nepali	community,	as	well	as	the	potential	barriers	and	facilitators	that	exist	at	the	(macro)	policy	
level	towards	CVH	testing	in	migrant	communities,	and	at	the	primary	care	(micro)	level	towards	CVH	
testing	in	migrant	groups.			
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The	objectives	of	the	thesis	are	as	follows:	
1. To	explore	the	political,	social	and	health	pressures	faced	by	migrants,	and	the	newly	arrived	
Nepali	community;	and	the	implications	of	these	determinants	on	health	engagement.	
2. To	explore	NICE	CVH	testing	guidance	as	part	of	a	(macro-level)	policy	analysis	to	understand	
the	potential	barriers	and	facilitators	that	exist	in	policy	prioritisation.		
3. To	identify	the	potential	barriers	and	facilitators	at	the	(micro)	primary	care	level	towards	CVH	
testing	in	migrant	groups,	and	the	recently	arrived	Nepali	community.		
4. To	explore	the	awareness,	knowledge	and	perception	of	CVH	in	the	Nepali	community,	and	
beliefs	or	practices	that	may	 influence	the	development	and	uptake	of	health	engagement	
strategies.		
5. To	 develop	 a	 community-based	 testing	 intervention	 with	 members	 of	 the	 local	 Nepali	
community	to	establish	CVH	risks	through	direct	study.		
6. To	develop	an	overarching	analysis	of	the	gaps	that	exist	at	the	policy	(macro)	level	and	at	the	
primary	care	(micro)	level	towards	CVH	testing	in	migrant	groups,	and	to	utilise	findings	from	
the	Nepali	community	to	explore	how	CVH	testing	delivery	can	be	delivered	and	prioritised	to	
this	community,	and	other	migrant	groups.		
The	thesis	aims	to	contribute	an	understanding	firstly	of	CVH	risks	in	the	Nepali	community,	and	in	the	
development	of	a	community-based	engagement	strategy;	and	at	a	higher	level	looks	to	understand	
the	barriers	that	exist	in	testing	in	migrant	groups	at	the	macro	and	micro	levels;	focusing	on	deficits	
that	exist	at	the	policy	level,	and	in	primary	care,	with	direct	impact	that	these	factors	will	have	on	
CVH	testing	in	the	newly	arrived	Nepali	community,	as	well	as	migrant	groups	nationally.		
	
Structure	of	thesis:	
The	chapters	in	this	dissertation	are	organised	as	follows:		
Chapter	 1	 looks	 at	 the	 political,	 social	 and	 health	 determinants	 that	 affect	 migrant	 groups,	 and	
challenges	particular	to	the	newly	arrived	Nepali	community	in	the	UK.	Health	in	migrant	communities,	
and	the	potential	burden	of	undiagnosed	CVH	is	explored,	as	well	as	the	broader	inequalities	that	exist	
in	health	access	and	engagement	in	migrant	communities.		
Chapter	2	presents	the	research	objectives	of	the	study,	and	the	research	methodology	and	design,	
including	 the	 philosophy	 and	 theoretical	 framework	 utilised.	 An	 overview	 of	 the	 mixed-methods	
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approach	 used	 to	 achieve	 my	 research	 objectives	 is	 presented;	 with	 the	 findings	 of	 the	 study	
presented	in	chapters	3	to	6		
Chapter	3	explores	the	findings	of	policy	level	analysis	using	the	National	Institute	of	Health	and	Care	
Excellence	(NICE)	public	health	guideline:	“Hepatitis	B	and	C	testing:	people	at	risk	of	infection”.	The	
history	and	context	of	CVH	testing	policy	 is	explored	on	an	 international	and	national	basis,	with	a	
Policy	Prioritisation	framework	selected	to	explore	the	gaps	that	exist	in	CVH	testing	policy	reaching	
the	agenda	for	adoption	and	successful	implementation	for	migrant	testing.		
Chapter	 4	 presents	 the	 findings	 of	 a	 qualitative	 study	 exploring	 the	 awareness,	 knowledge	 and	
perception	towards	liver	disease	and	CVH	in	the	Nepali	community.	Focus	Group	study	results	across	
4	groups	in	the	local	Nepali	community	are	presented	using	a	thematic	analysis	approach.		
Chapter	 5	 presents	 the	 findings	 of	 qualitative	 studies	 in	 primary	 care,	 exploring	 the	 awareness,	
understanding	 (knowledge)	 and	 perception	 towards	 CVH	 testing	 in	 migrant	 groups	 in	 General	
Practitioners	(GPs),	with	comparisons	that	are	applied	to	the	qualitative	findings	from	studies	in	the	
Nepali	community	who	are	served	by	these	practitioners.		
Chapter	6	explores	and	presents	the	findings	of	a	testing	programme	designed	to	establish	CVH	risks	
in	the	local	Nepali	community.	
The	Discussion	and	Conclusions	of	my	 study	are	presented	 in	Chapter	7,	with	 inclusion	of	 the	key	
findings	of	the	study,	and	the	potential	gaps	that	are	found	from	policy	to	practice	at	the	primary	care	
level	 in	 CVH	 testing	 in	 migrant	 communities,	 as	 well	 as	 potential	 levers	 for	 action	 in	 future	
interventions.		
	
Chapter	Summary:		
The	current	chapter	presents	an	introduction	into	the	aims	of	this	thesis,	to	identify	the	burden	placed	
by	CVH	 in	migrant	 communities,	 and	 the	uncertainties	 that	exist	 in	CVH	 risks	 in	 the	newly	arrived	
Nepali	community.	The	principal	research	aims	of	the	study,	as	well	as	an	overview	of	the	structure	of	
the	thesis	is	presented.		
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Chapter	1		
	
The	 political,	 social	 and	 health	 context	 of	
migration,	 and	 implications	 for	 CVH	 testing	
engagement	
	
	
	
	
	
	
	 22	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 23	
Chapter	1:	Migration:	Political,	Social	and	Health	aspects	
Abstract:	
This	chapter	explores	the	pressures	faced	by	migrant	communities,	and	the	potential	impact	on	health	
access	and	engagement.	 It	explores	the	political	and	social	context	of	migration	to	the	UK,	and	the	
political	and	social	determinants	of	migrant	health.	The	global	burden	of	CVH	is	explored:	the	risks	that	
are	poorly	defined,	and	disease	may	be	undiagnosed	in	migrant	communities.	The	specific	political	and	
social	determinants	affecting	the	newly	arrived	Nepali	community	are	described,	with	the	potential	
impact	on	health	engagement,	and	the	need	for	study	to	assess	their	CVH	risks.		
	
Migration,	with	the	flow	of	people	within	and	between	countries	and	continents	is	an	integral	part	of	
human	 society.	 Migration	 can	 produce	 economic,	 cultural	 and	 socio-political	 change,	 but	 also	
stigmatisation,	 conflict	 and	 vulnerabilities.	 	Migrants	 include	 those	 individuals	who	 have	 left	 their	
home	country	to	seek	a	life	in	another	country,	and	may	be	short	or	long	term	residents	in	the	host	
nation.		
There	is	frequently	overlap	in	how	migrants	are	defined	in	literature	[WHO	2010],	but	for	the	purposes	
of	this	thesis	the	term	“migrant”	is	used	to	reference	those	individuals	born	outside	the	UK,	with	“new	
migrants”	 used	 to	 reference	 those	 individuals	 who	 are	 recently	 arrived,	 referencing	 the	 Nepali	
community,	who	form	the	focus	of	this	study	[Wagner	KS	2013].		
Migration	patterns	fluctuate	in	time	and	place,	but	the	past	few	years	have	seen	a	dramatic	increase	
in	 the	 number	 of	 individuals	 displaced	 by	 war,	 conflict	 or	 persecution,	 with	 close	 to	 60	 million	
individuals	affected	worldwide.	During	2014,	an	average	of	42,500	persons	per	day	were	forced	to	
leave	their	homes	due	to	conflict,	seeking	protection	elsewhere	within	their	country	or	abroad.	The	
resulting	refugee	crisis	of	this	and	previous	conflicts	is	substantial,	with	close	to	20	million	refugees	
worldwide,	 and	with	 the	ongoing	Syrian	 conflict	now	 the	 largest	 contributor	of	 this	 refugee	 crisis.	
Developing	 countries	 are	 hosting	more	 of	 these	 refugees	 than	 ever	 before,	 but	 the	 pressures	 of	
migration	on	the	EU	from	these	conflicts	as	well	as	existing	migrant	communities	are	substantial,	with	
no	anticipated	easing	in	the	complex	migration	trends	in	sight	[UNHCR	2015,	Eurostat	2015].		
The	UK	is	the	end-destination	point	for	many	of	those	displaced	and	seeking	new	opportunities,	with	
the	Calais	Jungle	a	manifestation	of	the	pressures	and	plight	of	migration	and	migrants	[Eurostat	news	
release,	March	2015,	Guardian,	Taylor	M	2015].	Immigration	rates	to	the	UK	have	doubled	since	the	
1990’s,	and	England	and	Wales	have	a	higher	proportion	of	foreign-born	residents	in	comparison	to	
similar	sized	European	countries,	including	France	and	Germany.	Citizenship	acquisition	is	among	the	
	 24	
highest	in	the	UK	compared	to	other	EU	states,	and	foreign	born	individuals	make	up	close	to	13%	of	
the	population,	with	the	majority	of	 individuals	 (8.1%)	born	outside	the	EU	[Eurostat	news	release	
March	2015].	Census	data	from	2011	in	England	and	Wales	shows	that	there	has	been	an	increase	in	
minority	ethnic	groups,	whilst	 those	defined	as	“White	British”	has	declined	over	 the	same	period	
[ONS	2011].		
Migration	 rates	 to	 England	 and	 Wales	 have	 risen	 sharply	 since	 2001,	 driven	 principally	 by	 the	
expansion	of	the	EU	to	include	Central	Eastern	European	countries	in	2004.	India,	Poland	and	Pakistan	
are	the	three	most	common	countries	of	origin	for	those	born	abroad,	with	an	897%	increase	in	the	
recorded	Polish	population	between	2001	and	2011,	which	is	likely	to	have	contributed	to	the	46%	of	
non-UK	 born	 respondents	 who	 identified	 themselves	 as	 White	 in	 the	 2011	 census	 [ONS	 2012].	
Cumulatively	 though,	 members	 of	 the	 South	 Asian	 community	 (India,	 Pakistan	 and	 Bangladesh)	
continue	 to	 be	one	of	 the	predominant	migrant	 communities	 to	 the	UK,	which	 is	 in	 keeping	with	
previous	census	reports	and	trends	over	the	past	few	decades	[ONS	2012]	(figure	3).		
	
Figure	4:	Census	data	on	top	4	migrant	groups	by	country	of	birth	-	across	England	and	Wales	from	1951-2011	–	the	
fluctuating	nature	of	migrant	groups	over	time	can	be	seen	-	[taken	from	ONS	2012]		
Migrant	groups	may	face	a	higher	burden	of	disease,	compounded	by	known	inequalities	in	healthcare	
access	 and	 quality.	 Migrant	 health	 is	 complex,	 and	 related	 to	 multiple	 determinants	 across	
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socioeconomic,	cultural	and	environmental	conditions	that	consider	the	political	and	social	context,	
as	well	as	individual	characteristics;	and	considers	these	concepts	across	the	host	nation	and	country	
of	origin	[WHO	2010].		
CVH	 carries	 a	 global	 risk	 burden,	 with	 a	 risk	 profile	 that	 is	 unknown	 in	 the	 newly	 arrived	 Nepali	
community.	 In	developing	a	strategy	to	engage	with	this	new	population,	and	in	trying	to	optimise	
CVH	 testing	 and	 linkage	 to	 care	 across	 the	 healthcare	 system,	 it	 is	 important	 to	 first	 gain	 an	
understanding	of	the	broader	determinants	of	health	that	may	affect	this	newly	arrived	population,	
and	 how	 these	 factors	 may	 influence	 our	 current	 research	 testing	 objectives,	 and	 future	 health	
engagement	 in	 the	 UK	 Nepali	 community.	 	 To	 this	 endeavour,	 the	 following	 section	 presents	 an	
overview	 of	 the	 Political,	 Social	 and	 Health	 aspects	 affecting	 migrant	 communities,	 and	 a	 more	
detailed	assessment	of	potential	CVH	risks	that	may	be	seen	in	migrant	communities,	and	the	need	
for	study	in	the	newly	arrived	Nepali	communities.		
Political	impact	of	migration:	
Net	UK	migration	rates	in	2014	were	close	to	the	peak	levels	of	320,000	seen	in	2005	following	EU	
expansion,	with	rising	rates	of	migration	from	within	and	outside	of	the	EU	[ONS	2015].	Net	migration	
has	been	a	target	of	senior	politicians	since	at	least	2011,	with	commitments	and	initiatives	issued	to	
bring	(net)	migration	to	within	the	“tens	of	thousands”	per	year	[Eurostat	news	release,	March	2015,	
Guardian,	 Taylor	M	2015].	 	 However,	 only	 recently	 has	 net	migration	 fallen,	 associated	 to	 the	 EU	
referendum	and	looming	Brexit	uncertainties	[Guardian	November	2017].		
Indeed,	it	is	likely	that	rising	anti-migrant	sentiment	played	a	part	in	the	EU	referendum	outcome	in	
the	UK	[Independent	June	2017],	with	migration	that	has	had	a	particular	focus	in	political	campaigns	
and	 in	 the	pressures	 felt	by	 the	two	mainstream	political	parties	 this	decade.	Migration	was	a	key	
political	 factor	 in	the	2015	election	campaign,	and	was	 labelled	as	the	2nd	most	 important	 issue	to	
voters	behind	the	NHS;	and	the	UK	Independence	Party	(UKIP)	accordingly	took	12.6%	of	the	UK	vote	
in	2015,	and	despite	having	only	one	MP	maintained	a	large	political	profile	in	the	run	up	to	the	2016	
EU	referendum	[Financial	Times	2015,	Guardian	May	2015].		
Likewise,	across	Europe	there	has	been	a	surge	in	support	for	nationalist	political	parties	with	far-right	
sympathies	over	the	last	two	decades	(figure	5)	[BBC	May	2016],	with	mainstream	commentary	that	
Europe	has	taken	“a	right-turn”	over	the	last	decade,	with	EU	communities	perceiving	an	economic,	
social,	religious	and	cultural	threat	from	migrant	populations	and	religions	(namely	Islam)	[Wikipedia,	
List	of	Active	Nationalist	Parties	in	Europe;	Economist	2014]	
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Figure	5:	vote	shares	as	received	by	nationalist	groups	across	Europe	in	2015/16;	taken	from	BBC	news	[BBC	
May	2016]	
In	 the	UK,	 the	 rise	 of	UKIP	has	 replaced	much	of	 the	 focus	 and	support	 for	 other	 recent	 far-right	
groups,	 including	the	British	National	Party	(BNP)	and	the	English	Defence	League	(EDL),	both	with	
more	 extreme	 and	 explicit	 anti-immigrant	 and	 anti-Islam	 ideologies.	 Electoral	 support	 for	 UKIP	 is	
principally	 thought	 to	 be	 in	 relation	 to	 threats	 seen	 through	 the	 changing	 demographics	 from	
migration,	as	well	as	political	disengagement	 from	the	main	political	parties	 in	 the	UK,	particularly	
amongst	White,	working	class	individuals	[Guardian	April	2014,	YouGov	April	2014].	And	whilst	some	
of	the	political	rhetoric	over	the	past	few	years	from	the	governing	parties	may	need	to	be	seen	as	a	
response	to	this	surge	in	UKIP	popularity,	some	actions	such	as	the	use	of	buses	advertising	“go-home”	
to	illegal	migrants	by	the	conservative	party	have	been	strongly	criticised	across	the	spectrum,	even	
by	Nigel	Farrage,	the	then	leader	of	UKIP	[Guardian	July	2013].		
From	a	health	perspective,	Nigel	Farrage	received	significant	amounts	of	media	coverage	for	his	focus	
on	health	 tourism	 in	migrant	 individuals,	and	 in	particular	his	 focus	on	HIV,	using	 the	 live	political	
debates	of	2015	to	label	higher	rates	of	HIV	infection	in	migrant	communities.	He	focussed	on	using	
HIV	above	other	health	conditions,	which	was	reported	as	pre-planned	in	its	attempts	to	promote	a	
shock-effect,	 and	 galvanise	 like-minded	 UKIP	 supporters	 rather	 than	 a	 spontaneous	 comment	
[Telegraph	July	2015].	Similar	high-profile	comments	by	the	previous	UKIP	 leader	have	been	made	
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over	the	past	few	years,	to	highlight	higher	rates	of	TB,	HBV	and	other	disease	in	migrant	groups,	and	
to	lobby	for	entry	checks	and	refusal	options	to	migrants	trying	to	enter	the	UK,	as	well	as	measures	
to	refuse	treatment	to	non-British	citizens	in	the	UK.	Such	comments	have	been	promoted	by	some	
media	outlets,	and	the	Daily	Mail	ran	its’	own	commentary	piece:	“Immigrants	in	the	NHS;	HIV	and	
the	true	cost	to	the	NHS:	Should	the	“International	Health	Service”	be	treating	patients	who	come	
here	with	 the	killer	disease?”;	 in	which	the	 journalist	uses	 the	higher	number	of	 foreign	 faces	and	
voices	in	an	inner	city	London	GUM	(Genito-urinary	medicine)	clinic	to	link	these	and	most	migrants	
towards	health	tourism	and	HIV	testing	[Daily	Mail	October	2014].	Such	articles	and	supportive	related	
social	media	comments	highlight	the	provocative	and	stigmatising	nature	of	comments	from	UKIP	and	
other	right-leaning	political	sources,	as	well	as	the	flawed	generalisations	of	data	and	stereotyping	
used	by	these	groups	to	justify	concepts	of	health	tourism,	for	which	contradictory	evidence	exists	
both	from	the	House	of	Commons	report	of	2005	and	the	National	AIDS	Trust	[Guardian	April	2015].		
In	recent	years,	the	Conservative	government	has	taken	steps	to	introduce	(£35K)	pay-caps	to	non-EU	
migrants	seeking	UK	residency,	as	well	as	NHS	user	fee	charges	applied	to	non-EU	migrants	without	
settlement	rights,	and	has	publicised	drives	to	keep	only	the	“best	and	the	brightest”	migrants	in	the	
UK	[BBC	February	2012,	Guardian	June	2015,	The	Migration	Observatory	2011,	Guardian	November	
2014,	Home	Office	2013,	Bowsher	G	2015]	
Overall	then,	the	explicitly	negative	focus	taken	towards	migration	over	the	recent	years	seems	a	step-
change	 in	 comparison	 to	 the	 political	 view	 taken	 over	 the	 last	 two	 decades.	 And	 whilst	 the	 UK	
government	 is	 clear	 that	 it	 is	 not	 against	 all	 forms	 of	 migration,	 and	 emphasises	 the	 value	 and	
contribution	that	it	can	bring;	it	remains	to	be	seen	how	this	negative	focus	impacts	the	known	health	
inequalities	that	migrant	groups	face,	and	the	broader	socio-economic,	cultural	and	environmental	
conditions	that	effect	the	health	and	health	engagement	in	migrant	communities	(figure	6).		
Social	aspects	of	migration	
Migrant	groups	are	hugely	diverse,	and	individuals	may	be	considered	as	migrant	workers,	students,	
refugees,	 asylum-seekers	 (including	 failed	 asylum	 applicants),	 family	 re-union	migrants,	 trafficked	
persons	and	undocumented	migrants	[Aspinall	PJ	2014].	Government	policy	is	an	important	driver	in	
migration,	but	the	influences	behind	overall	migration	trends	are	multifactorial,	with	economic	and	
labour	market	forces	the	principal	drivers	of	international	migration	[The	Migration	Observatory	May	
2015].	In	the	UK,	work	is	the	most	commonly	cited	reason	for	travel	by	non-UK	citizen,	although	in	
non-EU	individuals	study	becomes	a	more	prominent	factor,	presumably	in	relation	to	government	
policy	 on	 visa	 restrictions	 to	 non-EU	 migrants.	 Most	 UK	 citizenship	 is	 however	 granted	 for	 work	
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reasons,	and	economic	and	labour	market	considerations	are	therefore	key	aspects	in	UK	migration	
[The	Migration	Observatory	May	2015].		
Migration	trends	are	more	complex	however	than	labour	supply	alone,	and	the	UK	has	a	strong	history	
of	migration	from	former	colonial	states,	with	many	individuals	who	started	to	arrive	in	the	UK	from	
the	1950’s	and	60’s	from	the	Caribbean	and	South	Asian	countries.	Once	migrant	communities	are	
established,	 they	 can	 in	 turn	 facilitate	 further	 migration	 through	 transnational	 ties	 and	 migrant-
networks,	encouraging	and	easing	the	process	for	new	arrivals.	Indeed	these	associations	are	likely	to	
account	for	the	relatively	high	level	of	migration	seen	from	post-colonial	South	Asian	countries	over	
the	past	few	decades,	and	for	the	steady	distribution	of	countries	contributing	to	UK	migration	over	
the	same	period	(figure	3)	[Czaika	M	2013].	Accordingly,	new	migrant	communities	may	face	particular	
challenges	 over	 established	 communities,	 with	 limited	 migration-networks	 in	 place	 to	 support	
settlement	 and	 integration,	 and	 therefore	 may	 be	 more	 vulnerable	 with	 regard	 to	 access	 for	
employment,	housing	and	healthcare	access.		
Within	 the	UK,	most	migrant	 communities	 are	 closely	 clustered	 in	 certain	 geographic	 areas.	 Such	
clustering	may	be	manifest	of	the	support	gained	from	migration-network	links,	as	well	as	available	
housing	and	employment	opportunities	for	these	individuals.	Some	areas,	such	as	that	in	East	London	
have	served	as	centres	for	new-migrant	arrivals,	from	Jewish	settlers	to	members	of	the	South	Asian	
community,	whereas	 other	 areas	 in	 Eastern	 England	 have	 only	 recently	 become	 popular	 sites	 for	
migration	of	Eastern	European	migrants.	Clustering	of	migrant	groups	can	lead	to	rapid	or	generational	
changes	in	the	pre-existing	native	community,	provoking	ethnic	tensions	that	can	rapidly	flare,	as	seen	
in	the	Oldham	riots	of	2001	[BBC	news	2013,	Wikipedia	2015].		
Integration	 of	 migrant	 groups	 into	 society	 is	 a	 complex	 area,	 with	 multiple	 definitions	 used	 to	
characterise	and	measure	integration	as	well	as	a	paucity	of	data	collection,	which	is	most	lacking	in	
new	 migrant	 communities.	 Societal	 integration	 is	 therefore	 best	 described	 in	 established	
communities,	 but	 even	 here	 there	 are	 differences	 in	 how	 integration	 is	 viewed,	 whether	 as	
“assimilation”,	or	perhaps	more	inclusively	and	appropriately	defined	as	“a	series	of	processes	relating	
to	participation	in	the	labour	market	and	social	institutions	(such	as	education),	social	interaction	and	
civil	 participation”	 [The	 Migration	 Observatory	 2011].	 Such	 broad	 variation	 in	 how	 integration	 is	
viewed	may	relate	to	lack	of	central	strategy	to	address	integration,	but	also	reflects	conflict	at	the	
societal	level	on	the	impacts	of	migration.	From	a	policy	perspective,	there	are	frameworks	which	exist	
to	 try	 and	 facilitate	 integration	 for	 refugees,	 and	 following	 the	 conflicts	 seen	 in	 Oldham	 and	
surrounding	 areas	 in	 the	 early	 2000’s,	 there	 is	 now	 a	 citizenship	 programme	 for	 those	 seeking	
settlement	in	the	UK.	However	for	new	migrant	groups,	there	is	no	structured	approach	to	guide	or	
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facilitate	societal	integration.	These	groups	may	be	further	hindered	by	language	or	cultural	barriers,	
and	reduced	support	from	existing	migrant	networks	that	limit	awareness	and	access	to	employment	
and	services,	including	access	and	uptake	of	health	services,	particularly	in	first-generation	migrants.	
At	a	socio-economic	 level,	migrant	 individuals	have	poorer	outcomes	overall	with	regard	to	 labour	
participation,	 unemployment	 and	 over-qualification	 compared	 to	 native	 born	 individuals	 across	
Europe.	Lower	income	levels	are	also	documented	for	non-EU	migrants,	with	the	increased	risks	of	
poverty,	social	exclusion	and	overcrowding	that	are	co-existent	to	this.	First	generation	migrants	are	
at	particular	risk	from	these	outcomes,	and	new-migrant	populations	perhaps	even	more	so,	although	
collective	information	for	this	group	is	 limited	in	relation	to	established	migrant	communities,	who	
are	more	likely	to	be	in	work	and	educational	settings	[Eurostat	2011].		
As	such,	individuals	from	migrant	communities	are	often	considered	vulnerable,	and	whilst	there	is	
very	 wide	 differential	 in	 socio-economic	 status	 amongst	 migrant	 workers,	 individuals	 from	 these	
groups	 are	 overall	 at	 increased	 risk	 of	 many	 determinants	 of	 health	 and	 wellbeing,	 including	
education,	employment,	housing	and	access	to	services.		
	
Health	in	migrant	communities:		
Health	disparities	are	widely	 reported	 in	migrant	communities,	with	ethnicity	 typically	used	as	 the	
identifying	characteristic	in	disease	prevalence	and	health	inequality	studies.	New	migrant	groups	are	
therefore	 typically	 underrepresented	 in	 these	 studies,	 as	 ethnicity	 definitions	 are	 usually	 tailored	
toward	the	existing	minority	communities	[Jeyaweera	H	2010].		
Avoidable	 inequalities	 in	 the	 health	 status	 of	migrants,	 as	 well	 as	 the	 quality	 and	 accessibility	 of	
services	for	migrant	groups	have	been	reported	across	the	European	WHO	region.	These	inequities	
have	been	related	to	social	determinants	of	health,	and	social	exclusion	in	particular,	with	individuals,	
households	 or	 communities	 excluded	 from	 access	 and	 engagement	 in	 health	 services.	 This	 social	
exclusion	may	be	the	result	of	unequal	power	distributions	across	economic,	political,	societal	and	/	
or	cultural	grounds,	with	individual	or	institutional	discrimination	eroding	the	self-empowerment	and	
ability	of	groups	to	manage	their	health	effectively	[WHO	2010].	Socioeconomic	status	is	an	important	
consideration	 and	 likely	 co-factor	 in	 health	 inequities	 in	 migrant	 groups,	 and	 certainly	 lower	
socioeconomic	status	in	arriving	migrants	would	account	for	risks	including	overcrowding,	nutrition	
and	poor	sanitation,	as	well	as	 risk	behaviours,	 including	drug	use	and	sexual	practices	that	would	
increase	 the	 risk	 of	 BBV	 in	 these	 groups.	 There	 is	 however	 clearly	more	 to	 health	 inequities	 than	
socioeconomic	status	alone	 [Marmot	M	2017],	with	 individual	 risks,	cultural	practices	 that	may	be	
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associated	with	disease	or	wellness	states,	 the	background	prevalence	of	disease	 in	the	country	of	
origin,	as	well	as	an	additional	socio-economic	burden	that	many	migrant	groups	face	on	arrival	to	the	
host	country	that	is	independent	of	their	background	and	educational	status	[WHO	2010,	Ingleby	D	
2012,	Eurostat	2011].		
An	illustration	of	these	complex	relations,	and	the	modifiable	nature	of	these	interactions	is	explored	
and	 demonstrated	 in	 the	 social	 determinants	 of	 health	 model,	 utilised	 and	 championed	 by	
international	bodies	including	the	WHO	[WHO	2003].		The	social	determinants	of	health	explore	the	
political,	social,	economic	and	environmental	forces	that	influence	how	people	are	born,	grow	up,	live,	
work	and	age;	 influencing	health	 inequalities.	The	model	considers	multiple	 layers	 including	socio-
economic	and	environmental	conditions,	social	and	community	networks	and	individual	and	lifestyle	
factors,	as	 illustrated	 in	the	 (adapted)	Dahlgren-Whitehead	representation	 in	 figure	6.	Migration	 is	
then	 an	 additional	 layer	 to	 this	 complex	 relationship,	 with	 the	 status	 and	 determinants	 of	 the	
individual	in	their	origin-nation	interacting	with	the	determinants	in	the	new	host	country	acting	to	
potentially	 improve	 or	 worsen	 health	 and	 health	 inequities	 [IOM	 2006,	 WHO	 Health	 Impact	
Assessment].	
	
	
	
	
	
	
	
Modifiable	factors	Figure	6:	
that	influence	health	at	the	personal	(including	predisposition),	environmental	and	societal	level	[image	
taken	from	NHS	Scotland,	Bridging	the	Gap]	
Accessible	 health	 services	 are	 often	 lacking	 for	migrant	 communities,	with	 a	 lack	 of	 awareness	 of	
existing	facilities,	and	a	mismatch	in	the	provision	of	language	and	culturally	appropriate	services	for	
these	 groups.	 Perceptions	 towards	 healthcare	 are	 known	 to	 vary	 in	 migrant	 groups,	 and	 newer	
communities	 may	 be	 unfamiliar	 with	 preventative	 strategies	 in	 healthcare	 or	 broader	 models	 of	
Western	healthcare	provision.	It	may	also	be	that	the	migration	process	itself	influences	healthcare	
access	and	uptake,	with	“official”	migrants	perhaps	more	visible	and	likely	to	engage	with	healthcare	
	 31	
services	 [Davies	 A	 2010].	Multiple	 factors	 are	 likely	 to	 influence	 healthcare	 access	 and	 uptake	 in	
migrant	communities,	with	previous	reports	that	identify	six	key	factors	to	be	considered:	the	legal	
entitlement	 of	migrants,	 knowledge	 and	 awareness	 of	 the	 healthcare	 system	 in	 the	 new	 country,	
previous	experiences	of	healthcare,	language	and	cultural	barriers,	health	beliefs	and	attitudes,	as	well	
as	the	structure	of	the	healthcare	system	in	the	host	country	[O’Donnell	CA	et	al.	July	2015]	
Migrant	groups	across	Europe	and	the	UK	are	heterogeneous	 in	nature,	but	are	generally	younger	
than	the	native	population,	and	most	migrant	groups	are	healthy	and	active	contributors	to	society	
[Fitzpatrick	J	2005].	Nevertheless,	certain	chronic	disease	states	and	infectious	diseases	are	identified	
more	frequently	in	some	migrant	groups.	Disease	states	may	be	linked	to	exposure	in	the	country	of	
origin,	 cultural	 practices,	 as	well	 as	 environmental	 risk-factors	 in	 the	 host	 country	 on	 arrival	 (e.g.	
smoking,	diet,	alcohol	or	drug-use).	In	the	UK,	chronic	disease	states	such	as	cardiovascular	disease	
and	diabetes	are	more	common	in	members	of	the	Pakistani	and	Bangladeshi	communities,	which	are	
likely	related	to	environmental	exposures	(e.g.	diet,	smoking)	as	well	as	pre-existing	risks.	There	are	
also	 differences	 in	 health	 perception,	 and	 service	 utilisation	 in	 some	migrant	 groups.	 And	whilst,	
socioeconomic	status	may	account	for	some	of	these	differences,	it	is	likely	an	oversimplification	to	
account	this	factor	alone	in	relation	to	these	associations	[Ingleby	D	2012,	Health	Survey	for	England	
2004].		
Among	 the	 infectious	 diseases	 that	 may	 be	 seen	 in	 higher	 proportion	 in	 UK	 migrant	 groups,	
Tuberculosis,	Malaria	and	Blood	Borne	Viruses,	 including	HIV,	HBV	and	HCV	are	perhaps	 the	most	
commonly	cited.	Estimates	for	these	disease	risks	are	frequently	extrapolated	from	sentinel	laboratory	
data	by	PHE	(Public	Health	England)	or	research	studies,	and	there	are	risks	therefore	in	generalising	
or	stereotyping	intrinsically	heterogeneous	groups.	However,	it	remains	important	that	these	risks	are	
acted	upon	to	improve	our	risk	stratification,	and	crucially	to	identify	and	treat	those	individuals	who	
would	otherwise	go	undetected	[Ingleby	D	2012].	
Many	 disease	 states	 produce	 symptoms	 that	may	 facilitate	 diagnosis	 in	 an	 early	 stage,	 but	 some	
diseases	 such	 as	 chronic	 Hepatitis	 B	 and	 C	 (HBV	 and	 HCV)	 infection	 produce	 little	 in	 the	 way	 of	
symptoms	until	advanced	and	potentially	fatal	complications	have	set	in.	Migrant	groups	in	the	UK	
have	higher	 rates	of	HBV	and	HCV	based	on	 sentinel	 surveillance	and	 research	 studies.	Delivering	
testing	in	migrant	communities	therefore	becomes	of	paramount	importance	to	bring	people	forward	
for	treatment,	as	well	as	preventing	the	spread	of	infection	further	in	the	wider	community.		
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HBV	and	HCV	in	migrant	communities:		potential	impact	and	the	need	for	study	
Hepatitis	B	and	C	(HBV	and	HCV)	are	blood	borne	viruses	(BBV),	which	target	the	liver	with	the	risks	of	
progressive	scarring	(cirrhosis),	liver	failure	and	primary	liver	cancer.	The	prevalence	of	HBV	and	HCV	
is	 low	 in	 the	background	UK	population,	 but	 is	 disproportionately	 higher	 in	 certain	 at-risk	 groups,	
linked	to	geographic	variation,	iatrogenic	exposure	and	risk	activity.	The	health	impacts	of	HBV	and	
HCV	 can	 be	 severe,	 with	 significantly	 increased	morbidity	 and	mortality	 in	 those	 individuals	 who	
progress	to	end	stage	liver	disease	without	effective	treatment.	Indeed,	HBV	and	HCV	are	the	leading	
cause	of	 cirrhosis	 and	 liver	 cancer	worldwide	with	 close	 to	 390,000,000	 individuals	 thought	 to	 be	
affected,	and	1.46	million	deaths	registered	worldwide	in	relation	to	CVH	in	2013,	with	comparable	
mortality	rates	to	that	seen	with	TB	and	higher	than	that	seen	with	HIV;	but	with	a	lower	global	priority	
and	public	recognition	[WHO	May	2016].		In	the	UK,	liver	disease	was	the	5th	leading	cause	of	death,	
with	chronic	viral	hepatitis	one	of	the	leading	drivers	for	this,	behind	alcohol	[Davies	SC	2012],	and	
remains	a	global	priority	for	control	and	eradication	by	2030	[WHO	May	2016].		
Although	both	HBV	and	HCV	are	blood	borne	 viruses,	 and	 carry	 the	 same	generic	 risks	of	 disease	
transmission,	there	are	differences	in	the	likely	routes	and	patterns	of	this	transmission,	as	well	as	the	
risks	of	chronicity	in	affected	individuals.		
HBV	is	around	a	hundred	times	more	infective	than	the	HIV	virus,	but	with	vertical	transmission	rates	
from	mother	to	child	that	may	be	as	high	as	90%,	coupled	with	perinatal	or	childhood	acquisition	that	
are	the	main	drivers	of	the	endemicity	of	HBV	seen	globally	(figure	7).		HBV	may	be	also	transmitted	
sexually,	as	well	as	potential	risks	with	the	sharing	of	razors	or	toothbrushes	in	some	circumstances	
[Foundation	for	Liver	Research	2004].	Not	all	affected	individuals	become	chronic	carriers,	with	age	a	
particularly	 important	 risk-factor	 for	HBV,	with	neonatal	and	perinatal	exposure	 leading	 to	chronic	
infection	in	over	80-90%	of	cases,	and	adult	exposure	that	may	lead	to	chronicity	in	only	around	5%	
of	cases	[Hyams	1995].	
HCV	is	transmitted	principally	by	exposure	to	contaminated	blood	or	body	fluids,	with	injecting	drug	
use	thought	to	account	for	up	to	90%	of	cases	in	the	UK	[PHE	2013].	Vertical	transmission	is	less	well	
defined,	but	likely	to	be	an	important	factor	on	a	global	scale,	with	perinatal	transmission	risks	that	
may	be	towards	6%	[Benova	L	2014],	and	with	household	transmission	that	is	not	widely	recognised.	
The	risks	of	chronicity	again	vary	with	age,	but	are	less	marked;	with	around	75-80%	of	all	exposed	
individuals	developing	chronic	HCV	infection,	and	with	chronicity	that	may	be	less	likely	in	younger	
individuals	as	compared	to	older	individuals.	
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Epidemiology	of	HBV	and	HCV:	
There	 is	 marked	 geographic	 variation	 in	 Hepatitis	 B	 (HBV)	 and	 Hepatitis	 C	 (HCV)	 worldwide,	
particularly	for	HBV,	which	is	endemic	to	certain	parts	of	the	world.	Prevalence	data	is	lacking	in	many	
countries,	particularly	in	those	with	deprived	health	infrastructure	systems,	but	overall	across	Europe	
reported	rates	of	HBV	and	HCV	infection	are	between	2-6	times	higher	in	migrant	groups	than	that	
seen	in	the	existing	population	[Hahne	2013].		
HBV	prevalence:		
Globally	around	350-400	milliion	individuals	are	through	to	be	affected	by	HBV	[Sharma	S	2015],	and	
HBV	is	endemic	in	some	parts	of	the	world	(figure	4);	with	endemicity	defined	by	a	prevalence	rate	>	
8%,	moderate	endemic	countries	having	prevalence	rates	of	2-7%,	and	low	prevalence	countries	with	
rates	<2%.			
	
Figure	7:	Estimated	global	prevalence	of	HBV	infection	in	adults	19-49	yrs;	up	to	2005	[adapted	from	Ott	J,	
2005]	
	
As	shown	in	fig	7,	Western	Europe	including	the	UK	has	low	HBV	prevalence	rates	(<2%),	whilst	parts	
of	South-east	Asia	and	Sub-Saharan	Africa	have	high	rates	of	HBV,	between	10-20%.	It	is	estimated	
that	up	to	80%	of	people	 in	 regions	of	sub-Saharan	Africa	and	Asia	have	been	exposed	to	HBV,	as	
compared	to	<15%	of	people	in	regions	of	Europe	and	the	USA	[Thomas	2012].	Vertical	transmission	
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is	thought	to	be	the	predominant	route	of	transmission	in	China,	whereas	horizontal	transmission	in	
the	first	few	years	of	life	is	thought	to	be	the	main	route	of	transmission	in	Africa	[Dooley	2012].		
In	developed	countries	 such	as	 the	UK	adult	acquisition	of	HBV	 tends	 to	be	 the	 result	of	high-risk	
activity	 (mostly	 sexual	 activity),	 with	 the	 burden	 of	 new	 chronic	 HBV	 disease	 being	 the	 result	 of	
migration	of	persons	from	endemic,	or	higher	risk	regions.	Prevalence	risks	have	been	estimated	to	
be	higher	across	many	different	migrant	groups,	with	Hepatitis	B	surface	antigen	positivity	reported	
as	close	to	13%	in	East	Asian	migrants	in	the	US	[Sharma	S	2015].	
Hepatitis	B	rates	in	the	UK:	
For	both	HBV	and	HCV,	there	is	uncertainty	about	the	exact	number	of	cases	that	have	been	diagnosed	
or	 treated	 in	 the	 UK	 [Ramsay	M	 1998].	 Apart	 from	 antenatal	 HBV	 screening	 there	 is	 no	 national	
screening	policy	for	viral	hepatitis	(B	or	C).	Incidence	and	prevalence	rates	(for	both	HBV	and	HCV)	are	
therefore	 derived	 from	 several	 sources	 including	 research	 studies,	 antenatal	 screening,	 and	 the	
sentinel	 surveillance	 blood-borne	 virus	 testing	 programme	 (SBV),	 which	 collects	 demographic	
information	on	viral	hepatitis	and	testing	results	across	certain	designated	laboratory	sites	in	England.			
The	most	widely	used	estimates	of	chronic	HBV	infection	in	the	UK	arises	from	Department	of	Health	
(DoH)	data	in	2002,	with	prevalence	rates	of	0.3%	and	an	estimated	180,000	affected	[Department	of	
Health	2002;	Getting	Ahead	of	the	Curve],	but	there	is	variation	in	this	estimate	with	some	experts	
placing	this	figure	close	to	500,000	[NICE	press-release	1].		
Importantly,	up	to	95%	of	new	chronic	HBV	cases	in	the	UK	occur	in	migrant	individuals,	with	most	
individuals	who	would	have	acquired	Hepatitis	B	in	early	childhood	in	the	country	of	birth	[NICE	2012].	
Rates	of	HBV	are	also	consistently	higher	in	those	individuals	recorded	to	be	of	Asian	British	(AB),	Black	
British	 (BB)	 or	Other	Mixed	 (OM)	 groups	 from	previous	 sentinel	 laboratory	 data;	with	 8.9%	of	 BB	
individuals	testing	positive	compared	to	6.9%	of	OM	individuals,	2.8%	of	AB	individuals	and	0.9%	of	
WB	(White	British)	individuals	in	non-antenatal	testing	samples.	Further	information	from	blood	donor	
testing	shows	that	of	91	positively	identified	HBV	cases,	60%	of	patients	were	born	in	Africa	or	Asia	
[HPA	Migrant	Health	2011].	
Chronic	HBV	predominates	in	the	positive	cases	identified,	and	given	the	asymptomatic	nature	of	HBV,	
there	is	likely	to	be	a	large	poor	of	undiagnosed	HBV	infections	that	would	not	be	reached	without	a	
targeted	testing	approach	[HPA	Targeting	Testing,	2011].		
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HCV	prevalence:		
Approximately	2-3%	of	the	world	population	(160	million)	are	thought	to	be	infected	with	chronic	HCV	
[Lavanchy	2011],	and	whilst	prevalence	data	is	lacking	or	underrepresented	in	many	countries,	there	
is	marked	geographic	variation	in	prevalence	rates	worldwide	(figure	8).		
Most	European	countries	report	chronic	HCV	prevalence	rates	between	0.5	-	2%,	although	Italy	has	
rates	as	high	as	3.9%.	Egypt	has	the	highest	reported	chronic	HCV	rates	with	rates	quoted	between	
20-30%	[Hyams	1995,	WHO	2002],	which	is	thought	to	be	secondary	to	an	iatrogenic	schistosomiasis	
programme.	 One	 of	 the	 largest	 HCV	 populations	 is	 thought	 to	 be	 in	 East	 Asia	 and	 the	 Indian	
subcontinent,	 with	 an	 estimated	 100	 million	 HCV	 positive	 individuals	 in	 this	 region,	 and	 with	
prevalence	rates	of	4.9%	reported	in	Pakistan	[Sharma	S	2015].	Parenteral	spread	through	iatrogenic	
procedures,	such	as	blood	transfusions,	surgery	and	unclear	needle	use,	as	well	as	injecting	drug	use	
are	thought	to	have	contributed	to	the	rapid	spread	of	HCV	in	the	20th	century;	but	with	the	underlying	
recognition	that	there	is	a	natural	geographic	variation	in	HCV	that	pre-date	these	factors	[EASL	2013].	
	
	
	
Figure	8:	Global	distribution	of	chronic	HCV	(%)	–	taken	from	Lavanchy	2011	
	
HCV	rates	in	the	UK:	
Within	 the	 UK	 around	 215,000	 individuals	 are	 chronically	 infected	 with	 HCV,	 with	 160,000	 (0.4%	
prevalence)	 cases	 in	 England	 and	 38,000	 (0.7%	 prevalence)	 in	 Scotland.	 HCV	 exists	 in	 distinct	
genotypes,	with	 genotypes	 that	 are	more	 common	 in	 some	parts	 of	 the	world.	Genotype	 I	 and	 3	
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predominate	within	England,	with	Genotype	3	and	4	patients	often	seen	more	commonly	 in	some	
migrant	groups,	including	the	South	Asian	population	and	migrants	from	Egypt.			
Injecting	drug	use	 is	 the	biggest	risk	 factor	 for	chronic	HCV	 in	the	UK,	but	HCV	 is	disproportionally	
higher	in	migrant	groups,	particularly	in	those	from	South	Asian	origin	(Indian,	Pakistani	or	Bangladeshi	
origin)	and	Eastern	Europe	compared	to	 the	non-injecting	White	British	population.	Data	 from	the	
sentinel	 surveillance	 programme	 shows	 a	 HCV	 prevalence	 rate	 of	 2.7%	 in	 Asian/Asian-British	
individuals,	and	although	there	 is	no	categorisation	 for	 those	of	Eastern	European	origin,	post-hoc	
name	recognition	software	has	shown	prevalence	rates	as	high	as	5.4%	in	this	groups	of	patients	[PHE	
2013].			
Importantly,	it	is	estimated	that	between	50-75%	of	patients	with	HCV	are	unaware	of	their	infective	
status.	The	majority	of	 chronic	HCV	 therefore	exists	undetected	 in	 the	community,	with	projected	
morbidity	and	mortality	that	is	expected	to	rise	in	this	undiagnosed	population	[PHE	2013,	Williams	
2014].		
Natural	history	of	CVH	infection:	
Chronic	 HBV	 and	 HCV	 infection	 may	 cause	 atypical	 symptoms	 or	 remain	 asymptomatic	 until	
complications	develop,	with	cirrhosis	and	hepatocellular	carcinoma	the	most	feared,	as	well	as	other	
systemic	 complications	 (such	 as	 cryoglobulinaemias)	 that	 may	 also	 be	 seen	 with	 CVH.	 These	
complications	may	develop	over	decades,	with	treatment	decisions	are	directed	 in	the	UK	through	
specialist	hospital	services.		
Around	15-40%	of	chronic	HBV	patients	are	thought	to	be	at-risk	of	progression	to	cirrhosis	or	hepatic	
decompensation	[Dooley	2012],	and	HBV	may	have	its	own	independent	risks	in	the	development	of	
HCC	 (hepatocellular	 carcinoma);	 albeit	 at	 a	 significantly	 lower	 rate	 than	 that	 seen	 in	 cirrhotic	
individuals	[Do	AL	2014].		
For	HCV	the	risks	of	developing	cirrhosis	in	chronic	infection	is	reported	to	be	close	to	20%	at	20	years,	
rising	 to	 36-45%	 at	 30	 years	 [Thein	 2008],	 with	 chronic	 HCV	 infection	 now	 one	 of	 the	 leading	
indications	 for	 Europe	 and	North	 America	 [WHO	March	 2015,	World	Gastroenterology	Guidelines	
2013].		
Whilst	not	all	patients	with	HBV	may	require	 treatment	 initially,	highly	effective	and	cost-effective	
treatments	exist	overall	for	CVH,	with	a	treatment	revolution	in	HCV	that	has	now	been	translated	
into	 most	 developed	 health	 systems	 worldwide.	 These	 developments,	 in	 conjunction	 with	 HBV	
vaccination	goals	have	led	to	global	and	national	initiatives	calling	for	CVH	to	be	eradicated	as	a	public	
health	threat	by	2030	(with	a	90%	reduction	in	new	chronic	infections,	and	65%	reduction	in	mortality)	
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[WHO	May	2016,	Williams	R	2014].	Treatment	is	highly	efficacious	if	delivered	at	the	right	time,	to	
reduce	or	prevent	the	development	of	cirrhosis	or	primary	liver	cancer	with	significant	individual,	and	
health	system	savings.		
Current	case-finding	practice	for	CVH:	
For	HBV	and	HCV,	case-finding	 is	 internationally	 recommended	 in	at-risk	 individuals	 (figure	9)	 [Del	
Poggio,	2006],	and	forms	the	basis	for	NICE	testing	recommendations	published	in	2012	[NICE	2012].	
The	aims	of	such	a	testing	programme	are	to	identify	at-risk	groups,	as	well	as	to	bring	patients	forward	
for	therapy	if	disease	is	detected	[NHS	England	2015;	Ruf	M	2008].		
	
Figure	9	–	The	dynamic	and	active	processes	involved	in	effective	case-finding	activity		
In	the	UK,	policy	exists	to	recommend	CVH	testing	in	migrant	groups	through	the	national	institute	for	
health	 and	 care	 excellence	 (NICE),	 with	 community	 testing	 the	 aim	 of	 these	 public	 health	
recommendations;	and	primary	care	the	principal	agent	to	deliver	testing	to	migrant	groups	 in	the	
community	 (as	 explored	 in	 the	 following	 chapter).	 Our	 knowledge	 regarding	 the	 awareness	 and	
uptake	of	this	policy	is	limited,	particularly	in	primary	care,	and	is	one	of	the	key	aspects	to	be	explored	
in	 this	 thesis.	 However,	 the	 historic	 understanding	 and	 uptake	 of	 (prior)	 national	 CVH	 policy	
endeavours	has	been	low	in	primary	care	[D’Souza	RFC	2004,	RCGP	2007],	with	studies	that	continue	
to	show	a	low	priority	afforded	to	CVH	in	primary	care,	and	low	levels	of	testing	that	is	thought	to	
continue	 in	at-risk	groups	 in	primary	 care,	 including	migrant	 communities	 [Jewett	A	2015,	Datta	S	
2014,	Evlampidou	I	2016].	
HBV	&	HCV	risks	in	new	migrant	groups	
Within	 migrant	 populations,	 new	 migrant	 groups	 may	 be	 particularly	 vulnerable	 with	 regard	 to	
healthcare.	Accessible	healthcare	services	for	these	groups	are	typically	 limited,	with	most	existing	
services	designed	around	established	minority	groups	[The	Migration	Observatory	2014].	Diminished	
migrant-networks	 in	the	new	community,	as	well	as	 language	and	cultural	barriers	may	impact	the	
Identification:	 Identifying	the	at-risk	group	/	individual	within	the	background	population,	
- based	on	the	“visibility”	of	this	group,	including	social	exclusion	factors
Engagement:	 Develop	methods	of	engagement	for	awareness-raising	and	testing	
Culturally-appropriate	interactions
Based	on	perceptions	of	health	(stigma)	and	healthcare	services
Testing: Develop	effective	methods	to	deliver	testing,	which	may	relate	to:
Accessibility	and	Awareness
Tolerability	and	efficacy	(sensitivity,	specificity)
Available	treatment	pathway	(if	positive)
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awareness	of	health	services,	and	there	may	be	perceptual	differences	in	how	health	and	disease	is	
viewed	in	these	new	communities,	as	well	as	the	need	and	importance	of	healthcare	engagement.	
New	 migrant	 groups	 may	 also	 face	 socio-economic	 difficulties	 through	 housing,	 education	 and	
employment	 that	 increase	 their	 social	 exclusion	 and	 further	 erode	 self-empowerment,	 as	 well	 as	
perhaps	introducing	new	risks	through	overcrowding	and	environmental	risks,	particularly	in	the	most	
marginalised	 groups	 [WHO	 2010].	 The	 existing	 health	monitoring	 systems	 are	 also	 limited	 in	 new	
migrant	groups,	with	the	routine	use	of	ethnicity	data	that	may	mis-code	new	communities,	or	fail	to	
identify	them	at	all.		
For	 HBV	 and	 HCV,	 first	 generation	 migrants	 and	 those	 in	 new-migrant	 communities	 may	 be	 at	
particularly	risk,	with	higher	rates	of	cirrhosis	and	primary	liver	cancer	that	have	been	noted	in	this	
group	[HPA	South	East	2011,	Haworth	1999].	Developing	testing	strategies	to	identify	and	engage	with	
new-migrant	groups	is	therefore	a	priority	within	migrant	testing,	and	an	area	that	often	receives	little	
attention.		
Understanding	the	health	needs	in	new	migrant	communities,	and	developing	engagement	strategies	
to	assess	 these	 risks	 is	 therefore	 important,	with	a	 global	burden	of	CVH	and	highly	effective	and	
deliverable	treatments	that	necessitate	an	exploration	of	CVH	risks	in	new	migrant	communities	such	
as	the	UK	Nepali	community.		
The	UK	Nepali	population;	a	new	and	unique	migrant	community:	
The	UK	Nepali	community	represent	such	a	new	migrant	group,	with	a	population	that	has	grown	by	
over	969%	from	2001	to	2011,	following	settlement	rights	granted	to	ex-Gurkha	servicemen	and	their	
dependents	in	2004	and	then	2009	[ONS	2011	census	data,	CNSUK	2013].	Given	close	military	ties,	
this	 community	has	 clustered	around	 traditional	 army	 sites,	with	 the	 result	 that	 the	areas	 around	
Aldershot,	including	Frimley	Park	Hospital	(where	I	undertake	my	clinical	duties)	have	now	acquired	
the	2nd	largest	Nepali	population	in	the	UK	(outside	of	London).	The	migration	of	these	ex-servicemen	
and	their	dependents	has	produced	a	rapid	change	in	the	baseline	community,	with	Nepali	migrants	
said	to	make	up	between	6-10%	of	the	local	population	in	some	council-administered	areas	[Telegraph	
2011].	
Political	context	in	Nepal:	
Nepal	is	classified	as	one	of	the	Least	Developed	Countries	by	the	UN	[UNDP	2016],	and	is	one	of	the	
poorest	countries	in	Asia	with	an	estimated	40%	who	live	in	poverty	[World	Bank	2015],	and	with	an	
average	life	expectancy	of	68	years	[WHO	Global	Atlas	2014].	The	Human	Development	Index	(HDI)	is	
a	global	index	that	attempts	to	measure	the	development	of	a	country	based	on	the	potentials	and	
capabilities	of	its	population	(over	economic	growth	alone),	and	utilises	an	average	assessment	of	life	
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expectancy	at	birth,	years	of	schooling,	and	gross	national	 income	per	capita	[UNDP	2014].	On	this	
measure,	Nepal	performs	just	above	Afghanistan	in	comparison	to	other	South	Asian	countries,	with	
the	additional	difficulties	of	significant	variations	in	HDI	measures	that	are	seen	geographically	within	
Nepal,	 seemingly	 based	 on	 divides	 in	 ethnicity,	 caste	 and	 religion	 [UNDP	 HDI	 2016].	Most	 of	 the	
population	depend	on	agriculture,	which	employs	an	around	80%	of	the	population,	with	tourism	also	
important;	with	Nepal	 offering	eight	of	 the	 ten	 tallest	 peaks	 in	 the	world	 amongst	other	UNESCO	
heritage	sites.	Foreign	aid	though	remains	vital,	particularly	following	the	catastrophic	earthquakes	of	
2015	[BBC	Nepal	2015,	Time	April	2015].		
Nepal	 has	 strong	 and	 unique	 links	 to	 the	 UK,	 with	 Gurkha	military	 recruitment	 to	 the	 UK	 Armed	
services	that	extends	back	to	the	early	19th	century.		Nepal	was	not	however	a	formal	colony	of	the	
UK,	and	migration	patterns	from	Nepal	differ	to	the	other	South	Asian	countries	(India,	Bangladesh	
and	 Pakistan)	 in	 the	 UK,	 with	 restrictions	 that	 applied	 to	 many	 Nepali’s	 during	 the	 reign	 of	 the	
monarchy	 before	 1990	 [Washington	 Post	 March	 2014].	 Nepal	 has	 therefore	 remained	 relatively	
isolated	compared	to	its	South	Asian	neighbours,	with	According	to	the	2001	census	there	were	close	
to	6,000	Nepali	 resident	 in	England	and	Wales,	a	 figure	that	has	grown	dramatically	since,	with	an	
estimated	80,000	Nepali	resident	 in	the	UK	in	2012	[CNSUK	2013].	This	growth	has	been	driven	by	
Gurkha	 settlement	 rights	 introduced	 first	 in	 2004,	 and	 expanded	 in	 2009	 to	 allow	 retired	Gurkha	
soldiers	and	their	dependents	(<18	yrs)	the	right	to	settle	in	the	UK	[BBC	May	2009].		
Politically	Nepal	has	experienced	much	volatility	with	significant	gaps	in	effective	national,	regional	
and	local	governance	infrastructure	that	was	readily	exposed	in	the	devastating	earthquakes	of	2015	
[Washington	 Post	 April	 2015].	 Years	 of	 Maoist	 insurgency	 ended	 in	 2006,	 with	 abolition	 of	 the	
monarchy	 in	2008,	but	with	a	national	 constitution	 that	has	yet	 to	be	agreed	over	 the	 seven	year	
interim	period,	highlighting	the	conflicts	and	inefficiencies	that	exist	in	the	current	system	[The	Hindu	
2015].	 Emigration	 from	 Nepal	 has	 therefore	 increased	 as	 a	 result	 of	 political	 indecisions,	 poor	
infrastructure	 and	 employment	 opportunities,	 with	 close	 to	 10%	 of	 the	 population	 now	 working	
abroad,	typically	in	low-skilled	jobs	[Washington	Post	2014].		
Gurkha	recruitment	on	the	other	hand	has	continued	largely	undaunted	since	the	early	19th	century,	
following	initial	recruitment	of	Gurkha	soldiers	by	the	East	India	Company.	Gurkha	recruitment	has	
traditionally	occurred	from	certain	castes,	and	the	UK	Nepali	community	is	drawn	almost	exclusively	
from	15	out	of	the	total	75	districts	in	Nepal	as	a	result	[CNSUK	PPT	2013].	Becoming	a	Gurkha	officer	
is	one	of	the	most	prized	positions	in	Nepali	society,	with	a	prestigious	salary	and	pension	that	can	
transform	families’	lives,	and	with	competition	rates	far	higher	than	entry	to	the	UK	Army	[Telegraph	
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March	2014].	Traditionally	Gurkha	soldiers	were	recruited	and	discharged	as	Nepali	citizens,	with	a	
British	base	that	was	in	Hong	Kong	before	moving	to	the	UK	in	1997.	
It	was	only	in	2004	that	the	(then)	Labour	government	provided	settlement	rights	to	Gurkha	soldiers;	
initially	restricting	this	to	those	soldiers	who	had	retired	after	1997.	However	servicemen	who	retired	
before	this	period	were	not	granted	UK	settlement	rights,	and	extensive	lobbying	from	the	Gurkha	
Justice	Campaign	and	most	notably	by	 the	celebrity	 Joanna	Lumley	pressured	 for	 this	policy	 to	be	
expanded.	The	campaign	achieved	widespread	publicity	and	support	from	liberal	and	right-minded	
media	sources	alike,	with	the	Labour	government	eventually	overturned	in	its	settlement	restrictions	
in	2009,	with	support	from	the	Liberal	Democrat	and	Conservative	parties	[Daily	Mail	2008,	Guardian	
2009].	 Financial	 support	 for	 the	 settlement	 of	 ex-Gurkha	 servicemen	 has	 however	 been	 widely	
criticised	by	 the	 responsible	councils,	who	have	managed	a	clustering	of	new	residents	during	 the	
austerity	period,	with	a	cut	of	£2.4million	reported	to	the	Rushmoor	council	budget	in	2011	[Telegraph	
2011].		
Social	aspects	of	migration	in	the	Nepali	community:		
There	are	over	a	100	caste	/	ethnic	categories	in	Nepal,	with	several	religious	affiliations	that	generally	
pursue	harmonious	interactions.	Hinduism	is	the	most	common	religious	affiliation,	with	Buddhism,	
Islam	and	Christianity	also	seen.	The	majority	of	people	live	in	rural	areas,	with	many	who		occupy	hilly	
or	mountainous	terrains	where	road	links	will	be	limited	or	non-existent	[Rural	Poverty	website].	
There	 UK	 Nepali	 community	 is	 drawn	 predominately	 from	 ex-military	 servicemen	 and	 their	
dependents.	Data	in	the	UK	community	is	limited,	but	studies	from	the	Centre	for	Nepali	Studies	UK	
(CNSUK)	 in	 the	 Aldershot	 area	 looking	 at	 the	 date	 of	military	 discharge	 demonstrated	 that	 those	
servicemen	 discharged	 in	 the	 late	 1960’s	 and	 early	 1970’s	 with	 an	 average	 of	 65-67	 years	 have	
significant	issues	in	literacy	and	economic	contribution	compared	to	their	younger	compatriots.	Older	
male	servicemen	in	 late	60’s	(67	years)	were	found	to	be	functionally	 illiterate	even	 in	Nepali,	and	
therefore	with	reading	and	writing	skills	in	Nepali	that	would	be	inappropriate	for	most	work	settings,	
and	Female	dependents	were	particularly	limited	from	a	literacy	perspective,	with	the	vast	majority	
(94%)	of	those	over	60	years’	illiterate	in	Nepali	[CNSUK	PPT	Laksamba	2013].		This	suggests	that	many	
in	the	recently	arrived	community	may	face	disadvantages	in	the	social	determinants	model,	and	may	
face	challenges	in	accessing	conventional	health	care	services	[CNSUK	PPT	Laksamba	2013].			
Social	exclusion	in	this	subset	of	the	community	is	therefore	a	particularly	strong	concern,	with	many	
new	Nepali-migrants	 thought	to	be	 in	this	older	category.	 Indeed	media	reports	over	the	past	 few	
years	have	focused	negatively	on	the	numbers	of	elderly	Nepali	migrants	seen	in	the	Aldershot	area	
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in	particular,	with	socioeconomic	concerns	raised	about	welfare	support	and	sub-optimal	housing	in	
many	older	individuals,	who	have	pensions	designed	and	issued	by	the	UK	government	to	provide	a	
high	standard	of	living	in	Nepal,	and	pensions	in	these	older	Gurkha	veterans	are	not	matched	to	UK	
servicemen	 [Daily	Mail	 November	 2014].	 It	 may	 also	 be	 that	 women,	 particularly	 Nepali	 migrant	
widows	may	be	less	able	to	access	and	engage	with	services	due	to	language	restrictions	that	seem	
substantially	higher	than	that	seen	 in	the	age-matched	male	population.	Some	elderly	Nepali	have	
commented	 that	 they	were	enticed	 to	move	 to	 the	UK	 for	a	better	 life	with	promises	of	 jobs	and	
employment,	but	have	found	their	reality	very	different.	Media	reports	have	also	commented	upon	
the	hostility	 faced	by	members	of	 the	Nepali	 community,	with	perhaps	 the	most	 vocal	 comments	
towards	 elderly	 Nepali	 migrants	 made	 by	 the	 Aldershot	 Conservative	 MP,	 Sir	 Gerald	 Howarth	
[Huffington	Post	March	2012],	including	the	comment	that:	
"I	was	walking	around	in	Aldershot	on	Saturday	and	everywhere	I	went	there	were	Nepalese	just	
basically	sitting	out	in	the	open,	sitting	out	on	the	park	benches…..	
"You	may	find	this	bizarre,	but	some	of	my	constituents	say	'if	I	go	into	town,	I	haven't	got	a	park	
bench	to	sit	on	because	they	are	all	taken	by	the	Nepalese'."	
	These	comments	seem	directed	mostly	at	the	elderly	Nepali	community,	who	conversely	would	seem	
the	 most	 at-risk	 for	 social	 exclusion,	 and	 given	 their	 age	 the	 group	 most	 at	 risk	 for	 health	
complications,	including	from	hepatitis	B	and	C.		
Concerns	 about	 social	 exclusion	 in	 this	 group	 are	 supported	 in	 the	 Health	 Needs	 Assessment	
undertaken	by	Hampshire	council	in	2010,	involving	stakeholders	from	the	local	Nepali	community,	as	
well	as	healthcare	practitioners	and	members	of	the	education	and	Police	force	among	others.	Wider	
social	determinants	identified	from	these	focus	groups	identified	concerns	about	racism	and	bullying	
from	 members	 of	 the	 local	 community,	 concerns	 about	 overcrowding,	 including	 a	 lack	 of	
understanding	amongst	Nepali	migrants	how	to	access	existing	services	in	the	UK,	as	discussed	further	
below	[NHS	Hampshire	2010]		
Health	aspects	of	migration	in	the	Nepali	community:		
There	is	no	robust	data	on	disease	prevalence	and	health	needs	in	the	UK	Nepali	community,	with	our	
understanding	of	the	health	awareness,	knowledge	and	perception	in	the	community	equally	limited.		
Following	the	initial	settlement	of	Nepalese	ex-servicemen	in	the	Rushmoor	district,	a	Health	Needs	
Assessment	 was	 conducted	 by	 NHS	 Hampshire	 in	 2010,	 with	 input	 from	 GPs,	 local	 clinicians,	
pharmacists	and	allied	health	professionals.	Suggested	risks	and	health	needs	were	made	based	on	
the	 initial	 experiences	of	 these	health	professionals,	 and	public	health	 information,	with	diabetes,	
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cardiovascular	 disease,	 and	 certain	 gynaecological	 cancers	 raised	 by	 these	 stakeholders.	 Among	
infectious	diseases,	Tuberculosis	was	 identified	as	a	possible	 risk	 from	preliminary	data,	as	well	as	
Hepatitis	B	and	C,	albeit	with	low	numbers	of	individuals	tested	at	the	time	of	consultation.	Substance	
abuse	 in	 young	males	was	 also	mentioned	 by	members	 of	 the	 community,	with	 these	 individuals	
smoking	heroin	[Casey	M	2010].		
The	Health	Needs	Assessment	also	included	focus	groups	in	the	Nepali	community,	with	a	combined	
presentation	of	the	key	health	priority	areas	raised	by	stakeholders	and	by	members	of	the	Nepali	
community	during	focus	group	discussions.	Whilst	CVH	appears	as	a	potential	(under-tested)	risk	in	
stakeholder	discussions,	it	is	interesting	to	note	that	HBV	appears	as	a	specific	risk	raised	during	focus	
group	discussions	in	the	Nepali	community,	but	with	no	transcripts	or	further	analysis	provided	by	the	
authors	to	understand	this	expression	and	the	reasons	behind	it	(figure	10)	[Casey	M	2010].	
	
	
	
	
	
	
	
	
Figure	10:	Perceived	common	or	important	health	issues	to	address	in	the	Nepali	community	according	to	the	different	
stakeholders.	Members	of	the	Nepali	community	thought	HBV	was	one	of	the	most	pressing	issues	to	address;	taken	
from	NHS	Hampshire	Health	Needs	Assessment	2010	
Health	Systems	in	Nepal	
Healthcare	services	in	Nepal	are	generally	considered	to	be	poor.	Services	are	provided	by	public	and	
private	 institutions,	 but	 with	 private	 out	 of	 pocket	 expenses	 making	 close	 to	 80%	 of	 all	 heath	
expenditure,	and	with	limited	facilities	and	treatments	offered	in	public	settings.	Access	to	healthcare	
is	also	poor,	with	around	0.67	doctors	and	nurses	per	1,000	population,	and	access	to	health	services	
within	30	minutes	that	is	available	to	less	than	60%	of	those	living	in	rural	settings	in	Nepal	[Mishra	SR	
2015].	Nutrition	and	sanitation	services	are	also	limited	in	places,	thereby	further	affecting	the	poorest	
and	most	marginalised	rural	communities	[Karkee	R	2013,	Water	Aid	Nepal].		
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Infectious	diseases	account	for	a	greater	burden,	with	up	to	2/3rds	of	all	health	problems	related	to	
infectious	disease	reported	in	2001	[Rai	S	2001].	Average	life	expectancy	in	Nepal	is	68	years,	which	
has	increased	by	6	years	in	the	period	from	2001	to	2012,	but	“healthy-life	expectancy”,	with	that	free	
from	morbidity	is	however	9	years	lower	at	59	years	[WHO	2012].		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Table	1:	WHO	top	ten	causes	of	mortality	in	Nepal	in	2002	and	2012;	the	burden	of	chronic	(non-infectious)	diseases	
seem	to	have	risen	over	this	period	[WHO	2012,	NHS	Hampshire	2010]	
HBV	and	HCV	in	the	Nepali	population	–	the	need	for	study	
Nepal	lies	between	China	and	India,	two	countries	with	a	higher	prevalence	of	viral	hepatitis.	Rates	of	
viral	hepatitis	may	therefore	be	higher	in	the	Nepali	population.	According	to	the	WHO	Global	Policy	
Report,	 there	 are	 no	 official	 reports	 on	 Hepatitis	 B	 and	 C	 rates	 from	 Nepal,	 and	 with	 no	 regular	
surveillance	 programmes	 that	 are	 in	 place	 in	 keeping	with	 the	 known	 deficits	 that	 exist	 in	 health	
infrastructure	within	Nepal.	There	is	no	central	policy	to	guide	testing	practice,	and	patients	must	pay	
for	 HBV	 and	 HCV	 testing	 as	 well	 as	 any	 necessary	 treatments,	 which	 may	 therefore	 impact	
(unmonitored)	testing	practice	at	multiple	levels	[WHO	Global	Policy	Report	2013].		
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Figure	11:	Map	of	Nepal		
	
Available	information	on	HBV	and	HCV	prevalence	in	Nepal	is	limited	to	research	from	a	few	cohort	
studies,	as	well	as	blood	donor	analyses.	Rates	of	active	HBV	infection	have	been	reported	in	between	
0.9%	to	7.3%	of	individuals,	with	significant	variations	based	on	Nepali	ethnicity,	and	with	high	rates	
of	 previous	 HBV	 exposure;	 seen	 in	 up	 to	 35-44%	 of	 subjects	 [Shrestha	 S	 2012].	 For	 HCV,	 existing	
evidence	is	more	limited	with	studies	from	blood	donors	that	have	identified	rates	that	vary	from	0.3%	
to	0.7%	[Tiwari	BR	2010,	Karki	S	2008].		
The	UK	Nepali	population	is	however	unique,	originating	almost	exclusively	from	set-districts	in	Nepal,	
and	of	certain	ethnic	groups;	based	on	traditional	Gurkha	recruitment	practices	[CNSUK	2013].	There	
have	been	no	studies	of	HBV	and	HCV	in	the	UK	community,	and	no	studies	with	regard	to	health	and	
healthcare	perception	in	this	new	migrant	community.		
There	are	significant	variations	in	CVH	rates	documented	within	and	between	migrant	groups	in	some	
studies	in	the	South	Asian	community	[Uddin	G	2010],	and	given	the	uncertainties	and	lack	of	study	
that	exists	in	CVH	risks	in	the	newly	arrived	Nepali	community	it	becomes	important	that	these	risks	
are	understood	through	direct	study.		
The	 following	 study	 therefore	 attempts	 to	 understand	 the	 CVH	 risks	 that	 exist	 in	 the	 Nepali	
community,	as	well	as	the	broader	gaps	that	exist	across	the	health	system	in	how	CVH	testing	can	be	
optimised	and	delivered	to	all	migrant	groups,	who	share	current	political	and	social	pressures	that	
may	adversely	influence	health	access	and	engagement.		
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Chapter	Summary:		
Migrant	 communities	 face	health	vulnerabilities,	 including	 the	global	 risks	of	CVH	 that	 require	 the	
delivery	of	effective	testing	strategies	 to	understand	and	manage	these	risks,	which	will	otherwise	
remain	undetected	until	potentially	fatal	complications	develop.	The	existing	health	infrastructure	in	
Nepal	is	poor,	with	little	knowledge	of	the	CVH	health	risks	in	the	newly	arrived	population,	coupled	
with	increased	CVH	risks	that	are	seen	in	the	neighbouring	South	Asian	countries,	and	these	migrant	
population	groups	in	the	UK.		
At	the	same	time,	migrant	communities	across	Europe	are	facing	increasing	anti-migrant	sentiment,	
expressed	at	the	political	and	social	level,	with	migration	a	prominent	feature	in	recent	UK	elections,	
as	well	as	the	lead	up	to	the	EU	referendum.		
The	UK	Nepali	community	 is	unique	in	 its	characteristics	and	context,	and	despite	high-level	public	
support	 UK	 settlement	 rights,	 is	 facing	 anti-migrant	 sentiments	 in	 the	 local	 political	 and	 social	
spectrum.		
The	effect	of	these	determinants	on	migrant	health	with	regard	to	health	access	and	engagement	is	
likely	to	be	negative,	with	particular	deficits	that	may	be	faced	in	new	migrant	communities	such	as	
the	newly	arrived	UK	Nepali	population.		
CVH	risks	can	only	be	assessed	and	managed	through	effective	testing	strategies	and	linkage	to	health	
services,	 but	with	 current	 testing	 practice	 and	 policy	 implementation	 that	 is	 broadly	 perceived	 to	
receive	 low	 priority,	 particularly	 in	 primary	 care	 services.	 It	 is	 imperative	 therefore	 to	 gain	 an	
understanding	of	 the	current	gaps	 that	exist	across	 the	health	 system	 in	delivering	CVH	 testing	 to	
migrant	communities,	and	 in	developing	a	dedicated	 testing	 intervention	 to	assess	 the	risks	 in	 the	
Nepali	community,	who	may	otherwise	not	access	or	engage	with	current	adhoc	testing-practices.					
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Chapter	2	–	Research	Methodology:	Aims	&	objectives	and	research	design	
Chapter	introduction:		
The	following	chapter	presents	an	outline	of	the	methodology	used	in	the	research	study	and	research	
objective.	An	outline	of	the	key	research	methods	used	to	achieve	these	objectives	is	presented,	with	a	
more	detailed	description	presented	alongside	each	intervention	study	in	the	following	chapters.		
Research	aims	and	objectives:		
The	principal	 aim	of	 this	 study	 to	 identify	 the	hepatitis	B	 and	C	 risks	 that	 exist	 in	 the	 local	Nepali	
community;	with	an	exploration	of	the	potential	facilitators	and	barriers	that	exist	across	the	health	
system	towards	CVH	testing	in	the	Nepali	community,	as	well	as	other	migrant	populations.		
The	 chosen	 research	 objectives	 and	 methods	 used	 for	 assessment	 are	 built	 on	 the	 hypotheses	
(evidenced	 in	 chapter	 1)	 that	 community	 CVH	 testing	 in	migrant	 groups	 is	 likely	 to	 be	 poor,	with	
particular	deficits	that	are	thought	to	continue	in	primary	care,	and	with	current	CVH	testing	policy	
that	is	thought	to	have	achieved	limited	recognition	and	priority	in	primary	care,	which	remains	the	
principal	community	agent	to	deliver	wide-scale	CVH	testing	to	heterogeneous	migrant	populations.		
The	UK	Nepali	community	 is	a	recent	migrant	community,	and	may	be	more	at	risk	with	regard	to	
health	determinants	that	affect	access	and	health	engagement,	as	well	as	the	risks	of	CVH:	but	with	
the	overarching	research	objectives	of	this	study	across	the	health	system	that	should	be	applicable	
to	diverse	migrant	groups.		
The	research	objectives	of	the	thesis	are	as	follows:		
1. To	 explore	 the	 determinants	 of	 health	 across	 political	 and	 social	 frameworks,	 and	 the	
implication	on	CVH	health	engagement.		
2. To	 explore	 the	 current	 role	 and	 effectiveness	 of	 CVH	 testing	 policy,	within	 the	 context	 of	
national	CVH	policy	initiatives	in	the	UK;	with	the	application	of	a	policy	analysis	framework.	
3. To	identify	the	awareness,	understanding	and	perception	of	liver	disease	and	CVH	in	the	newly	
arrived	Nepali	 population,	 and	 the	 potential	 barriers	 or	 facilitators	 that	may	 exist	 to	 CVH	
testing	endeavours,	and	health	engagement	for	testing.		
4. To	 explore	 the	 awareness,	 practice	 and	 perception	 of	 CVH	 testing	 for	 migrant	 groups	 in	
primary	care;	contrasting	these	ideals	with	that	seen	in	the	local	Nepali	community	
5. To	develop	a	community	based	intervention	to	engage	with	and	test	members	of	the	newly	
arrived	Nepali	population	for	CVH	
6. To	 identify	 the	principal	 gaps	 and	 levers	 for	 action	 to	 improve	CVH	 testing	delivery	 in	 the	
Nepali	community	and	migrant	groups	in	general.		
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Research	Philosophy	
Research	philosophy	 considers	how	one	views’	 the	world,	 and	determines	my	 research	 strategies,	
theory	and	analysis.	Research	philosophy	considers	both	Ontological	and	Epistemological	positions,	
with	influence	that	these	factors	place	on	study	design	and	discussion.		
Ontology:	
Ontology	studies	the	nature	of	reality,	and	in	particular	it	considers	if	reality	exists	entirely	separate	
to	human	practices	and	interactions,	or	whether	reality	(including	research)	remains	integrally	linked	
to	 human	 practices	 and	 social	 interactions	 [Braun	 and	 Clarke,	 Chapter	 2	 2014,	 Saunders	 B	 2009,	
chapter	 4].	 	 Ontological	 positions	 include	 Realism	 -	 where	 the	 natural	 and	 social	 world	 exists	
independent	 of	 human	 action,	 and	 where	 a	 single	 truth	 can	 be	 demonstrated	 through	 research	
techniques,	and	Relativism	–	where	reality	is	considered	in	terms	of	multiple	(possible)	constructed	
social	realities	that	differs	across	time	and	context,	which	therefore	remains	outside	our	ability	to	truly	
comprehend	[Braun	and	Clarke,	Chapter	2,	2014;	Morgan	ST].	In	between	these	two	approaches	lies	
Critical	 Realism,	 where	 an	 interface	 exists	 between	 social	 interactions	 and	 realism,	 that	 helps	 to	
illuminate	reality,	even	if	it	does	not	provide	a	fully	reproducible	measure	of	this	(singe	truth)	reality	
[Braun	and	Clarke,	Chapter	2,	2014].		
Given	the	relative	extremes	and	limitations	of	realist	and	relativist	based	approaches,	I	adopt	a	critical	
realist	approach	during	my	thesis,	including	in	my	focus	group	studies,	with	outcomes	that	are	viewed	
as	 socially	 influenced	 as	well	 as	 determined	by	 aspects	 of	 reality	 outside	 these	 social	 interactions	
[Braun	V	2006].		
Epistemology:	
Epistemology	is	the	study	of	“how	we	know	what	we	know”,	and	considers	the	nature	of	knowledge,	
and	what	it	 is	possible	for	us	to	know	[Crotty	M	1998,	Chapter	1,	Braun	V	Clarke	2013,	Chapter	2].	
Epistemology	 considers	 what	 one	 counts	 as	 legitimate	 knowledge,	 and	 how	 one	 views’	 how	
meaningful	 (valid)	knowledge	can	be	created	and	obtained	 in	the	research	process	 [Braun	V	2013,	
Chapter	2].	Understanding	one’s	epistemological	perspective	is	of	crucial	importance	in	the	research	
process,	 and	 it	 can	 be	 visualised	 at	 the	 top	 of	 a	 hierarchical	 chain	 that	 informs	 the	 theoretical	
perspective	 and	 subsequent	 methodology	 and	 methods	 utilised	 to	 conduct	 the	 research	 project	
[Crotty	M	1998,	Chapter	1].	
Epistemological	positioning	shapes	how	research	is	conducted	and	how	conclusions	are	drawn,	with	
many	different	philosophies	 that	exist	 [Saunders	B	2009,	Chapter	4].	Commonly	 invoked	positions	
include	Positivism,	with	knowledge	that	is	closely	aligned	to	the	natural	sciences,	and	that	is	obtained	
through	 objective	 laws	 and	 generalisations,	 as	well	 as	 Interpretivism,	where	 knowledge	 is	 viewed	
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through	our	role	and	interactions	as	social	actors	in	the	research	process	[Saunders	B	2009,	Chapter	
4;	 Braun	 V	 2013].	 Positivist	 approaches	 imply	 that	 the	 real	 world	 can	 be	 seen	 through	 objective	
measurements	 with	 hypothesis	 that	 can	 be	 drawn	 based	 on	 laws	 that	 can	 be	 proven,	 whilst	
interpretivist	positions	suggest	that	the	world	can	only	be	inferred	through	our	social	interactions	and	
own	relations	and	role	in	society.		
There	 are	 limitations	 to	 epistemological	 positions	 and	 in	 the	 relative	 extremes	 of	 a	 positivist	 or	
interpretivist	approach.	Positivism	has	received	criticism	for	its	exclusive	focus	on	objectivity,	and	that	
only	the	observed	phenomenon	will	lead	to	credible	data,	and	a	singular	truth.	As	is	to	be	expected,	
Interpretivism	also	 receives	 criticism	 in	 the	opposing	 lack	of	objectivity,	 and	 the	 reliance	on	 social	
interactions	that	exclusively	frame	the	knowledge	one	obtains,	and	how	we	make	sense	of	the	world	
[Saunders	B	2009,	Chapter	4;	Braun	V	2013].		
	The	current	study	aims	to	understand	the	potential	barriers	and	facilitators	to	viral	hepatitis	testing	
across	multiple	levels;	exploring	testing	policy,	as	well	as	the	awareness	and	perception	of	disease,	
and	the	ability	to	develop	a	successful	engagement	strategy	in	members	of	Nepali	community.	The	
epistemological	position	taken	in	this	study	is	a	Critical	Realist	approach,	based	on	the	work	by	Roy	
Bhaskar,	 developed	 in	 part	 to	 deal	 with	 the	 limitations	 posed	 by	 traditional	 epistemological	
approaches	 [Gorski	 P	 2013].	 Critical	 realism	 adopts	 the	 position	 that	 the	 objects,	 structures	 and	
practices	that	make	up	reality	exist	independently	of	whether	their	existence	or	nature	is	observable,	
known	or	understood	by	humans	[Clark	AM	2007].	Critical	realism	positions	reality	as	existing	beyond	
just	 observable	 phenomena,	 to	 include	 potential	 structures	 and	 powers	 that	 may	 actually,	 or	
potentially	influence	what	is	observed.	It	also	acknowledges	that	different	contextual	factors	may	exist	
and	 interact	 to	 influence	 outcomes,	 including	 social,	 cultural	 and	 environmental	 factors.	 Critical	
realism	aims	to	explain	outcomes,	taking	account	of	these	contextual	factors	that	may,	or	may	not	be	
directly	measurable,	but	causative	and	cumulative	in	certain	circumstances	and	settings	to	produce	
the	 end	 outcome	 [Clark	 AM	 2007,	 Gorski	 P	 2013].	 Critical	 realism	 considers	 a	 single	 reality,	 but	
provides	 a	 position	 to	 explore	 outcomes	 and	 the	 “truth”	 of	 relations	 through	 a	 rational	 basis,	
considering	the	multiple	contextual	factors,	including	cultural	and	social	factors	that	are	likely	to	be	
pivotal	in	analysing	data	in	studies	in	migrant	communities.		
	
Theoretical	Framework:		
The	theoretical	framework	provides	structure	and	support	for	the	foundations	and	rationale	of	the	
study,	and	provides	a	lens	through	which	to	visualise	and	analyse	data	[Reeves	S	2008,	Grant	C	2015].	
This	 framework	 is	 therefore	 crucial	 in	 informing	methodology	 and	 the	 research	 process,	 and	 the	
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theoretical	framework	utilised	of	course	reflects	one’s	research	philosophy	as	identified	above	[Grant	
C	2015].		
In	keeping	with	this,	the	theoretical	framework	utilised	in	this	thesis	is	a	Realist	Evaluation	framework,	
drawing	 upon	 the	 work	 of	 Pawson	 and	 Tilley,	 and	 built	 upon	 my	 critical	 realist	 epistemological	
positioning.		
Realist	 Evaluation	 (RE)	 considers	 human	 action	 and	 outcomes	 within	 a	 stratified	 nature	 of	 social	
reality,	with	 this	 stratified	 reality	 that	 considers	all	 actions	and	outcomes	within	 its	broader	 social	
construct	and	meaning.	It	also	considers	outcomes	and	causal	mechanisms	as	issues	that	are	not	fixed,	
but	which	develop	in	the	context	of	the	surrounding	social	structure,	events	and	perception	[Pawson	
R	1997].		
RE	looks	to	explore	a	particular	programme	activity	to	answer	the	question:	“what	works,	for	whom,	
in	what	circumstances	and	why”	[Pawson	R	2004].	In	RE,	programmes	are	explored	to	see	how	and	
why	they	work,	with	particular	emphasis	on	the	component	actions	and	societal	context	that	leads	to	
success,	 or	 that	 may	 lead	 to	 failure	 in	 different	 circumstances,	 based	 on	 these	 components	 or	
contextual	factors	[Herepath	A	2015,	Jagosh	J	2015].		
RE	therefore	provides	an	explanatory	approach	that	looks	to	generate	causal	associations	that	remains	
sensitive	 to	 contextual	 and	 social	 influences	 [Salter	 2014],	 and	 considers	 both	 qualitative	 and	
quantitative	data	across	multiple	(micro,	macro)	levels	within	this	social	and	contextual	reality	[Jagosh	
J	2015,	Pawson	R	2004].		
RE	is	a	middle-range	theory	that	explores	a	programme	activity,	where	the	programme	is	considered	
as	a	sophisticated	set	of	social	interactions,	grounded	in	a	complex	social	reality	[Pawson	R	2004].	The	
programme	is	then	explored	to	generate	causal	associations	through	the	construction	of	a	context,	
mechanism,	outcome	(CMO)	configuration	that	is	discussed	below.		
• Context	 considers	 the	social,	political,	economic	and	other	 relationships	 that	 influence	 the	
aspects	 of	 “for	 whom”	 and	 “in	 what	 aspects”	 would	 a	 programme	 action	 be	 successful	
[Pawson	 R	 2004].	 These	 include	 the	 social	 and	 political	 factors	 that	 influence	 healthcare	
provision,	as	well	as	access	and	engagement	factors	to	healthcare	uptake.			
• Mechanisms	 describe	 the	 aspect	 (action)	 of	 the	 programme	 that	 brings	 about	 its	 effects,	
including	the	perceived	actions	or	inactions	in	the	intervention	that	lead	to	success	or	failure	
[Herepath	 A	 2015].	 For	 a	 particular	 programme	 activity	 or	 goal,	 there	 may	 be	 different	
mechanisms,	 or	 ways	 through	 which	 the	 action	 achieves	 success	 or	 failure.	 Mechanisms	
consider	 not	 just	 individual	 component	 actions,	 but	 rather	 it	 explores	 the	 component,	 or	
components	that	works	to	produce	change.	The	mechanism	aspect	therefore	looks	to	identify	
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the	 crucial	 programme	 component/s	 that	work	 to	 produce	 change,	whether	 successful	 or	
unsuccessful	[Pawson	R	2004].		
• Outcome:	 Outcome	 patterns	 consider	 the	 intentional	 and	 unintentional	 consequences	 of	
programmes,	which	may	be	successful	or	unsuccessful	in	their	nature;	relating	to	mechanisms	
that	act	under	different	contextual	situations	[Pawson	R	2004,	Salter	K	2015].		
This	configuration	can	be	applied	to	consider	a	whole	programme	intervention,	or	it	may	relate	to	a	
particular	aspect	of	the	programme.	The	CMO	configuration	is	essentially	heuristic,	acting	to	provide	
a	causative	explanation	about	the	outcomes	seen	from	the	observed	data	[Jagosh	J	2015].		It	provides	
a	hypothesis	that	a	particular	programme	outcome	(O)	is	seen	because	of	the	specific	action/actions	
seen	in	the	mechanism	(M),	that	is	dependent	upon	the	particular	context	(C)	working	at	the	time.		
Realist	 Evaluation	 (RE)	 therefore	 provides	 an	 explanatory	 approach	 that	 looks	 to	 generate	 causal	
associations	that	remains	sensitive	to	contextual	and	social	influences,	which	is	of	key	importance	in	
the	exploratory	analysis	of	factors	influencing	viral	hepatitis	testing	in	migrant	communities	that	will	
be	heavily	influenced	by	context,	including	political	and	societal	factors.		
	
Research	Methods:		
The	 thesis	 takes	 an	 exploratory	 approach	 to	 seek	 new	 insights	 into	 the	 potential	 barriers	 and	
facilitators	to	viral	hepatitis	testing	in	the	UK	Nepali	community,	as	well	as	the	burden	of	disease	that	
exists	in	this	new	migrant	community,	through	the	establishment	of	a	novel	engagement	strategy	to	
reach	out	to	this	new	population.		
A	mixed-methods	approach	is	used	to	explore	my	research	objectives,	with	an	explanation	of	these	
approaches	 that	 is	described	 in	each	 intervention	chapter.	Qualitative	 strategies	are	used	 through	
policy	 analysis	 and	 focus	 group	 based	 studies	 in	 the	 Nepali	 community	 and	 with	 local	 General	
Practitioners	(GPs),	with	quantitative	data	collection	used	to	explore	HBV	and	HCV	risks	in	a	defined	
population	of	the	Nepali	community	through	our	testing	intervention.		
A	summary	of	the	principal	research	methods	used	in	the	thesis	is	presented	below:		
Policy	Analysis:			
CVH	testing	recommendations	from	NICE	were	analysed	through	a	policy	analysis	framework,	utilising	
the	 Policy	 Prioritisation	 framework	 developed	 by	 Shiffman	 and	 Smith,	 and	 validated	 by	Walt	 and	
Gilson	[Shiffman	J	2007,	Walt	G	2014].	The	framework	 looks	to	establish	how	policy	can	reach	the	
political	agenda,	and	 its	 implementation	 into	practice.	 	Whilst	 initially	applied	 in	 relation	 to	global	
maternal	 mortality	 in	 low	 and	middle	 income	 countries,	 the	 framework	 has	 received	 recognition	
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across	 many	 diverse	 health	 settings,	 including	 mental	 health	 [Tomlinson	 M	 2012],	 as	 well	 as	 a	
heterogeneous	exposure	in	the	review	by	Walt	and	Galt,	covering	22	policy	papers,	including	health	
conditions	such	as	family	planning,	HIV	care,	and	HBV	vaccination.	[Walt	G	2014].	Policy	analysis	 is	
based	on	the	context	of	the	health	system,	and	whilst	the	Policy	Prioritisation	framework	has	been	
principally	applied	in	low	to	middle	income	settings,	the	research	findings	from	this	analysis	should	be	
transferrable;	with	recognition	of	the	changing	relationships	and	greater	infrastructural	support	that	
should	be	available	to	developed	health	settings	[Walt	G	2008].		Qualitative	studies:	
Focus	group	studies	were	selected	to	explore	the	awareness,	understanding	and	perception	of	CVH	in	
the	 Nepali	 community,	 as	 well	 as	 qualitative	 studies	 in	 primary	 care.	 Members	 of	 the	 Nepali	
community	were	invited	to	participate	with	the	help	of	Nepali	community	leaders,	and	identified	in	a	
purposive	 manner,	 given	 the	 new	 status	 of	 this	 migrant	 community.	 Nepali	 (bilingual)	 speaking	
moderators	were	used	to	run	these	focus	group	sessions.		
Focus	groups	are	a	well	utilised	tool	to	explore	knowledge	and	experience,	and	participants’	points	of	
view	towards	health	and	disease.	They	offer	a	way	to	expand	the	approach	offered	through	semi-
structured	interviews	to	a	wider	group,	with	the	group	process	that	 is	thought	to	help	participants	
“explore	and	clarify	their	views	in	a	way	that	would	be	less	accessible	in	one	to	one	interviews”,	and	
may	 also	 provide	 a	 more	 in-depth	 view	 of	 interpersonal	 relations,	 and	 cultural	 perceptions	 that	
become	apparent	through	verbal	and	non-verbal	group	interactions	[Kitzinger	J	1995].	There	may	also	
be	advantages	to	using	focus	groups	in	potentially	sensitive	subject	areas,	and	in	communities	where	
sensitivities	 to	 engagement	 may	 be	 considered;	 with	 focus	 groups	 well	 utilised	 in	 migrant	
communities	 [Greenwood	 N	 2014].	 Participants	 often	 feel	 more	 comfortable	 and	 expressive	 in	
homogenous	groupings	[Greenwood	N	2014].,	with	focus	group	studies	that	were	designed	therefore	
to	4	separate	discussions	between	older	and	younger	Nepali	male	and	female	participants.	
A	Thematic	Analysis	(TA)	approach,	as	developed	by	Braun	and	Clarke	was	used	to	analyse	and	identify	
patterns	 (themes)	 in	 the	 focus	 group	 data,	 providing	 a	 method	 to	 organise	 and	 interpret	 data	
expressed	by	participants	[Braun	V	2006].	This	process	relies	upon	“coding”	to	identify	ideas	expressed	
within	 the	 focus	 group	 text,	 and	 developing	 this	 through	 analysis	 to	 higher-level	 and	 overarching	
themes.	Coding	was	undertaken	by	myself	in	all	focus	group	work,	with	these	codes	generated	in	an	
inductive	and	iterative	fashion,	based	on	my	research	objectives,	and	with	an	aim	to	identify	codes	in	
a	“latent	(interpretative)”	fashion;	 looking	to	 identify	patterns	and	meaning	 in	the	expressed	focus	
group	data	[Braun	V	2006].	High	level	codes,	making	up	the	candidate	themes	and	overarching	themes	
were	then	reviewed	within	the	study	group	(consisting	of	the	study	supervisors,	JH	and	SL).		
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A	 TA	 approach	 was	 chosen	 in	 addition	 due	 to	 its	 flexibility,	 [Braun	 V	 2006]	 with	 language	
considerations	 in	 view	 of	 Nepalese	medium	 focus	 groups	 that	 first	 required	 translation	 and	 then	
transcription,	 with	 the	 aim	 of	 identifying	 overarching	 themes	 (patterns)	 expressed	 by	 Nepali	
participants	towards	liver	disease.		
In	our	Primary	Care	qualitative	studies,	the	same	focus	group	methodology	was	used	to	collect	data,	
with	the	aim	for	 these	 focus	groups	to	help	 identify	perceptions	and	deeper	 feelings	 towards	CVH	
testing	in	migrant	communities.	TA	was	similarly	used	for	data	analysis,	with	the	aim	of	 identifying	
qualitative	data	that	could	be	compared	between	GPs	and	the	newly	arrived	Nepali	community	who	
are	served	by	them.	GPs	were	also	identified	in	a	purposive	manner,	with	dedicated	study	promotion	
to	local	practices	and	Clinical	Commissioning	Groups	(CCGs).		
Community-based	testing	intervention:	
The	UK	Nepali	 community	 are	 a	heterogeneous	new	migrant	 community	with	 regard	 to	 ethnicity,	
caste	and	religion,	with	no	understanding	regarding	methods	that	can	be	used	to	engage	with	this	
population,	or	how	this	would	be	received.		
Given	 the	 uncertainties	 that	 exist	 in	 reaching	 out	 to	 this	 population,	we	 developed	 a	 new	Nepali	
research	 group,	 to	 work	 together	 to	 identify	 and	 develop	 locations	 and	 delivery	models	 for	 CVH	
engagement.		
A	community-based	testing	intervention	was	developed	utilising	dry-blood	spot	testing	for	HBV	and	
HCV.	We	promoted	testing	to	members	of	the	local	community	to	test	over	1000	Nepali	participants,	
with	 the	 help	 of	 a	 dedicated	 research	 team,	 as	 well	 as	 the	 integral	 and	 vital	 support	 of	 Nepali	
community	volunteers.		
Quantitative	research	data	was	analysed	through	R-statistical	software,	as	well	as	Microsoft	Excel.		
Rigor:	
The	rigor	and	quality	of	research	can	be	considered	with	regard	to	the	“authenticity”	of	the	data,	as	
well	as	the	quality	or	“trustworthiness”	of	the	data	analysis	[Sargeant	J	2012].		
To	try	and	capture	this	authenticity	and	quality	at	the	policy	level,	current	NICE	CVH	testing	policy	was	
considered	and	analysed	in	the	context	of	existing	international	and	UK	wide	policy,	with	identification	
of	the	similarities	and	differences	in	policy	at	these	levels.		
For	qualitative	studies	in	the	Nepali	community,	we	developed	focus	group	studies	across	4	groups	
separated	 by	 sex	 and	 age,	 to	 improve	 our	 (purposive)	 study	 sampling	 and	 to	 explore	 perceptions	
across	 wider	 community	 representation.	 Nepali-speaking	 moderators	 were	 trained	 by	 study	
supervisors	 with	 qualitative	 study	 expertise	 (JH),	 and	 provided	 open-ended	 questions	 to	 explore	
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perceptions	 in	 the	 Nepali	 participants,	 as	 well	 as	 the	 broad	 subject	 of	 “liver	 disease”	 that	 was	
identified	 as	 the	 primary	 subject	 to	 avoid	 difficulties	 that	 may	 be	 faced	 with	 a	 specific	 lack	 of	
awareness	of	this	term,	and	to	explore	broader	aspects	that	may	be	at	play.		
Nepali	transcripts	were	translated	and	transcribed	by	a	single	Nepali	co-investigator	(R	Tiwari),	with	
all	initial	coding	undertaken	by	myself,	with	higher	codes	reviewed	and	modified	through	an	iterative	
process	within	the	research	team	(JH,	SL).		
Primary	care	focus	group	studies	also	relied	on	purposive	sampling	to	recruit	GPs,	but	were	held	in	
pre-arranged	educational	sessions,	with	a	range	of	senior	GP	partners,	salaried	GPs	and	GP	trainees	
in	 attendance	 from	 several	 regional	 practices.	 I	 acted	 as	 moderator	 in	 these	 sessions,	 with	 all	
participants	aware	of	my	clinical	specialist	role	and	current	research	objectives	prior	to	the	start	of	
focus	 groups.	 Moderator	 questions	 were	 designed	 to	 be	 neutral,	 but	 focused	 to	 the	 research	
objectives	of	the	study.		
Initial	coding	was	developed	by	myself,	with	the	same	Thematic	Analysis	process	used	for	consistency,	
and	 with	 higher	 level	 codes	 and	 overarching	 themes	 that	 were	 reviewed	 and	 developed	 in	 the	
research	team	(JH,	SL).	
For	 our	 community	 testing	 study,	 a	 comprehensive	 multidisciplinary	 team	 was	 formed	 with	 the	
inclusion	 of	 Public	 Health,	 Local	 Council	 representatives,	 Patient	 liaison	 representatives,	 and	 a	
dedicated	Nepali	 community	 research	 team,	 specially	 created	 for	 the	 study.	Open-invitation	 to	 all	
adult	 groups	 in	 the	Nepali	 community	were	 promoted,	with	 several	 testing	 sites	 in	 the	 local	 area	
developed	 to	 try	 and	 improve	 patient	 access.	Quantitative	 statistical	 analysis	was	 conducted	with	
input	from	the	Clinical	Informatics	Team	at	the	University	of	Surrey,	with	the	use	of	dedicated	R-Studio	
software	in	logistic	regression	analysis.		
Research	Ethics	
Formal	national	ethics	application	through	the	Health	Research	Authority	was	established	for	focus	
group	 testing	 studies	 in	 the	 Nepali	 community,	 as	 well	 as	 testing	 studies	 for	 CVH	 in	 the	 Nepali	
community.	The	study	sponsor	for	this	work	was	Frimley	Park	Hospital	(Appendix)		
Ethics	 approval	 for	 focus	 group	 studies	 in	 primary	 care	was	 completed	 through	 the	 University	 of	
Surrey,	 without	 the	 (suggested)	 need	 for	 formal	 ethics	 approval	 given	 the	 nature	 of	 these	 focus	
groups,	being	conducted	by	myself	as	moderator	in	NHS	to	NHS	staff	sessions.		
Ethics	application	for	qualitative	studies	in	the	Nepali	population,	and	developing	a	community	testing	
intervention	were	submitted	by	one	of	the	study	supervisors	Aftab	Ala,	with	further	ethics	application	
for	primary	care	qualitative	studies	submitted	to	the	University	of	Surrey	by	myself.		
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Chapter	Summary:	
The	current	chapter	presents	an	overview	of	the	principal	research	objectives	of	the	thesis,	and	the	
intervention	strategies	and	analysis	tools	used	to	meet	these	objectives.		
A	 Realist	 Evaluation	 (RE)	 framework	 is	 used	 as	 the	 theoretical	 framework	 in	 the	 design	 and	
interpretation	 of	 the	 study,	 with	 a	mixed-methods	 approach	 that	 is	 used	 with	 the	 application	 of	
qualitative	 focus	 group	 studies	 using	 a	 Thematic	 Analysis	 approach,	 as	well	 as	 a	 quantitative	 CVH	
testing	study	that	is	developed	as	part	of	a	novel	community-based	testing	intervention	in	the	newly	
arrived	Nepali	community.		
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Chapter	3:	The	role	of	CVH	testing	policy;	applying	a	policy	prioritisation	framework	to	national	CVH	testing	recommendations	
Introduction:	
This		chapter	explores	the	potential	role	of	policy	in	CVH	testing;	looking	at	the	historic	context	of	policy	
development	 in	 the	 UK,	 as	 well	 as	 testing	 recommendations	 considered	 within	 an	 international	
context.	A	political	prioritisation	framework	is	utilised	to	analyse	current	NICE	CVH	testing	guidance,	
and	 the	potential	barriers	and	 facilitators	 that	exist	 to	achieving	policy	priority	and	uptake	of	CVH	
testing	in	migrant	communities.		
Context:	
CVH	 testing	 in	 new	 migrant	 communities	 such	 as	 the	 Nepali	 population	 will	 be	 most	 influenced	
through	policy	that	achieves	wide	uptake	and	implementation.	Policy	uptake	is	influenced	by	multiple	
factors,	including	the	political,	financial	and	environmental	context,	as	well	as	the	historic	context	of	
testing	 and	 how	 CVH	 is	 viewed	 between	 health	 professionals,	 the	 wider	 public,	 and	 migrant	
communities,	who	are	one	of	the	key	groups	targeted	in	CVH	testing	recommendations.		
Policy	is	an	initiative	that	can	take	shape	in	numerous	forms,	whether	written	(e.g.	national	guidelines)	
or	unwritten,	explicit	or	implicit,	and	provides	a	broad	set	of	objectives	to	be	achieved	through	the	
shared	action	of	stakeholders	(individuals	/	groups)	at	different	hierarchical	levels.	Health	policy	can	
be	 viewed	more	 specifically	 as	 those	 decisions,	 plans,	 actions	 (or	 inactions)	 that	 achieve	 a	 health	
objective	within	society	[WHO	Health	Policy	2015].		
Health	 policy	 can	 involve	 and	 affect	 all	 the	 institutions,	 organisations,	 services	 and	 funding	
arrangements	in	the	healthcare	system,	as	well	as	external	voluntary,	private	and	public	organisations	
(such	as	patient	charity	groups)	that	influence	the	policy	process	(stakeholders)	[Buse,	Mays	and	Walt,	
2005,	pg.6].	Policies	may	be	developed	at	the	central	(e.g.	government)	level,	or	equally	they	may	be	
led	and	developed	by	practitioners	(e.g.	GPs/Nurses)	or	patient-advocacy	groups	[Erasmus	E	2014].		
The	 importance	and	need	for	effective	health	policy	 is	 to	provide	better	outcomes	for	patients,	or	
improved	cost-effectiveness	through	well-structured	guidelines	[Eccles	2004].	Health	policy	provides	
a	vision	for	a	specific	health	objective,	as	well	as	short	and	medium	term	targets	for	care,	and	outlines	
the	priorities	and	expected	roles	for	stakeholders	involved	in	the	policy	process	[WHO	Health	Policy	
2015].		
Effective	 health	 policy	 is	 therefore	 fundamental	 towards	 achieving	 and	 standardising	 health	
objectives,	and	in	building	consensus	amongst	practitioners.	However,	the	policy	process	is	complex,	
and	policy	outputs	may	not	match	their	intended	outcomes,	with	deficits	or	barriers	that	may	exist	
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across	 multiple	 levels;	 from	 initiation	 and	 agenda-setting,	 across	 policy	 formulation	 to	 actual	
implementation	[Buse,	Mays	and	Walt,	2005,	pg	13;	Berlan	D	et	al.	2014].	
In	the	case	of	viral	hepatitis	testing,	several	policy	guidelines	have	been	issued	over	the	past	ten	years	
in	the	UK,	with	updated	HBV	and	HCV	testing	guidance	issued	by	the	National	Institute	of	Health	and	
Care	Excellence	(NICE)	in	December	2012	[NICE	PH43	2012].		
These	 guidelines	 identify	 those	 individuals	 who	 should	 be	 offered	 HBV	 and	 HCV	 testing,	 and	 are	
applicable	to	all	health	professionals	and	workers	associated	with	these	at-risk	groups.	Such	testing	
policy	therefore	affords	the	potential	to	improve,	focus	and	standardise	testing	in	all	at-risk	groups,	
including	 migrant	 communities	 who	 may	 otherwise	 be	 socially	 excluded,	 or	 be	 missed	 in	 ad-hoc	
testing	patterns	employed	by	heterogeneous	health	professionals.		
National	CVH	testing	policy	has	many	advantages,	but	little	is	known	about	the	awareness	and	uptake	
of	this	policy,	with	testing	practice	that	is	likely	to	be	influenced	by	the	historic	and	current	context	
affecting	CVH	across	multiple	levels.	Policy	analysis	offers	a	structured	approach	to	understand	the	
factors	that	influence	and	affect	policy	uptake,	and	that	therefore	affect	the	uptake	of	CVH	testing	in	
migrant	communities,	including	the	newly	arrived	Nepali	population.		
Research	objectives:	
The	following	chapter	looks	to	explore	the	context	leading	up	to	the	development	of	updated	NICE	
CVH	testing	guidance	issued	in	2012/13,	utilising	a	policy	analysis	framework	to	explore	the	factors	
that	may	influence	the	implementation	and	uptake	of	testing	policy.		
• To	explore	the	international	and	national	historic	context	of	CVH	testing	policy	
• To	explore	previous	national	CVH	testing	policy	endeavours	in	the	UK	
• To	explore	the	development	of	current	NICE	CVH	testing	policy,	and	its	recommendations	
• To	 conduct	 a	 policy	 analysis	 to	understand	 the	 factors	 that	may	 influence	 the	uptake	 and	
implementation	of	testing	policy	in	migrant	communities	
• To	identify	potential	facilitators	or	barriers	towards	CVH	testing	policy	uptake		
Reflexivity:	
As	 a	 working	 clinician,	 health	 policy	 documents	 are	 frequent	 across	 multiple	 specialities,	 and	
remaining	 abreast	 of	 these	 guidelines,	 and	 the	 priority	 that	 is	 afforded	 to	 policy	 reaching	 clinical	
consciousness	is	complex,	and	poorly	appreciated	in	day	to	day	practice.		
Indeed	 I	 approached	 policy	 analysis	 with	 great	 interest,	 as	 a	 concept	 that	 is	 intuitive	 as	 well	 as	
complex,	and	greatly	dependent	upon	the	political,	financial	and	public	context,	as	well	as	the	core	
message	and	certainty	of	the	clinical	message	that	policy	puts	forward.		
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Research	Methods:	
NICE	HBV	and	HCV	recommendations	consider	ways	to	improve	awareness-raising	in	CVH	as	well	as	
improving	testing	uptake,	with	the	following	analysis	focused	to	explore	and	analysis	NICE	CVH	testing	
recommendations	 in	 migrant	 groups.	 Community	 testing	 is	 the	 focus	 of	 NICE	 CVH	 testing	
recommendations,	with	primary	care	the	principal	and	visible	group	 in	policy	recommendations	to	
consider	and	analyse	at	the	ground	(community)	level	directed	to	action	testing	policy.		
A	 historic	 context	 was	 developed	 first	 on	 an	 international	 and	 national	 basis	 to	 help	 explore	 the	
development	and	potential	 impact	of	NICE	CVH	testing	policy	 in	relation	to	previous	testing	policy,	
and	other	international	experiences	of	CVH	testing.		
A	policy	analysis	framework	was	then	chosen	to	explore	the	potential	barriers	and	facilitators	towards	
achieving	effective	policy	uptake	and	implementation	at	the	community	level	in	migrant	populations.		
Policy	Analysis:	International	and	Historic	context		
International	guidance	on	HBV	&	HCV	testing:	
Viral	hepatitis	 is	a	global	public	health	problem,	and	achieved	WHO	recognition	 in	the	2010	World	
Health	 Assembly,	 with	 testing	 policy	 and	management	 guidelines	 that	 have	 been	 issued	 by	most	
developed	nations	[WHO	63.18].		
NICE	 testing	policy	 can	 therefore	be	 viewed	 in	 regard	 to	 international	 policy,	 as	well	 as	within	 its	
historic	context	leading	up	to	current	guidance	and	practice.		
Potential	 acquisition	 routes	 for	HBV	 and	HCV	 are	well	 defined,	 and	 as	 previously	 discussed	 relate	
principally	 to	 contact	 exposure	 (familial,	 sexual),	 injecting	 drug	 use	 and	 iatrogenic	 transmission.	
Transmission	 and	 the	 risks	 of	 chronicity	 vary	 though	 between	 HBV	 and	 HCV,	 and	 all	 guideline	
documents	present	 testing	recommendations	separately	 for	HBV	and	HCV,	although	on	a	practical	
level	these	groups	overlap,	 in	keeping	with	common	routes	of	acquisition	amongst	all	blood	borne	
viruses.		
International	testing	practice	varies	widely	based	on	country	resources	and	government	priorities,	but	
globally	the	focus	has	generally	been	to	adopt	an	at-risk	testing	strategy	for	HBV	&	HCV	(case-finding);	
focusing	on	specific	risk	groups,	rather	than	population	based	screening	[Del-Poggio	2006].		
International	Testing	Policy:	
Testing	recommendations	in	the	USA	are	the	exception	to	this,	with	the	Centres	for	Disease	Control	
(CDC)	being	the	only	advisory	body	to	recommend	HCV	testing	in	all	individuals	born	between	1945	
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and	1965;	the	so-called	“baby-boomer”	generation,	 introduced	in	2012	[table	2a,	2b].	Over	75%	of	
those	identified	with	hepatitis	C	in	the	US	originate	from	this	generation,	which	may	be	due	to	a	higher	
HCV	prevalence	during	this	period	and/or	to	patterns	of	unsafe	needle	practices.	Such	policy	has	not	
been	adopted	in	the	UK,	with	a	lower	prevalence	(<2%)	rate	cited	in	this	age	group	[NICE	2012],	and	
CDC	guidance	is	therefore	the	first	to	recommend	HCV	testing	across	a	defined	age	group	[CDC,	Why	
baby	boomers	should	get	tested].		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Summary	of	CDC/AASLD	recommendations	for	HCV	testing:
Persons	who	should	be	routinely	tested	for		HCV	based	on	their	risk	for	infection	
include	those	who:
• Currently	inject	drugs
o Ever	injected	drugs,	including	those	who	injected	once	or	a	few	times	many	
years	ago
Have	certain	medical	conditions,	including	persons:
• who	received	clotting	factor	concentrates	produced	before	1987
• who	were	ever	on	long-term	hemodialysis
• with	persistently	abnormal	alanine	aminotransferase	levels	(ALT)
• Were	prior	recipients	of	transfusions	or	organ	transplants,	including	persons	
who:
• were	notified	that	they	received	blood	from	a	donor	who	later	tested	positive	
for	HCV	infection
• received	a	transfusion	of	blood,	blood	components	or	an	organ	transplant	
before	July	1992/Clotting	factor	before	1987(*)
• All	HIV-infected	patients
Persons	who	should	be	tested	once	for	HCV	without	prior	risk	factors	include:
• Adults	born	during	1945	through	1965
Persons	who	should	be	tested	routinely	for	HCV-infection	based	on	a recognized	
exposure:
• Healthcare,	emergency	medical,	and	public	safety	workers	after	needle	sticks,	
sharps,	or	mucosal	exposures	to	HCV-positive	blood
• Children	born	to	HCV-positive	women
Persons	for	Whom	routine	HCV	testing	is	of	Uncertain	need:
• Recipients	of	transplanted	tissue	(e.g.,	corneal,	musculoskeletal,	skin,	ova,	
sperm)
• Intranasal	cocaine	and	other	non-injecting	illegal	drug	users
• Persons	with	a	history	of	tattooing	or	body	piercing
• Persons	with	a	history	of	multiple	sex	partners	or	sexually	transmitted	diseases
• Long-term	steady	sex	partners	of	HCV-positive	persons
Centers for	Disease	Control	and	Prevention	(CDC):	Hepatitis	C	information	for	health	
professionals	[http://www.cdc.gov/hepatitis/hcv/guidelinesc.htm]
AASLD	recommendations:	*AASLD	recommends	in	addition	the	testing	of	those	who	
received	clotting	factors	before	1987
Summary	of	CDC/AASLD	recommendations	for	HBV	testing	
Recommendations	for	routine	HBsAg testing	in	at-risk	individuals,	including:	
• Persons	born	in	regions	of	high	and	intermediate	HBV	endemicity (HBsAg 2%)
o Including:	Immigrants,	refugees,	asylum	seekers,	internationally	
adopted	children
• US	born	persons	not	vaccinated	as	infants	where	parents	(or	one	parent)	
were	born	in	regions	with	intermediate	(*)/high	prevalence
• Injecting	drug	users
• Men	who	have	sex	with	men	(MSM)
• Immunosuppressed	patients	(chemotherapy,	organ	transplant)
• Elevated	ALT	/	AST	of	unknown	aietiology
• Donors	of	blood/plasma/organs/tissue/semen
• Haemodialysis	patients
• All	Pregnant	women/Infants	born	to	HBsAg mothers
• Household/Sexual	contacts/needle-sharing	of	HBsAg persons
• Persons	at	risk	of	HBV	exposure	(needlestick/sexual	assault)
• HIV	positive	persons
Taken	from	CDC:	http://www.cdc.gov/hepatitis/hbv/PDFs/ChronicHepBTestingFlwUp-
BW.pdf 2014
AASLD:	https://aasld.org/patients/Pages/ViralHepatitisPrevention.aspx#screening
*AASLD	guidance	recommends	testing	all	US	born	individuals	with	even	one	parent	born	
in	intermediate	prevalence	(>2%)		HBV	settings.	
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There	 are	 differences	 in	 CVH	 testing	 policy	 in	 migrant	 groups	 in	 US	 policy,	 and	 whilst	 US	 (CDC)	
recommendations	identify	HBV	testing	in	migrant	groups	born	in	intermediate	or	high	risk	areas,	there	
is	no	specific	testing	recommendations	in	migrant	groups	in	the	absence	of	additional	risk	factors,	with	
a	population	birth-cohort	method	recommended	for	this	group	as	well.	The	rationale	for	this	variance	
is	not	explicit,	and	whilst	there	is	recognition	in	AASLD	guidance	of	the	risks	that	migrant	groups	may	
Table	4a:	CDC	+	AASLD	testing	recommendations	for	Hepatitis	C	
Table	2:	CDC	+	AASLD	guidelines	for	HBV	&	HCV	testing	
Summary	of	CDC/AASLD	recommendations	for	HCV	testing:
Persons	who	should	be	routinely	tested	for		HCV	based	on	their	risk	for	infection	
include	those	who:
• Currently	inject	drugs
o Ever	injected	drugs,	including	those	who	injected	once	or	a	few	times	many	
years	ago
Have	certain	medical	conditions,	including	persons:
• who	received	clotting	factor	concentrates	produced	before	1987
• who	were	ever	on	long-term	hemodialysis
• with	persistently	abnormal	alanine	aminotransferase	levels	(ALT)
• Were	prior	recipients	of	transfusions	or	organ	transplants,	including	persons	
who:
• were	notified	that	they	received	blood	from	a	donor	who	later	tested	positive	
for	HCV	infection
• received	a	transfusion	of	blood,	blood	components	or	an	organ	transplant	
before	July	1992/Clotting	factor	before	1987(*)
• All	HIV-infected	patients
Persons	who	should	be	tested	once	for	HCV	without	prior	risk	factors	include:
• Adults	born	during	1945	through	1965
Persons	who	should	be	tested	routinely	for	HCV-infection	based	on	a recognized	
exposure:
• Healthcare,	emergency	medical,	and	public	safety	workers	after	needle	sticks,	
sharps,	or	mucosal	exposures	to	HCV-positive	blood
• Children	born	to	HCV-positive	women
Persons	for	Whom	routine	HCV	testing	is	of	Uncertain	need:
• Recipients	of	transplanted	tissue	(e.g.,	corneal,	musculoskeletal,	skin,	ova,	
sperm)
• Intranasal	cocaine	and	other	non-injecting	illegal	drug	users
• Persons	with	a	history	of	tattooing	or	body	piercing
• Persons	with	a	history	of	multiple	sex	partners	or	sexually	transmitted	diseases
• Long-term	steady	sex	partners	of	HCV-positive	persons
Centers for	Disease	Control	and	Prevention	(CDC):	Hepatitis	C	information	for	health	
professionals	[http://www.cdc.gov/hepatitis/hcv/guidelinesc.htm]
AASLD	recommendations:	*AASLD	recommends	in	addition	the	testing	of	those	who	
received	clotting	factors	before	1987
Summary	of	CDC/AASLD	recommendations	for	HBV	testing	
Recommendations	for	routine	HBsAg testing	in	at-risk	individuals,	including:	
• Persons	born	in	regions	of	high	and	intermediate	HBV	endemicity (HBsAg 2%)
o Including:	Immigrants,	refugees,	asylum	seekers,	internationally	
adopted	children
• US	born	persons	not	vaccinated	as	infants	where	parents	(or	one	parent)	
were	born	in	regions	with	intermediate	(*)/high	prevalence
• Injecting	drug	users
• Men	who	have	sex	with	men	(MSM)
• Immunosuppressed	patients	(chemotherapy,	organ	transplant)
• Elevated	ALT	/	AST	of	unknown	aietiology
• Donors	of	blood/plasma/organs/tissue/semen
• Haemodialysis	patients
• All	Pregnant	women/Infants	born	to	HBsAg mothers
• Household/Sexual	contacts/needle-sharing	of	HBsAg persons
• Persons	at	risk	of	HBV	exposure	(needlestick/sexual	assault)
• HIV	positive	persons
Taken	from	CDC:	http://www.cdc.gov/hepatitis/hbv/PDFs/ChronicHepBTestingFlwUp-
BW.pdf 2014
AASLD:	https://aasld.org/patients/Pages/ViralHepatitisPrevention.aspx#screening
*AASLD	guidance	recommends	testing	all	US	born	individuals	with	even	one	parent	born	
in	intermediate	prevalence	(>2%)		HBV	settings.	
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face	with	regard	to	HCV,	it	seems	that	this	variance	is	driven	by	a	lack	of	primary	testing	data	in	migrant	
communities	in	the	host	and	native	countries,	as	well	as	a	reliance	on	the	birth	cohort	system	in	the	
US	system	[CDC	2014,	AASLD	IDSA	2017].		
CVH	testing	in	migrant	communities	may	take	the	form	of	testing	through	dedicated	community-based	
interventions,	or	through	health	facility-based	testing	through	primary	or	secondary	care,	or	during	
the	migrant	entry	process.	Medical	screening	examinations	for	visa	applications	and	new	arrivals	are	
an	effective	route	to	identifying	and	(potentially)	treating	medical	conditions,	including	viral	hepatitis	
at	the	point	of	arrival.	However	the	visa-entry	process	often	differs	to	internal	health-testing	policy,	
and	in	North	America	only	refugees	(including	undocumented	migrants)	are	assessed	for	viral	hepatitis	
according	the	above	policy,	but	other	immigrant	(so-called	“alien”)	groups	seeking	visa,	or	permanent	
residency	are	not	routinely	approached	for	viral	hepatitis	testing	[CDC	2012,	Sharma	2015].		
Similarly,	 medical-screening	 examinations	 (assessments)	 for	 entry	 to	 the	 UK,	 Canada	 and	 most	
European	 countries	 operate	 separately	 to	 internal	 health	 policy,	 and	 do	 not	 include	 routine	 viral	
hepatitis	assessments,	although	some	countries	do	employ	a	risk-assessment	approach	at	the	initial	
entry	stage.	Importantly	though,	the	presence	of	viral	hepatitis	is	not	a	barrier	to	country-entry	[UK	
Visas	and	Immigration	2013,	Sharma	2015].		
UK	and	European	context	at	the	time	of	NICE	policy	development	
There	is	wide	variation	across	Europe	both	with	regard	to	the	prevalence	of	HBV	and	HCV,	as	well	as	
the	surveillance	practices	and	testing	strategies	used.	Certain	elements	of	HBV	&	HCV	testing,	such	as	
blood	and	organ	screening	is	mandatory	across	the	EU,	but	there	are	no	pan-European	guidelines	on	
HBV	and	HCV	testing.	Nearly	all	countries	screen	pregnant	women	for	HBV,	or	have	routine	neonatal	
vaccination	 strategies,	 and	 occupational	 risks	 are	 universally	 recognised.	 However	 there	 is	 wide	
variation	in	the	testing	strategies	adopted	for	“at-risk”	groups	between	countries,	and	the	UK	has	only	
recently	introduced	universal	vaccination	for	HBV	at	birth	from	2017.		
A	summary	of	European	testing	and	case-finding	practice	at	time	of	NICE	guideline	development	is	
presented	 in	 table	 11,	 based	 on	 data	 presented	 in	 the	 Euro-hepatitis	 report	 2012,	 as	 well	 as	
information	from	the	European	Centre	for	Disease	Prevention	and	Control	[ECDC	2010].	The	testing	
practice	presented	for	each	country	 is	a	cumulative	of	national	testing	policy	guidelines,	as	well	as	
questionnaire	surveys	of	clinical	practice.	This	data	was	collected	before	the	introduction	of	updated	
NICE	guidance,	and	shows	that	the	UK	had	few	standardised-testing	recommendations	in	place	across	
Britain	in	comparison	to	other	European	nations,	as	well	as	a	perceived	lack	of	standardised	clinical	
action	on	testing	in	many	at-risk	groups.		Adding	updated	NICE	testing	recommendations	to	this	table	
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does	however	highlight	the	potential	impact	of	this	policy;	particularly	with	respect	to	migrant	groups,	
who	otherwise	feature	in	a	very	limited	context	across	much	of	Europe	at	this	point	[table	3].	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Table	3:	HBV	and	HCV	testing	practice	in	European	countries	–	UK	data	updated	to	represent	2012	NICE	guideline	[UK	
(NICE)];	Adapted	from	ECDC	2010	and	Cebolla	B	2012				
	
	
According	to	the	WHO	Global	Policy	Report,	close	to	50%	of	countries	across	Europe	had	a	national	
policy	in	place	for	testing	and	referral	for	HBV	and	HCV	(table	5)	[WHO	Global	Policy	report	2012],	with	
a	further	66%	of	countries	who	had	policy	in	place	for	the	management	(treatment)	of	CVH;	with	NICE	
issuing	 several	 technology	 appraisals	 over	 the	 past	 15	 years	 advocating	 the	 evolution	 of	 different	
treatment	 strategies	 for	HBV	and	HCV.	 	 Importantly	 though,	 at	 a	 central	 governmental	 level,	 only	
France	had	provision	of	a	designated	Government	body	charged	with	oversight	and	monitoring	of	CVH	
services	at	this	time	[Table	4].		
FRANCE GERMANY	 IRELAND	 ITALY	
NETHERLAND
S UK	 UK	(NICE)
Pregnant B B B B B B B
IVDU C B C B C C B C
Immigrants B B C
GUM B B C B B C
Multiple	
Sexual	
Partner
B C B C
Prison	 B C B C B C B C
Long-term	
healthcare
B B C
Occupational-
exposure
B C B C B C B C B C
MSM B B C B
(if	
HIV)
	 68	
	
	
	
	
	
	
	
	
	
	
	
	
Table	4:	Testing	policy	and	government	control	of	testing	and	management	in	Europe;	countries	are	presented	with	their	
relative	health	expenditure	as	a	measure	of	GDP	(%);CHB	=	Chronic	HBV,	CHCV	=	Chronic	HCV	-	adapted	from	WHO		
Global	Policy	Report	2013			
Overall	then,	there	is	policy	variation	at	the	international	level	towards	CVH	testing,	as	well	as	variation	
in	CVH	care,	with	the	UK	felt	to	be	performing	poorly	with	regard	to	CVH	care	despite	the	existence	of	
multiple	policy	documents.	 This	 fact	was	emphasised	 in	 the	2010	 report	by	Sir	Mike	Richards,	 the	
(then)	National	Cancer	Director,	who	identified	the	UK	as	coming	13th	out	of	14	developed	countries	
in	the	appropriate	use	and	provision	of	HCV	drugs	for	eligible	patients.	In	this	report	Italy	and	France	
(1st	and	3rd	places	respectively)	were	in	the	top	rankings,	and	looking	at	tables	3	and	4,	these	rankings	
would	 seem	 independent	 of	 policy	 content	 alone,	 and	 also	 independent	 of	 national	 healthcare	
expenditure	[Richards	M	2010].	
Migrant	testing	policy	is	seen	to	vary	significantly	between	countries,	despite	shared	risks	that	many	
of	these	countries	will	face.	As	with	US	policy,	the	rationale	for	this	is	not	explicit,	but	felt	to	represent	
gaps	in	data	that	exist	regarding	CVH	risks	from	many	countries	in	the	world,	who	continue	to	suffer	
from	 structural	 resource	 constraints,	 as	 well	 as	 a	 lack	 of	 prevalence	 data	 on	 migrant	 groups	 in	
developed	countries,	with	testing	recommendations	in	these	policy	documents	frequently	qualified	
as	“low	quality	evidence”	accordingly	[WHO	February	2017].		
The	history	of	HBV	&	HCV	testing	policy	and	practice	in	England:	
The	Department	of	Health	first	recognised	HBV	and	HCV	as	a	priority	following	the	report	“Getting	
Ahead	of	the	Curve”	by	the	then	Chief	Medical	Officer,	Sir	Liam	Donaldson	[DoH,	Getting	Ahead	of	the	
Curve	2002].	This	report	highlighted	the	growing	burden	of	HBV	and	HCV	infection,	and	the	benefits	
Country
(Health	
expendit
ure	%)
Written	
National	
Guideline	
HBV/HCV
Designate
d	Gov.	
Body	
oversight
Gov.	Viral	
Hep	B/C	
prevention	
and	control	
policy
Chronic	
HBV	/	HCV	
monitoring
National	
Policy	to	
prevent	
viral	
hepatitis	in	
PWID
National	
HBV/HCV	
management	
guidelines
National	
Screening	
and	Referral	
Guidelines
France
(11.88%)
ü ü ü CHB ü ü ü
Germany
(11.64%)
û û û CHCV û ü Only	HCV
Ireland
9.19%
û û ü ü ? û û
Italy
9.53%
û û ü û ü û û
Netherlan
ds
11.92%
û û ü CHB ü ü ü
UK
9.64%
ü û ü ü ü ü ü
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of	treating	these	diseases	early	before	complications	develop.	The	report	also	demonstrated	many	of	
the	risk	factors	for	HBV	and	HCV	that	warrant	viral	testing,	and	the	importance	of	HBV	vaccination	
strategies	in	at	risk	groups.		
Chronic	 HCV	 infection	 was	 highlighted	 as	 an	 important	 disease	 to	 tackle	 in	 this	 report,	 with	 the	
consequent	publication	of	 the	HCV	Strategy	 for	England	 in	2002	 [DoH,	Hepatitis	C	 Strategy	2002],	
outlining	testing	and	management	guidance	for	HCV,	focusing	principally	on	harm-reduction	in	those	
who	use,	or	who	are	likely	to	inject	drugs	(namely	injecting	drug	users,	and	the	prison	population	in	
this	report).	Specific	linked	strategies	were	also	recommended,	including	the	formation	of	Managed-
Clinical	Networks:	where	GPs	could	refer	suspected	HCV	cases	into	a	central	hepatology	hub	allocated	
to	each	region.		A	formal	“Hepatitis	C	Action	Plan”	was	published	shortly	after	this	in	2004,	acting	as	a	
framework	 to	 institute	 earlier	 recommendations,	 and	 to	 highlight	 the	 importance	 of	 awareness-
raising	in	the	public	and	healthcare	setting.		
Best-practice	guidelines	on	 testing	at-risk	 groups	 for	HCV	were	also	 issued	 in	2004,	 aimed	at	GPs,	
Genito-Urinary	clinics	(GUM),	Prison	health	workers	and	Drug	and	Alcohol	teams	to	improve	testing	
rates	[DoH,	Hepatitis	C,	Essential	Information	for	professionals	and	guidance	on	testing,	2004].	These	
guidelines	recommended	offering	HCV	testing	to	all	people	if	they	had/were:	
• Ever	injected	drugs/currently	inject	
• Received	blood	transfusion	in	UK	before	1991,	or	blood	products	before	1986	
• Recipient	of	organ/tissue	transplant	in	the	UK	before	1992,	or	abroad	in	med/high-risk	setting	
• Children,	if	maternal	HCV	
• Regular	sexual	partner	of	HCV	individual	
• Exposed	health-care	worker	
• Received	medical/dental	work	abroad	in	risk-setting	
• HIV	positive	individual	
• Received	tattoo	or	piercing	in	at-risk	area/surroundings	
DoH	 guidelines	 were	 coupled	 with	 promotional	 and	 educational	 material,	 with	 the	 provision	 of	
detailed	HCV	booklets,	DVDs	and	Case-Examples	to	all	General	Practitioners	following	the	2004	HCV	
strategy	 (The	 DoH	 “FaCe	 it”	 campaign).	 However	 despite	 guideline	 development	 and	 educational	
endeavours,	uptake	and	integration	of	guidance	was	perceived	to	be	poor	and	variable	across	the	UK.		
A	study	by	D’Souza	et	al	in	2004	following	guideline	and	educational	delivery	showed	varying	levels	of	
knowledge	 regarding	HCV,	with	 14%	of	GPs	 incorrectly	 believing	 that	 an	 anti-HCV	 antibody	 result	
represented	a	cure,	rather	than	potential	acute	infection	from	HCV.	Further	studies	by	the	same	group	
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identified	a	poor	knowledge	base	in	primary	care	regarding	at-risk	groups	for	testing	and	those	who	
should	be	referred	for	treatment;	a	fact	recognised	in	subsequent	HCV-specific	guidance	issued	by	the	
RCGP	(Royal	College	of	General	Practitioners)	in	2007	[D’Souza	2004b;	RCGP	2007]	
Audit	studies	conducted	by	the	APPHG	(All	Party	Parliamentary	Hepatology	Group)	amongst	Primary	
Care	Trusts	(PCTs)	in	2006	showed	poor	uptake	and	prioritisation	of	the	HCV	Action	plan	at	the	regional	
(community)	level,	with	only	8%	having	reported	enacting	the	plan,	and	over	a	third	of	PCTs	nationally	
(36%)	 making	 little	 or	 no	 steps	 to	 implement	 the	 plans.	 Follow-up	 audits	 in	 2008	 showed	
improvement,	but	with	still	only	1/3rd	of	PCTs	having	managed	to	engage	with	the	HCV	Action	Plan;	
leading	 to	 the	APPHG’s	 conclusions	 that	HCV	 care	was	 conducted	 in	 a	 “post-code	 lottery”	 system	
across	the	country	[All	–Party	Parliamentary	Hepatology	Group,	2006;	2008].		
HBV	testing	policy	has	historically	 focused	on	testing	and	vaccination	strategies	 in	certain	high	risk	
groups,	with	antenatal	screening	being	the	main	policy	focus	(with	high	risks	of	vertical	transmission	
for	HBV,	as	well	as	available	treatment	options	for	pregnant	HBV	women).	Many	high	risk	groups	were	
highlighted	in	the	initial	2002	DoH	report,	but	migrant	groups	were	not	highlighted	as	a	specific	risk	
group	until	subsequent	reports	in	2006	[HPA	migrant	health	2006],	and	only	appear	definitively	in	the	
latest	2012	NICE	document.	Universal	HBV	vaccination	was	only	recently	introduced	in	the	UK	in	2017.		
Antenatal	HBV	screening	has	been	 in	place	 in	the	UK	since	2000	following	a	Department	of	Health	
directive,	which	standardised	previously	adhoc	testing	systems.	Over	time,	and	with	the	existence	of	
HBV	therapies	that	can	be	delivered	during	pregnancy,	antenatal	HBV	testing	has	become	culturally	
ingrained	 into	 health	 practice,	 but	 even	 in	 this	 well	 adopted	 testing	 system	 there	 are	 problems.	
Maternal	testing	results	are	typically	relayed	to	the	responsible	midwifery	team,	who	may	or	may	not	
be	based	in	primary	care.	Onward	referrals	are	made	during	pregnancy	by	the	obstetric	team	(or	GP),	
with	 the	 focus	 primarily	 to	 prevent	 transmission	 to	 baby.	 Maternal	 treatment	 is	 generally	 only	
indicated	if	very	high	viral	loads	are	detected,	and	for	most	mothers	identified	through	this	system,	
follow-up	 post-delivery	 relies	 upon	 continued	 patient	 engagement,	 with	 or	 without	 active	 GP	
engagement.	Prior	to	the	recent	universal	vaccination	policy,	vaccination	rates	to	at-risk	babies	was	
known	to	be	sub-optimal,	with	only	49%	receiving	a	full	course	of	injections	[DoH	2011],	and	there	is	
no	organised	strategy	to	identify	or	test	the	father	/	partner	of	an	infected	mother,	which	is	reflected	
more	 globally	 across	 the	 health-system,	 with	 the	 lack	 of	 priority,	 oversight,	 coordination	 and	
integration	 of	 services	 that	 is	 required	 to	 fulfil	 the	 contact	 tracing	 (policy)	 requirements	 for	 CVH	
[Personal	experience	and	reports	–	Surrey	Pathology	Service,	2015].	
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Testing	in	migrant	communities	
Prior	to	the	development	of	NICE	guidance,	policy	guidance	from	the	DoH	did	not	include	specific	CVH	
testing	recommendations	for	migrant	communities,	but	had	listed	support	for	chronic	HBV	testing	in	
UK	migrant	communities	presented	in	the	2006	HPA	report	into	Migrant	Health;	based	upon	sentinel	
surveillance	 data	 and	 research	 studies.	 Likewise	 for	 HCV,	 testing	 recommendations	 in	 migrant	
communities	arose	 later,	and	the	UK	were	directed	primarily	 towards	the	South	Asian	community,	
based	upon	 information	from	HPA	surveillance	data,	as	well	as	research	studies.	The	DoH	acted	 in	
2009	based	upon	these	findings	to	issue	a	targeted	awareness-raising	campaign:	“hepatitis	C,	the	more	
you	know	the	better”,	with	distribution	among	existing	South	Asian	media	and	website	platforms	with	
advice-line	 support.	 It	 is	 interesting	 to	 note	 though	 that	 such	 formal	 advertising	 strategies	 or	 a	
combined	 approach	was	 not	 used	 for	 HBV,	 despite	 similar	 uncertainties	 of	 existing	 numbers,	 and	
surveillance	studies	showing	higher	prevalence	rates	in	migrant	groups	[NHS	Choices	2009,	HPA	2006]		
Policy	variation	across	the	UK		
Policy	 has	 not	 been	 designed	 or	 implemented	 universally	 across	 the	 UK.	 DoH	 guidance	 has	 been	
principally	directed	at	England,	with	Scotland,	Wales	and	to	a	lesser	degree	Northern	Ireland	adopting	
their	own	policy	action	plans.		
The	 Scottish	 HCV	 action	 plan	 deserves	mention	within	 the	 UK	 picture,	 with	 a	 structured	 2-phase	
approach	that	was	introduced	in	2006	and	been	widely	lauded.	The	three	main	aims	of	the	HCV	Action	
Plan	were	to:		
• Prevent	the	spread	of	HCV,	particularly	among	IVDUs	
• To	increase	diagnosis	among	those	at-risk	
• To	ensure	that	those	who	are	infected	receive	optimal	treatment	and	support	
Phase	1	of	 this	plan	 (2006-08)	was	developed	 to	 identify	 the	actual	prevalence/burden	of	disease	
posed	by	HCV;	 the	needs	of	 these	at-risk	 individuals,	and	 the	quality	and	quantity	of	existing	HCV	
services.	Phase	2	(2008-11)	was	developed	based	on	these	findings,	and	allocated	a	dedicated	budget	
of	£43.2	million,	allocated	to	a	total	of	34	actions	identified	from	phase	1	(over	a	3	year	period).	Of	
this	budget,	£8	million	was	allocated	to	NHS	boards	for	prevention,	and	£28.7	million	allocated	for	
testing,	treating	and	support	costs,	with	a	further	£6.5	million	defined	for	national	coordination	and	
information	generation.		
Specific	actions	generated	from	this	plan	included	the	development	of	learning	and	support	tools	for	
the	HCV	workforce	(including	Scottish	Intercollegiate	Guidelines	Network;	SIGN	recommendations),	
the	 formation	 of	Managed	 Care	 Networks	 (MCNs)	 comprising	 healthcare	 specialists	 and	 relevant	
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stakeholders	to	provide	coordinated	and	standardised	care	to	patients,	and	the	development	of	an	
organisational	structure	with	accountability	reporting	from	lead	organisations	to	the	central	Scottish	
Government	Public	Health	and	Health	Improvement	Directorate	(SGPHHID)	(summarised	in	Fig	5)	[HPS	
2010].	
	
	
Figure	12:	Governance	structure	for	HCV	detection	and	management	in	the	Scottish	HCV	Action	Plan,	taken	from	Health	
Protection	Scotland,	HCV	action	plan,	phase	II	2009/10	[HPS	2010]		
	
Since	the	introduction	of	the	HCV	action	plan	(phase	II),	the	number	of	people	initiated	on	therapy	has	
increased	from	around	468	in	2007/08	to	1049	individuals	in	2010/11	and	has	reportedly	remained	
stable	since.	It	is	estimated	that	around	55%	of	HCV	cases	are	know	identified,	and	this	represents	an	
improvement	from	around	38%	in	2006	before	the	start	of	the	initiative.	Patient	groups,	including	the	
Hepatitis	 C	 trust	 have	 worked	 alongside	 government	 bodies	 to	 increase	 the	 awareness	 of	 HCV,	
including	 dedicated	 large-scale	 awareness-raising	 of	HCV	 at	 the	 2014	Commonwealth	 games	 [HPS	
weekly	report	2014].	Since	2011	Scottish	HCV	care	funding	has	continued	alongside	HBV	and	HIV	care	
into	 an	 integrated	 sexual	 health	 and	 blood-borne	 viruses	 framework,	with	 the	 continuing	 aims	 of	
providing	an	outcomes	driven	framework	[HPS	weekly	report	2014].	This	has	the	added	advantage	of	
pulling	HBV	care	(and	HIV)	into	an	already	successful	model	of	HCV	care].		
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A	similar	combined	Blood	borne	viruses	programme	for	HBV	and	HCV	was	also	put	into	place	in	Wales	
in	2010	[Welsh	Assembly	Government,	Blood	Borne	Viral	Hepatitis	Action	Plan	for	Wales	2010-2015].	
In	Northern	Ireland	a	HCV	action	plan	was	introduced	in	2007,	although	there	is	no	specific	policy	on	
HBV	apart	from	vaccination	strategies	[Health,	Social	Services	and	Public	Health,	2007].	As	such	there	
is	wide	variation	in	strategy	and	practice	within	the	UK,	and	the	Scottish	strategy	is	highly	praised	for	
its	 structured	 and	 coordinated	 approach	 to	 disease	 assessment	 and	 management	 [Eurohepatitis	
2012].			
NICE	hepatitis	B	and	C	testing	guidelines:	
The	National	Institute	for	Health	and	Care	Excellence	(NICE)	produced	new	specific	testing	guidance	
for	 hepatitis	 B	 and	 C	 in	 December	 2012	 (updated	 with	minor	 amendments	 in	March	 2013).	 This	
document:	Ways	to	Promote	and	Offer	Testing	to	People	at	Increased	Risk	of	Infection;	public	health	
guidance	43,	 is	 unique	 in	 its	 focus	being	directed	 at	 the	 risk	 groups	 that	 should	be	 identified	 and	
offered	testing	for	HBV	and	HCV,	and	provides	a	basis	for	case-finding	practice	in	the	UK	[NICE	hepatitis	
B	and	C	2012].	This	public	health	guidance	 is	disseminated	across	 the	UK,	but	 its	 focus	 is	directed	
primarily	 at	 practice	 in	 England.	 Unlike	 technology	 appraisals	 public	 health	 guidance	 carries	 no	
mandatory	requirements,	but	all	NHS	services,	local	authorities	as	well	as	the	wider	public	(including	
voluntary	and	community	services)	in	England	are	expected	to	take	these	guidelines	into	account	in	
their	practice	[NICE	and	the	NHS].	As	such	public	health	guidance	aims	to	direct	health	policy	through	
its	listed	recommendations.		
NICE	hepatitis	B	and	C	testing	guidelines	were	developed	following	a	request	from	the	Department	of	
Health	with	the	stated	aims:		
	“To	produce	programme	guidance	for	commissioners	and	clinicians	working	in	various	settings	on	the	
most	cost-effective	methods	for	offering	testing	for	hepatitis	B	and	C	to	those	at	risk	of	infection”	[NICE	
website:http://www.NICE.org.uk/NICEmedia/live/11957/52314/52314.pdf]		
	
Guideline	objectives:	
The	guideline	aims	are	to	increase	testing	uptake	in	at-risk	groups	and	covers	areas	including:	
• Awareness-raising	in	the	general	population	&	people	at	increased	risk	of	infection	
• Developing	the	knowledge	and	skills	of	healthcare	workers	and	professionals	who	manage	or	
interact	with	at-risk	groups	
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• Testing-uptake	in:	
o Primary	Care	
o Prisons	and	Youth	offender	instituitons	
o Immigration	removal	centres	
o Drug	services	
o Genitourinary	medicine	(GUM)	and	Sexual	health	clinics	
• Contact	tracing	of	infected	individuals	
• Auditing	and	provision	of	neonatal	HBV	vaccination		
• Commissioning	HBV	and	HCV	testing	and	treatment	services		
• Laboratory	services	for	testing	Target	groups	
The	guideline	is	aimed	at	multiple	healthcare	and	non-healthcare	groups	that	organise,	co-ordinate	
and	undertake	testing,	and	those	services	that	interact	with	at-risk	patient	groups.	This	includes:		
• Commissioners	and	providers	of	public	health	services	
• Hepatitis	testing	and	treatment	services	
• Laboratory	services	
• NHS	services	/	local	authorities	/	prisons	/	immigration	removal	centres	/	drug	services	–	that	
care	for	at-risk	groups	
• Voluntary	sector	groups	that	work	with	at-risk	individuals.		
• At-risk	groups	(e.g.	migrant	groups,	injecting	drug	use	and	next-of-kin),	or	close-contacts	Guideline	development:	
Guidance	 was	 developed	 by	 the	 Programme	 Development	 Group	 (PDG)	 based	 on	 evidence	 from	
systematic	reviews	of	study	publications,	as	well	as	expert	opinion.	The	document	considered	cost-
effectiveness	 of	 interventions,	 as	 well	 as	 facilitators	 and	 barriers	 to	 testing	 uptake	 among	 at-risk	
groups.	Draft	guidelines	were	released	for	stakeholder	and	expert	consultation	in	mid-2012,	before	
being	 amended	 and	 finalised	 in	 December	 2012	 (minor	 amendments	were	 subsequently	made	 in	
March	2013).		
	
Groups	identified	as	at-risk	for	HBV	and	HCV	
The	 risk	 groups	 identified	 at-risk	 for	 HBV	 and	 HCV	 testing	 in	 NICE	 guidance	 are	 similar	 to	 those	
previously	described,	but	are	far-reaching	 in	many	respects	to	prior	DoH	testing	recommendations	
(Table	7	&	8).		For	Hepatitis	B	the	specific	risk	groups	identified	in	NICE	guidelines	are:		
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HBV:	specific	risk	groups	“Whose	health	will	benefit?”	
• People	born	or	brought	up	 in	a	country	with	an	 intermediate	or	high	prevalence	(2%	or	greater)	of	
chronic	hepatitis	B.	This	includes	all	countries	in:	
• Africa,	Asia,	 the	Caribbean,	Central	and	South	America,	Eastern	and	Southern	Europe,	 the	
Middle	East	and	the	Pacific	islands	
• Babies	born	to	mothers	infected	with	hepatitis	B	
• People	who	have	ever	injected	drugs	
• Men	who	have	sex	with	men	
• Anyone	who	has	had	unprotected	sex,	particularly:	
o 					people	who	have	had	multiple	sexual	partners	
o 					people	reporting	unprotected	sexual	contact	in	areas	of	intermediate	and	high	
o 					prevalence)	
o 					people	presenting	at	sexual	health	and	genitourinary	medicine	clinics	
o 					people	diagnosed	with	a	sexually	transmitted	disease	
o 					commercial	sex	worker	
• Looked-after	children	and	young	people,	including	those	living	in	care	homes	
• Prisoners,	including	young	offenders	
• Immigration	detainees	
• Close	contacts	of	someone	known	to	be	chronically	infected	with	hepatitis	B	
Table	5:	NICE	risk	groups	for	HBV;	whose	health	will	benefit	[NICE	2012]		
HCV:	specific	risk	groups	“Whose	health	will	benefit?”	
• People	who	have	ever	injected	drugs.	
• People	 who	 received	 a	 blood	 transfusion	 before	 1991	 or	 blood	 products	 before	 1986,	 when	
screening	of	blood	donors	for	hepatitis	C	infection,	or	heat	treatment	for	inactivation	of	viruses	were	
introduced.	
• People	born	or	brought	up	in	a	country	with	an	intermediate	or	high	prevalence	(2%	or	greater)	of	
chronic	hepatitis	C;	this	includes	all	countries	in:	
è Africa,	Asia,	 the	Caribbean,	Central	and	South	America,	Eastern	and	Southern	Europe,	
the	Middle	East	and	the	Pacific	islands.	
• Babies	born	to	mothers	infected	with	hepatitis	C.	
• Prisoners,	including	young	offenders.	
• Looked-after	children	and	young	people,	including	those	living	in	care	homes.	
• People	living	in	hostels	for	the	homeless	or	sleeping	on	the	streets.	
• HIV-positive	men	who	have	sex	with	men.	
• Close	contacts	of	someone	known	to	be	chronically	infected	with	hepatitis	C.	
Table	6:	NICE	risk	groups	for	HCV;	whose	health	will	benefit	[NICE	2012]			
	
	 76	
The	inclusion	of	testing	recommendations	in	all	 individuals	who	have	had	unprotected	intercourse,	
and	the	wide	inclusion	of	testing	in	all	migrant	groups	born	or	originating	outside	of	Northern	Europe	
and	the	US	highlight	how	wide	reaching	these	testing	recommendations	are,	and	the	ambitious	nature	
of	these	recommendations	over	previous	national	guidance.		
	
Guideline	Recommendations:	
The	NICE	document	 identifies	 11	 recommendations	 based	upon	evidence	presented	 in	 systematic	
review	 papers,	 as	 well	 as	 expert	 consensus	 opinion.	 The	 full	 recommendations	 provide	 a	
comprehensive	 list	 of	 testing	 recommendations	 that	 are	 aimed	 at	 all	 healthcare	 and	 allied	
professionals	that	interact	with	the	diverse	at	risk	groups	who	should	be	offered	testing.		
These	 recommendations	 cover	 awareness-raising,	 testing	 activity,	 contact	 tracing,	 as	 well	 as	
commissioning	responsibilities.	Some	of	the	groups	referenced	are	in	prison	and	immigration	centres,	
and	GUM	clinics,	and	the	most	relevant	of	NICE	recommendations	towards	community	migrant	testing	
is	presented	in	table	7	below:	
Recommendation	1:	Awareness-raising	in	the	general	population	
This	recommendation	is	to	raise	the	profile	of	HBV	and	HCV	in	the	general	community;	including	the	main	
routes	of	 transmission,	 the	 asymptomatic	 nature	of	 chronic	 infection	 and	benefits	 of	 early	 diagnosis	 and	
treatment.		
Recommendation	2:	Awareness-raising	for	people	at	increased	risk	of	HBV	or	HCV	
These	 aims	 are	 similar	 but	 targeted	 to	 at-risk	 groups,	 including	 those	 attending	 drug	 services,	 migrant	
community	meetings	or	cultural	sessions.	Healthcare	and	community	workers	are	advised	to	promote	the	
importance	of	testing,	the	implications	of	having	HBV	and	HCV	and	the	benefits	of	early	identification	and	
treatment.		
In	both	recommendations	the	importance	of	overcoming	the	stigma	surrounding	HBV	and	HCV	is	emphasised,	
as	well	 as	 the	 need	 to	 address	material	 in	 a	 culturally	 appropriate	manner.	Many	 groups	may	 also	 have	
difficulty	 with	 written	 material,	 and	 other	 methods	 of	 communication	 may	 also	 be	 needed.	 These	
recommendations	 are	 targeted	 at	 Government	 health	 departments,	 Local	 authority	 groups,	 Primary	 and	
Secondary	care,	GUM	services	and	not-for-profit	and	non-governmental	agencies.		
	
Recommendation	3:	Developing	the	knowledge	and	skills	of	healthcare	professionals	and	others	providing	
services	to	at-risk	groups	
On-going	education	programmes	are	advised	for	doctors,	nurses,	allied-healthcare	professionals	as	well	as	
non-medical	staff	working	with	at-risk	groups	to	increase	adherence	to	guidelines,	to	improve	testing	uptake,	
and	to	improve	the	care	and	of	established	HBV	and	HCV	individuals	who	may	not	be	under	appropriate	follow	
up.		
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These	educational	recommendations	are	aimed	at	the	Royal	colleges,	Public	Health	England,	Local	authorities,	
local	education	centres	and	clinical	commissioning	groups.		
Recommendation	4:	Testing	for	Hepatitis	B	and	C	in	primary	care	
This	is	aimed	at	General	Practitioners	and	practice	nurses,	antenatal	services	and	local	community	services	
that	 serve	 migrant	 groups.	 This	 recommends	 testing	 among	 at-risk	 groups	 that	 present	 to	 primary	
care/community	services,	and	provides	advice	that	includes:	
• GPs	and	practice	nurses	should	offer	testing	for	adults	and	children	at-risk	for	HBV/HCV,	particularly	
in	migrant	groups	from	medium-,	or	high-prevalent	countries,	and	in	those	with	an	injecting	history	
(including	performance	enhancing	drugs).		
• Newly	registered	adults	should	be	questioned	about	injecting	drug	use	history.		
• HBV	testing	and	vaccination	should	be	offered	to	men	who	have	sex	with	men	who	are	offered	a	HIV	
test	(if	no	evidence	of	HBV	immunity)		(This	relies	upon	co-existing	NICE	HIV	testing	guidance	that	
recommends	offering	HIV	testing	to	men	who	disclose	that	they	have	sex	with	other	men,	or	if	there	
is	a	large	community	of	men	who	has	sex	with	men,	a	high	local	HIV	prevalence	rate,	or	if	requesting	
testing	for	other	sexually	transmitted	infections	[NICE,	March	2011].		
• HBV	vaccination	should	be	administered	to	all	groups	 in	primary	care	that	are	at-risk	of	on-going	
infection,	 and	 HCV	 testing	 should	 be	 offered	 annually	 to	 at-risk	 groups	 regardless	 of	 an	 initial	
negative	test.		
• All	HBV	or	HCV	diagnosed	patients	should	be	referred	to	speciality	care	
• Local	community	services	working	with	migrant	groups	should	work	in	partnership	with	primary	care	
practitioners	 to	promoted	HBV	and	HCV	 testing	 in	 adult	 and	 children	at-risk	 groups.	Awareness-
raising	should	be	a	priority,	with	promotion	of	local	health	testing	and	treatment	support.		
• Antenatal	staff	at	a	hospital,	community	and	primary	care	level	should	ask	about	risk	factors	for	HCV	
during	pregnancy,	and	offer	testing	to	those	with	an	increased	risk.			
	
Recommendation	10:	Commissioning	locally	appropriate	integrated	services	for	hepatitis	B	and	C	testing	
and	treatment	
This	covers	the	formation	of	a	locally	tailored	service	for	HBV	and	HCV	based	on	the	underlying	prevalence	in	
each	region.	It	recommends	the	addition	of	HBV	and	HCV	into	the	health	and	wellbeing	board’s	joint	strategic	
needs	assessment,	which	would	involve	CCG’s	monitoring	absolute	HBV	and	HCV	numbers	in	each	area,	as	
well	as	predictions	based	on	the	prevalence	of	at-risk	groups	(including	migrant	and	injecting	users)	to	take	
account	of	 those	 yet	 to	be	 tested.	Recommendations	 are	 also	 given	 for	GPs	 to	develop	 locally	 enhanced	
services	with	extra	service	provisions	offered	in	areas	of	high	HBV	and	HCV	prevalence.	Specific	information	
is	not	given	on	how	these	services	can	be	set-up,	but	the	role	of	audit	is	emphasised	to	monitor	the	uptake	
of	testing,	referral	and	treatment	success	to	ensure	care	plans	are	achieved.		Recommendations	are	given	for	
community	 services	 to	 be	 integrated	 with	 local	 specialist	 care	 to	 ensure	 there	 is	 a	 continuity	 between	
community	testing	services	and	treatment	centres.		
Table	7:	NICE	CVH	testing	recommendations		(selected,	in	relation	to	community	(documented)	migrant	testing)	
Looking	 at	 these	 recommendations	 and	 the	 “at-risk”	 groups	 that	 they	 apply	 to,	 these	
recommendations	seem	far-reaching	 in	comparison	 to	previous	national	policy	endeavours,	and	 in	
comparison	to	international	guidance	issued	at	the	same	time.	Testing	in	primary	care	is	a	key	facet	in	
these	recommendations,	with	priority	status	in	the	potential	provision	of	CVH	testing	to	members	of	
the	newly	arrived	UK	Nepali	population.		
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The	potential	of	this	policy	to	facilitate	and	standardise	testing,	as	well	as	linkage	to	care	in	migrant	
groups	 including	 the	Nepali	 community	 therefore	 seems	 substantial	 and	 significant.	However,	 the	
adoption	and	implementation	of	this	policy	is	largely	unknown,	with	real	concern	that	NICE	guidance	
may	experience	the	same	difficulties	in	uptake	and	understanding	as	previous	DoH	led	guidance	over	
the	past	10	years	[De	Souza	2005,	APPHG	2011].		
The	following	section	presents	a	policy	analysis	of	these	NICE	testing	recommendations,	as	an	attempt	
to	understand	and	demonstrate	the	potential	 facilitators	and	barriers	 that	exist	 in	achieving	policy	
potential,	and	bringing	NICE	CVH	testing	recommendations	into	priority	and	focus.		
Policy	Analysis	–	Prioritising	HBV	and	HCV	testing	policy	
Policy	analysis	 is	a	method	to	explore	and	explain	aspects	that	 influence	the	success	and	failure	of	
policy.	Analysis	may	look	at	the	(written)	content	of	policy	alone,	but	more	importantly	policy	analysis	
can	be	framed	and	focused	to	understand	how	Power	and	Process	influences	the	policy	process	[Buse	
2005].		
Policy	 arises	 from	 a	 process	 of	 actions	 (or	 inactions)	 and	 relies	 upon	 a	 process	 of	 events	 for	
implementation.	This	policy	process	is	complex	and	dynamic,	with	the	Stages-Heuristic	model	one	of	
the	 most	 widely	 used	 methods	 to	 consider	 this	 process	 in	 linear	 (simplified)	 component	 parts		
[Sabatier	2007,	Buse	2005]	(figure	13).	
Figure	13:	The	Stages	Heuristic	model	of	the	policy	process	–	this	policy	process	can	be	further	considered	as	
following	a	“rational-choice	approach”	–	following	top-down	chain	of	command	following	shared	objectives,	
or	an	“advocacy	coalition	framework”	–	with	belief	systems	and	affiliations	between	actors	and	institutions	
that	influence	objectives	and	policy	activities	[Sabatier	2007]						
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Policy	analysis	can	therefore	take	many	forms,	framed	to	look	at	different	parts	of	this	policy	process;	
considering	the	focus	and	impact	of	those	who	make	decisions	(Actors,	and	the	Power	they	possess	
and	utilise),	as	well	as	how	decisions	are	made	and	implemented	(Processes)	[Buse	2005].		
Well	 utilised	 policy	 analysis	 approaches	 include	 the	 broad-systematic	 Health	 Policy	 Triangle	
framework	presented	by	Walt	et	al,	looking	at	the	role	and	relations	between	(central)	actors,	policy	
content,	context	and	processes	in	how	(and	why)	policy	is	(or	is	not)	formed	and	implemented		[Walt	
et	al.	1994].	Policy	analysis	 frameworks	may	explore	theories	of	Top-down	(rational)	or	Bottom-up	
(incremental)	approaches	 to	policy	 implementation,	such	as	 the	use	of	Street-level	Bureaucracy	 to	
explore	 the	 role	 and	 interaction	 of	 front-line	 staff	 in	 policy	 implementation	 [Buse	 2005].	 	 Other	
approaches	 may	 focus	 on	 the	 complex	 interactions	 between	 Actors	 across	 different	 healthcare	
settings	 (Actor	 Networks),	 such	 as	 the	 Advocacy	 Coalition	 framework;	 looking	 at	 how	 shared	
beliefs/values	influence	policy	across	multiple	levels	in	the	policy	process	[Sabatier	2007,	Cerna	L	OECD	
2013,	Walt	2008].	
Current	NICE	 testing	policy	 is	 far-reaching	 in	comparison	to	historic	 testing	recommendations,	and	
international	policy.	However,	as	we	have	already	 seen,	previous	 recommendations	have	 received	
little	 priority,	 particularly	 in	 community	 (Primary)	 healthcare,	 where	 the	 burden	 of	 disease	 is	 the	
highest	 [APPHG	 2008,	 2011,	 D’Souza	 2004].	 It	 is	 important	 to	 therefore	 understand	 factors	 that	
influence	the	level	of	support	that	NICE	policy	receives,	and	how	testing	policy	can	prioritised	so	as	to	
increase	testing	opportunities	in	migrant	communities.		
The	Policy	Prioritisation	Framework:		
Analysing	policy	prioritisation	looks	at	the	barriers	to	achieving	political	attention	and	support,	and	
the	 effect	 of	 this	 on	 policy	 goals.	 The	 framework	 presented	 by	 Schiffman	 and	 Smith,	 and	 further	
developed	by	Walt	et	al.	provides	such	an	analytical	approach,	with	political	priority	defined	as	when:	
“political	leaders	consider	an	issue	to	be	worthy	of	sustained	attention	and	will	back	up	that	attention	
with	the	provision	of	financial,	human,	and	technical	resources	commensurate	with	the	severity	of	the	
problem”	 [Schiffman	 et	 al.	 2007].	 Schiffman	 further	 describes	 this	 state	 as	 being	 met	 when	 3	
conditions	are	achieved	[Schiffman	2007,	Tomlinson	2012]:	
1. National	political	leaders	publicly	and	privately	express	sustained	concern	for	the	issue	
2. The	government	enacts	policies	to	address	the	issue	
3. Resources	(appropriate	to	the	disease	burden)	are	allocated	and	released		
The	following	discussion	will	use	this	framework	to	analyse	the	level	of	prioritisation	that	is	seen,	or	
could	 be	 expected	 to	 be	 achieved	 with	 current	 NICE	 testing	 policy.	 Policy	 prioritisation	 can	 be	
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visualised	as	part	of	the	“agenda-setting”	process	in	the	stages-heuristic	model,	and	therefore	whilst	
it	does	not	focus	on	all	aspects	of	the	policy	process	(including	implementation);	achieving	this	political	
priority	is	of	crucial	importance	to	NICE	testing	policy,	and	in	improving	the	uptake	of	viral	hepatitis	
testing	in	migrant	groups.		
The	original	framework	presented	by	Schiffman	and	Smith	include	11	determinant	of	political	priority	
grouped	into	4	categories:	Actor	Power,	 Ideas,	Political	Context	and	Issue	Characteristics.	Although	
initially	applied	to	the	international	stage,	the	framework	has	also	been	utilised	on	the	national	health	
policy	stage	[Walt	2014,	Tomlinson	2012].	This	framework	was	further	adapted	in	a	review	conducted	
by	Walt	et	al,	with	the	addition	of	an	“Outcome”	category	to	the	original	framework	[Walt	2014].		
Support	(prioritisation)	is	more	likely	to	be	achieved	if	specific	objectives	are	met	across	each	of	the	
framework	components,	with	a	summary	of	this	adapted	framework	presented	in	figure	14.		
	
	
Figure	14:	The	political	priority	framework,	adapted	with	input	from	Walt	and	Gilson	[Shiffman	et	al.	2007,	Walt	2014]	
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The	following	discussion	utilises	this	framework	to	analyse	the	support	that	is	seen,	or	could	be	seen	
for	NICE	viral	hepatitis	testing	policy	in	migrant	communities.		
Actor	Power:	
The	actors	(stakeholders)	involved	in	health	policy	consider	the	individuals,	groups	and	organisations	
that	affect	health	policy.	This	may	include	members	of	(central	and	local)	government,	policy	advisors,	
healthcare	professionals,	and	patient	and	charity	groups.	Most	actors	cause	effect	as	part	of	a	group	
or	organisation,	and	their	role	or	action	typically	reflects	the	standing	(power)	of	the	group	to	promote	
or	attenuate	policy	outcomes	[Buse	2005].		
Actors	 may	 affect	 policy	 through	 its	 promotion,	 but	 equally	 may	 act	 to	 limit	 or	 hinder	 policy	
development	and	adoption.	The	power	or	ability	of	each	group	to	effect	policy	 is	a	measure	of	 its	
influence	to	exert	outcome,	and	this	“power”	can	be	thought	of	as	the	political	resources	available	to	
the	 group/individual;	whether	or	 not	 this	 power	 is	 real	 or	 perceived.	 Political	 resources	may	be	 a	
measure	of	social	standing,	wealth,	job	or	official	position,	as	well	as	the	level	of	access	to	knowledge	
in	a	particular	field	that	facilitates	an	authoritative	status	[Buse	2005].	
The	 role	 and	 position	 of	 Actors	 is	 therefore	 crucial	 in	 the	 policy	 process,	 from	 initiation	 to	
implementation	and	reform;	with	successful	initiatives	known	to	differ	based	on	the	strength	of	those	
who	participate	 in	 them,	as	well	as	 the	quality	of	 linkages	between	these	actors	 in	 their	collective	
efforts	[Shiffman	et	al	.	2007].		
Actors	in	the	CVH	testing	policy	process:		
The	actors	 involved	 in	CVH	 testing	and	care	 include	Government	and	departmental	agencies	 (NHS	
England),	Local	Authorities,	PHE,	CCGs,	Primary	Care	and	other	community	health	organisations,	as	
well	as	patient	advocacy	groups	and	pharmaceutical	agencies.	These	actors	can	occupy	positions	that	
are	unique	or	multiple	across	the	macro,	meso	and	micro	levels	linked	towards	policy	and	its	action;	
in	this	case	with	the	micro-level	delivery	of	CVH	testing	at	the	community	level.		
The	priority-setting	framework	identified	by	Shiffman	and	Smith	considers	Actor	Power	as	a	measure	
of	Community	Cohesion,	Strength	and	Leadership,	the	Effectiveness	of	organisations,	as	well	as	the	
Mobilisation	of	civil-society	and	grass-roots	organisations	in	achieving	policy	objectives	(figure	14).		
The	commissioning	responsibilities	of	the	principal	stakeholders	in	CVH	testing	and	management	is	
presented	 in	fig	15..	Commissioning	 is	the	process	of	planning,	purchasing	and	monitoring	services	
[Kings	 Fund	 Clinical	 Commissioning],	 with	 commissioning	 responsibilities	 for	 CVH	 testing	 that	 lies	
between	 NHS	 England,	 Local	 Authorities,	 PHE	 and	 CCGs.	 In	 CVH	 care,	 NHS	 England	 commissions	
services	 for	 testing	 activity	 in	 primary	 care,	 with	 Local	 Authorities	 responsible	 for	 commissioning	
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activity	that	takes	place	in	drug	and	alcohol	centres,	or	sexual	health/GUM	clinics.	Specialist	referral	
to	 secondary	 care,	 and	monitoring	 activity	 in	 clinics	 is	 commissioned	 by	 CCGs,	 and	 CCGs	 are	 also	
responsible	for	commissioning	services	for	those	individuals	who	develop	end	stage	complications	of	
cirrhosis,	 including	HCC	and	 transplantation	 (with	 the	exception	of	drug	 costs)	 [HCV	Action	2016].	
CCGs	are	also	tasked	with	the	development	of	established	referral	networks	to	secondary	care,	which	
may	 then	 be	 used	 by	 Local	 Authority	 agencies	 if	 required	 under	 other	 community	 based	 testing	
initiatives.	Antenatal	testing	as	part	of	the	Infectious	diseases	in	pregnancy	screening	programme	falls	
under	the	commissioning	responsibilities	of	NHS	England	area	teams,	as	well	as	CCG	linked	antenatal	
teams	[NICE	2014].	Importantly,	recent	specialist	commissioning	arrangements	taken	by	NHS	England	
have	 led	 to	 the	 centralised	 commissioning	 of	 CVH	 treatments	 [NHS	 England	 September	 2017],	
reducing	the	burden	on	CCGs,	and	driving	the	establishment	and	legitimacy	of	Operational	Delivery	
Networks	(ODNs);	created	in	the	UK	to	deliver	high	cost	CVH	drugs	in	expert	central	(hub)	centres,	to	
other	peripheral	(spoke)	hospitals	[NHS	England	July	2017]	(figure	15).		
	
	
	
Figure	15:	:	The	commissioning	relationship	&	responsibilities	for	NHS	England,	CCGs	(Clinical	Commissioning	Groups)	
and	Local	Authorities	in	the	testing	and	management	of	CVH.	PHE	(Public	Health	England)	plays	a	role	at	all	levels,	as	
well	as	its	role	in	the	Health	and	Wellbeing	Boards	in	monitoring	and	providing	feedback	on	local	CVH	needs	in	the	
population	(adapted	from	NHS	England	HIV	services	2015)
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	Policy	Community	Cohesion:	
“A	policy	 community	 that	 agrees	 on	 how	 the	 problem	 should	 be	 solved	 are	more	 likely	 to	 acquire	
political	support”	[Shiffman	J	2007].		
Cohesion	in	the	Policy	development	process:	Looking	at	the	CVH	policy	development	process,	it	can	be	
seen	that	this	follows	largely	a	“top-down”	approach	[Buse	K	2005],	with	little	direct	involvement	of	
primary	care	or	representatives	from	the	(then)	Primary	Care	Trusts	(PCTs).	A	representation	of	this	
programme	development	group	(PDG)	is	demonstrated	in	figure	x,	with	the	PDG	receiving	evidence	
from	2	systematic	public	health	reviews,	1	economic	modelling	study	[Jones	a,	2012;	Jones	b,	2012;	
Martin	2013],	 as	well	 as	oral	 testimonies	 from	health	experts	 (including	1	GP)	and	members	 from	
potentially	at-risk	communities	(the	International	Union	of	Sex	Workers,	and	a	presentation	on	behalf	
of	Chinese	interpreters)	(figure	16,	table	8).		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	16:		:	NICE	guideline	stakeholders	
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Presentation	 Content	 Position	
UK	 National	 Screening	 Council	
(UKNSC)	
Difference	 between	 Case-finding	
and	Screening	
Unclear:	Previous	publications	
[Allaby	M	2010]	did	not	
recommend	a	screening	
programme	for	Hepatitis	B	&	C	
among	ethnic	minorities	
HPA	 Selective	 vaccination	 of	 high-risk	
groups	is	not	cost-effective			
There	are	gaps	in	the	knowledge	of	
viral	 hepatitis;	 with	 regard	 to	
epidemiology	 and	 progression	
(cirrhosis	 rates	 are	 higher	 in	
Taiwan	vs	USA	for	HBV)	
Supportive		
Ministry	of	Justice	 High	 rates	 of	 HCV	 in	 prisons	
(14.7%),	 second	 only	 to	 PWID.		
HBV	 vaccination	 and	 HCV	
treatment	aims	presented.	
Supportive		
Birmingham	Hospitals	Children’s	
Services	
Overall	limited	data	on	paediatric	
HBV	and	HCV.	Role	of	testing	new	
immigrant	families	and	asylum	
seekers	presented,	but	again	
limited	data	sets.	Benefit	of	early	
harm-reduction	strategies,	
including	in	care-homes.	Role	of	
GPs	and	Community	centres	in	
reaching	at-risk	groups	presented	
Supportive	
Primary	Care	Physician		
(GP	 with	 Special	 Interest	 in	
Substance	Abuse;	Royal	College	of	
General	Practitioners)	
There	 is	 a	 knowledge	 gap	 in	
primary	 care	 relating	 to	 viral	
hepatitis,	with	accompanying	fear.	
Lack	 of	 prioritisation	 concerning	
viral	 hepatitis,	 and	 the	 role	 of	
case-finding	 in	 primary	 care.	
Recommends	the	development	of	
clear	concise	guidelines	 for	GP	 to	
improve	testing	practice	
Supportive	
LSHTM	(Public	Health)	 The	role	and	benefit	of	testing	for	
viral	 hepatitis	 in	 Drug	 and	
Addiction	Services	
Supportive	
Table	8:	Summary	of	expert	testimony	presentations	to	the	NICE	PDG	(Programme	Development	Group)	
with	the	inferred	position	statement	of	each	group;	PWID	=	People	who	inject	drugs,	LSHTM	=	London	
School	of	Hygiene	and	Tropical	Medicine		
Overall,	the	position	of	these	evidence	pieces	is	supportive	towards	improved	CVH	testing	initiatives,	
and	whilst	there	are	uncertainties	that	are	discussed	regarding	the	understanding	of	underlying	CVH	
risks,	there	is	broad	consensus	to	improve	CVH	testing	initiatives,	and	this	is	represented	in	the	policy	
wording.	The	position	taken	by	the	UK	National	Screening	Council	(UKNSC)	is	somewhat	unclear,	and	
previous	screening	estimates	in	2010	identified	numerous	gaps	in	the	attempted	implementation	of	
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such	policy	(although	screening,	over	case-finding),	and	it	is	likely	that	the	PDG	would	have	been	aware	
of	these	previous	suggestions	[Allaby	2010].	
Policy	cohesion	in	principal	stakeholders:	The	actor	network	involved	with	CVH	case-finding	activity	is	
complex,	with	a	summary	of	these	relations	that	is	presented	in	figure	17.	Case-finding	activity	and	
testing	in	migrant	groups	is	delivered	at	the	micro-level,	with	primary	care	testing	activity	that	is	likely	
to	be	the	most	effective	route	of	intervention	on	a	wide	scale.			
Figure	17:		A	network	map	of	relations	between	the	principal	Actors	involved	in	community	CVH	testing	and	
onward	care.	Red-lines	indicate	the	feedback	loops	that	should	be	in	place	to	report	and	monitor	CVH	rates	
as	part	of	the	Joint	Health	and	Wellbeing	Strategy.		
At	the	central	government	level,	senior	(executive)	politicians	have	expressed	support	for	liver	disease	
and	 HCV	 in	 particular,	 with	 the	 Prime	 Minister	 David	 Cameron	 expressing	 his	 support	 whilst	 in	
opposition	 and	 in	 government;	 including	 his	 statement	 issued	 on	 World	 Hepatitis	 day	 in	 2012	
highlighting	the	need	to	improve	testing	for	HCV	[Hep	C	trust	website	March	2013]:		
“With	 more	 people	 being	 tested	 for	 hepatitis	 C,	 and	 treatments	 improving	 all	 the	 time,	 an	 early	
diagnosis	can	make	a	real	difference.	But	it's	critical	that	people	who	could	be	at	risk	continue	to	be	
tested,	as	it’s	a	disease	which	can	go	undetected	for	years.	We	are	looking	at	how	we	can	strengthen	
efforts	 to	prevent	and	 control	hepatitis	C	 in	 the	 future,	as	part	of	our	 strategy	 for	 combating	 liver	
disease.	But	today,	on	World	Hepatitis	Day,	I	urge	everyone	who	could	be	at	risk	to	go	and	get	checked	
out.”	
Support	for	CVH	testing	policy	would	also	seem	evident	at	the	government	departmental	level,	with	
the	DoH	(Department	of	Health)	having	issued	high	level	policy	documents	to	advocate	for	CVH	testing	
for	over	10	years,	including	specific	targeted	interventions	to	improve	and	explore	CVH	testing	in	the	
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South	Asian	community	[Hepatitis	C;	the	more	you	know,	the	better,	2009].		The	Chief	Medical	Officer	
(CMO)	has	been	likewise	been	consistent	in	raising	the	profile	of	CVH	in	reports	to	the	DoH,	including	
the	 2012	 “On	 the	 State	 of	 the	 Public	 Health”	 report,	 which	 highlighted	 the	 growing	 burden	 of	
morbidity	and	mortality	from	liver	diseases	 in	the	UK	over	other	developed	European	nations,	and	
identifying	CVH	as	one	of	the	3	leading	causes	for	this	[Davies	2012].		
Criticisms	 have	 been	 made	 against	 the	 omission	 of	 liver	 diseases	 within	 the	 original	 195	 Quality	
Improvement	 Indicators	 set	 by	NHS	 England;	 but	 on	 the	 positive	 side	 the	 government	 has	 shown	
commitment	towards	liver	disease	with	the	inclusion	of	liver	disease	in	domain	1	of	the	NHS	Outcomes	
Framework,	and	domain	4	of	the	Public	Health	Outcomes	Framework;	with	HCV	identified	in	draft	NHS	
England	 consultation	 documents	 as	 the	 “cause	 of	 liver	 disease	 most	 amenable	 to	 healthcare	
intervention”	 [Williams	 R	 2014,	Heath	 and	 Social	 Care	website,	 DoH	Nov	 2013,	NHS	 England	HCV	
network	2015].			
More	 recently	 NHS	 England	 has	 led	 the	 way	 with	 support	 for	 national	 commissioning	 of	 HCV	
treatments	through	the	Early	Access	Scheme	in	the	UK,	and	with	the	development	of	ODN	models	to	
procure	and	deliver	new	DAA	therapy	to	nearly	all	patient	groups,	supported	by	positive	appraisal	
recommendations	by	NICE	[NHS	Clinical	Commissioning	2015],	and	overall	senior	government	level	
support	appears	evident	 in	 improving	CVH	case-finding	 initiatives,	albeit	 in	the	context	of	resource	
constraints	and	the	difficulties	faced	by	the	radical	overhaul	of	the	Health	and	Social	Care	Act	that	are	
discussed	in	later	sections.	
PHE	 occupies	 now	 a	 role	 at	 the	 local	 and	 national	 level,	 fulfilling	 a	meso-level	 function	 in	 health	
monitoring	and	advocacy	following	the	Health	and	Social	Care	reforms.	PHE,	and	the	previous	HPA	
representatives	have	demonstrated	support	for	CVH	testing	initiatives,	and	in	the	recent	goals	of	CVH	
eradication.	However,	the	newly	formed	PHE	has	received	criticism	for	role	and	independence	as	a	
public	health	champion,	and	therefore	in	the	direction	and	power	it	now	yields	[House	of	Commons	
Health	Committee,	Feb	2014].			
At	 the	 local	 and	 regional	 level,	 the	 support	 and	 cohesiveness	 of	 this	 support	 is	 more	 difficult	 to	
ascertain.	In	primary	care,	previous	CVH	policy	endeavours	were	met	with	low	levels	of	awareness	and	
confidence	 in	managing	 CVH	 [D’Souza	 2004,	 RCGP	 2007],	with	 these	 concerns	 raised	 again	 in	 the	
expert	presentations	made	to	the	NICE	PDG	[NICE	2012].		
Support	is	evident	at	the	level	of	the	RCGP	(Royal	College	of	General	Practitioners),	with	interim	CVH	
guidelines	released	in	2007,	and	educational	tools	issued	to	all	practitioners	following	the	release	of	
current	NICE	guidance;	with	around	1380	individuals	who	had	completed	the	e-module	by	late	2013,	
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and	around	710	individuals	who	had	attended	face	to	face	sessions	arranged	by	the	RCGP	[PHE	HCV	
2014,	RCGP	2007].	Findings	from	PHE	suggest	that	these	educational	interventions	may	have	led	to	an	
improvement	in	HCV	testing	rates,	although	the	perception	of	primary	care	physicians	to	testing,	and	
updated	NICE	CVH	testing	guidance	is	essentially	unknown	[PHE	HCV	2014].		
CCG	level	support	towards	CVH	testing	policy	is	also	difficult	to	interpret,	with	few	studies	in	this	area,	
and	with	211	(largely)	independent	CCGs	set	up	as	part	of	the	Health	and	Social	Care	Act.	Recent	audit	
studies	by	the	Hepatitis	C	Trust	would	though	do	suggest	ongoing	deficits	in	the	priority	afforded	to	
HCV	[Hepatitis	C	Trust,	Feb	2013;	Kingston	CCG	July	2015,	Warwickshire	CCG	website],	and	a	reduced	
cohesion	 in	 policy	 support	 overall	 for	 CVH	 testing	 that	 appears	 evident	 at	 the	micro-level,	where	
testing	activity	should	be	delivered.	
Similar	concerns	can	also	be	seen	at	the	Local	Authority	level,	with	a		low	priority	that	CVH	receives	at	
Health	and	Wellbeing	Boards,	where	CVH	rates	should	otherwise	be	monitored	and	coordinated	at	a	
regional	level	through	the	formulation	of	Joint	Health	and	Wellbeing	Strategies	[HCV	Action	2014].	
Overall	then,	there	is	an	apparent	loss	of	support	and	policy	cohesion	that	is	seen	in	moving	from	the	
top-down	actors	involved	in	championing	and	supporting	policy	development,	and	the	local	regional	
meso	and	micro-level	actors	involved	with	facilitating	testing	at	the	community	level,	that	may	impact	
migrant	testing.				
Leadership:		
Looking	back	at	the	network	map	of	actor	relations	in	CVH	(figure	15),	it	can	be	seen	that	there	is	no	
formal	 body	 charged	 with	 providing	 oversight	 or	 coordination	 for	 testing	 services	 between	 NHS	
England	and	micro-level	interventions	in	primary	care.		
A	 National	 Liver	 Disease	 Strategy	 was	 one	 of	 the	 election	 pledges	 of	 David	 Cameron’s	 Coalition	
government,	with	the	recruitment	and	appointment	of	a	national	clinical	director	for	liver	diseases	in	
2010	before	the	strategy	was	abandoned	in	2013	without	replacement,	with	the	Health	and	Social	
Care	 Act	 likely	 to	 have	 played	 a	 significant	 part	 in	 the	 abandonment	 of	 a	 senior	 level	 political	
commitment	[Parliamentary	Reports	Nov	2013].		
Looking	at	the	local	and	regional	level,	Health	and	Wellbeing	Boards	were	established	as	part	of	the	
same	Health	and	Social	Care	Act,	with	the	responsibility	to	understand	the	health	needs	of	the	local	
population,	 and	 to	develop	 strategic	 vision	 to	 commission	and	monitor	 services	according	 to	 local	
needs.	 Accordingly,	 these	 Health	 and	 Wellbeing	 Boards	 should	 develop	 Joint	 Strategic	 Needs	
Assessments	(JSNAs)	and	Joint	Health	and	Wellbeing	Strategies	(JHWS)	that	takes	account	of	CVH	risks,	
and	 the	management	 needs.	 The	Health	 and	Wellbeing	 Boards	 are	 a	 combined	measure	 of	 Local	
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Authority	representatives,	CCG	representatives,	as	well	as	PHE,	and	appear	attractive	in	their	potential	
to	offer	leadership	to	CVH	testing	in	migrant	communities.		
However,	whilst	the	Health	and	Wellbeing	Boards	have	a	statutory	duty	along	with	CCGs	to	produce	
these	strategic	needs	assessments,	it	is	left	to	these	boards	to	prioritise	their	own	direction	[DoH	2011]	
and	data	from	the	HCV	Action	charity	identified	that	even	in	high	prevalence	Health	and	Wellbeing	
Board	regions,	only	3	out	of	10	had	developed	a	health	needs	assessment	for	HCV,	with	additional	
formal	criticism	raised	in	the	House	of	Commons	over	its	inability	to	follow	commission	direction	[HCV	
Action	2014,	House	of	Commons	Report	2013].		
	Liver	disease	also	 falls	under	 the	 targets	of	 Local	Authorities	 as	part	of	 the	NHS	Public	Outcomes	
Framework	 [Social	 Policy	 Section	 2014].	 The	 introduction	 of	 this	 framework	 has	meant	 that	 local	
authorities	now	record	specific	information	on	mortality	rates	related	to	liver	disease,	and	as	seen	in	
the	 resulting	 data	 sets	 drawn	 across	 the	UK	 (figure	 18),	 associations	 can	 be	 drawn	 between	 liver	
disease	 and	 markers	 of	 social	 deprivation,	 with	 additional	 concerns	 for	 newly	 arriving	 migrant	
communities,	who	may	face	social	deprivation	themselves	on	arrival	to	the	host	country.	Aldershot	is	
the	main	location	of	later	testing	work,	and	despite	the	relative	affluence	seen	in	Hampshire,	there	is	
heterogeneity	and	areas	of	deprivation,	with	 two	areas	 in	Aldershot	 that	 fall	within	 the	20%	most	
deprived	in	the	UK	based	on	local	authority	deprivation	scores		(figure	18)[Rushmoor	council	2015].	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	18:	Liver	disease	mortality	and	socioeconomic	deprivation	-	adapted	from	Public	Health	England	
(Public	Health	Outcomes	Frameworks)	http://longerlives.phe.org.uk/.	Aldershot	is	identified	within	
Hampshire	
Aldershot
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The	involvement	of	Local	Authorities	 in	this	monitoring	activity	may	provide	an	additional	role	and	
motivation	for	improved	engagement	in	CVH	monitoring	at	the	Local	Authority	level,	which	can	then	
be	filtered	into	the	Joint	and	Health	Wellbeing	structure	with	the	aim	of	improved	local	leadership	in	
CVH	testing	activity.	
PHE	also	demonstrates	potential	in	its	ability	to	lead	and	champion	CVH	testing	policy,	with	its	action	
across	multiple	 levels	 in	the	new	NHS	structure,	and	given	that	CVH	fits	well	 into	the	 ideology	and	
context	of	PHE	objectives.	However,	this	too	has	come	under	criticisms	in	its	leadership	capacity,	with	
formal	rebukes	delivered	at	the	House	of	Commons	Health	Committee,	with	concerns	raised	over	its	
independence	from	government,	as	well	as	criticisms	over	health	 inequalities	demonstrated	across	
London	as	a	lack	of	oversight	and	control	by	local	PHE	in	identifying	and	targeting	these	factors	[House	
of	Commons	Health	Committee,	Feb	2014,	Guardian	January	2014].			
At	 a	 regional	 level,	 the	 recent	 creation	 of	 Operational	 Delivery	 Networks	 (ODNs);	 created	 as	 by-
product	of	commissioning	guidance	issued	by	NHS	England	to	control	and	facilitate	the	standardised	
delivery	of	high-cost	HCV	(DAA)	treatments,	may	serve	a	leadership	role	for	the	wider	community.	By	
standardising	 the	 referral	 and	 care	pathway	 for	 patients	diagnosed	with	HCV	 (through	designated	
hospital	multidisciplinary	settings),	this	system	should	improve	the	awareness	and	confidence	of	local	
practitioners	 toward	 diagnosing	 and	 managing	 CVH	 patients,	 and	 may	 filter	 through	 local	
commissioning	services	to	facilitate	testing	offers	to	other	at-risk	groups.	Given	the	very	high	rates	of	
success	for	newer	HCV	treatments,	this	system	should	facilitate	confidence	 in	testing	 in	the	 longer	
term.	 Whilst,	 these	 systems	 were	 developed	 as	 “hospital-centric”	 organisations	 made	 up	 of	
hepatology	specialists,	they	have	evolved	over	time	and	drawn	CQUIN	(Commissioning	for	Quality	and	
Innovation)	funding	and	a	lauded	status.	Recent	publications	suggest	that	as	the	current	number	of	
“known”	HCV	patients	are	exhausted,	the	attention	of	this	body	will	evolve	and	turn	towards	case-
finding,	with	a	potentially	very	attractive	(and	funded)	specialist	team	who	can	help	provide	leadership	
and	coordination	to	CVH	testing.		
Overall,	leadership	at	the	local	and	regional	level	through	the	established	structures	of	the	Health	and	
Social	Care	Act	seem	limited	in	their	ability	to	provide	clear	leadership	and	coordination	to	CVH	testing,	
but	with	the	potential	for	the	newly	formed	ODNs	to	act	in	a	leadership	and	coordination	role	in	CVH	
testing	activity.		
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Guiding	Organisations:		
The	speciality	societies	in	Hepatology	across	Europe	and	the	UK	have	provided	guidance	primarily	on	
treatment	strategies	for	those	known	to	be	effected	by	CVH,	and	may	not	be	well	accessed	by	non-
specialists,	including	those	in	primary	care.		
One	of	the	most	ambitious	and	inclusive	framework	to	target	liver	disease	is	that	put	forward	in	the	
Lancet	commissioned,	 led	by	Roger	Williams.	It	draws	together	collaboration	from	the	principal	UK	
charity	groups	(British	Liver	Trust,	Hepatitis	C	Trust	and	The	Foundation	for	Liver	Research),	as	well	as	
the	medical	society	groups,	including	the	RCGP	[Williams	2014].		
The	 original	 commission	 provided	 a	 clear	 evidence	 base	 to	 highlight	 the	 growing	 burden	 of	 liver	
disease	in	the	UK	compared	to	other	European	nations,	and	presented	10	key	evidence-based	targets	
for	intervention	(figure	19).		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	19:	Summary	of	the	10	recommendations	from	the	initial	2014	Lancet	Commission	[Williams	2014]	
Whilst	the	commission	targets	all	aspects	of	liver	disease,	including	the	need	for	Minimum	Unit	Pricing	
for	alcohol	and	controls	for	obesity,	it	draws	special	attention	to	the	need	to	target	liver	disease	in	at-
risk	groups	 in	the	community	through	 improved	awareness	raising	and	resources,	and	places	a	set	
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target	to	eradicate	HBV	and	HCV	by	2030;	based	upon	the	efficacy	predictive	benefits	of	new	HCV	
therapies,	 as	 well	 as	 universal	 vaccination	 and	 appropriate	 treatment	 for	 HBV.	 The	 commission	
identifies	the	need	to	offer	testing	to	migrant	communities,	as	well	as	the	uncertainties	that	exist	in	
how	best	to	reach	these	communities.		
The	 2030	 target	 has	 been	 further	 adopted	 in	 the	 WHO	 report	 in	 response	 to	 the	 World	 Health	
Assembly	request,	and	whilst	the	target	for	intervention	is	aimed	principally	at	low	and	middle	income	
countries,	 it	 provides	 clear	 vision	and	 justification	 that	effective	 control	of	CVH	 is	 achievable	on	a	
global	scale	with	5	practical	steps;	with	an	upscaling	in	CVH	testing	to	diagnose	90%	of	all	cases	by	
2030	(table	9)	[WHO	2016].	
Table	9:	The	5	key	targets	to	achieve	as	part	of	WHO	modelling	to	achieve	control	of	CVH	worldwide	by	2030	
[WHO	2016].			
	
The	Lancet	commission	group	released	a	further	update	in	2015	highlighting	the	challenges	that	exist	
in	translating	guidance	into	practice	at	the	community	level,	and	proposing	a	bid	through	the	RCGP	to	
make	liver	diseases	a	priority	through	a	Clinical	Priorities	Programme	[Williams	2015].		
The	strength	of	 the	commission	 lays	 in	 its	 inclusiveness	of	 the	major	patient	advocacy	 (grass-root)	
groups,	and	attempts	to	unify	specialist	clinicians	and	primary	care	groups,	as	well	as	providing	an	
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evidenced-based	assessment	of	the	issues	at	hand,	and	the	practical	steps	that	can	be	achieved	to	
reach	now	global	aims	of	CVH	control	by	2030.		
Whilst	the	Commission	does	not	function	as	a	real-time	organisation,	 it	provides	motivation	to	the	
policy	community,	and	builds	support	in	the	external	frame	to	support	increased	CVH	testing.		
Civil	Society	Mobilisation:	 In	 the	original	policy	prioritisation	 framework	by	Shiffman	and	Smith,	
policy	 success	 is	 deemed	 to	be	more	 likely	 if	 it	 includes	 the	 support	 and	 “pressure”	of	 grassroots	
organisations.		
Grassroots	patient	organisations	in	CVH	are	skewed	to	HCV	care,	with	the	British	Liver	Trust	the	most	
vocal	of	the	generic	patient	advocacy	groups.	The	Hepatitis	C	Trust	is	the	most	well-known	of	patient	
charities,	and	has	a	 formal	role	and	voice	at	government	 level	 through	the	All	Party	Parliamentary	
Hepatology	Group	(APPHG),	with	the	same	founder	(Charles	Gore)	also	involved	in	the	World	Hepatitis	
Alliance.		
The	advocacy	achieved	through	charity	work	has	no	doubt	been	instrumental	in	raising	the	profile	of	
CVH,	with	likely	impact	at	the	government	level	given	its	formal	links	and	publications.	The	Hepatitis	
C	 Trust	 has	 also	 raised	 high	 profile	 legal	 challenges	 to	 NHS	 England	 with	 regard	 to	 the	 access	
availability	for	DAA	treatments	to	patients	with	HCV.	
These	patient	charities,	and	medical	multidisciplinary	teams	in	the	form	of	HCV	Action	have	produced	
studies	to	identify	deficits	in	CVH	testing,	through	submissions	to	community	actors,	such	as	CCGs	and	
Local	Authorities.	The	impact	of	these	interventions	should	be	to	improve	the	awareness	and	uptake	
of	 testing	activity	 in	 these	 institutions.	However,	 the	ability	of	 these	groups	 to	 reach	primary	care	
physicians	and	the	lay	public	is	less	clear,	and	the	reach	of	these	organisations	would	seem	less	than	
the	reach	or	power	of	patient	advocacy	groups	in	HIV,	where	public	recognition	and	political	support	
as	a	result	is	more	established.		
	
Ideas:	Internal	and	External	frames		
The	concept	of	“ideas”	and	“framing”	in	the	priority	setting	framework	looks	at	how	the	policy	issues	
are	 understood	 and	 portrayed,	 both	 inside	 and	 outside	 the	 (stakeholder)	 policy	 community.	 It	
considers	 the	 degree	 in	 which	 the	 policy	 community	 agree	 on	 the	 policy	 problem;	 it’s	 definition,	
causes	and	solutions,	and	how	the	policy	issue	is	portrayed	in	this	internal	frame,	as	well	as	the	public	
(external)	arena	[Walt	G	2014].		
93	
	
In	 the	 NICE	 guideline	 development	 process,	 and	 within	 the	 stakeholder	 community,	 there	 is	
recognition	of	the	uncertainties	that	exist	in	CVH	prevalence	rates	between	different	at-risk	groups,	
including	 migrant	 communities	 [Uddin	 G	 2010],	 and	 in	 the	 optimum	 strategies	 that	 should	 be	
employed	to	facilitate	testing;	with	these	issues	recognised	as	formal	research	recommendations	to	
be	met	in	future	reviews	[NICE	research	recommendations	2012].	There	is	however,	broad	consensus	
and	support	regarding	the	increased	burden	of	disease	that	is	seen	in	migrant	communities	in	the	UK,	
and	the	need	to	improve	our	efforts	to	understand	and	manage	these	risks,	with	supporting	evidence	
delivered	to	the	NICE	PDG,	and	in	the	 internal	hepatology	communities	(with	stakeholder	support)	
publications	in	support	of	increased	testing	endeavours	[NICE	expert	papers	2012,	Williams	R	2014].		
The	view	and	frame	adopted	in	primary	care	towards	CVH	is	less	clear,	and	whilst	the	RCGP	provides	
education	resources	to	GPs,	and	remains	a	stakeholder	partner	 in	supportive	publications	with	the	
(internal)	 hepatology	 community,	 the	 perspective	 and	 frame	 taken	 at	 the	 ground	 level	 with	
practitioners	and	the	disparate	CCGs	is	largely	unknown.	And	given	the	limited	awareness	and	uptake	
of	previous	national	CVH	policy	drives	in	primary	care	[D’Souza	2004,	RCGP	2007,	APPHG	2008],	it	is	
conceivable	 that	 CVH	 is	 viewed	 in	 a	 different	 (less	 relevant)	 perspective	 in	 community	 healthcare	
setting.		
The	External	Frame	considers	how	CVH	is	viewed	in	the	wider	public.		Historic	and	current	awareness	
of	CVH	is	poor,	with	global	surveys	by	the	World	Hepatitis	Alliance	(WHA)	suggesting	that	only	around	
7	out	of	10	patients	were	aware	of	HCV	prior	to	their	diagnosis	[WHA	HCV	Toolkit	2016].	Annual	global	
and	national	initiatives	were	established	over	the	last	decade	or	so	to	try	and	improve	CVH	awareness,	
but	many	individuals	with	CVH	reported	feelings	and	experiences	of	stigma	in	day	to	day	life,	with	only	
around	1/3rd	of	HCV	positive	individuals	having	informed	their	families	of	their	HCV	status	[WHA	HCV	
Toolkit	 2016,	WHA	world	 hepatitis	 day].	 Stigmatisation	 therefore	 remains	 a	 concern	 in	 the	 public	
perception	 towards	 CVH,	 with	 many	 of	 patients	 expressing	 concern	 that	 family	 or	 community	
members	may	treat	them	differently	if	they	knew	about	their	CVH	status,	with	these	concerns	most	
evident	in	migrant	community	members	that	I	have	treated.		
On	 a	 more	 positive	 note,	 the	 recent	 years	 have	 seen	 an	 increased	 media	 reporting	 of	 the	 huge	
therapeutic	advances	that	have	been	achieved	with	HCV,	with	wide	reporting	of	the	“revolutionary”	
new	HCV	cures,	and	their	 (initial)	eye-watering	prices,	with	 tag-lines	of	a	“$1000	a	day	pill”	across	
multiple	news	outlets	when	Sofosbuvir	was	first	marketed.	Patient	stories,	and	publicity	from	patient	
charities	such	as	the	Hepatitis	C	Trust,	and	global	government	led	initiatives	to	provide	and	fund	CVH	
treatments	on	a	national	scale	for	the	first	time	are	all	likely	to	have	increased	the	positive	messages	
of	 the	 treatment	success	 that	can	be	delivered	 for	CVH	[Channel	4	blog	16th	April	2014;	New	York	
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Times	December	2015];	with	many	patients	having	come	to	see	my	in	clinic	after	having	heard	of	these	
stories	through	friends	or	the	media.		
At	the	political	(public)	level,	the	UK	government	recently	announced	official	plans	to	investigate	the	
contamination	 of	 many	 individuals	 with	 CVH	 due	 to	 blood	 transfusions	 in	 the	 1970s	 and	 1980s,	
highlighting	the	iatrogenic	route	of	acquisition	in	these	individuals	[Guardian	2017].	However,	at	the	
specific	level	of	CVH	case-finding	in	migrant	communities,	the	negative	viewpoints	portrayed	by	UKIP	
and	 more	 right-wing	 British	 groups	 may	 prove	 more	 evocative	 [Guardian	 October	 2014,	 British	
Democrats],	and	have	 led	to	a	greater	degree	of	stigma	associated	with	testing	uptake	and	testing	
initiatives	at	the	community	level.		
Context:		
Shiffman	and	Smith	use	the	notion	of	“policy	windows”	to	explore	moments	when	conditions	align	
favourably	 for	 an	 issue,	 as	well	 as	 “governance	 structure”	 that	provides	 a	 contextual	 platform	 for	
effective	action.		
Looking	at	the	timeline	of	events	leading	up	to	the	development	of	NICE	testing	policy	(Figure	21),	the	
abandonment	of	the	National	Liver	Disease	Strategy	is	a	key	loss	in	both	the	profile	and	oversight	of	
CVH	testing.		
The	National	Liver	Strategy	was	modelled	on	existing	collaborative	reports,	and	had	received	executive	
political	support,	with	the	appointment	of	Professor	Marin	Lombard	to	the	post	of	National	Clinical	
Director	for	Liver	Diseases	in	January	2010.	Political	support	continued	for	this	post	in	David	Cameron’s		
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Figure	20:	Tim
eline	of	HBV	and	HCV	related	events	and	publications	
leading	up	to	2013	
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coalition	government,	with	the	remit,	budget	and	timetable	of	this	strategy	presented	to	the	House	
of	Commons	by	the	Secretary	of	State	for	Health,	Simon	Burns	in	July	2011:	
“Professor	Martin	Lombard…remit	was	to	provide	clinical	leadership	to	the	development	of	a	national	
strategy	 for	 liver	 disease	 that	 matches	 measures	 designed	 to	 achieve	 quality	 improvement	 (and	
improvements	in	outcomes	for	patients)	with	the	identification	of	where	the	national	health	service	
might	release	resources	to	support	them.	The	National	Liver	Strategy	will	be	an	integrated	programme,	
recommending	 actions	 to	 improve	 the	 prevention,	 identification,	 treatment,	 care	 and	 support	 of	
people	 with	 liver	 disease	 within	 evidence-based	 and	 dignity	 assured	 standards	 of	 care.	 Professor	
Lombard’s	budget	for	this	task	(net	of	core	staffing	costs)	has	been	£560,000	in	2010-11,	and	£224,440	
in	 2011-12.	 As	 previously	 announced”	 [Parliamentary	 questions	 July	 2011],	 website	
http://www.publications.parliament.uk/pa/cm201011/cmhansrd/cm110719/text/110719w0006.ht
m	,	accessed	11th	March	2013].	
However,	 the	 development	 of	 the	 radical	 Health	 and	 Social	 Care	 Act	 eventually	 led	 to	 the	
abandonment	 of	 this	 strategy,	 with	 fundamental	 changes	 in	 the	 provision	 and	 commissioning	 of	
health	services	[Jane	Ellis,	Parliamentary	Under	Secretary	of	State	for	Public	Health,	Nov	2013].		
NICE	testing	guidance	was	developed	in	the	most	part	before	the	introduction	of	the	Health	and	Social	
Care	Act,	and	the	recommendations	generated	would	have	been	directed	towards	the	existing	PCTs,	
and	 whilst	 these	 recommendations	 were	 not	 altered	 following	 the	 Act’s	 introduction,	 these	
recommendations	 are	 unlikely	 to	 have	 been	 aimed	 at	 the	 coordinated	 CCGs	 and	 Local	 Authority	
groups	who	were	subsequently	tasked	with	CVH	testing	practice.		
Both	the	loss	of	the	National	Liver	Disease	Strategy	and	the	development	of	the	Health	and	Social	Care	
Act	 are	 policy	 window	 points,	 at	 which	 the	 loss	 of	 intervention,	 and	 the	 failure	 to	 integrate	 and	
coordinate	testing	responsibility	would	have	impacted	CVH	testing	provision.		
More	recently,	the	raised	profile	of	new-HCV	medications	created	an	opportune	moment	to	introduce	
targeted	awareness-raising	sessions	in	migrant	communities,	particularly	given	the	positive	messages	
of	 the	 existence	 of	 “effective	 cures”	 for	 these	 viruses.	 However,	 there	 has	 been	 an	 absence	 of	
organised	awareness-raising	measures	since	the	DoH	programme	to	approach	members	of	the	South	
Asian	 community	 in	 2009	 [DoH	2009].	 To	 some	degree	 this	may	 relate	 to	 the	 rise	of	 anti-migrant	
sentiment,	 and	popular	 right-wing	politicians	 such	 as	Nigel	 Farage	who	 received	 significant	media	
coverage	and	electoral	votes	in	the	2015	general	election	[Telegraph	October	2014].	
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The	development	of	such	effective	(and	costly)	DAA	based	therapies	in	HCV	has	also	contributed	to	
the	 development	 of	 22	 Operational	 Delivery	 Networks	 (ODNs),	 delivering	 centralised	 care	 to	
geographic	regions	under	the	management	of	NHS	England,	who	have	taken	on	the	commissioning	
responsibilities	 for	 these	 treatments.	This	has	 seen	a	huge	 increase	 in	 the	coordination,	 focus	and	
treatment	scale	that	has	been	delivered	nationally	over	a	very	short	space	of	time,	with	estimates	of	
mortality	declines	in	relation	to	HCV	of	close	to	10%,	as	well	as	reduced	transplantation	requirements	
due	to	HCV	even	in	this	short	period	[NHS	England	July	17].	A	more	pertinent	aspect	to	consider	here	
is	 the	shift	 in	 focus	 that	 these	ODNs	will	 take	 in	 the	 future	period	to	 try	and	 improve	case-finding	
activity.	At	present,	these	groups	are	focused	and	tasked	with	delivering	and	coordinating	treatment,	
with	 aims	 of	 identifying	 and	 treating	 the	 sickest	 patients	 first,	 with	 the	 added	 benefit	 of	 CQUIN	
(Commissioning	for	Quality	and	Innovation)	(financial)	resources	made	available	to	these	ODN	groups	
[NHS	England	BL1	2016].	These	ODN	groups	will	likely	move	towards	HCV	case-finding	initiatives	as	
time	 progresses,	 and	 similar	 systems	 may	 well	 be	 employed	 in	 delivering	 care	 for	 HBV,	 with	
improvements	that	one	would	hope	to	see	in	case-finding	activity	and	CVH	care	overall	as	a	result.			
Overall	 then,	the	contextual	 factors	 leading	up	to	NICE	policy	development	 identify	the	 loss	of	the	
National	Liver	Disease	Strategy	and	the	introduction	of	the	Health	and	Social	Care	Act	as	key	policy	
windows	for	(missed)	action,	with	a	loss	of	oversight	in	testing	provision,	and	concerns	of	coordination	
and	testing	responsibilities	that	 likely	continue	today,	but	with	hope	through	the	newly	developed	
ODN	models	to	improve	case-finding	and	treatment	activity	in	the	future.		
Issue	Characteristics:	
Issue	Characteristics	within	the	Policy	Prioritisation	framework	considers	the	features	of	the	problem,	
looking	at	what	levels	of	knowledge	exist	about	the	problem;	how	the	policy	subject	is	measured	and	
quantified	 with	 regard	 to	 its	 severity	 and	 effect,	 as	 well	 as	 the	 effectiveness	 (including	 cost-
effectiveness)	and	nature	of	the	interventions	available	to	act	[Walt	G	2014,	Shiffman	J	2007]	(figure	
14).		
Measure	of	policy	issue	
The	first	consideration	in	this	are	the	“indicators”	of	the	policy	subject,	with	“problems	that	are	easily	
measured	more	likely	to	gain	political	support”	[Shiffman	J	2007].	In	CVH	testing,	there	is	an	inherent	
gap	in	the	knowledge	of	physical	testing	activity,	as	well	as	the	actual	number	of	individuals	who	are	
positive	for	CVH.	Testing	activity	is	split	between	primary	and	secondary	care,	as	well	as	community	
providers	(drug	and	alcohol	services)	and	prisons,	with	no	central	oversight.	Central	data	is	also	not	
collected	on	testing	activity,	nor	on	the	proportion	of	those	tested	who	are	identified	as	positive.		
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CVH	is	measured	and	understood	with	regard	to	severity	in	terms	of	cases	collected	through	multiple	
providers	and	surrogate	markers,	including	the	complications	recorded	through	the	development	of	
HCC,	cirrhosis,	transplantation	assessment	(as	well	as	liver	transplant	recipients),	and	mortality	related	
to	CVH	complications.		
Rates	of	CVH	are	measured	through	several	different	streams,	with	data	collection	and	focus	more	
robust	for	HCV	over	HBV	in	view	of	the	recent	availability	of	highly-effective	cures,	and	the	subsequent	
development	of	ODNs	tasked	with	monitoring	and	delivering	treatment,	with	central	data	fed	back	to	
NHS	England.		
For	 HCV,	 PHE	 reports	 on	 prevalence	 and	 effect	 through	 multiple	 sources	 in	 healthcare,	 prisons,	
community	services,	as	well	as	private	agencies,	with	30	data	sources	used	in	the	2015	report.	Current	
estimates	of	prevalence	rates	in	the	UK	are	based	on	data	collected	now	over	10	years	ago	[PHE	2017,	
Harris	RJ	2012],	with	data	from	the	Unlinked	Anonymous	Monitoring	(UAM)	survey	in	participating	
drug	users	(PWID),	as	well	as	laboratory	data,	and	more	recently	ODN	activity	providing	an	overview	
of	HCV	incidence	and	prevalence	across	the	country.	Testing	activity	and	patient	monitoring	is	divided	
across	 multiple	 separate	 organisations	 in	 primary	 and	 secondary	 care,	 as	 well	 as	 prisons	 and	
community	services,	with	no	routine	platforms	of	data	sharing	between	these	organisations,	and	with	
communication	routes	that	may	be	sub-optimal	between	these	actors,	relying	for	example	on	faxed	
referrals	to	specialist	hospital	based	clinicians	to	assess	complex	psychosocial	patients	looked	after	in	
community	 drug	 and	 alcohol	 services.	 Recently,	 the	 National	 Strategic	 Group	 on	 Viral	 Hepatitis	
(NSGVH)	was	set	up	England	to	try	better	coordinate	and	record	the	activity	between	these	different	
agencies,	 building	 on	 the	 coordinate	 oversight	 bodies	 already	 in	 place	 in	 the	 other	 devolved	 UK	
nations	[PHE	2017,	PHE	Harris	H	2017].		
Severity	of	issue:		
The	severity	of	HCV	can	be	measured	by	looking	at	the	Hospital	Episode	Statistics	(HES)	in	England,	
developing	a	picture	of	those	individuals	admitted	with	end	stage	liver	disease,	and	the	complications	
of	HCC,	 as	well	 as	mortality	 cases	 related	 to	HCV.	However,	 this	 relies	 on	 accurate	 data	 input	 on	
patients,	as	well	as	accurate	coding	of	data,	with	inaccuracies	as	well	as	missed	patient	data	that	may	
result.	Nevertheless,	the	use	of	data	identifying	the	complications	of	end	stage	liver	disease,	including	
HCC	and	transplantation	have	had	an	 impact	 in	achieving	central	 recognition,	 including	 the	call	by	
David	Cameron’s	government	[Hep	C	trust	website	March	2013].		
For	HBV,	measures	of	those	infected,	as	well	as	the	severity	of	this	impact	is	less	well	defined,	with	
HCV	having	taken	prominence	in	view	of	the	recent	burden	of	disease	and	liver	disease	complications	
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from	untreated	HCV,	the	runaway	success	of	recent	treatment	developments,	as	well	as	the	voice	of	
vocal	advocacy	groups	such	as	the	Hepatitis	C	Trust.		
PHE	report	annually	on	acute	HBV	incidence	rates	detected	through	mandatory	laboratory	reporting	
and	sentinel	surveillance	data,	but	there	are	no	central	reports	on	the	number	of	chronic	HBV	cases	
identified	each	year,	or	those	who	are	in,	or	previously	been	seen	in	primary,	secondary,	or	community	
based	services	 [PHE	Acute	Hepatitis	Sept	2017].	As	with	HCV,	 there	 remains	a	 lack	of	 coordinated	
testing	activity	between	services,	including	maternity	services,	with	no	central	oversight	to	testing	or	
treatment	activity.		
A	measure	of	HBV	cases	is	obtained	through	sentinel	surveillance	data,	taking	a	snapshot	of	testing	
activity,	as	well	as	a	snapshot	of	antenatal	 testing	that	occurs	nationally,	with	the	 last	official	data	
publication	 from	 2015	 [PHE	 Health	 Protection	 Report	 2016].	 Data	 monitoring	 on	 chronic	 HBV	 is	
otherwise	 less	 robust,	with	mandatory	 laboratory	reporting	that	was	 introduced	only	 in	2010,	and	
with	 wide	 variations	 in	 the	 quality	 of	 key	 data	 collection	 for	 HBV	 even	 across	 London	 hospital	
laboratories	[Foundation	for	Liver	Research	2004,	PHE	Hepatitis	B	2012],		
Severity	data	for	HBV	can	be	drawn	from	liver	transplant	data	for	the	UK	centres,	as	well	as	HES	data,	
but	with	the	last	official	PHE	publications	available	on	morbidity	and	mortality	complications	for	HBV	
in	2012,	with	HBV	constituting	2%	of	transplant	activity	in	2015/16	(compared	to	6%	activity	for	HCV),	
and	with	an	increased	number	of	hospital	admissions	and	liver	disease	complications	(including	HCC)	
recorded	in	2012	secondary	to	HBV	[PHE	Hepatitis	B	2012,	NHSBT	2016]		
Effectiveness	of	policy	intervention:		
The	 effectiveness	 of	 CVH	 testing	 considers	 the	 background	 prevalence	 of	 CVH,	 the	 efficacy	 of	
treatments	available	for	those	who	are	identified	as	positive,	as	well	as	the	efficacy	(uptake)	of	testing	
activity,	with	the	cost-effectiveness	of	these	interventions	a	key	consideration	in	this	analysis.		
Focusing	 on	 policy	 in	 relation	 to	 testing	 in	 migrant	 communities,	 the	 NICE	 testing	 guideline	
development	process	utilised	a	commissioned	cost-effectiveness	analysis	from	the	London	School	of	
Hygiene	and	Tropical	Medicine	on	CVH	 testing	 in	UK	migrant	populations	 [Miners	A	2012].	 In	 this	
analysis,	 the	 authors	 considered	 the	 incremental	 cost-effectiveness	 ratio	 (ICER)	 of	 testing	
interventions,	modelling	assessments	with	assumed	variables	based	on	disease	prevalence,	 testing	
uptake,	the	numbers	subsequently	requiring	treatment	(for	HBV),	and	the	effectiveness	of	treatments;	
modelling	a	hypothesised	testing	event	compared	to	the	standard	of	care,	where	no	structured	testing	
occurs,	and	taking	into	account	the	inherent	difficulties	that	exist	in	the	current	CVH	data	set	[Miners	
A	2012].	ICERs	were	developed	for	HBV	and	HCV,	and	compared	to	(NICE)	established	quality-adjusted	
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life	year	(QALY)	thresholds	(of	£20-£30,000)	designed	to	give	an	overall	measure	of	health	outcomes	
weighted	to	the	life	expectancy	of	the	patient,	and	an	estimate	of	their	health	related	quality	of	life	
(HRQoL)	outcomes	[NICE	guidelines	manual	2012].		
During	their	analysis,	the	authors	modelled	a	HCV	prevalence	rate	of	2%	in	the	population	tested,	with	
testing	activity	expected	to	increase	to	17%	with	new	intervention,	and	costs	of	£50-75	per	individual	
tested,	predicting	cost-effective	ICER	QALY	thresholds	of	£20,000	through	these	predictions.	For	HBV,	
assuming	the	same	prevalence	of	%2,	ICER	values	of	£21,000	were	calculated,	which	were	thought	
acceptable	in	view	of	the	variables	and	uncertainties	used	in	modelling	calculations	[Miners	A	2012].	
The	cost-effectiveness	findings	of	the	NICE	development	group	are	further	supported	by	other	global	
studies,	 including	 a	 systematic	 review	 of	 cost-effectiveness	 in	 CVH	 testing,	 funded	 by	 the	 ECDC	
(European	 Centre	 for	 Disease	 Prevention	 and	 Control)	 in	 2015	 [Geue	 C	 2015].	 In	 this	 analysis,	
modelling	was	 seen	 to	 vary	 based	 on	 the	 background	 prevalence	 of	 disease,	 the	 testing	 strategy	
adopted,	and	the	treatments	available,	with	newer	studies	demonstrating	improved	ICERs	in	testing	
and	treating	for	CVH	[Geue	C	2015].	Modelling	studies	in	this	analysis	considered	screening,	as	well	as	
case-finding	in	in	at-risk	groups,	including	HBV	testing	in	migrant	populations,	which	was	identified	as	
a	 risk-group	 to	 continue	 monitoring	 [Geue	 C	 2015].	 For	 HCV,	 case-finding,	 and	 screening	 is	 also	
discussed	 in	 this	 systematic	 review,	with	 now	 outdated	 protease	 based	 regimens	 providing	more	
favourable	ICERs	than	conventional	therapy,	with	ICER	values	of	£23,000	per	QALY	gained	achieved	in	
these	Protease-based	intervention	arms	of	HCV	therapy	[Geue	C	2015].	Further	support	for	the	cost-
effectiveness	 of	 HCV	 testing	 (screening)	 is	 available	 from	 the	 US,	 with	 a	 well-publicised	 drive	 to	
increase	birth	cohort	testing.		
The	advent	of	DAA	therapies	in	HCV	has	also	led	to	considerable	advances,	with	a	recent	study	from	
South	Korea	identifying	ICERs	from	$5,714	to	$8,889	per	QALY	for	HCV,	utilising	DAA	based	therapies,	
with	a	modelled	(HCV)	prevalence	estimate	of	0.6	to	1.53%	in	the	background	population,	but	with	a	
well-established	HBV	screening	programme	that	is	already	in	place	nationally	[Young	Kim	D	2017].			
The	effectiveness	and	uptake	of	CVH	testing	activity	is	difficult	to	qualify,	and	is	likely	to	vary	based	
on	the	 intervention,	or	 lack	of	 intervention	adopted.	 In	studies	 in	the	US	as	part	of	 the	HCV	birth-
cohort	testing	programme,	intervention	with	testing	prompts	via	letter,	or	electronic	health	record	
prompted	 physician	 interaction	 identified	 more	 individuals	 as	 compared	 to	 standard	 (no	
intervention/prompting)	testing,	with	testing	uptake	of	27%	vs	1.4%	in	mailed	invite	studies,	and	31%	
vs.	3.6%	in	electronic	health	record	prompted	physician	interactions	[Brady	JE	2017].	In	the	NICE	cost-
effectiveness	analysis,	an	uptake	of	17.5%	was	taken	in	modelling	estimates	over	a	6-month	period	
following	the	introduction	of	a	testing	intervention.	This	estimate	was	taken	based	on	an	earlier	pilot	
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opt-out	study	based	in	East	London	primary	care,	where	South	Asian	registered	patients	were	given	
mailed,	 and	 then	phone	based	 invites	 to	 attend	 for	 testing,	with	 an	uptake	of	 around	20%	of	 the	
sampled	population,	and	with	an	expectation	that	uptake	rates	in	a	stable	population	may	then	return	
to	a	low	level	after	the	initial	intervention	period	[Miners	A	2012,	Lewis	H	2011].		
However,	the	final	NICE	CVH	testing	document	does	not	identify	a	standardised	way	to	“intervene”	to	
identify	and	offer	testing,	with	uptake	rates	that	are	then	difficult	to	estimate	in	a	standardised	way	
across	 primary	 care	 [NICE	 2012].	 Without	 a	 standardised	 testing	 activity,	 the	 actors	 (individual	
practitioners	or	departments)	involved	in	testing	activity	is	also	not	defined	in	policy,	with	difficulties	
that	exist	therefore	in	identifying	the	potential	complexities	that	testing	may	pose	on	a	regional	or	
national	scale	[Walt	G	2014].		
The	efficacy	of	treatment	for	CVH,	and	the	rationale	to	identify	infection	is	however	well	defined.		In	
HCV,	 DAA	 therapies	 can	 provide	 cure	 in	 95-100%	 of	 cases	 [EASL	 HCV	 2016],	 and	 with	
nucleoside/nucleotide	analogues	 that	 can	provide	complete	viral	 suppression	 in	HBV	 in	97-99%	of	
cases,	and	prevent	or	reduce	the	risks	of	onward	progression	to	HCC,	cirrhosis,	and	end-stage	liver	
complications	[EASL	HBV	2017].		
Outcome:	
The	concept	of	an	“Outcome”	category	was	added	by	Walt	and	Gilson	to	the	original	Shiffman	and	
Smith	priority	setting	framework;	with	the	aim	of	understanding	how	seriously	the	policy	objective	is	
taken	and	its	likelihood	therefore	of	being	put	into	practice	[Walt	G	2014].		
This	 aspect	 of	 the	 framework	 considers	 the	 authority	 and	 decisiveness	 of	 the	 policy	 decision,	 the	
resources	allocated	to	deliver	it,	as	well	as	the	hierarchy	and	relations	of	the	actors	involved	in	the	
policy	process.	Given	the	complexities	and	sensitivities	of	many	topics,	policy	objectives	and	decisions	
may	not	be	clear,	with	opposing	views	held	among	actors,	or	there	may	be	a	 lack	of	data	to	guide	
single	actions	that	will	address	the	policy	issue.	The	hierarchy	of	those	involved	in	championing	policy	
is	also	important,	as	well	as	considering	the	resources	that	is	allocated;	across	technical,	financial	and	
human	resources	perspectives	[Walt	G	2014].		
NICE	CVH	testing	policy	is	a	Public	Health	document,	and	therefore	not	designed	to	be	adopted	in	the	
same	mandatory	 format	across	 the	NHS	as	Technology	Appraisals,	but	nevertheless	 is	designed	 to	
provide	clear	and	authoritative	practical	strategic	recommendations	that	can	be	readily	implemented	
by	practitioners	[NICE	Process	and	Methods	2012].	
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NICE	 CVH	 testing	 policy	 does	 accordingly	 provide	 clear	 recommendations	 to	 community	 services	
(principally	in	primary	care)	to	guide	testing	activity:		
“GPs	and	practice	nurses	should	offer	testing	for	hepatitis	B	and	C	to	adults	and	children	at	increased	
risk	of	 infection,	particularly	migrants	 from	medium-	or	high-prevalence	 countries	and	people	who	
inject	or	have	injected	drugs	(see	Whose	health	will	benefit?).”	
“GPs	and	practice	nurses	should	offer	testing	for	hepatitis	B	and	C	to	people	who	are	newly	registered	
with	the	practice	and	belong	to	a	group	at	increased	risk	of	infection	(see	Whose	health	will	benefit?).	
“	
However,	as	identified	earlier,	there	is	a	lack	of	direction	into	how	testing	should,	or	could	be	achieved,	
with	the	suggested	responsibility	placed	on	practitioners	to	pursue	an	unknown,	self-directed	route	
to	testing	activity.	Whilst	new-patient	testing	is	suggested	as	a	strategy	to	CVH	testing,	there	is	little	
structured	advice	about	how	this	can	be	delivered,	with	many	practices	having	abandoned	clinician	or	
nurse	based	assessments	at	new-registration	visits;	opting	rather	for	paper	based	forms	and	reception	
interaction	 [personal	 discussions	 with	 primary	 care	 physicians].	 There	 is	 also	 the	 need	 to	 cross-
reference	with	the	“whose	health	will	benefit”	section	at	each	point,	even	with	migrant	groups,	where	
the	geographic	scale	used	to	reference	migrants	approaches	a	continent	 level,	 rather	 than	a	more	
concise	or	nuanced	definition.	Although	NICE	guidance	has	a	specific	“implementation”	tool	section,	
this	 process	 fails	 to	 provide	 any	 examples	 or	 recommendations	 of	 how	 testing	 delivery	 can	 be	
achieved	 in	 primary	 care	 or	 the	 local	 authority	 level,	 where	 the	 majority	 of	 testing	 work,	 and	
coordination	of	health	to	secondary	services	should	take	place	[NICE	Practice-based	implementation	
2012].	 	 Community	 groups	 who	 interact	 with	 migrant	 populations	 are	 also	 included	 in	 NICE	
recommendations	as	possible	actors	 to	 facilitate	testing,	but	again	with	 little	structure	or	practical	
guidance	as	to	how	this	can	be	delivered,	or	integrated	to	primary	care.		
As	such,	the	lack	of	clarity	in	practical	application	limits	the	decisive	authority	that	the	core	message	
of	NICE	testing	policy	may	achieve.	And	in	addition,	the	responsibility	to	audit	and	drive	testing	activity	
is	 left	 to	 the	 newly	 formed	 Local	 Health	 and	Wellbeing	 Boards;	 made	 up	 of	 separate	 PHE,	 Local	
Authority	and	CCG	organisations	[NICE	2012],	with	a	lack	of	central	or	regulated	oversight	to	see	that	
testing	and	monitoring	is	taking	place.	
Political	Support:	
Political	support	for	CVH	has	been	demonstrated	at	the	highest	level	in	official	statements	issued	by	
David	Cameron,	and	whilst	his	successor	Theresa	May	has	vocalised	support	for	a	greater	focus	on	
HCV	 as	 an	 MP,	 in	 her	 role	 as	 PM	 her	 support	 for	 CVH	 has	 involved	 a	 formal	 enquiry	 into	 the	
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contamination	of	blood	supplies	[Maidenhead	MP	2006,	British	Liver	Trust	November	2017].	Rather	
political	support	for	CVH	is	most	evident	in	the	increasing	role	and	funding	provision	provided	by	NHS	
England	under	the	Department	of	Health	to	treat	HCV	with	new	DAA	based	therapies,	with	the	real	
goals	and	support	to	help	meet	the	objectives	of	the	Lancet	Commission	and	others	to	achieve	an	
elimination	target	of	HCV	by	2030.	And	whilst	current	focus	and	high-level	support	is	directed	towards	
CVH	treatment	(and	in	particular	HCV),	there	is	a	growing	recognition	of	the	need	to	move	towards	
improved	CVH	testing,	with	an	impact	that	should	be	seen	in	the	core	aims	of	NICE	CVH	testing	policy	
[NHS	England	Blog	July	2017,	Williams	R	2014,	British	Liver	Trust	November	2017].	
Support	at	the	provider	level	is	also	evident	with	the	multiple	separate	CCGs	issuing	publications	to	
advocate	awareness	raising	for	CVH	 linked	to	World	Hepatitis	Day,	and	with	e-learning	modules	 in	
CVH	promoted	by	the	RCGP,	albeit	with	the	recognised	difficulties	that	GPs	now	have	with	trying	to	
squeeze	 additional	 practice	 learning	 points	 into	 ever	 demanding	 work	 pressures	 [RCGP	 elearning	
2017].	 Support	 for	CVH	 testing	 at	 the	 community	 level	 is	 also	 likely	 to	be	 influenced	by	a	historic	
background	of	low	levels	of	awareness	and	understanding	of	CVH	[RCGP	2007],	and	with	the	ongoing	
lack	of	a	systematic	vision	or	oversight	that	is	in	place	to	conduct	and	monitor	testing	in	primary	care.		Resources:	
No	 specific	 financial	 resources	 are	 mentioned	 in	 NICE	 CVH	 testing	 policy,	 with	 no	 additional	 or	
dedicated	funding	allocated	to	testing.	An	estimate	of	potential	costs	is	presented	in	supporting	NICE	
guideline	 documents,	 with	 cost	 estimates	 presented	 over	 a	 5	 year	 period,	 but	 is	 based	 on	many	
uncertainties	that	exist	in	underlying	prevalence	rates,	and	older	treatment	regimens	for	HCV	[NICE	
costing	template	2012].		
These	costs	are	presented	as	a	cost	to	the	NHS,	with	CCGs	tasked	with	commissioning	this	activity,	
without	clear	reciprocal	demonstration	of	the	savings	estimates	that	may	be	achieved	at	the	CCG	level	
through	this	activity.	Although	potential	costing	templates	are	offered	to	help	commissioning	groups	
understand	 the	 financial	 implications	of	 testing	 (based	on	 these	groups	measuring	and	calculating	
their	 own	 prevalence	 rates),	 these	 are	 presented	 at	 the	 (now	 disbanded)	 PCT	 level.	 Financial	
considerations	in	the	supporting	policy	documents	were	also	unable	to	fully	predict	the	role	that	NHS	
England	would	take	in	commissioning	all	treatments	for	CVH,	and	therefore	to	remove	this	budgetary	
need	from	CCG	financial	considerations	[NHS	costing	template	2012].		
Additionally,	there	is	no	recommendation	to	include	any	financial	resource	incentive	schemes	towards	
CVH	 testing,	 such	 as	 the	 Quality	 and	 Outcomes	 Framework	 (QOF)	 in	 primary	 care,	 despite	 these	
incentives	being	advocated	by	patient	charity	groups,	and	by	clinicians	in	the	field	with	the	hope	of	
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increasing	the	awareness	and	practice	of	CVH	testing	[Commons	Select	Committee	2011,	Williams	R	
2014].		
Technical	resource	limitations	are	also	apparent	in	CVH	testing	policy,	with	the	inability	to	foresee	the	
arrival	and	complexities	of	the	incoming	CCGs,	and	the	newly	formed	Health	and	Social	Care	bill,	as	
well	as	the	inherent	uncertainties	that	exist	in	the	underlying	prevalence	and	uptake	of	CVH	testing	in	
estimating	 community	 models.	 The	 implementation	 tools	 offered	 in	 conjunction	 with	 the	 NICE	
guideline	document	are	also	limited	by	these	data	uncertainties,	and	in	providing	practical	direction.	
There	is	also	no	mention	of	any	technology	based	approaches	that	can	be	used	to	facilitate	testing,	
such	as	electronic	coding	data,	or	the	linkage	of	data	across	separate	provider	services	which	could	be	
used	 to	 develop	 and	 facilitate	 better	 testing	 and	 treatment	 programmes,	 as	well	 as	 help	 support	
separate	organisations	explore	potential	data	merging	across	Information	Governance	obstacles.		
The	 rapid	 pace	 of	 change	 in	 recent	 treatment	 developments	 was	 also	 not	 predicted	 in	 guideline	
development,	 with	 many	 of	 the	 original	 supporting	 documents,	 and	 effectiveness	 estimates	 that	
would	be	expected	to	perform	better	in	the	current	era	of	CVH	treatment	options.	
Human	and	technical	resource	limitations	are	also	apparent	in	CVH	testing	policy,	with	a	failure	to	link	
testing	activity	to	a	dedicated	oversight	body,	or	group	of	individuals,	with	a	reliance	rather	on	self-
directed	testing	and	monitoring	responsibilities	run	by	Local	Health	and	Wellbeing	Boards;	made	up	
of	separate	PHE,	Local	Authority	and	CCG	organisations	[NICE	2012].	There	is	no	national	monitor	of	
CVH	testing	activity,	or	rates	of	infection	nationally,	and	only	recently	in	2017	did	the	first	indicator	of	
liver	disease	appear	in	the	NHS	Outcomes	Framework,	with	liver	disease	mortality	(in	the	under	75s)	
now	monitored	nationally	as	one	of	the	NHS	outcome	goals	[NHS	digital	Feb	207,	Williams	R	2014].		
Taking	 these	 resource	 considerations	 together;	 the	 lack	 of	 dedicated	 funding	 mechanisms	 and	
oversight	 responsibility	 /accountability	 for	 testing	 activity	 leaves	 one	 to	 presume	 that	 the	 human	
resource	priority	that	is	actioned	towards	testing	activity	at	the	practice	/	community	level,	as	well	as	
higher	CCG	or	Local	Authority	level	is	therefore	likely	to	be	low.		
	
Key	Findings:	
NICE	 hepatitis	 B	 and	 C	 testing	 policy	was	 developed	 to	 raise	 awareness	 of	 HBV	 and	 HCV,	 and	 to	
improve	 CVH	 testing;	 being	 developed	 with	 high	 level	 political	 support	 in	 the	 face	 of	 a	 growing	
mortality	seen	in	relation	to	liver	disease,	and	HCV	in	particular.	NICE	CVH	testing	recommendations	
are	directed	towards	community	services,	with	primary	care	the	principal	group	with	access	to	these	
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at-risk	 individuals,	 and	migrant	 groups	 in	 particular.	 Testing	 recommendations	 are	 far-reaching	 in	
comparison	to	other	policies	across	Europe	at	the	same	period,	with	a	specific	focus	to	provide	testing	
in	migrant	 communities.	 However,	 previous	 national	 CVH	 testing	 policy	 endeavours	 received	 low	
levels	of	awareness	and	uptake	 in	clinical	practice,	with	particular	deficit	 in	primary	care,	and	with	
concerns	then	that	current	testing	policy	may	met	with	a	low	priority	that	impacts	its’	adoption	and	
implementation.		
The	Policy	Prioritisation	Framework	developed	by	Shiffman	and	Smith,	and	 furthered	by	Walt	and	
Gilson	 provides	 a	 structure	 to	 understand	 the	 factors	 that	 influence	 policy	 reaching	 the	 political	
agenda,	and	receiving	the	attention	and	resources	for	its	implementation.	In	the	context	of	this	thesis,	
the	 framework	 looks	 to	establish	how	CVH	 testing	policy	 in	migrant	 communities	 can	achieve	 this	
political	 priority;	 considering	 the	 concepts	 of	 Actor	 Power,	 Ideas,	 Political	 Context,	 Issue	
Characteristics	and	Outcome	in	assessing	how	migrant	testing	can	be	prioritised.		
• Actors:	 The	 actors	 involved	 in	 policy	 development	 are	 supportive	 of	 its’	 objectives	 and	
implementation,	 but	 without	 clear	 leadership	 that	 is	 identified,	 and	 with	 policy	 that	 was	
designed	largely	in	a	top-down	approach,	with	little	evidence	of	community	involvement	and	
incentive	in	testing	objectives.		
• Ideas:	there	are	uncertainties	that	exist	in	our	understanding	of	CVH	risks,	and	how	to	best	
achieve	 testing.	 The	 internal	 community	 remains	 committed	 to	 endeavours	 to	 improve	
current	activity,	but	the	view	and	commitment	at	the	primary	care	(ground)	level	is	unclear.	
At	 the	 external	 frame,	 the	 public	 are	 likely	more	 aware	 of	 CVH	 through	 recent	 (positive)	
initiatives	and	developments,	but	concerns	of	stigmatisation	remain,	particularly	in	migrant	
communities.		
• Context:	 CVH	 testing	 policy	was	 developed	with	 high-level	 political	 support,	with	 national	
oversight	 that	 was	 developed	 at	 the	 same	 time	 through	 the	 National	 Liver	 Strategy.	 The	
introduction	of	the	Health	and	Social	Care	Act	does	not	appear	to	have	been	predicted,	or	
factored	into	CVH	policy,	with	the	subsequent	loss	of	the	National	Liver	Strategy.	The	recent	
introduction	 of	 the	 ODNs,	 and	 central	 role	 played	 by	 NHS	 England	 may	 provide	 greater	
coordination	and	oversight	of	CVH	case-finding	and	treatment	going	forward.	
• Issue	Characteristics:	there	is	ongoing	uncertainty	in	the	measures	used	to	currently	monitor	
CVH	testing,	with	no	established	oversight	(coordination)	of	testing	activity.		The	severity	of	
CVH	can	be	assessed	through	surrogate	markers	in	hospital	statistics,	but	there	remains	gaps	
in	 our	 understanding	 of	 the	 effective	 (practical)	 routes	 to	 achieve	 testing	 uptake	 in	
heterogeneous	 at-risk	 groups,	 including	 migrant	 communities.	 Previous	 (positive)	 cost-
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effectiveness	assessments	of	CVH	testing	are	likely	to	be	improved	in	consideration	of	the	vast	
improvement	in	treatment	options	and	treatment	uptake.	
• Outcome:	Whilst	there	are	clear	recommendations	to	primary	care	and	community	groups	to	
action	testing	in	migrant	groups	and	other	at-risk	groups,	there	is	little	in	the	way	of	practical	
direction	as	to	how	this	can	be	achieved,	reducing	the	authoritative	decisiveness	of	policy.	
Dedicated	resources	to	facilitate	testing	are	difficult	to	find,	with	a	lack	of	financial	and	human	
resources	that	are	additional	or	identified	from	policy.	The	development	of	the	newly	formed	
ODNs,	 and	 recent	drives	 in	 the	wake	of	DAA	 successes	may	however	 act	 as	 a	 resource	 to	
facilitate	policy	objectives.		
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Chapter	4:	Focus	Group	studies	in	the	UK	Nepali	community:	The	awareness,	knowledge	
and	perception	of	liver	disease	among	members	of	the	local	community		
Focus	group	discussions	in	the	Nepali	community:	
Abstract:	
Whilst	policy	can	achieve	improved	CVH	testing	activity	in	a	top-down	approach,	it	is	dependent	not	
on	only	on	the	ground-level	actors	who	provide	testing	(principally	in	primary	care),	but	is	also	
dependent	on	the	awareness	and	perception	of	disease	in	the	migrant	communities	served,	with	
particular	difficulties	that	are	faced	in	developing	strategies	to	engage	with	new	migrant	
communities	such	as	the	UK	Nepali	community,	where	disease	risks	and	health	engagement	patterns	
are	unknown.		
Developing	an	understanding	of	the	factors	that	may	influence	underlying	CVH	health	risks	in	the	
community,	and	the	awareness	and	perception	towards	liver	disease	is	important	in	developing	
practical	CVH	testing	and	management	strategies,	as	well	as	developing	and	maintaining	long	term	
health	engagement	patterns	in	this	new	migrant	community.	
Context:	
Patterns	of	healthcare	engagement	are	known	to	differ	in	migrant	communities,	with	concerns	that	
some	 may	 present	 late	 in	 their	 disease	 process,	 or	 to	 not	 interact	 with	 conventional	 healthcare	
services;	adding	to	concerns	regarding	the	health	vulnerability	of	these	individuals.		
The	underlying	factors	that	may	affect	healthcare	interaction	can	be	complex,	and	include	previous	
healthcare	experiences,	national	and	transnational	ties,	as	well	as	factors	influencing	health	access	in	
the	host	country.	Understanding	the	awareness	and	perception	of	health	and	health	engagement	is	
important	in	developing	strategies	to	reach	out	to	these	communities,	in	understanding	underlying	
health	risks,	and	in	developing	effective	testing	and	management	interventions.		
The	UK	Nepali	population	is	a	new	migrant	community,	with	little	known	about	health	awareness	and	
perception,	 and	 how	 the	 community	 would	 engage	 with	 CVH	 testing	 endeavours.	 Understanding	
these	 factors,	 and	 any	 potential	 facilitators	 or	 barriers	 towards	 testing	 delivery	 and	 uptake	 is	
important	in	endeavours	to	improve	CVH	testing,	and	future	health	engagement.			
Literature	Review:	
Awareness,	understanding	and	perception	of	disease	(CVH)	in	migrant	communities:		
Factors	that	influence	health-testing	uptake	are	multifactorial,	including	those	aspects	that	lie	at	the	
practitioner	level,	the	system	structure,	as	well	as	the	patient.	Language	barriers	are	well	known	to	be	
a	 factor	 in	 patient-practitioner	 interactions,	 but	 developing	 successful	 testing	 engagement	
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endeavours	require	a	more	detailed	understanding	of	the	awareness,	beliefs	and	attitudes	relating	
towards	disease	states,	and	disease	management	[Cochrane	A	2016].		
Migrant	communities	may	have	different	health	perceptions,	as	well	as	differences	in	health-seeking	
behaviour	that	may	be	linked	to	cultural	experience	or	transnational	ties	[Norredam	M	2010,	Kessing	
L	2013].	Culture	and	traditional	beliefs	may	also	impact	on	the	perception	and	treatment	paradigms	
that	individuals	may	follow,	with	a	role	for	Spirits	and	other	external	agents	that	individuals	may	see	
in	controlling	their	disease	process,	and	in	how	this	may	influence	health-seeking	behaviours	[Uehara	
ES	2001].	 Indeed,	the	baseline	complexities	(fragilities)	of	migrant	groups	native	social	and	cultural	
history	and	circumstances,	including	tragedy	and	displacement	is	likely	to	influence	how	wellness	and	
disease	is	perceived,	and	is	likely	to	influence	health-seeking	behaviour,	as	suggested	in	studies	in	the	
US	Cambodian	population	[Uehara	ES	2001].	Previous	systematic	reviews	have	shown	that	migrant	
groups	may	be	less	likely	to	engage	with	cancer	screening	services,	and	that	there	are	often	complex	
multi-faceted	reasons	for	this	lack	of	health-engagement	that	seems	independent	of,	and	more	than	
a	mere	lack	of	knowledge	relating	to	disease	implications	[Kessing	L	2013].		
In	CVH	testing,	stigma	is	described	amongst	patients	with	diagnosed	HBV	and	HCV,	and	is	mentioned	
as	a	possible	barrier	to	testing	in	several	qualitative	studies	in	migrant	communities	[Drazic	NY	2013,	
Rafique	I	2014,	Sriphanlop	P	2014].	Studies	conducted	within	South	Asian	countries	suggest	that	the	
level	of	stigmatisation	and	isolation	felt	by	viral	hepatitis	patients	here	in	the	native	country,	may	be	
greater	than	that	elicited	by	South-Asian	migrants	in	Western	countries.	Direct	comparisons	between	
these	groups	are	not	possible,	and	differences	may	be	accounted	by	multiple	factors;	including	socio-
economic	 status,	 socio-cultural,	 religious	 and	 environmental	 factors;	 but	 the	 strength	of	 assertion	
made	by	patients’	resident	in	South	Asian	countries	raises	the	potential	for	greater	perceived	stigma	
in	new	members	from	these	communities	[Drazic	NY	2013,	Rafique	I	2014].		
However,	not	all	migrants	see	stigma	in	their	condition	within	their	community	[Cochrane	A	2016],	
and	there	are	likely	to	be	differences	in	how	HBV	and	HCV	are	seen.	The	impact	of	stigma	alone	as	a	
barrier	to	testing	is	unclear,	and	studies	in	the	UK	among	migrant-community	healthcare	leaders	have	
suggested	 low	 levels	 of	 awareness	 in	 testing	 programmes	 as	 perhaps	 a	more	 important	 factor	 in	
uptake,	 and	 despite	 stigmatisation	 expressed	 by	 migrants,	 there	 seems	 to	 be	 a	 high	 level	 of	
acceptability	 towards	 the	 delivery	 of	 better	 coordinated	 testing	 services	 in	 community	 settings.	
[Seedat	F	2014].			
Knowledge	regarding	HBV	and	HCV	is	universally	 low	in	reported	studies,	and	liver	disease	is	often	
understood	and	referenced	as	jaundice	in	qualitative	studies	[Cochrane	A	2016].	Although	stigma	is	
mentioned	by	migrant	groups	in	focus	group	studies	on	viral	hepatitis,	most	express	the	consensus	
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view	to	learn	more	about	viral	hepatitis,	and	to	engage	in	community	intervention	programmes	that	
will	offer	individuals	long-term	benefit	[Blanas	A	2015].	Focus	group	studies	in	migrant	populations	
commonly	cite	cultural	and	religious	factors	as	drivers	to	support	testing,	with	 Islam	often	used	to	
support	testing	and	treatment	as	part	of	one’s	overall	health	responsibilities	[Blanas	A	2015,	Van	der	
Veen	 YJ	 2009].	 These	 studies	 also	 identify	 differences	 that	 exist	 between	 sexes	 and	 age	 groups	
towards	how	disease	is	viewed,	and	in	potential	barriers	and	facilitators	to	testing.	Older	individuals	
may	express	less	stigmatising	factors,	but	express	externalising	factors	in	controlling	health-states	that	
may	itself	impact	testing	and	engagement	[Van	der	Veen	IJJ	2009].	Adding	cultural	and	religious	(Islam)	
framed	 support	 for	 testing	 has	 been	 assessed	 in	 the	 Dutch	 Turkish	 population,	 but	 without	 any	
significant	 difference	 in	 testing	uptake	 compared	 to	 simple	mailed	 invites	 alone	 [Van	der	Veen	YJ	
2010].	However,	the	authors	reported	a	high	level	of	satisfaction	with	these	methods,	and	such	testing	
approaches	with	 religious	and/or	cultural	 framing	may	be	beneficial	 in	groups	who	express	 strong	
stigmatising	perceptions,	or	with	groups	that	are	particularly	difficult	to	engage	with	[Rafique	I	2014].		
Cultural	perceptions	towards	health,	illness	and	therapy	vary	between	communities.	In	the	study	by	
Burke	et	al.	into	HBV	perceptions	in	the	Cambodian	American	(US)	population;	traditional	paradigms	
of	health	were	seen	to	mix	with	modern	approaches	in	the	US,	demonstrating	a	medical	pluralism	that	
exists	 between	 traditional	models	 of	 health	 and	modern	 day	medical	 practices.	 Suffering	 is	 often	
viewed	as	an	 integral	and	 inevitable	part	of	 life	and	happiness,	and	some	participants	 in	the	study	
reported	the	use	of	dermabrasive	techniques	with	pinching	or	coining	(rubbing	the	skin	with	a	hard	
object,	such	as	coin	in	a	linear	fashion)	in	an	attempt	to	manage	illness	[Burke	N	2011,	Tan	AK	2011].	
Participants	 in	 the	 group	 also	 reported	 seeking	 traditional	Western	 healthcare	 consults	 only	 after	
having	 tried	 these	 traditional	 methods,	 with	 the	 concerns	 therefore	 of	 delayed	 healthcare	
presentations	despite	clinical	concerns	[Burke	N	2011].	Levels	of	understanding	towards	CVH	was	poor	
in	the	focus	groups	conducted,	with	many	aware	of	specific	medical	terms	through	formal	healthcare	
interaction,	such	as	hepatitis	A,	B	and	C,	but	associating	this	to	a	step-wise	progression	that	occurs	
due	to	a	 lack	of	self-care,	progressing	 from	HAV	to	HCV,	and	beyond	to	severe	complications.	The	
majority	of	participants	(n=97)	had	been	in	the	US	for	over	10	years,	and	whilst	the	views	above	were	
not	expressed	by	all,	there	is	evidence	of	significant	variation	in	healthcare	beliefs	and	practices	that	
would	adversely	affect	healthcare	interactions,	and	CVH	care	specifically,	with	a	pluralism	of	beliefs	
that	seem	detrimental	[Burke	N	2011].		
Overall,	these	studies	demonstrate	that	there	is	heterogeneity	between	communities	in	how	health	
and	disease	awareness	and	perception,	with	complex	national	and	transnational	ties	that	are	likely	to	
underpin	this,	as	well	as	health	access	and	integration	factors	in	the	host	nation.	Improving	awareness	
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of	disease	and	 the	benefits	of	 treatment	 is	widely	expressed	as	positive	 facilitators	 in	 testing,	and	
health	uptake.	Awareness	of	CVH	is	likely	to	be	low	in	most	migrant	communities,	and	is	commonly	
understood	 as	 “jaundice”	 or	 “liver	 disease”	 in	 qualitative	 studies	 [Burke	 N	 2011].	 ,	 and	 whilst	
stigmatisation	 is	widely	mentioned,	 it	does	not	feature	as	a	non-modifiable	barrier	to	testing,	with	
large	educational	campaigns	able	to	de-stigmatise	viral	hepatitis,	moving	stereotypes	away	from	the	
“bad-individual”	to	the	management	of	a	chronic	disease	state	that	is	geographically	prevalent	[Yoo	
GJ	2011].		
Exploring	 the	perceptions	 towards	health	and	 treatment	 in	migrant	communities	can	help	 identify	
fixed	beliefs	that	may	be	held,	and	pluralisms	that	may	adversely	affect	healthcare	engagement	and	
treatment	abilities,	with	intrinsic	(self)	and	extrinsic	(e.g.	spiritual)	factors	that	may	be	evident.	
	
Research	Objectives:		
In	 looking	 to	 develop	 and	 improve	 the	 provision	 of	 CVH	 testing	 and	 onward	 care	 in	 the	 Nepali	
community,	we	sought	to	first	understand	the	awareness	and	perception	of	disease	to	achieve	the	
following	research	objectives:	
• To	explore	the	awareness	of	liver	disease	in	the	Nepali	community	
• To	 explore	 the	 knowledge	 and	 understanding	 of	 liver	 disease	 related	 to	 aetiology,	
pathogenesis	and	treatments.		
• To	explore	the	perceptions	of	the	community	towards	liver	disease,	considering	its	priority,	
severity,	and	perceived	risk	factors.		
• To	explore	perceptions	towards	treatment	paradigms	and	healthcare	interactions	in	the	UK	
• To	 understand	 perceptions	 of	 stigma	 towards	 liver	 disease,	 and	 potential	 barriers	 and	
facilitators	 towards	 CVH	 testing,	 and	 factors	 that	may	 influence	 the	 development	 of	 CVH	
testing	initiatives	in	the	local	Nepali	population.	
• To	 inform	 and	 shape	 the	 development	 and	 delivery	 of	 a	 (future)	 community	 CVH	 testing	
initiative	in	the	UK	Nepali	population	
An	 overarching	 objective	 with	 our	 Focus	 Group	 work	 was	 to	 help	 develop	 a	 culturally-sensitive	
approach	to	the	development	of	a	community	CVH	testing	study,	with	focus	group	studies	conducted	
as	the	first	part	of	this	approach,	and	framed	as	first	part	of	our	study	aims	in	formal	ethics	applications	
for	our	research	work.	
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Focus	Groups	–	background	and	rationale:	 Focus	groups	were	chosen	 to	explore	our	 research	
objectives	 given	 their	 pedigree	 in	 qualitative	 studies,	 and	 given	 their	 utilisation	 in	 prior	 studies	 in	
migrant	health.		
Focus	group	were	first	widely	utilised	in	political	and	market	research,	before	being	adopted	more	
widely	into	health	and	social	sciences	[Braun	and	Clarke	2013].	Focus	groups	allow	the	researcher	to	
explore	the	understanding	and	perception	of	multiple	participants,	benefiting	from	the	shared	social	
interaction	 and	 discourse	 facilitated	 through	 group	 discussions	 [Braun	 and	 Clarke	 2013].	 These	
discussions	can	be	help	identify	personal	opinions	that	exist,	as	well	as	those	that	are	shaped	or	arise	
through	group	discourse,	replicating	opinions	that	exist	and	form	through	social	group	interactions	
[Krueger	1994].		
Focus	 groups	 offer	 particular	 benefit	 in	 exploring	 the	 perceptions	 of	 under-represented	 and	
marginalised	groups,	where	the	group	can	help	facilitate	expression,	and	to	give	voice	to	individuals	
who	may	not	otherwise	be	express	themselves	in	other	settings	[Braun	and	Clarke	2013].	In	a	similar	
way,	 focus	groups	can	also	help	explore	sensitive	 topics,	where	 the	non-formal	and	 relaxed	group	
environment	can	help	facilitate	discussion	and	opinion	[Braun	and	Clarke	2013].	Focus	groups	have	
therefore	 been	 employed	 successfully	 among	 diverse	 patient	 groups	 to	 explore	 perceptions	 in	
sensitive	areas	such	as	HIV,	injecting	drug	use,	as	well	as	viral	hepatitis	[Frew	PM	2016;	Lindkvist	P	
2015;	Sweeney	L	2015].		
In	 migrant	 health,	 focus	 groups	 have	 been	 well	 utilised	 in	 exploring	 knowledge	 and	 perceptions	
towards	health	and	disease	states,	as	well	as	health	seeking	behaviour,	allowing	the	researcher	to	
explore	the	opinions	and	shared	cultural	beliefs	of	individuals	through	these	sessions	[Burke	NJ	2011,	
Cochrane	A	2016,	Sweeney	L	2015;	Vatcharavongvan	P	2014]	
As	with	all	qualitative	methods,	Focus	Groups	do	have	their	disadvantages,	which	 include	a	 loss	of	
detailed	 personal	 experience	 and	 narratives,	 as	 well	 as	 the	 effects	 of	 group	 heterogeneity	 in	
discussions	and	the	relative	loudness	of	particular	participants	in	expressing	opinions	that	may	mask	
those	 of	 others	 [Krueger	 1994,	 Braun	 and	Clarke	 2013].	However,	 overall	 focus	 groups	 are	 a	well	
proven	method	of	exploring	new	and	sensitive	information	among	migrant	communities,	and	provides	
a	level	of	meaning	making	[Braun	and	Clarke	2013]	that	can	be	employed	to	explore	factors	relating	
toward	knowledge,	perception	and	influencing	factors	on	healthcare	access	and	engagement	in	new	
communities	such	as	the	UK	Nepali	population.		
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Awareness,	knowledge	and	perception:	The	concepts	of	“awareness,	knowledge	(understanding)	and	
perception”	are	related,	and	not	mutually	exclusive.	Rather	they	sit	on	a	spectrum,	with	relationships	
that	exists	between	these	concepts	and	that	influence	one	another.		
These	 terms	 are	 often	 used	 interchangeably,	 and	 dictionary	 definitions	 further	 the	 difficulties	 in	
distinguishing	clear	distinctions	between	them.	But	for	the	purposes	of	this	thesis,	awareness	is	used	
to	 reference	 a	 “general	 awareness”	 of	 liver	 disease,	 and	 utilises	 the	 concept	 of	 a	 knowledge	
continuum	where	knowledge	 is	 referenced	as	“detailed	and	specific	knowledge”,	which	sits	at	 the	
opposite	end	this	continuum.	Whilst	these	terms	are	not	distinct,	I	use	the	concept	of	awareness	to	
establish	 the	 general	 and	 reflex	 awareness	 of	 the	 community	 towards	 liver	 disease	 [Trevethan	 R	
2017].	This	awareness	 is	dependent	on	personal	experience,	and	 is	 reflective	of	an	almost	visceral	
response	to	the	condition,	that	relates	to	the	severity	in	which	the	condition	is	seen,	and	that	of	course	
feeds	into	the	knowledge	and	perceptual	domains	extracted	throughout	focus	group	discussions.		
Knowledge	and	understanding	is	explored	as	a	more	detailed	concept	[Trevethan	R	2017),	considering	
the	 aetiology,	 risks,	 and	 treatment	 experiences	 in	 the	 community,	 based	 on	 lived	 experience	 and	
learned	knowledge.	This	knowledge	is	therefore	taken	to	be	a	more	detailed	account	and	analysis	of	
the	experiences	gathered	during	focus	group	discussions,	that	identify	the	knowledge	and	certainty	in	
the	community	towards	liver	disease.		
Perception	 of	 a	 disease	 is	 related	 to	 one’s	 awareness	 and	 knowledge,	 and	 in	 the	 absence	 of	 any	
awareness	 of	 liver	 disease,	 one’s	 perception	 will	 be	 very	 different	 to	 a	 person	 with	 first-hand	
experience	 [Dretske	 F,	 2006].	 Perception	 is	 therefore	 very	 much	 dependent	 on	 one’s	 lived,	 and	
learned	experiences.	Perception	is	not	taken	as	separate	to	awareness	or	knowledge,	but	is	used	in	
this	 thesis	 to	 explore	 the	 community’s	 views	 towards	 liver	 disease,	 its	 causes,	 and	 certainties	 of	
association,	 therapy,	 as	well	 as	 stigma.	 Stigma	 features	within	 the	 realm	 of	 perception,	 including	
public	 stigma,	 with	 the	 perception	 that	 is	 held	 within	 wider	 society,	 and	 self-stigma	 with	 the	
internalisation	of	perceived	prejudices	that	they	may	encounter,	and	the	onward	 implications	that	
these	may	have	[Latalova	K	2014].		
Reflexivity:	
In	looking	to	engage	with	members	of	the	UK	Nepali	community	for	the	first	time,	I	became	aware	of	
the	importance	of	understanding	the	awareness	and	perception	of	viral	hepatitis	and	liver	disease	in	
this	migrant	community.	Working	as	a	clinician,	one	often	approaches	disease	states	and	management	
decisions	in	a	dogmatic	fashion,	following	a	well-established	medical	model.		
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Understanding	 the	 awareness	 and	 perception	 of	 health	 and	 disease	 in	 the	 patient	 is	 not	 often	
considered,	and	the	access	and	effectiveness	of	health	care	approaches	may	be	negatively	impacted	
as	a	result.	 	 I	therefore	adopted	this	qualitative	work	with	great	 interest,	and	intuitive	qualities,	to	
explore	 how	 liver	 disease	was	 understood	 and	perceived	 in	 the	Nepali	 community,	 and	 remained	
mindful	of	my	own	limitations	in	not	involving	these	considerations	in	my	previous	clinical	work.		
Methods:	
Focus	group	sessions	were	designed	along	the	principles	identified	by	Krueger	and	Braun	and	Clarke	
[Krueger	1994,	Braun	and	Clarke	2013].		
We	developed	 a	 research	 steering	 group,	 involving	Nepali	 community	 leaders	 in	 order	 to	 identify	
potential	focus	group	participants.	Nepali	community	leaders	were	identified	with	the	help	of	hospital	
community	liaison	leads	from	Frimley	Park	Hospital,	Nepali	nursing	staff,	local	council	leads,	and	the	
Rushmoor	Healthy	Living	social	enterprise	charity.	Ramji	Tiwari	was	identified	from	Rushmoor	Healthy	
Living	as	having	had	Public	Health	experience	in	Nepal,	and	was	involved	as	one	of	the	core	members	
of	the	research	steering	group.		
The	role	of	Nepali	community	leaders	was	vital,	and	given	the	religious	heterogeneity	and	the	lack	of	
existing	 infrastructure	 in	 community	 healthcare	 links,	 we	 developed	 this	 group	 from	 its	 infancy,	
drawing	 in	 many	 Nepali	 community	 volunteers	 and	 stakeholders	 as	 the	 project	 evolved.	 A	 more	
detailed	description	of	this	process	is	presented	in	the	CVH	testing	study	chapter.		
Focus	group	participants	were	identified	with	the	initial	members	of	our	Nepali	steering	group,	made	
principally	 of	 nursing	 staff,	 hospital	 liaison	 links	 (Kathryn	 Stuart)	 and	 Ramji	 Tiwari,	 working	 with	
Rushmoor	Healthy	Living.	Formal	academic	 input	and	qualitative	support	was	provided	by	Dr	 Jane	
Hendy	from	the	University	of	Surrey	(now	Professor	Jane	Hendy	at	Brunel	University).		
In	keeping	with	early	discussions	among	our	Nepali	colleagues,	focus	group	discussions	were	delivered	
in	Nepalese,	with	Nepalese	speaking	(bi-lingual)	moderators	identified	from	our	steering	group	(Ramji	
Tiwari,	Mrs	Tiwari,	and	a	Nepali	nursing	student	at	Frimley	Park	Hospital	and	the	University	of	Surrey).	
English	was	 felt	 to	be	poorly	understood	 in	the	recently	arrived	community,	and	moderators	were	
given	face	to	face	verbal	training	in	conducting	focus	group	work	prior	to	undertaking	sessions.		
Focus	group	sessions	were	held	 in	 the	Rushmoor	Health	Living	centre	 in	central	Farnborough,	 in	a	
popular	 shopping	 area	 familiar	 to	 most	 locals	 and	 Nepali	 alike,	 with	 sessions	 held	 in	 a	 neutral	
community	environment.	Clinical	members	of	the	team	were	not	present	during	discussions	to	try	and	
encourage	natural	discussions	in	familiar	settings.		Self-moderated	focus	groups	were	chosen	given	
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their	 potential	 benefit	 to	 de-formalise	 sensitive	 discussions,	 and	 to	 encourage	 certain	 aspects	 of	
discourse	in	a	more	culturally	appropriate	setting	[Braun	and	Clarke	2013].	
A	 formal	 national	 ethics	 process	was	 completed	 prior	 to	 commencing	 our	 study,	with	 application	
through	the	national	NHS	Health	Research	Authority	(HRA),	and	a	favourable	opinion	granted	through	
the	South	East	Coast	HRA	committee	(REC	12/LO/1530)	[Appendix	2].	Ethics	application	for	our	Focus	
Group	work	was	submitted	as	the	first	part	of	a	study	to	inform	and	develop	a	subsequent	CVH	testing	
study	in	the	UK	Nepali	community	[Appendix].	
Focus	 group	 guides	 were	 created	 (Dr	 Jane	 Hendy)	 to	 elicit	 discussions	 relating	 to	 our	 research	
objectives.	Focus	group	guides	were	used	universally	across	all	4	focus	group	sessions.	Moderators	
primarily	 used	 the	 term	 “liver	 disease”	 in	 discussions,	 given	 our	 level	 of	 uncertainty	 how	 specific	
disease	 references	 such	 as	 viral	 hepatitis,	 or	 hepatitis	 B	&	C	would	be	understood,	 as	well	 as	 our	
desires	 to	 explore	 broader	 concepts	 of	 how	 liver	 disease	was	 perceived,	 and	 in	 identifying	 broad	
factors	that	may	influence	healthcare	engagement.		
Participants	were	purposively	identified	through	input	from	our	community	leaders	and	stakeholders,	
including	the	hospital	liaison	team	at	Frimley	Park	Hospital.	Participants	were	invited	by	a	standardised	
letter,	as	well	as	personal	(word	of	mouth)	invitation	from	our	Nepali	volunteers.		
It	was	recognised	in	early	discussions	that	many	of	the	recently	arrived	Nepali	were	likely	to	be	older,	
and	 in	an	attempt	 to	 improve	representation,	our	Nepali	community	group	suggested	recruitment	
invites	to	be	targeted	to	Nepali	participants	above	or	below	30	years	of	age,	with	these	definitions	
maintained	during	analysis.	Four	focus	groups	were	therefore	organised,;	 inviting	male	and	female	
participants	with	ages	above	or	below	30	years	to	participate.		
Focus	group	guides	were	used	universally	across	all	4	focus	group	sessions.	Moderators	primarily	used	
the	term	“liver	disease”	in	discussions,	given	our	level	of	uncertainty	how	specific	disease	references	
such	 as	 viral	 hepatitis,	 or	 hepatitis	 B	&	 C	would	 be	 understood,	 as	well	 as	 our	 desires	 to	 explore	
broader	 concepts	 of	 how	 liver	 disease	 was	 perceived,	 and	 in	 identifying	 broad	 factors	 that	 may	
influence	healthcare	engagement.		
Focus	group	sessions	were	audio-recorded,	 transcribed	and	 then	 translated	with	help	 from	Nepali	
speaking	members	of	our	advisory	group	(Ramji	Tiwari).	Participants	were	given	written	information	
and	consent	sheets	in	Nepalese	and	English	detailing	the	aims	of	our	study,	as	well	as	how	information	
would	be	recorded	and	processed.	The	importance	of	sharing	thoughts	in	a	confidential	area,	as	well	
as	the	lack	of	a	“right-or-wrong”	answer	was	stressed	to	all	members	before	starting	each	group.	Each	
focus	group	session	was	audio-recorded.		
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Moderators	were	given	autonomy	to	phrase	questions	as	they	felt	best	according	to	each	group,	and	
to	explore	additional	avenues	related	to	liver	disease	if	they	arose	during	discussion.	Feedback	was	
taken	at	the	end	of	each	session	to	gauge	for	sensitivity	provoked	by	questioning/comments.		
Data	Analysis:	Thematic	Analysis		
Several	qualitative	data	analysis	methods	were	considered	 in	 the	context	of	 focus	group	data	 that	
would	require	translation	and	transcription	from	Nepali	to	English,	and	with	expert	opinion	garnered	
through	the	qualitative	data	analysis	workshops:	“Introduction	to	Qualitative	Data	Analysis,	Surrey	
Social	 Sciences	 School”,	Dec	 2015;	 	 and	 “Doing	 and	Communicating	Qualitative	Research	 Summer	
School	2016”,	Kingston	University.			
A	thematic	analysis	(TA)	approach	was	eventually	chosen	given	its	proven	utilisation	in	focus	group	
analysis,	as	well	as	its	relative	flexibility	in	providing	an	inductive	bottom-up	approach	to	explore	the	
ideas	and	concepts	expressed	in	focus	group	discussions	[Braun	and	Clarke	2013].		
Alternative	data	analysis	strategies	including	interpretative	Phenomenological	Analysis	(IPA)	were	also	
considered	prior	to	adopting	a	TA	approach,	with	 IPA	 initially	reviewed	given	 its	experiential	 (lived	
experiences)	approach	to	identifying	patient	meaning	and	sense-making	[Braun	and	Clarke	2013].	IPA	
may	 provide	 richer	 data	 analysis	 and	 coding	 at	 the	 individual	 participant	 level,	 focusing	 on	 the	
characteristics	and	meanings	expressed	by	each	participant.	However,	the	role	of	IPA	in	focus	group	
analyses	of	multiple	participants	is	less	established	[Tomkins	L	2010].	The	loss	of	interpretative	quality	
that	occurs	through	the	translation	process	from	Nepalese	to	English	is	also	not	well	described,	and	is	
likely	to	lead	to	a	loss	in	the	quality	of	experiential	analysis	that	will	arise.	The	choice	of	qualitative	
methodology	 was	 made	 following	 my	 attendance	 at	 formal	 qualitative	 workshops	 held	 at	 the	
University	of	Surrey	and	Kingston	University.			
Thematic	 Analysis	 was	 therefore	 used	 in	 focus	 group	 analyses	 to	 explore	 the	 ideas	 and	 concepts	
(meanings)	expressed	in	participant	groups,	utilising	a	RE	(Realist	Evaluation)	framework	to	generate	
associations	from	these	discussions.	Initial	coding	was	performed	by	myself	as	the	primary	researcher,	
with	higher	organising	themes	presented	and	discussed	among	the	research	team	with	the	principal	
study	supervisors.			
Overarching	themes	from	TA	were	then	analysed	to	explore	how	these	findings	may	impact	the	way	
that	the	Nepali	community	interact	with	CVH	testing.	
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Results/Analysis	
32	Nepali	individuals	attended	the	focus	group	sessions	with	all	individuals	born	in	Nepal.	Groups	were	
divided	according	to	sex	and	age;	males	and	females	above	or	below	30	years	of	age.		The	average	
number	of	focus	group	attendees	was	8	(range	6-11),	with	each	session	lasting	30-60	minutes.	
Question	guides	were	used	to	structure	each	focus	group,	with	additional	avenues	of	thought	explored	
by	the	moderator	if	felt	appropriate.	Open-ended	questions	were	posed,	with	broad	themes	exploring	
the	definition	of	liver	disease,	the	causes	of	liver	disease	and	personal	experience,	as	well	as	how	liver	
disease	is	viewed	in	the	Nepali	community.		
Focus	group	guides	were	developed	by	Dr	Jane	Hendy,	with	10	key	questions	(table	10)	designed	to	
explore	the	awareness	and	perception	of	liver	disease	in	the	Nepali	community,	with	specific	aims	to	
identify	potential	barriers	and	facilitators	that	may	exist	in	the	subsequent	development	of	a	CVH		
Table	10:	key	questions	posed	to	the	focus	group	members	(all	4	groups)	by	the	moderator	
	
Focus	Group	Guide	used	by	Nepali	moderators	(key	questions):
Can you tell me - what do you think liver disease is?
Prompts: Is it infectious, is it fatal, how do you know you have it, how do you get it, what can you do if 
you have it?
What sort of people do you think are most likely to get liver disease?
Prompts: young, old, lifestyle factors (drinking, drugs), dirty/clean, and other beliefs, including 
religious?
Do you know anyone who has ever had liver disease? 
Can you tell me about them?
What do you think happens to you if you have liver disease?
Prompts: what type of things might you notice; can you be cured? What does the cure involve? Do 
you die?
Tell me what you think might cause liver disease in the Nepali community?
Prompt: how might this be different for other groups of people?
What do you thing Nepali people think about others who have liver disease?
When I say hepatitis - what does this word mean for you?
How would you go about finding out more about health issues liver disease?
Prompt: where and why?
What sort of information would you like? What is most useful? 
Probe: for brochures, booklets, flyers, newspaper articles, videos, television) 
Do you prefer information in English or Nepalese?
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testing	 study.	Questions	were	also	designed	 to	explore	potential	 risk	 factors	 that	may	exist	 in	 the	
community	 towards	 liver	disease,	 and	how	 future	education	and	health	engagement	may	best	be	
delivered	 to	 the	community.	Moderators	were	briefed	 to	explore	 the	 role	of	 traditional	 cures	and	
disease	paradigms	in	the	Nepali	community,	including	the	role	of	extrinsic	agents	such	as	Spirits	and	
Witch	Doctors.	These	traditional	beliefs	were	explored	during	discussions,	with	particular	relevance	
given	their	strong	emphasis	in	some	of	the	early	focus	groups	among	older	male	participants.		
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Analysis	results:		Males	Under	30:	
Two	 overarching	 themes	 were	 identified	 in	 our	 focus	 group	 session	 in	males	 less	 than	 30	 years:	
Uncertainty,	and	the	need	for	constant	vigilance,	and	Responsibility	and	Impact.	An	overview	of	these	
themes	and	their	candidate	themes	is	presented	in	table	11,	with	a	network	map	in	figure	21	
Table	11:		an	overview	of	the	2	Overarching	themes	identified	in	males	<	30	yrs	
	
	
Uncertainty and the need for constant vigilance 
An overarching theme that reflects the struggle participants expressed in defining liver 
disease, its causes, as well as how one could guard against a disease with a myriad of 
often conflicting causes. The theme “liver disease is (nearly always) jaundice” explores 
how liver disease is largely experienced as a short-lived episodes of transient illness, 
with Jaundice often considered as an almost separate disease state affecting the liver, 
rather than a manifestation of disease. “How do we explain illness” explores the almost 
universal difficulties participants expressed in knowledge regarding the causes of 
disease, and the unpredictable nature of disease and disease recurrence. The theme 
“external causes of disease” looks at the strongly expressed beliefs of external agents 
such as food and water that can cause disease, as well as spirits that cause disease. 
“Universal risk and constant vigilance” encompasses the participants concern and 
uncertainty regarding how to protect against disease given its many potential causes, 
and external agency. “Traditional vs. medical (scientific) therapy” explores the 
participants predominant views on the place of faith, and traditional based therapies in 
early disease management, but also the uncertainty and place of modern medicine in 
providing ultimate success in controlling disease. 
 Responsibility and Impact 
Reflects the individual actions that participants express as a cause of liver disease, as 
well as the predominantly negative self-image associations seen in those with liver 
disease. The theme “Accountability and blame” explores the predominantly negative 
actions of negligence that participants associate with disease acquisition, whilst “Image 
and Agency” considers the negative perceptions and consequences that participants link 
to those who suffer disease, as well as the wider family in some cases. 
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Figure	21:		Network	map	of	relations	between	the	2	overarching	themes	in	males	<	30	yrs	(“Uncertainty	and	the	need	for	
constant	 vigilance”,	 and	 “	 Responsibility	 and	 Impact”).	 Bilateral	 closed	 and	 dotted	 lines	 represent	 close	 relationships	
between	candidate	themes.			
“Uncertainty	and	the	need	for	constant	vigilance”	
Younger	male	participants	seemed	well	aware	of	liver	disease,	but	expressed	considerable	uncertainty	
in	 identifying	 the	 causes	 and	 nature	 of	 disease,	 and	 in	 particular	 how	 to	 guard	 against	 disease	
acquisition.	Participants	identify	liver	disease	principally	as	jaundice,	identifying	jaundice	as	a	distinct	
disease	states	of	multiple	causes:		
“I	heard	about	it,	my	friend	was	infected	with	jaundice	(Participant	1);	There	are	different	types	
of	jaundice;	one	is	yellow	type	and	the	other	is…I	heard	A	and	B	(Participant	2)”.		
Participants	conceptualise	 liver	disease	as	 jaundice,	with	the	potential	 implications	of	viewing	 liver	
disease	 as	 only	 present	 in	 symptomatic	 patients,	 and	 the	 potential	 needs	 to	 expand	 education	
regarding	the	chronic	and	asymptomatic	nature	of	CVH.	
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Considerable	 uncertainty	was	 expressed	 as	 to	 the	 causes	 of	 liver	 disease	 in	 the	 group,	 but	 some	
participants	did	express	knowledge	regarding	different	types	of	liver	disease,	and	in	these	expressions	
there	is	also	mention	that	some	disease	states	are	more	severe	than	others,	and	potentially	fatal:	
“I	heard	that	hepatitis	B	 is	very	dangerous,	and	 if	 it	becomes	worse	 it	can	take	 life,	 I	mean	
death	(participant	2);	If	get,	liver	disease	is	not	good.	Surely	there	is	the	possibility	of	death	
(participant	4)”	
There	is	the	suggestion	that	some	conditions	are	worse	than	others,	with	the	specific	mention	of	HBV	
in	this	context.	 It	also	suggests	that	there	may	be	a	potential	fear	for	patients	to	engage	with	CVH	
testing,	and	a	role	for	education	in	the	community.		
The	candidate	theme	“how	do	we	explain	illness”	explores	the	uncertainty	and	often	conflicting	views	
that	are	expressed	by	participants	in	and	how	and	why	disease	occurs,	and	even	recurs.	Participants	
conflicted	in	their	opinion	of	how	liver	disease	occurs,	with	opposing	views	expressed:	
“…my	friend	was	infected	with	jaundice.	It	is	not	a	communicable	disease	(participant	1);	…It	
is	communicable	and	transmit	easily	to	others,	so	need	to	stay	in	isolation	(participant	2)”	
These	extracts	demonstrate	a	clear	conflict	in	perception	of	how	disease	is	caused,	and	importantly	
how	it	is	transmitted.	It	is	also	of	interest	to	note	the	language	used	by	participant	1,	and	the	term	
“infected”	to	define	how	his	friend	was	affected	with	liver	disease,	and	at	the	same	time	to	consider	
liver	disease	to	be	non-communicable.	The	views	of	participant	2	are	very	different	with	regard	to	
how	disease	can	be	spread	between	individuals,	and	is	of	interest	in	the	ease	of	disease	transmission	
that	he	describes,	as	well	as	the	need	to	keep	those	who	are	infected	in	isolation,	with	a	potentially	
profound	impact	on	developing	and	engaging	with	community	members	for	testing	campaigns.	This	
concept	of	needing	to	isolate	oneself,	also	feeds	into	the	candidate	themes	identified	in	“universal	
risks	and	constant	vigilance”,	as	well	as	“accountability	and	blame”,	with	the	need	to	be	on	guard	to	
prevent	illness,	as	well	as	the	consequent	blame	responsibility	that	acquires	if	one	becomes	infected.		
External	causes	of	liver	disease	were	expressed	by	many	participants,	but	with	a	recognition	that	even	
in	these	traditionally	held	views,	there	is	an	element	of	uncertainty	that	they	feel	in	explaining	these	
(largely	food	based)	relationship:	
“Water	is	the	main…	In	Nepal	water	is	the	main	cause	of	hepatitis	(participant	5)”;	“…..It	is	due	
to	food…because	of	not	taking	care	in	their	food	habit	it	occurs	(participant	2)”	
	“If	you	do	not	care	and	careful	while	taking	food,	the	disease	likely	to	get	reoccurrence,	is	that	
true?”	(participant	6)	
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Food	and	water	sources	are	widely	cited	as	causative	risks	 for	 liver	disease,	and	also	uncertainties	
about	these	risks,	and	re-acquisition	risks	that	may	be	outside	their	control.			
Water	is	expressed	as	a	strong	sentiment	as	the	leading	cause	of	liver	disease,	but	with	food	and	in	
particular	“food	habits”	appearing	as	an	equally	prominent	feature	across	the	focus	group	discussion.	
On	the	one	hand,	this	may	fit	with	the	lived-experiences	of	community	members	growing	up	in	Nepal,	
where	Hepatitis	A	(HAV)	is	endemic,	with	faeco-oral	contaminated	water	and	food	being	the	mode	of	
transmission	[Jacobsen	KH	2009].		
Alcohol	is	addressed	in	discussions,	but	largely	as	a	possible	cause	of	disease	(participant	5)	with	some	
expressing	no	association	to	 jaundice	 (participant	4);	and	with	 food	expressed	as	the	predominant	
cause	for	disease	when	participants	were	asked	directly	about	the	relation	between	alcohol	and	liver	
disease	(participant	2):	
“Umm….you	should	not	take	alcohol	and	local	beer…	(participant	5);	I	think,	in	my	opinion,	I	
do	 not	 believe	 drinking	 alcohol	 and	 local	 beer	 cause	 the	 jaundice.	 Person	 rather	 dies	 but	
without	jaundice	(participant	4);	It	does	not	matter	the	age.	It	is	due	to	food	(participant	2)”	
As	such,	alcohol	seems	to	feature	as	a	 low	level	association	with	 liver	disease,	suggesting	a	 lack	of	
understanding,	 or	 perhaps	 acceptance	 of	 the	 place	 alcohol	 holds	 in	 relation	 to	 liver	 disease;	
particularly	in	their	new	home	in	the	UK.		
During	these	discussions	the	moderator	probed	participants	to	ask	about	possible	relations	of	 liver	
disease	with	ghost	or	spirit	invasion:	
“Yes,	 I’ve	 heard!	 (about)	 this	 (participant	 3);	 I’ve	 also	 heard	 about	 this	 jaundice.	 If	 it	 is	 in	
women,	new	born	baby	also	gets	jaundice	(participant	1)”	
Here	participant	3	enthusiastically	expresses	his	awareness	of	spirit	 invasion	as	a	possible	cause	of	
liver	 disease	with	 further	 expansion	of	 spirit	 invasion	 that	 can	 affect	 both	mother	 and	 child,	with	
implications	that	are	further	explored	in	the	candidate	theme	“self-image	and	agency”.	The	expressed	
belief	 that	 spirit	 invasion	 can	 cause	 disease	 illustrates	 a	 significant	 divergence	 from	 medical	
understanding	and	practice	in	the	UK,	with	implications	that	may	be	effect	healthcare	engagement,	
management	and	disease	prevention.		
Traditional	therapy	approaches	are	raised	during	discussions,	with	herbal	therapies	and	specific	food	
and	drink	approaches	raised:		
“papaya	and	lots	of	water!	Sugarcane	juice	is	said	to	be	best	(participant	4)”	
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During	 specific	 probing,	 participants	 recounted	 their	 beliefs	 and	 experiences	 on	 faith-healers	 and	
witch	doctors	in	treating	disease:		
“It	did	not	work	for	me.		I	believed	it	in	the	beginning……but,	not	for	me	(participant	1);	No,	it	
did	not	work	[…]	one	time	I	went	to	the	faith	healer.	At	last,	I	went	to	hospital.	I	got	better	
within	2-3	weeks.	One	time	an	old	man	asked	me	if	I	am	from	Nepal.	When	I	nod	my	head,	he	
asked	me	if	I	know	some	spiritual	preacher	(healer)?	I	did	not	know	anybody,	so	I	referred	him	
to	the	hospital	(participant	2)	(–	followed	by	laughter	amongst	the	group)”	
These	 extracts	 highlight	 the	 role	 that	 traditional	 therapies	 still	 hold,	 but	 also	 an	 expression	 that	
Western	or	modern	medical	strategies	offer	the	potential	for	treatment,	even	if	these	strategies	are	
not	viewed	as	separate	or	mutually	exclusive	to	these	traditional	approaches.		
There	is	overall	an	expression	that	treatment	can	restore	health,	and	that	there	is	an	importance	in	
seeking	treatment:	
“[…]	Surely	there	is	a	possibility	of	death.	So	that	it	is	necessary	to	do	treatment	and	prevention	
activities	in	time	(participant	4);	After	2-3	weeks	of	suffering,	I	went	to	see	doctor	and	took	
medicine	and	got	recovered	(participant	2)”	
These	 extracts	 identify	 the	 participants	 belief	 that	 seeking	 help	 and	 treatment	 is	 important,	 and	
successful,	with	the	aim	of	detecting	disease	in	time;	with	potential	strengthening	of	goals	to	develop	
healthcare	engagement	programmes	in	the	community.		
Responsibility	and	Impact:	
This	overarching	theme	captures	two	related	candidate	themes,	and	explores	the	perceptions	of	the	
individual	as	being	responsible	through	their	actions	for	acquiring	liver	disease,	and	the	predominantly	
negative	impacts	that	occur	as	a	result.		
The	 candidate	 theme	 “accountability	 and	 blame”	 explores	 the	 individual	 responsibility	 that	
participants	express	in	preventing	disease,	as	well	as	the	implications	that	arise	in	those	who	develop	
liver	disease:	
“	[..]	It	is	necessary	to	take	care	on	food.	It	is	caused	by	negligence	(participant	1);	“[…]	Because	
of	not	taking	care	in	their	food	habit	it	occurs	(participant	2)”	
Participants	refer	to	the	need	to	“take	care”	at	multiple	points	in	the	focus	group	discussion,	with	a	
particular	emphasis	and	association	placed	on	the	need	to	control	food	intake.	Participant	1	develops	
this	further,	expressing	this	loss	of	care	as	negligence,	rather	than	an	accidental	event,	or	temporary	
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lapse,	although	as	addressed	in	the	candidate	themes	“how	to	explain	illness”	and	“universal	risk	and	
constant	vigilance”,	participants	also	express	doubts	as	to	what	these	risks	and	agents	are,	and	how	
one	can	maintain	constant	vigilance.	Nevertheless,	participants	seem	to	express	“taking-care”	as	an	
important	factor	in	preventing	disease,	and	as	responsible	for	disease	acquisition.		
This	perception	of	“negligence”	as	a	factor	in	disease	acquisition	is	echoed	by	several	participants,	and	
is	further	expanded	upon	by	Participant	3,	when	recounting	a	discussion,	he	had	with	a	friend	who	
had	developed	jaundice	twice:	
“Then	 I	 thought,	 he	himself	 not	 safe,	 I	 just	 kept	quite	 […];	Ok	 for	 the	 first	 time	he	blamed	
Momo,	but	the	next	time	I	did	not	know	what	he	ate…?	(Laughter)	(Participant	3)”	
Here,	the	participant	raises	a	level	of	discomfort	that	he	feels	with	his	friend	in	relation	to	his	liver	
disease.	Food	and	food	hygiene	 is	raised	as	the	potential	driver	of	disease	and	re-infection,	with	a	
mistrust	in	the	individual	that	is	suggested.		
The	theme	“Image	and	Agency”	considers	how	individuals	with	liver	disease	are	viewed,	and	shares	
many	 of	 the	 concepts,	 such	 as	 negligence,	 explored	 in	 the	 theme	 “accountability	 and	 blame”.	
Participants	generally	express	a	negative	perception	of	disease	and	self-image	in	those	effected	by	
liver	disease,	with	the	concept	of	“isolation”	and	separation	raised	by	participant	4:		
“…It	is	communicable	and	transmit	easily	to	others	so	need	to	stay	in	isolation”	
This	expression	is	likely	framed	by	the	widespread	uncertainty	regarding	external	agents	that	cause	
disease,	but	has	implications	for	how	people	with	infection	may	be	viewed,	as	well	as	the	potential	
ability	 to	engage	with	members	of	 the	community	who	may	 fear	 this	 isolation	or	segregation	as	a	
result	of	a	positive	investigation.	
The	opinions	raised	during	discussions	on	spirit	and	ghost	invasion	raise	further	considerations	on	how	
individuals,	and	even	families	with	liver	disease	may	be	viewed:		
“I	 have	also	heard	about	 this	 jaundice.	 If	 it	 is	 in	women,	 new	born	baby	also	get	 jaundice	
(participant	1)”	
The	participant	here	not	only	identifies	that	spirits	can	cause	disease,	but	that	if	a	mother	is	affected,	
or	“invaded”;	then	that	the	child	also	suffers	from	this	same	invasion.	Given	the	likely,	although	not	
expressly	stated	negative	associations	of	ghost	or	spirit	invasion	and	disease	[Uehara	ES	2001],	this	
suggests	 a	 perception	 that	 the	 “sins	 of	 the	 mother”	 can	 pass	 onto	 the	 (her)	 child,	 with	 broader	
implications	that	may	apply	to	families	with	liver	disease.		
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Issues	of	agency	and	support	are	also	addressed	in	this	theme:		
“we	don’t	neglect	him.	He	himself	need	to	cure	for	his	health.	It	needs	to	get	good	treatment.	
We	will	guide	him	in	our	limited	capacity.	We	have	to	help	him	to	raise	his	self-confidence.	We	
need	to	support	and	encourage.	We	have	to	convince	him	that	the	disease	will	be	cured	and	
you	will	become	healthy	after	treatment	(participant	1)”.	
This	extract	demonstrates	a	strong	commitment	to	support	those	who	are	affected,	and	is	positive	in	
its	expression	not	to	abandon	those	individuals	with	liver	disease.	A	reduced	agency	is	suggested	with	
liver	disease,	with	the	ability	of	individuals	to	manage	illness,	as	well	as	the	broader	aspects	of	self-
management	and	self-confidence	affected	by	liver	disease.	Encouragingly	there	is	the	recognition	that	
community	support	is	important	to	improve	agency,	and	that	even	despite	the	uncertainties	that	exist	
with	regard	to	treatment,	that	help	and	advice	should	be	sought.		
Questions	relating	to	health	education	and	 information	 in	participants	 identified	that	Primary	Care	
Physicians	were	seen	as	the	first	port-of-call:	“GP!	We	go	to	our	GP	(participant	3)”.	This	supports	the	
needs	to	understand	and	develop	engagement	strategies	in	primary	care.		
Summary:	 	 The	 two	 overarching	 themes	 therefore	 identify	 the	 uncertainty	 that	 exists	 among	
participants	 in	 how	 to	 explain	 and	 guard	 against	 liver	 disease,	 despite	 a	 potentially	 constant,	 but	
unknown	disease	risk,	as	well	as	the	predominately	negative	associations	of	disease	towards	those	
affected.		
Awareness	of	liver	disease	is	clearly	stated	within	the	group,	with	jaundice	the	defining,	if	not	exclusive	
feature	of	disease.	Food	and	water	based	pollutants	are	described	as	the	principal	driver	of	disease,	
with	 only	 limited	 expression	 of	 other	 causes	 such	 as	 CVH.	 Awareness	 and	 knowledge	 of	 extrinsic	
agents	such	as	spirits	and	witches	are	discussed,	but	with	the	suggestion	that	these	agents	are	not	
prominent	in	the	hierarchy	of	aetiology	and	cure.		
Liver	 disease	 is	 generally	 conceptualised	 as	 a	 transient	 and	 discrete	 illness,	 and	 whilst	 there	 is	 a	
perception	 of	 “negligence”	 and	 a	 “loss	 of	 care”	 associated	with	 liver	 disease,	 there	 is	 the	 overall	
expression	within	the	group	to	support	and	encourage	those	who	are	affected	with	liver	disease	in	
the	community.	There	is	also	appreciation	within	the	group	to	engage	with	modern	medicine,	and	a	
strong	expression	to	engage	with	primary	care	in	particular.		
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Males	over	30:	
Three	overarching	themes	were	identified	through	analysis,	with	an	overview	of	these	overarching	
themes	is	presented	in	table	12,	and	a	network	map	presented	in	figure	22.		
Table	 12:	 A	 summary	 of	 the	 3	 overarching	 themes	 identified	 from	 focus	 group	 discussions	 in	Male	Nepali	
participants	over	30	years	
	
Difficult	to	spot	for	the	inexperienced:	
This	overarching	theme	explores	the	difficulties	that	participants	present	in	identifying	the	onset	
and	causes	of	disease,	as	well	as	the	abilities	gained	through	age	and	experience	to	recognise	and	
manage	liver	disease.		
The	candidate	theme	“Systemic	and	Insidious”	explores	the	unpredictable	and	often	
unrecognised	onset	of	liver	disease,	and	the	perception	that	age	and	experience	can	help	
facilitate	this	identification.	The	theme	“internal	and	external	causes	of	disease”	explores	the	
multiple,	conflicting	causes	of	disease	that	participants	express	from	both	internal	and	external	
agents.		The	theme	“knowledge	is	power”	looks	at	the	conflicts	and	uncertainty	that	exist	in	the	
causes	of	disease,	as	well	as	the	role	and	desired	place	of	education	and	experience	in	
understanding	and	managing	liver	disease.		
Negligence	and	the	loss	of	(Nepali)	traditions:	
This	overarching	theme	explores	the	perceptions	of	individual	accountability	in	disease	
acquisition,	as	well	as	the	ideas	that	a	loss	of	traditional	knowledge	and	practices	has	contributed	
towards	liver	disease.	
The	candidate	theme	“Negligence	and	blame”	explores	the	perceptions	that	unclean	practices	
contribute	towards	disease,	as	well	as	the	perceptions	expressed	towards	those	individuals	with	
liver	disease.	The	theme	“Loss	of	traditions	and	traditional	knowledge”	explores	the	ideas	that	
the	Nepali	community	have	lost	touch	and	disregarded	traditions	relating	to	methods	of	lifestyle	
and	cooking,	thereby	exposing	themselves	to	disease	through	this	abandonment.		
Modern	medicine	is	ineffective:	
Explores	the	belief	and	perceptions	that	modern	(Western)	medicine	is	ineffective	in	treating	liver	
disease,	and	the	cited	experiences	of	using	traditional	methods	to	cure	disease,	and	the	belief	in	
these	alternative	herbal	and	spiritual	methods	of	cure.	
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Figure	22:	The	3	overarching	themes	identified	from	the	focus	group	analysis	in	Nepali	males	over	30	years,	and	the	
principal	candidate	themes		
	Difficult	to	spot	for	inexperienced:		
An	overarching	theme	that	includes	three	related	candidate	themes:	“Internal	and	external	causes	of	
disease”,	“(liver	disease	is)	Systemic	and	insidious”	and	“Knowledge	if	power”,	exploring	the	concept	
that	multiple	agents	may	be	responsible	for	liver	disease;	and	that	recognising	and	managing	disease	
requires	knowledge	and	personal	experience.		
Internal	and	external	causes	of	disease:	
Participants	associate	multiple	individual	(internal)	and	external	driving	factors	towards	disease.	The	
mechanism(s)	of	these	associations	is	rarely	apparent,	and	despite	often	conflicting	opinions	in	the	
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group,	 there	 is	 conviction	 and	 certainty	 in	 these	 associations,	which	 are	often	 related	 in	 terms	of	
personal	or	first-hand	experience.		
Food	and	water	are	again	commonly	expressed	as	a	cause	for	disease,	with	additional	recognition	of	
particular	food	groups	which	cause	or	perhaps	contribute	towards	liver	disease:		
“Due	 to	 polluted	 water,	 the	 most	 is	 polluted	 food	 [Participant	 2]”,	 “It	 is	 a	 communicable	
disease	 […],	 it	 is	 not	 good	 to	 eat	 sour	 food	 during	 jaundice	 [Participant	 3]”,	 “the	 most	
important	is	food	[…]	hot	pepper	and	spices	are	no	good	[Participant	5]”	
Certain	 foods	 are	 confidently	 identified	 here	 with	 negative	 properties	 to	 exacerbate	 illness.	 The	
suggestion	is	that	these	“sour”	agents	may	act	to	worsen	disease	even	in	the	face	of	an	alternative	
communicable	 cause,	 identifying	 these	 foods	 as	 complex	 and	 almost	 dangerous	 agents	 that	 have	
intrinsic	risks,	which	may	go	beyond	a	causative	role.	There	is	also	the	suggestion	in	these	discussions	
that	knowledge	regarding	these	dangerous	food	groups	has	declined;	an	idea	that	is	expanded	further	
in	the	overarching	theme	“Negligence	and	the	loss	of	(Nepali)	traditions”.		
Participants	express	many	other	potential,	and	often	conflicting	causes	of	liver	disease	that	relate	to	
the	individual,	or	actions	of	the	individual,	as	well	as	external	factors.	This	includes	an	awareness	of	
viral	aetiologies	of	disease:	
“In	my	opinion,	this	disease	come	from	a	virus	[…]	In	my	knowledge	it	has	been	named	A,	B,	C.	
The	really	bad	one	is	hepatitis	C.	It	got	transmitted	blood	and	blood	products	[Participant	3]”	
This	 is	 one	 of	 the	 few	 instances	 during	 all	 four	 focus	 groups	where	 different	 viral	 aetiologies	 are	
specifically	 mentioned,	 and	 whilst	 there	 is	 little	 further	 expression	 to	 explore	 the	 depth	 of	 this	
understanding,	 it	 is	 interesting	 to	note	 that	 the	 same	participant	 expresses	plurality	 in	 identifying	
particular	“sour	food”	agents	with	these	specific	and	quite	detailed	viral	description:		
“It	is	communicable	disease.	B	and	C	hepatitis	are	very	serious	type.	At	that	time	we	need	to	
avoid	alcohol.	The	awareness	is	lacking	there.	It	is	not	good	to	eat	sour	food	during	jaundice	
(Participant	3)”	
The	transmissible	nature	of	liver	disease	is	expressed	by	several	participants,	but	with	conflicting	or	
multiple	views	expressed	by	the	same	individual,	as	well	as	within	the	group:	
	 “Yes,	liver	disease	is	a	contagious	disease;	It	is	communicable	disease	(Participant	3)”	
However,	other	expressions	suggest	a	more	holistic	approach	to	the	causes	of	liver	disease	that	may	
relate	to	the	individual:		
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“It	 might	 happen	 from	 the	 breakdown	 of	 our	 body	 system	 (Participant	 3);	 Liver	 can	 be	
damaged	if	diabetes	gone	to	complication	(Participant	6);	Jaundice	come	out	from	our	blood	
(Participant	7)”	
These	 ideas	 are	 often	 expressed	 within	 broader,	 and	 often	 conflicting	 discussions,	 but	 identify	 a	
concept	that	 liver	disease	can	be	related	to	the	wider	health	status	of	the	 individual,	 including	the	
experiences	of	participants	with	other	health	conditions,	such	as	Diabetes	Mellitus.		
Alcohol	is	portrayed	by	several	participants	as	an	important	agent	in	liver	disease:	
“[…]	Due	to	poor	knowledge	of	alcohol	it	might	come	to	people	(Participant	6);	Alcohol	makes	
the	liver	disease	(Participant	4);	[…]	B	and	C	hepatitis	are	very	serious	type.	At	that	time	we	
need	to	avoid	alcohol	(Participant	3)”	
Alcohol	therefore	features	as	a	primary	agent	responsible	for	liver	disease,	as	well	as	an	agent	that	
may	exacerbate	disease	(like	particular	food	groups),	with	the	suggestion	that	knowledge	regarding	
the	dangers	of	alcohol	are	not	well	understood	in	the	community.		
The	role	of	Spirits	and	Witches/Witch	doctors	to	cause	and	treat	disease	is	a	vivid	demonstration	of	
the	place	of	such	external	agents	in	liver	disease:	
“…We	did	also	listen	that	Witch	also	kill	people	[….]	In	this	place	our	seniors	advise	us	not	to	
eat	anything	there.	They	said	this	because	there	was	“Harital”.	When	Harital	become	matured	
and	spoiled	 it	become	 jaundice.	That	 is	 said	by	Witch	doctor.	These	Witch	Doctor	only	has	
“mantra”	which	heal	jaundice	(Participant	7)”	
This	extract	identifies	the	place	of	spirits	and	witches	by	one	of	the	more	senior	members	of	the	group.	
This	 places	 disease	 and	 disease	 management	 to	 some	 degree	 outside	 of	 personal	 control,	 and	
therefore	 external	 to	 the	 individual.	 But	 at	 the	 same	 time,	 there	 is	 also	 the	 suggestion	 that	 the	
individual	can	modify	the	action	of	spirits	and	witch	doctors	through	their	action	and	behaviours.		
Overall,	 these	extracts	 identify	multiple	 individual	and	external	 agents	 that	 can	cause	or	 influence	
disease,	with	a	negative	association	or	action	that	is	mostly	linked	to	liver	disease.	These	ideas	often	
seem	conflicting,	with	traditional	beliefs	that	seem	to	overlay	even	(seemingly)	high	levels	of	disease	
knowledge.	Throughout	these	extracts,	there	 is	as	well	the	suggestion	that	these	 ideas	are	formed	
based	upon	the	benefits	gained	through	experience	and	hindsight,	a	concept	that	is	explored	in	the	
following	candidate	themes.		
Systemic	and	Insidious:	
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The	second	candidate	theme	“Systemic	and	Insidious”	explores	the	expressed	ideas	that	liver	disease	
presents	with	subtle	features	that	may	arise	without	warning,	and	which	may	go	unrecognized,	with	
accounts	that	seem	to	reflect	either	personal	or	first-hand	recollections	that	they	have	experienced	
and	witnessed	in	Nepal.		
Older	male	participants	express	liver	disease	in	a	vivid	and	striking	fashion,	with	liver	disease	identified	
primarily	as	jaundice,	with	symptoms	that	can	be	generalized	and	unpredictable:		
“All	the	white	parts	of	our	eyes	turned	to	yellow,	if	we	had	worn	vest	it	would	all	get	yellow	
itself	after	3-4	days.	These	were	my	first	symptoms	[…]		After	few	days	I	became	so	weak	and	
did	not	have	energy	to	far,	so	I	went	down	to	Aarughat.	There,	one	Ayurvedic	doctor	(Baidya)	
saw	me	and	told	he	knew	the	disease	I	had	(Participant	2)”	
Here	the	symptoms	of	liver	disease	is	expressed	as	jaundice,	as	well	as	systemic	weakness	and	loss	of	
function,	with	 a	 diagnosis	 of	 liver	 disease	 established	 only	 after	 consult	with	 an	 Ayuverdic/Witch	
doctor;	highlighting	the	insidious	perception	of	disease,	and	the	role	of	experience	which	is	key	in	later	
in	discussions	by	Participant	2	in	how	disease	is	identified,	and	the	place	of	Nepali	traditions	as	a	cause	
of	 disease	 and	 poor	management;	 explored	 in	 the	 candidate	 theme:	 “Loss	 of	 traditional	 (Nepali)	
knowledge	and	practice”.	
The	systemic	and	vague	nature	perceived	nature	of	liver	disease	is	also	expressed	by	other	participants	
in	the	group:	
	“[…]	after,	I	did	not	know	how	would	be	liver	disease	look	like.	I	wanted	to	pee	and	went	but	
did	not	feel	that	it	came	out	actually	it	had	all	come	out.	You	see	when	we	pee,	our	private	
part	always	get	erected,	and	the	urine	comes	out	with	force	and	go	little	bit	farther.	When	I	
had	 Jaundice	 I	 did	 not	 have	 such	 energy.	 Another	 symptom	 I	 realized	 was	 yellow	 color	
underneath	my	tongue	(participant	2)”	
Here	the	participant	describes	the	onset	of	jaundice	in	symptoms	that	would	fall	outside	most	medical	
practitioners’	radars,	and	highlights	the	multi-system	and	insidious	nature	that	participants	associate	
with	liver	disease,	and	the	role	of	experience	in	identifying	disease	in	these	circumstances.		
Knowledge	is	Power	
The	third	candidate	theme	“Knowledge	is	power”	explores	the	importance	that	older	participants	give	
towards	age	and	experience	 in	 identifying	and	managing	 liver	disease,	and	the	wish	to	 learn	more	
about	the	disease	process.	
132	
	
This	idea	is	most	vividly	expressed	by	Participant	8,	after	recounting	his	experience	of	identifying	and	
managing	liver	disease	in	his	first-degree	relatives:	
“Then	I	learn	the	medication	of	jaundice	from	a	Chinese.	My	wife	and	son	also	did	had	jaundice	
and	the	Chinese	gave	the	medicine….. I	cured	many	people….	(Participant	8)”	
There	is	direct	importance	given	to	herbal	therapies	for	liver	disease	here,	but	also	the	suggested	need	
and	benefit	of	 learning	to	recognize	and	treat	liver	disease,	with	this	learning	likely	to	be	relatively	
unique,	but	hugely	beneficial.		
Education	levels	in	older	participants	is	described	as	low,	and	participants	express	the	wish	to	learn	
more	about	liver	disease,	with	the	(correct)	recognition	that	existing	education	in	liver	disease	is	poor	
across	many	groups	
“[..]	overall,	There	is	no	education	about	liver	in	school.	Children	do	not	know	about	it.	So	we	
uneducated	people	do	not	know	it	obviously	(Participant	6)”	
A	keenness	to	engage	is	readily	apparent	in	the	focus	group,	with	a	wish	in	the	group	to	learn	more	
about	liver	disease,	and	how	to	manage	liver	disease:		
“we	would	like	to	know	that	what	does	affect	the	liver?	We	want	to	learn	about	it	(Participant	
4)”	
“We	do	not	know	English	so	we	need	in	Nepali......laughing	(Participant	4);		Literate	can	use	
newspaper	 and	 such	 things	 but	 illiterate	 need	 video	 programme	 and	 video	 programme	 is	
effective	to	illiterate	people	(Participant	1)”	
A	low	baseline	educational	status	is	again	suggested,	with	the	additional	suggestion	that	some	may	
remain	unable	 to	engage	with	written	Nepalese	media,	 and	 therefore	 reliant	on	other	advertising	
media	such	as	radio	and	TV.	
	
Negligence	and	the	loss	of	(Nepali)	traditions:	
This	overarching	theme	explores	participants’	perceptions	towards	those	with	liver	disease,	as	well	as	
the	perceived	place	of	traditional	knowledge	and	practice	in	disease	aetiology	and	management.		
The	causes	of	liver	disease	explored	by	participants	are	often	expressed	in	relation	to	a	loss	of	care,	
or	negative	actions	by	the	individual.	The	perceived	role	of	food	and	water	provides	such	an	example:	
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“When	we	see	the	jaundice	from	a	Nepalese	perspective,	it	is	transmitted	through	stool,	urine	
and	food	[Participant	3]”		
This	extract	 identifies	 the	 important	place	that	 food-borne	transmission	routes	holds	 in	the	Nepali	
mindset,	and	in	translating	perceived	causes	of	disease	from	Nepal	to	the	UK.	It	also	associates	food-
borne	transmission	to	actions	of	diminished	hygiene,	either	through	a	loss	of	self-care	or	poor	living	
standards.		
When	asked	how	they	would	view	and	treat	individuals	with	liver	disease,	participants	responded	to	
identify	a	graded	stigmatization	response,	as	well	as	first-hand	negative	experiences	within	the	group:	
“I	do	not	think	people	hate	the	person.	Yes,	liver	diseases	is	contagious	disease,	it	would	not	
be	considered	as	big	as	leprosy	disease.	I	do	not	think	we	have	hated	jaundice	person	so	much	
(Participant	3)”	
Here,	the	participant	uses	the	word	“hate”	in	direct	response	to	the	moderators	questioning,	and	one	
hand	is	reassuring	in	his	expression	not	to	“hate	(the)	jaundice	person	so	much”,	but	clearly	identifies	
a	separation	and	likely	segregation	in	how	individuals	with	liver	disease	are	seen,	particularly	with	his	
very	visual	reference	to	the	use	of	Leprosy	in	stigmatizing	those	with	liver	disease.		
Following	this	extract,	and	with	further	prompting	for	other	opinions	by	the	moderator,	Participant	7	
provides	a	more	personal	reflection	of	experiences	in	the	community:	
“I	do	not	think	this	is	communicable	disease.	My	brother	had	jaundice	at	the	age	of	6-7	years.	
He	would	not	drink	milk.	He	use	to	have	porridge	(Maize/	wheat).	So	Jaundice	can	be	caught	
by	children	who	do	not	drink	alcohol.	I	thought	my	brother	might	have	drunk	water	from	dirty	
tap.	People	would	say	it	might	be	because	of	his	mother	who	drank	and	that	affected	the	son.	
But	I	have	also	seen	the	people	who	had	not	drunk	at	all	and	they	had	jaundice	(Participant	
7)”	
In	this	extract,	Participant	7	identifies	the	perceptions	faced	by	members	of	the	community	to	the	role	
of	alcohol	in	causing	liver	disease.	The	blame	attributed	to	the	mother	in	causing	disease	to	her	child	
is	again	suggestive	of	a	concept	where	the	“sins	of	the	mother”	is	seen	as	a	possible	cause	for	disease,	
with	potential	implications	for	healthcare	engagement	in	a	potentially	vulnerable	group	of	individuals.		
The	second	candidate	theme	“Loss	of	traditional	(Nepali)	knowledge	and	practices”	builds	upon	this	
to	 explore	 the	 perception	 that	 a	 loss	 of	 knowledge	 and	 appreciation	 for	 traditional	 and	 cultural	
practices	risks	liver	disease,	as	well	as	poorer	treatment	options	and	outcomes.		
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Food	 is	 again	 mentioned	 as	 a	 risk	 and	 direct	 cause	 for	 liver	 disease,	 with	 several	 participants	
expressing	a	loss	in	traditional	cooking	practices,	and	produce	availability	that	seem	contributory	to	
liver	disease:		
“The	most	 important	 is	 food.	 Instead	of	mustard	oil	people	are	taking	different	kinds	of	oil	
which	are	heavily	polluted….;	We	say	food	grains,	water	and	rice.	The	mixed	different	rice	for	
making	it	cheaper	price.	This	is	popular	in	Nepal	(Participant	5)”	
The	 same	 concept	 is	 expressed	 by	 several	 participants,	 and	 identifies	 a	 lack	 of	 knowledge,	 or	
abandonment	of	traditional	practices	to	newer	methods	of	cooking	with	oils	and	grains	that	expose	
individuals	to	the	risks	of	“polluted	foods”	that	can	cause	or	contribute	to	disease.	The	expression	that	
the	use	of	mixed	 rice	 is	 both	 cheaper	 and	popular	 also	 suggests	 a	 generational	 gap	with	 younger	
members	of	the	community	adopting	new	and	risky	practices,	taking	chance	with	cheaper	produce.		
Modern	medicine	is	ineffective:	
The	 overarching	 theme	 “Modern	medicine	 is	 ineffective”	 explores	 the	 perception	 by	many	 in	 the	
group	that	modern	medicine	offers	an	inferior	approach	and	efficacy	to	the	treatment	of	liver	disease.		
Traditional	 cures	 are	 valued,	 and	 a	 loss	 in	 traditional	 knowledge	 is	 explored	 by	 Participant	 8	 in	
recollecting	his	 experiences	 in	 treating	members	 of	 his	 own	 family	with	 liver	 disease	using	herbal	
(traditional)	treatments:	
“[…]	Then	I	learn	the	medication	of	jaundice	from	a	Chinese…..	Chinese	sold	this	medicine	in	
$5	 for	 a	 cup.	 This	 is	 called	 Batulejhar	 (A	 typical	 tropical	 herb).	 This	 plant	 can	 be	 found	 in	
Kathmandu	Nepal.	It	is	available	freely	in	village	of	Nepal.	First	of	all,	we	have	to	wash	this	
plant	with	hot	water	and	grinding	and	give	to	patient.	I	cured	many	people	(Participant	8)”	
During	this	extract	the	participant	recollects	his	journey	to	identify	a	treatment	for	liver	disease	after	
having	lost	his	mother	to	liver	disease	in	the	past,	before	discovering	a	treatment	sold	to	him	by	a	
Chinese	provider.	One	presumes	this	to	be	an	alternate	practitioner	of	traditional	of	Chinese	medicine,	
and	his	subsequent	discovery	the	agent	sold	to	him	is	a	herb	that	is	freely	available	to	him	in	Nepal,	
suggesting	a	traditional	knowledge	that	has	been	lost	or	neglected	by	the	Nepali	community.		
The	same	participant	then	goes	on	to	extol	in	vivid	detail	the	positive	benefits	of	this	knowledge,	and	
the	place	of	traditional	therapies	in	managing	liver	disease:	
“[…]	My	mother	died	from	jaundice.	She	died	in	hospital	after	operation	in	British	Army	Camp	
Dharan	Nepal.		Then	I	learn	the	medication	of	jaundice	from	a	Chinese.	My	wife	and	son	also	
did	had	jaundice	and	the	Chinese	gave	the	medicine	[…]	I	cured	many	people.	Some	died	but	
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many	people	cured	from	my	treatment	[…]	Doctor	takes	2-	3	moths	to	cure	but	this	treatment	
cured	within	2-3	days	(Participant	8)”	
Here,	Participant	8	explores	the	failed	treatment	achieved	in	the	British	camp,	taken	as	the	best	access	
point	for	modern	medicine,	as	well	as	the	personal	positive	experiences	gained	within	his	own	family	
and	the	relative	success	seen	replicating	this	with	many	other	members	of	the	community.	He	also	
describes	later	the	fast	efficacy	of	cure	in	comparison	to	(unspecified)	modern	medical	approaches,	
as	well	 as	 a	 broad	 range	 of	mental	 and	 physical	 benefits	 that	 can	 be	 achieved	with	 these	 herbal	
approaches.		
This	 idea	 is	also	supported	by	Participant	2	 in	discussing	his	route	to	treatment	through	Ayuverdic	
therapy:	
“There,	 	 one	Ayurvedic	doctor	 (Baidya)	 saw	me	and	 told	he	 knew	 the	disease	 I	 had.	 So	he	
suggested	me	not	to	go	for	further	checkup.	He	persuaded	me	to	treat	well	by	giving	the	herbal	
medicines	 […]	 It	 was	 difficult	 to	 get	 sugarcane	 and	was	 off	 season	 for	 papaya.	 Anyhow	 I	
searched	for	papaya	and	sugarcane	juice	elsewhere.	That	Ayurvedic	medicine	helped	to	treat	
me.	Some	people	at	that	time	had	told	me	 	 jaundice	would	reappear	but	till	now	I	am	fine	
(Participant	2)”	
Here,	 the	 Participant	 describes	 his	 positive	 and	 successful	 experiences	 of	 treatment	 through	
traditional	therapies,	but	it	is	interesting	to	note	the	reassurance	provided	and	perhaps	requested	by	
the	participant	in	“persuading”	him	to	commit	to	Ayuverdic	therapy,	and	the	commitment	involved	in	
searching	out	off-season	treatment	ingredients.	It	does	nevertheless	suggest	the	perceived	role	for	
traditional	health-providers	as	the	first	port	of	call	in	illness.		
Traditional	Witch	doctors	are	also	discussed	as	agents	who	can	modify	disease:		
“These	witch	Doctor	only	has	“mantra”	which	heal	 jaundice.	 	There	was	many	story	where	
Witch	Doctor	treated	jaundice.	Modern	medicine	and	injections	are	really	bad	for	jaundice.	I	
have	seen	even	a	British	army	officer	 in	Dharan	Nepal	went	 to	 treat	his	 jaundice	with	 that	
witch	Doctor	and	he	was	completely	cured	(Participant	7)”	
These	Witch	doctors	are	portrayed	as	having	significant	and	unique	power	to	treat	disease,	as	well	as	
a	 broad	 expression	 that	 these	 abilities	 surpass	 conventional	 medical	 treatments,	 with	 the	 gold-
standard	 example	 of	 a	 British	 Officer	 choosing	 to	 use	 these	 alternative	 therapies,	 and	 being	
successfully	 treated	 over	Modern-medical	 therapies	 for	 his	 jaundice,	 providing	 a	 strongly	worded	
personal	opinion	on	the	place	of	traditional	therapies	in	liver	disease.		
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There	 is	 little	 counter	 to	 these	 expressions	 during	 focus	 group	 discussions	 and	 overall	 there	 is	 a	
sentiment	 that	 liver	 disease	 assessment	 and	 treatment	 is	 best	 provided	 through	 traditional	
(alternative)	healthcare	providers	and	therapies.		
Summary:	
Awareness	of	liver	disease	seems	strong	in	the	group,	with	vivid	recollections	of	personal	experiences	
associated	to	 liver	disease.	Whilst	 there	 is	uncertainty	again	as	to	the	causes	of	disease,	 there	 is	a	
great	deal	of	certainty	expressed	for	a	heterogeneous	list	of	agents	linked	to	liver	disease,	with	food	
and	cooking	practices	the	most	strongly	expressed	agents.		
Disease	 is	understood	as	a	 severe	condition,	 that	 is	difficult	 to	 identify	and	manage,	with	age	and	
experience	 expressed	 as	 a	 positive	 force	 to	 help	 in	 disease	 identification	 and	management	 in	 the	
community.	Perceptions	of	stigma	are	expressed,	with	liver	disease	associated	to	a	loss	of	traditional	
practices,	 as	 well	 as	 possible	 association	 to	 food	 hygiene	 standards.	 Personal	 actions	 and	
responsibilities	are	also	expressed	through	the	external	role	of	spirits	and	witch	doctors	 in	causing	
disease.		
Several	participants	discuss	the	futile	efforts	seen	with	standard	medical	approaches	in	Nepal	in	the	
past,	and	herbal	and	traditional	therapies	are	strongly	mentioned	within	the	group.	Although	there	is	
a	negative	perception	that	is	implied	towards	those	with	liver	disease,	this	is	within	the	concept	of	
most	 participants	 who	 discuss	 their	 own	 first-hand	 or	 personal	 experiences	 of	 jaundice	 and	 liver	
disease,	and	it	is	likely	that	the	group	would	remain	supportive	to	other	members	of	the	community	
who	may	be	affected.		
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Female	participants	less	than	30	years:	
Three	overarching	themes	were	identified	from	the	focus	group	of	female	participants	less	than	30	
years:	(Liver	disease	has)	“Many	names	and	many	conflicting	causes”,	“Bad	people	and	bad	practices”,	
and	“Modern	versus	traditional	therapies”.	These	themes	are	summarised	in	table	13,	with	a	network	
map	presented	in	figure	23	below.		
Table	 13:	 summary	 of	 overarching	 themes	 from	 focus	 group	 exploring	 perceptions	 of	 liver	 disease	 in	 Nepali	 female	
participants	<	30	years	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	23:	network	map	of	overarching	themes,	and	relation	to	key	candidate	themes		
Many	names	and	many	causes:	
This	overarching	theme	explores	the	different	expressions	within	the	group	regarding	the	causes	
of	 liver	 disease,	 with	 the	 identification	 of	 multiple	 perceived	 routes	 of	 disease	 onset	 and	
acquisition,	but	with	often	conflicting	opinions	raised	within	the	group.		
	
Bad	practices	and	bad	people:	
Here,	the	predominantly	negative	associations	of	liver	disease,	and	perceptions	of	bad	(lifestyle)	
practices	leading	to	disease	are	explored.		
	
Modern	versus	Traditional	therapies:	
In	 this	 overarching	 theme,	 the	 perception	 of	 participants	 towards	 treatment	 is	 explored.	
Participants	 express	 little	 first-hand	experience	of	 liver	disease;	 expressing	on	one-hand	quite	
detailed	knowledge	of	modern	medical	treatment	options	for	liver	disease,	whilst	also	expressing	
strongly	held,	and	conflicting	views	on	the	role	of	traditional	(alternate)	therapies	 in	managing	
liver	disease.		
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Many	names	and	many	causes:	
This	 overarching	 theme	 explores	 the	 many	 different	 associations	 that	 participants	 express	 in	
describing	liver	disease,	and	its	potential	causes	or	contributing	factors.		
Younger	female	participants	in	this	focus	group	are	the	only	group	not	to	express	any	personal	or	first-
hand	experience	of	liver	disease,	and	there	is	a	wide	range	of	opinions	relating	to	the	possible	drivers	
of	liver	disease,	with	often	conflicting	viewpoints.		
A	communicable	or	hereditary	nature	for	developing	liver	disease	is	one	such	conflicting	viewpoint,	
with	participants	expressing	opposing	views:	
“No,	it	is	not	communicable	in	my	opinion	(Participant	1);	Hereditary,	genetic,	Diabetes	and	
foreign	country	are	also	risk	factors	(Participant	5);	Genetic,	not	communicable	(Participant	
3)”	
These	expressions	are	among	the	first	responses	to	the	moderators	probing	regarding	the	possible	
causes	of	liver	disease,	and	if	a	communicable	cause	could	be	responsible.	They	identify	quite	strong	
set	opinions	suggesting	an	inherited,	or	intrinsic	risk	for	liver	disease,	with	a	genetic	cause	specifically	
mentioned	by	two	participants.	Participant	5	also	identifies	Diabetes,	and	therefore	other	systemic	
disease	processes	that	may	contribute	towards	 liver	disease,	and	 identifies	 foreign	nationality	as	a	
possible	risk	factor	disease.	This	latter	point	is	not	expanded	on,	or	commented	upon	further	here	by	
other	participants.	As	such,	the	understanding	and	belief	related	to	this	“foreign	country”	association	
is	 difficult	 to	 unravel	 here,	 and	 potential	 associations	 and	 reflections	 towards	 risk	 in	 different	
nationalities	is	discussed	in	more	detail	in	the	following	section.	
Communicable	 causes	 of	 liver	 disease	 are	 addressed	 by	 several	 participants,	 raising	 potentially	
infective	and	non-infective	drivers	of	disease:	
“It	might	goes	from	one	person	to	another	person.	It	depend	on	what	kind	of	liver	disease	it	is.	
I	have	read	in	book	and	it	is	written	that	liver	disease	is	a	communicable	disease	(Participant	
4)”.	
Infectious	 causes	 of	 disease	 are	 also	 discussed	 by	 some	 participants	 as	 potential	 causes	 and	
transmission	routes:	
“Contacting	with	liver	patient	is	the	main	factor	for	spreading	disease	to	others	(Participant	
1);	[…]	It	might	transmit,	it	is	an	infectious	disease	by	nature	(Participant	5)”		
The	two	participants	here	identify	possible	routes	of	transmission	through	personal	contact,	with	the	
potential	 impact	 on	 contact	 and	 isolation.	 The	 level	 of	 certainty	 in	 these	 expressions	 though	 is	
variable,	with	further	expansion	of	this	theme	in	the	following	sections.		
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External	causes	of	disease	are	again	suggested,	with	pollutant	factors	from	environmental	sources:		
“Smoke,	dust,	air	and	water	are	the	source	of	infection.	It	is	a	matter	of	lifestyle……	(Participant	
6)”.	
Here,	there	is	mention	of	a	wide	range	of	potential	agents	that	may	act	as	direct	drivers,	or	carriers	to	
cause	and	transmit	disease,	with	the	additional	association	of	personal	action	and	responsibility	that	
may	lead	to	disease.	It	is	of	interest	to	note	though,	that	the	strength	of	these	associations	is	less	than	
the	role	placed	on	food	and	water	borne	transmission	routes	in	other	focus	group	discussions.		
Spiritual	associations	towards	liver	disease	are	explored	by	two	participants,	although	only	after	direct	
probing	by	the	moderator	on	the	role	of	these	factors	in	liver	disease:	
“Witch	person	can	also	give	the	disease.		People	says,	previous	life	sin	also	responsible	for	this	
disease	(Participant	2);	Spirit	also	invade	people	resulting	in	liver	disease,	people	says	so	[….]	
(Participant	1)”	
Spiritual	and	traditional	associations	to	disease	are	mentioned	late	on	in	focus	group	discussions,	and	
both	 participants	 frame	 their	 expressions	 as	 reflective	 of	 other	 peoples,	 or	 the	wider	 community	
perception.	However,	despite	this,	it	is	likely	that	these	perceptions	still	hold	relevance	to	how	people	
with	liver	disease	are	seen;	and	the	importance	placed	on	alternative	and	herbal	therapies	(discussed	
in	the	overarching	theme	Modern	versus	traditional	therapies)	highlights	that	traditional	perceptions	
hold	perhaps	a	greater	position	than	initially	suggested	in	these	expressions.		
The	 overall	 uncertainty	 raised	 by	 participants	 through	 these	 multiple	 and	 conflicting	 potential	
aetiologies	is	also	apparent	in	participants	efforts	to	define	and	describe	liver	disease:	
“It	might	be	many	names.	Different	stage	might	have	different	names.	I	do	not	know	much	
about	it.	I	know	only	liver	disease.	Liver	cancer	is	one	which	I	know.”	(Participant	5)	
Here	the	participant	identifies	a	potential	heterogeneity	that	exists	within	the	term	“liver	disease”,	as	
well	as	their	own	knowledge	gaps	in	defining	this.	Liver	cancer	is	suggested	as	the	most	memorable	
type	of	disease,	with	an	implied	severity	and	importance,	but	perhaps	also	a	level	of	potential	futility	
associated	with	disease.		
Similar	expressions	are	also	put	forward	by	other	participants,	with	a	broad	range	of	potential	drivers	
and	potentially	different	types	of	liver	disease	that	can	occur:	
“[…]	There	are	many………liver	cancer	and	hepatitis		A	B	C	D	etc.	It	can	be	prevented	through	
immunisation.”	(Participant	3)	
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Liver	disease	is	described	here	again	as	one	of	its	severe	end-stage	complications,	as	well	as	potentially	
infective	(viral)	causes	of	disease.	The	participant	demonstrates	a	relatively	wide	knowledge	of	these	
different	types	disease,	but	with	associations	and	stigmatisation	with	these	different	types	of	disease	
that	are	explored	in	the	following	overarching	theme	“Bad	people	and	bad	practices”	
Bad	People	and	Bad	Practices:	
This	overarching	theme	explores	the	predominantly	negative	associations	of	liver	disease	expressed	
by	participants	during	focus	group	discussions.		
When	 asked	 their	 perceptions	 about	 liver	 disease,	 and	 indeed	 if	 the	moderator	would	 have	 liver	
disease;	participants	demonstrated	largely	negative	associations:	
“Not	good,	it	is	bad.	We	think	you	are	alcoholic	and	smoker	so	that	your	get	the	disease.	We	
suspect	about	his	wrong	behaviours.	But	some	time	it	is	bad	when	good	people	get	infection	
(Participant	3)”	
Here,	participant	3	expresses	concern	about	bad	practices,	with	a	direct	relationship	drawn	towards	
those	with	liver	disease;	and	although	she	does	identify	the	possibility	of	“good	people”	developing	
liver	disease,	the	overwhelming	association	seem	negative.		
Smoking	 and	 alcohol	 are	mentioned	 as	 specific	 negative	 associations	 by	many	 participants	 during	
focus	 group	 discussions,	 with	 both	 activities	 largely	 mentioned	 simultaneously,	 with	 little	
differentiation	in	risk	and	associations:	
“Mainly	alcoholics	and	smokers	get	the	disease	(Participant	1)”	
Further	and	more	direct	negative	associations	are	raised	during	discussions	on	the	type	of	people	who	
may	get	liver	disease:	
“It	does	not	limit	within	age	and	sex.	Younger	or	older	young	or	children	and	male	or	female	
anybody	can	get	liver	disease.	Alcoholic	and	prostitutes	have	more	chance	to	get	it	(Participant	
4)”	
On	the	one	hand	the	participant	seems	to	take	a	levelled	approach	on	the	risks	and	unpredictability	
that	all	groups	may	face.	But	the	direct	and	blunt	associations	to	“alcoholics	and	prostitutes”	identifies	
clear	stigmatisation	towards	those	affected	by	liver	disease.		
Other	participants	also	express	similar	negative	associations	towards	the	profile	of	patients	who	may	
develop	liver	disease:	
“It	is	high	chance	of	getting	liver	disease	who	live	in	unhygienic	environment	(Participant	2)”	
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This	 association	 again	 raises	 the	 concern	 of	 stigmatisation	 towards	 those	with	 liver	 disease;	 with	
concern	also	regarding	how	individuals	are	seen	in	the	community:	
“Contacting	with	liver	patient	is	the	main	factor	for	spreading	disease	to	others	(Participant	
1)”	
Although	this	expression	is	a	solitary	comment,	it	does	further	raise	the	concern	that	individuals	with	
liver	disease	may	be	treated	differently	with	the	risks	of	 isolation,	and	separation	from	community	
links.		
Negative	associations	of	disease	are	also	identified	when	participants	were	asked	their	perception	of	
liver	disease	between	the	Nepali,	English	and	Chinese	communities:	
“I	think	more	English	and	Chinese	people	have	it	than	Nepali.		They	use	more	perfume	and	take	
less	shower.	They	smell	badly.	They	point	to	us	but	I	say	we	are	more	healthy	then	them.	I	felt	
they	are	neglecting	us.	Laughing	ha.........		(Participant	2)”		
The	overall	expression	here	is	playful,	but	there	is	the	clear	suggestion	that	liver	disease	is	a	negative	
issue,	 which	 communities	 would	 not	 want	 to	 be	 associated	 with.	 There	 is	 also	 the	 interesting	
identification	that	members	of	the	community	feel	themselves	separate	to,	and	looked	down	upon	by	
members	of	the	English	and	Chinese	communities.		
Modern	versus	Traditional	treatment	strategies:	
This	overarching	theme	explores	the	perception	of	participants	towards	treatments	for	liver	disease,	
with	conflicting	views	expressed	between	the	place	of	modern	medicine	and	traditional	therapies.		
On	 the	one	hand,	 participants	 responded	 to	questioning	 regarding	outcomes	 in	 liver	 disease	with	
positive	and	detailed	treatment	options:	
“it	might	be	recovered	in	first	stage	of	disease	(Participant	4)”	
“why	 not	 this	 is	 a	 liver	 transplant	 age;	 transplant	 like	 kidney.	 Diet	management,	 exercise	
alcohol	etc.	(Participant	5)”	
Here	the	participants	identify	that	liver	disease	may	produce	variable	outcomes,	with	early	disease	
that	may	even	recover	on	its	own.	In	addition,	Participant	5	explores	the	quite	complex	considerations	
of	 transplantation	 in	 liver	 disease,	 as	 well	 as	 the	 more	 holistic	 options	 that	 one	 can	 employ	 in	
managing	 liver	disease.	Transplant	considerations	are	not	explored	 in	 further	detail,	and	given	the	
absence	of	first-hand	contact	with	liver	disease	patients	in	the	group;	one	presumes	this	knowledge	
has	been	gained	through	(health)	work	or	study	practice.		
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Expressions	from	other	participants’	though	associate	a	more	pessimistic	outlook	with	regard	to	liver	
disease,	and	identify	treatments	that	are	best	served	through	traditional	methods:	
“If	we	get	it	herbal	remedies	are	very	good.	The	English	modern	medicine	is	necessary	to	take	
regularly.	But	herbal	medicine	cure	slowly.	When	recovered	it	is	not	necessary	to	take	again	
and	again.	It	is	said	that	herbal	medicine	is	best	but	it	does	not	cure	the	disease	completely	
(Participant	3)”	
“Get	cured	by	herbal	medicine.	I	heard.	I	think	ayurvedic	medicine	is	best	(Participant	2)”	
These	extracts	demonstrate	a	confident	expression	regarding	the	benefits	of	herbal	therapies	in	liver	
disease,	 including	 its’	 direct	 benefit	 over	modern	medical	 approaches;	 despite	 the	 possibility	 that	
these	herbal	therapies	may	“not	cure	the	disease	completely”.		
Some	opposition	 to	 this	 view	 is	 expressed,	but	with	 the	benefits	 of	 ayuverdic	 treatment	 reduced,	
rather	than	discounted:	
“I	do	not	believe	in	ayurvedic	medicine.	Why	so	I	do	not	know.	This	medicine	does	not	cure	any	
disease.	It	helps	only	to	slow	down	the	disease	(Participant	5)”.	
The	place	of	traditional	therapies	and	causative	factors	are	also	identified	in	discussions	regarding	the	
role	of	Spirits	in	liver	disease:	
“[…]	spirit	also	invade	people	resulting	in	liver	disease,	people	says	so.	If	Spirit	support	you	then	
the	disease	is	cured	(Participant	1)”	
Here,	Spirits	are	identified	as	a	potential	(external)	agent	that	can	cause	disease,	as	well	as	promote	
cure.	The	broader	concepts	relating	to	the	role	of	Spirits	in	disease,	also	suggest	an	associated	towards	
personal,	or	even	familial	action	that	may	have	provoked	Spirit	invasion,	and	transmission.	
	
Summary:		
Younger	 female	 participants	 are	 the	 only	 group	 to	 not	 frame	 their	 expressions	 within	 first	 hand	
contact,	 or	personal	 experience	of	 liver	disease.	 	Awareness	of	disease	 seems	 common	place,	but	
there	is	greater	conflict	and	uncertainty	expressed	in	the	knowledge	of	causative	agents	associated	
with	liver	disease.		
Perceptions	of	stigma	are	described	more	strongly,	with	associations	to	alcoholism	and	prostitutes	
specifically	mentioned.	However,	there	is	the	expression	within	the	group	to	support	those	who	may	
be	affected,	and	that	liver	disease	can	affect	anyone.		
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There	 is	 considerable	 heterogeneity	 in	 treatment	 options	 discussed	 for	 patients,	 but	 with	 strong	
expressions	of	certainty	in	many	of	the	options	discussed,	and	with	traditional	therapies	endorsed	by	
several	participants.		
	
Older	Female	Participants	>	30	years	
Older	 female	 participants	 took	 part	 in	 this	 focus	 group,	 with	 3	 overarching	 themes	 that	 were	
identified:	 (liver	 disease	 is)	 “Often	 too	 late”,	 “Control	 and	 personal	 strength”	 and	 “The	 role	 of	
advocacy”.	An	overview	is	presented	in	table	14,	with	a	network	map	summary	in	figure	24.	
	
	
Table	14–	overview	of	themes	identified	in	focus	group	discussions	among	elderly	female	Nepali	participants		
	
	
	
	
	
	
Often	too	late:	
This	overarching	theme	explores	participants’	views	and	first-hand	recollections	that	liver	disease	
often	presents	at	an	advanced	stage,	and	incorporates	two	candidate	themes:	“Sudden	and	
insidioua”	and	“Fatal	despite	best	treatment”.		
Control	and	personal	strength:	
This	overarching	theme	explores	the	perception	that	inner	strength	and	personal	will	are	
necessary	and	successful	measures	in	combating	liver	disease.	
It	includes	two	candidate	themes:	“Stigma	and	negative	perceptions	of	disease”	and	“Control,	
behaviour	and	personal	strength”,	exploring	the	negative	associations	that	participants	express,	
as	well	as	the	importance	placed	on	self-control	and	personal-strength	in	modifying	disease	
The	role	of	advocacy:	
This	overarching	theme	considers	the	role	the	participants	advocate	in	promoting	agency	in	
those	individuals	affected	by	liver	disease	to	seek	and	achieve	help	for	their	liver	disease.		
It	includes	two	candidate	themes:	“Support	the	ill”,	and	“Treatment	has	moved	on”,	exploring	
the	groups	expression	to	support	and	build	agency,	as	well	as	the	overall	wish	to	learn	and	
engage	with	health	treatment	strategies	that	can	be	gained	through	modern	medicine.		
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Figure	24.	Network	Map	of	relations	between	Overarching	and	Candidate	themes	Often	too	late:	
Older	 female	participants	discuss	and	describe	 liver	disease	principally	 in	 the	context	of	witnessed	
experiences	 through	close-contacts	or	 relatives.	Liver	disease	here	 is	 identified	as	severe,	with	the	
overarching	theme	that	it	is	“Often	too	late”	by	the	time	disease	is	identified;	explored	further	in	the	
two	candidate	themes:	“Sudden	and	insidious”	and	“Fatal	despite	the	best	treatment”.	
Sudden	and	 Insidious:	 Several	older	participants	 identify	 liver	disease	as	a	 condition	 that	presents	
suddenly,	with	little	or	no	warning	symptoms:	
“My	uncle	had	liver	cancer.	He	had	sudden	pain	in	stomach.	Initially	hospital	did	not	find	out	
the	problem.	Later	they	discovered	that	it	was	cancer.	He	was	died	after	2-	3week	of	cancer	
diagnosis.	That	was	so	sudden	(Participant	3)”	
“They	can	be	 	alive	 	and	 they	are	dying	when	 told	 so.	My	 father	was	died	because	of	 that	
(Participant	7)”	
“One	person	was	died	during	jaundice	because	of	alcohol.	He	was	died	on	the	way	during	his	
walk	(Participant	1)”	
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These	extracts	identify	the	severity	that	participants	associate	towards	liver	disease	through	powerful	
recollections	of	sudden	disease	onset	in	close	relatives.	It	identifies	an	insidious	nature	to	liver,	with	
even	the	doctors	unable	 to	 identify	 the	 true	 liver	disease	on	 first	presentation	 (Participant	3).	The	
latter	extract	from	Participant	1	also	identifies	the	striking	unpredictability	and	severity	associated	to	
this	insidious	disease,	as	well	as	possible	negative	associations	towards	liver	disease	through	alcohol	
that	are	discussed	in	the	overarching	theme:	“Control	and	personal	strength”.		
Fatal	despite	the	best	treatments:	As	well	as	the	insidious	nature	of	disease,	participants	also	identify	
liver	disease	as	a	condition	that	is	often	“fatal	despite	the	best	treatments”.		
“Recently,	one	of	our	sisters	mothers	 in	 law’s	son	died	at	Frimley	Park	Hospital	due	to	 liver	
disease.	He	had	operation	16	years	ago.		Last	year	December,	He	went	to	Nepal.	Doctor	told	
him	no	possibility	of	life	(Participant	1)”	
“That	my	sisters	son	was	always	busy	in	work	[…]	Finally,	they	took	him	hospital	and	came	to	
know	that	all	is	damaged.	Anyway,	now	I	heard	that	liver	is	finished	(Participant	9)”	
	“My	brother	had	a	pain	full	lump	in	abdomen	which	was	known	in	only	three	to	four	months	
advance	 […]	 Doctor	 told	 that	 it	 was	 too	 late.	 Liver	 is	 largely	 damaged.	 Operation	 was	
performed	but	not	recovered.	It	was	too	late	(Participant	3)”	
In	these	extracts,	participants	expand	on	the	insidious	nature	of	disease,	identifying	a	negative	outlook	
for	individuals	diagnosed	with	liver	disease,	even	despite	seeking	medical	help.	Participants	express	a	
level	of	futility	here	in	these	extracts,	with	medical	and	surgical	 interventions	that	cannot	save	the	
individual	once	liver	disease	has	taken	hold.	However,	it	is	of	note	that	these	personal	recollections	
describe	individuals	presenting	at	advanced	stages	of	liver	disease,	when	indeed	outcomes	are	worse;	
contour	to	our	aims	to	facilitate	early	testing,	diagnosis	and	health	care	intervention.		
During	 focus	 group	discussions,	 participants	 identify	 personal	 differences	 in	 treatment	 access	 and	
outcomes	based	on	social	class	and	location	(urban	versus	village	locations),	which	is	discussed	in	the	
overarching	theme	“Treatment	has	moved	on”.	However,	even	in	this	setting,	participants	identify	a	
relative	futility	that	extends	across	this	perceived	gap:	
“Like	this	many	people	died	in	Nepal.	Many	died	with	this	problem.	Even	rich	people	reaching	
Delhi	hospital	did	not	get	cure	(Participant	1)”	
Overall,	 these	 extracts	 identify	 a	 negative	 outlook	 and	 futility	 with	 regard	 to	 a	 diagnosis	 of	 liver	
disease,	with	powerful	descriptors	of	first-hand	experiences	in	close	relatives,	which	may	have	impact	
on	community	engagement	strategies.		
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Control	and	Personal	Strength:	
This	 overarching	 theme	 considers	 two	 candidate	 themes:	 “Stigma	 and	 negative	 perceptions	 of	
disease”,	 and	 “Control,	 behavior	 and	 personal	 strength”;	 exploring	 the	 perceptions	 that	 personal	
control	and	action	can	modify	liver	disease,	despite	the	presence	of	negative	stigmatizing	features.		
Stigma	 and	 negative	 perceptions	 of	 disease:	 Associations	 between	 liver	 disease	 and	 alcohol	 and	
smoking	 are	 frequently	 expressed	during	discussions,	with	negative	 associations	 towards	personal	
behavior:		
“[….]	People	says	heavy	smokers	and	heavy	drinkers	(	alcohol)	will	get	liver	disease	easily.	How	
does	it	happen	as	disease	I	do	not	know	(Participant	1)”	
“There	are	lot	we	can	see	who	have	problems	of	live	who	drink	alcohol.	I	have	heard	that	most	
of	the	liver	disease	person	are	alcoholic	(Participant	5)”	
“	[…]	Nepalese	have	poor	life	style	and	environment	[…].	They	do	not	care	about	health.	The	
do	lots	of	physical	hard	work.	Carrying	lots	of	weight.	When	they	are	tired	they	drink	alcohol	
(Participant	1)”	
These	extracts	identify	the	well	expressed	links	between	alcohol	and	liver	disease,	with	smoking	seen	
again	as	an	almost	equal	disease	risk.	A	failure	in	personal	actions	and	behaviour	are	suggested	factors	
here,	with	the	latter	extract	by	Participant	1	identifying	the	lifestyle	difficulties	that	many	Nepali	face,	
and	the	physical	demands	and	lack	of	current	healthcare	engagement	and	health	self-management	
that	are	suggested	to	go	hand	in	hand	with	ongoing	heavy	alcohol	intake.		
Control,	behaviour	and	personal	strength:	This	candidate	theme	explores	the	role	of	personal	action	
in	controlling	and	modifying	liver	disease:	
“[..]	From	food	to	all	things	need	to	take	care.		Need	to	eat	only	selected	food……Our		relative	
mothers	side	brother		was	like	this.	He	used	to	drink	alcohol	before.	When	he	was	identified	as	
liver	patient,	he	control	many	things	like	food.	After	liver	operation	he	survived	almost	16/17	
years.	That	was	great	 for	him.	Doctor	 told	him	 that	he	would	not	 survive	more	 than	 three	
months	but	with	his	strong	determination	and	meditation	he	died	after	six	months	(Participant	
1)”	
“Can	be	cured.	If	we	control	ourselves	we	can	survive	longer	otherwise	we	have	die	quicker	
(Participant	4)”	
These	 extracts	 identify	 the	 multifactorial	 and	 holistic	 approach	 participants	 link	 both	 to	 disease	
aetiology	and	to	its’	control.	A	need	for	care	and	caution	is	nearly	all	aspects	of	life	is	suggested	by	
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participant	1,	with	an	accompanying	powerful	testimony	of	the	positive	action	that	can	be	achieved	
through	these	measures.		
The	overall	 format	of	 these	control	measures	appear	heterogenous	 in	participant	discussions,	and	
incorporate	measures	such	as	alcohol	cessation;	but	more	broadly	seem	linked	to	a	positive	mental	
state,	 and	 are	 represented	 through	 positive	 stories	 of	 endeavour	 and	 hope,	 despite	 ultimately	
negative	outcomes.		
	
The	role	of	advocacy:	
This	overarching	theme	explores	the	views	of	older	female	participants	that	there	is	a	need	to	build	
and	promote	health-seeking	agency	 in	members	of	 the	Nepali	community,	with	treatment	options	
that	 offer	 a	 greater	 potential	 than	 healthcare	 opportunities	 in	 Nepal;	 explored	 through	 the	 two	
candidate	themes:	“Support	the	ill”	and	“Treatment	has	moved	on”.		
Support	the	ill:	The	importance	of	seeking	healthcare	is	expressed	during	discussions,	with	particular	
focus	placed	on	 the	disparity	 seen	 traditionally	by	poorer,	 isolated	members	of	 the	 community	 in	
Nepal:	
“It	 is	 necessary	 to	 get	 best	medical	 care	 and	medication.	Nepal	 does	 not	 such	 facilities	 of	
treating	liver	diseases.	Richer	will	survive	because	of	better	treatment	but	poorer	will	die.	It	is	
hard	and	difficult	for	poor	(Participant	1)”	
“Nepalese	have	poor	life	style	and	environment.	They	are	very	illiterate.	I	think	these	are	the	
distinct	cause	among	Nepalese	[…]	(Participant	1)”	
Here,	the	participant	describes	the	traditional	difficulties	that	certain	members	of	the	community	face	
in	access	to	healthcare	in	Nepal,	which	may	affect	the	engagement	process	of	these	individuals	in	the	
UK;	 with	 socioeconomically	 deprived	 groups	 whom	 are	 conversely	 more	 likely	 to	 have	 greater	
healthcare	needs	and	priority	[CSDH	2008,	Stringhini	S	et	al.	2017].		
Participant	1	also	uses	the	example	of	a	community	member	that	she	helps	to	seek	medical	help:	
“[…]	 Few	 days	 back,	 in	 our	 Aldershot,	 one	 old	 lady	 always	 coughing.	 I	 helped	 to	 take	
appointment	in	GP.	She	told	that	she	had	back	pain.	In	GP	Doctor	told	that	there	are	affects	in	
liver.	Then	she	stop	smoking	and	getting	better	now	(Participant	1)”	
Here	 the	 participant	 identifies	 the	 potential	 role	 that	 members	 of	 the	 community	 can	 play	 in	
supporting	and	facilitating	healthcare	engagement	for	those	who	may	not	be	aware	of	the	need	or	
benefits	of	seeking	help,	and	who	may	also	lack	the	agency	to	access	services.		
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Responses	within	the	group	towards	the	moderator	being	(hypothetically)	affected	by	liver	disease	
also	identifies	a	broader	sense	of	support	and	agency	that	exists:	
“We	need	to	ask	you.	How	did	happen	such	a	beautiful	girl.	What	she	had	eaten?	What	made	
her	liver	disease?	We	have	to	think	what	makes	her	good	(Participant	5)”	
	“Must	 be	 good	 perception.	 Need	 to	 give	 assurance.	 And	 need	 to	 treat	 in	 a	 right	 way	
(Participant	1)”	
Here,	despite	the	negative	associations	that	may	exist	towards	liver	disease,	there	is	the	suggested	
importance	of	looking	beyond	these	perceived	negatives	to	provide	support	and	agency	to	promote	
wellbeing	in	the	individual,	with	potential	encouragement	towards	endeavours	to	improve	healthcare	
engagement.		
Treatment	has	moved	on:		
Participants	provide	rich	detail	in	identifying	the	opportunities	and	outcomes	of	treatment	in	Nepal,	
with	some	uncertainty	in	how	to	approach	healthcare	here	in	the	UK:	
“[…]	 In	 our	 village	 sugar	 cane	 and	papaya	 is	 considered	 as	 a	 good	medicine.	 It	 also	 cured	
jaundice	but	here	we	do	not	know	what	is	better	for	jaundice	(Participant	3)”	
At	the	same	time,	there	is	strong	recognition	of	the	role	and	importance	of	healthcare	professionals	
in	bridging	this	gap,	and	in	identifying	disease	and	providing	treatment:	
	“We	 know	 the	 pain	 but	 Doctor	 is	 the	 real	 person	 to	 identify	 the	 cause	 of	 the	 problem	
(Participant	3)”	
“What	the	doctor	said,	we	trust	on	it.	Whatever	he	says.	Heart	or	liver???	We	trust	him.	We	
do	not	know	more	(Participant	2)”	
Here,	there	is	a	strong	desire	to	engage	with	healthcare	professionals,	and	a	recognition	of	the	lack	of	
ability	 that	 individuals	 may	 face	 in	 trying	 to	 diagnose	 the	 condition,	 and	 in	 providing	 effective	
treatment.		
Participants	also	identify	the	place	of	progress	and	opportunity	afforded	through	modern	medicine:	
“Now	many	 things	has	been	 changed.	 The	world	 is	 very	much	 forwarded.	 There	are	 lot	 of	
advance	technology	to	diagnose	and	treat	the	disease.	It	was	not	like	this	earlier.	People	did	
not	know	about	their	disease	in	the	past….	(Participant	1)”.		
These	expressions	suggest	a	positive	change	that	participants	see	in	healthcare	opportunities	in	UK,	
with	potential	encouragement	for	community	healthcare	engagement	strategies		
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Traditional	healthcare	approaches,	with	the	role	of	Witch	doctors	and	Spirits	are	also	discussed	by	
participants,	but	typically	to	frame	these	approaches	within	the	context	of	older	treatment	choices	in	
Nepal:		
“ha………..	No		it	does	not	happen	liver	disease		with	spirit	invasion.	I	do	not	believe	on	this.	If	
the	person	is	physically	look	healthy	the	people	say	spirit	invasion.	We	also	say	so	in	earlier.	
Now	a	day’s	people	go	to	doctor	when	they	are	sick	(Participant	4)”	
	“Take	 to	witch	Doctor.	 There	 is	 one	disease.	He	asked	 to	 kill	 the	 chicken,	 goat.	 Time	pass	
patient	died	(Participant	4)”	
“People	did	not	know	about	their	disease	in	the	past.	Now	a	day’s	also	people	died	who	live	in	
rural	areas.	They	do	not	know	the	cause	of	death.	They	might	died	from	heart	disease	or	liver	
disease	who	knows?”	(Participant	1)	
The	 two	 participants	 here	 place	 little	 relevance	 to	 the	 role	 of	 these	 treatment	 approaches	 in	 the	
modern	day,	with	a	lack	of	understanding	towards	disease	and	modern	treatment	options,	portrayed	
as	a	reason	behind	the	attractiveness	of	these	strategies.	However,	Participant	1	also	suggests	during	
these	discussions	that	members	of	the	rural	community	in	Nepal	still	face	difficulties	with	knowledge	
and	access	to	healthcare	that	may	still	keep	these	approaches	attractive	and	relevant	to	some	groups	
despite	 the	 overall	 group	 consensus	 to	 embrace	 the	 options	 afforded	 through	 access	 to	modern	
medical	healthcare.			
	
Summary:	
Awareness	of	disease	is	strong	in	the	group,	with	older	female	participants	providing	vivid	first-hand	
accounts	of	liver	disease.	There	is	heterogeneity	in	the	potential	risks	factors	associated	with	disease	
and	with	specific	aetiological	agents,	with	the	perception	that	liver	disease	is	often	a	severe	and	even	
futile	condition,	and	one	that	should	be	feared.		
Negative	 perceptions	 and	 potential	 stigmatising	 factors	 are	 discussed,	with	 additional	weight	 and	
association	given	to	the	need	and	role	of	self-control	and	responsibility	in	protecting	and	controlling	
liver	disease.		
The	concept	that	“treatment	has	moved	on”	is	identified	within	the	overarching	theme	of	“advocacy”	
to	support	the	community	to	embrace	new	therapies	in	the	UK	that	many	would	not	have	received	or	
been	able	to	access	in	Nepal,	with	health	perceptions	and	interactions	in	Nepal	that	may	have	been	
negatively	influenced	by	wider	inequalities	that	exist	for	some	(mostly	poor)	individuals	in	Nepal.		
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Chapter	5:	CVH	testing	in	Primary	Care:	Exploring	the	awareness,	knowledge	and	perception	of	CVH	testing	in	Migrant	Communities		
Chapter	Summary		
Primary	care	forms	the	bedrock	of	NHS	services,	with	the	vast	majority	of	NHS	patient	 interactions	
occurring	with	 General	 Practitioners	 [NHS	 England	March	 2017].	 It	 is	 the	 first	 port	 of	 contact	 for	
patients,	providing	access	to	care,	as	well	as	coordinating	and	commissioning	care	to	patients	in	the	
UK.		
The	involvement	of	primary	care	is	crucial	in	improving	testing	access	and	engagement	in	hard	to	reach	
and	marginalised	communities,	who	may	otherwise	be	left	isolated	and	exposed	to	the	development	
of	advanced	complications	from	untreated	disease	states.		
Context	
Primary	care	has	traditionally	acted	as	the	gatekeeper	for	all	non-emergency	NHS	interactions,	with	
close	to	300	million	patient	interactions	per	year	[King’s	Fund	2009].	GPs	initially	acted	as	independent	
contractors	 in	 the	NHS,	until	 contract	 re-negotiations	 in	2004	when	they	were	contracted	through	
practices	 to	 the	 local	 PCT.	 The	 2004	 contract	 also	 led	 to	 the	 introduction	 of	 Pay	 for	 Performance	
(Quality	and	Outcome	Frameworks	(QOF)),	providing	a	points	based	rewards	incentive	to	practices	for	
achieving	 targets	 in	 certain	 clinical	 and	 non-clinical	 service	 settings	 [King’s	 Fund	 2009],	 although	
without	 viral	 hepatitis	managing	 to	 be	 included	 as	 a	QOF	 indicator	 despite	 its	 advocacy	 by	many	
leading	professionals,	including	the	Lancet	commission	[Williams	2014].		
For	many	years	GPs	were	widely	derided	by	politicians	and	many	 in	 the	media	 for	being	overpaid	
following	these	contract	re-negotiations	[Times	May	2014],	and	it	is	only	over	the	past	few	years	that	
politicians	have	begun	to	recognise	the	increased	demand	that	GPs	have	been	facing	with	chronically	
reduced	 funding,	 and	 now	 a	 perilous	 situation	with	GP	 recruitment	 in	many	 parts	 of	 the	 country	
[Guardian	2014].		
Indeed,	politically	this	increased	demand	and	chronic	underfunding	was	nationally	recognised	in	the	
5	Year	Forward	View	(5YFV),	and	subsequent	General	Practice	Forward	View	created	in	August	2016	
[NHS	England	October	2014,	NHS	England	April	2016],	with	plans	for	increased	funding,	resources	and	
staff	recruitment	by	2020.	However,	ongoing	vacancies	persist	in	a	disproportionate	manner	in	many	
parts	of	the	country,	coupled	with	excessive	service	demands	that	have	led	to	a	significant	drop	in	
staff	morale	[Pulse	April	2017,	Pulse	November	2016].	
The	 future	shape	and	character	of	primary	care	services	also	 face	considerable	uncertainties,	with	
pressures	 to	 integrate	 health	 services	 lying	 at	 the	heart	 of	 the	powerful	 5YFV	 and	 the	 2017	5YFV	
review	documents	[NHS	England	2014,	NHS	England	March	2017].	Models	of	 integration	are	being	
trialled	 across	 the	 country,	 including	 in	 selected	 Vanguard	 centres	 between	 multidisciplinary	
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specialties	[NHS	England	Sept	2016],	but	with	the	successful	outcome,	and	implications	for	primary	
care	working	practice	that	will	remain	unknown	for	some	time.	Recent	reviews	have	also	raised	doubts	
over	the	merit	and	need	of	QOF	points,	which	have	received	criticism	for	their	cost	and	limited	direct	
evidence	for	clinical	effectiveness	in	improving	patient	outcomes	[King’s	Fund	2011,	BMJ	August	2016,	
NHS	England	March	2017].		QOF	points	are	likely	to	be	disbanded	given	these	concerns	[NHS	England	
March	 2017],	 and	 a	 replacement	 for	 this	 scheme	 has	 not	 yet	 been	 made	 clear,	 with	 further	
uncertainties	in	working	practice	that	may	result.		
Despite	though	these	pressures	and	increasing	workload,	primary	care	continues	to	enjoy	some	of	the	
highest	 satisfaction	 levels	 seen	 in	 the	NHS,	with	 recent	public	 support	 levels	of	85%	[NHS	England	
March	2017],	and	proven	efficacy	in	delivering	clinically	effective	holistic	care.		
Primary	care	testing	in	migrant	communities	-	Literature	review	and	need	for	study:	
Migrant	 groups	 can	 be	 considered	 as	 “hard	 to	 reach”	 groups,	 with	 differences	 in	 health	 seeking	
behaviour,	 and	 concerns	 relating	 to	 inequalities	 in	 healthcare	 access,	 and	 needless	 disease	
progression	 and	 healthcare	 costs	 [Flanagan	 SM].	 A	multidisciplinary	 range	 of	 factors	 are	 likely	 to	
influence	 access	 to	 healthcare,	 and	 these	 have	 previously	 been	 suggested	 to	 involve:	 legal	
entitlement,	knowledge	and	awareness	of	the	health	system	in	a	new	country,	previous	experience	of	
health	care,	language	and	cultural	barriers,	health	beliefs	and	attitudes,	and	the	existing	health	system	
configuration	[O’Donnell	CA	et	al.	July	2015].		
Primary	care	is	the	main	access	to	healthcare	in	the	NHS,	and	can	act	as	the	gateway	and	coordinator	
for	migrant	health	[O’Donnell	CA	et	al.	July	2015,	RCGP	2013].	GPs	have	a	responsibility	to	provide	
healthcare	to	all	those	seeking	it,	including	asylum	seekers,	refugees	and	other	migrant	groups,	with	
care	 that	 is	 provided	 without	 charge,	 and	 practices	 cannot	 refuse	 registration	 to	migrants	 whilst	
continuing	to	register	British	citizens	[RCGP	2013,	BMJ	2012].	In	secondary	care	some	NHS	services,	
including	emergency	services	in	A&E	are	free	to	all,	but	with	charges	that	then	depend	again	on	the	
health	condition,	residency	status,	and	health	surcharges	that	has	recently	been	introduced	for	some	
migrant	groups	 [DoH	2017]	Department	of	Health	 (DoH),	Guidance	on	 implementing	 the	overseas	
visitor	charging	regulation,	October	2017].	Whilst	patients	can	continue	diagnostic	and	management	
interventions	in	a	secondary	care	environment,	these	are	designed	to	manage	advanced,	or	specialist	
cases,	where	 a	 greater	 financial	 cost	 is	 likely	 to	 be	 evident,	 as	well	 as	morbidity	 impact	 to	 these	
individuals	[BMJ	2012].		
Primary	care	is	widely	cited	as	a	desirable	and	effective	intervention	in	migrant	health,	with	improved	
health	outcomes	and	long-term	cost	savings	that	can	be	achieved	through	effective	interactions	and	
early	interventions	in	migrant	communities	[O’Donnel	CA	et	al.	2015,	Montesi	L	et	al	2015,	NICE	2012].		
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However,	concerns	exist	regarding	the	practice	and	efficacy	of	such	primary	care	interactions,	with	
criticisms	 raised	 even	 in	 common	 and	 well	 understood	 disease	 states	 such	 as	 Diabetes	 and	
Cardiovascular	disease,	where	 the	healthcare	 consequences	 (and	costs)	of	 failed	 interventions	are	
better	studied,	and	with	higher	rates	of	non-communicable	diseases	that	are	higher,	and	may	increase	
over	 time	 in	migrant	 communities	 [Norredam	M,	 October	 2013].	 	 Lower	 consultation	 times	 with	
migrants,	as	well	as	lower	levels	of	non-verbal	empathy	during	discussions	have	been	demonstrated	
in	 studies	 in	 primary	 care,	 as	 have	 detrimental	 variations	 in	 prescribing	 habits	 that	 have	 been	
documented	by	primary	care	physicians	across	well-developed	health	systems	in	Europe	and	Australia	
[Montesi	L	et	al.	2015].			
The	Second	Translational	Gap	and	Clinical	Inertia	
Variations	in	practice	exist	despite	often	well	published	evidence-based	practice	guidelines,	with	these	
guidelines	 now	 a	 common	 feature	 across	 healthcare,	 including	 in	 primary	 care.	 However,	 the	
translation	of	guidelines	into	practice	is	not	always	achieved,	which	remains	a	problem	in	all	patient	
groups,	including	migrant	communities.	This	“second	translational	gap”	was	first	identified	in	studies	
into	 the	 context	 of	 the	 UK	 Health	 Research	 Strategy	 by	 Cooksey	 in	 2006	 [Cooksey	 D	 2006],	 with	
complex	multi-factorial	 characteristics	 that	 are	 likely	 to	 drive	 and	 effect	 this	 translational	 gap.	 In	
primary	care,	considerations	include	the	relatively	unique	research	and	implementation	culture	that	
exists	 in	primary	care,	as	well	as	 the	 individual	variations	that	exist	 in	the	make-up	and	context	of	
independent	primary	care	teams	across	the	country	[Lau	R	2014].		
Another	concept	that	explores	this	gap	 is	Clinical	 Inertia,	 looking	at	principally	the	clinician	related	
factors	that	impact	the	benefits	and	harms	that	are	seen	towards	treatment,	and	treatment	escalation	
[Khunti	 K	 2013].	 These	 clinician-related	 factors	 are	 well	 illustrated	 as	 a	 mixture	 of	 three	 linked	
problems	in	the	management	of	chronic	diseases:		the	use	of	“soft”	reasons	to	not	escalate	therapy	
appropriately;	an	overestimation	of	the	current	levels	of	care	provided,	and	a	lack	of	education	and	
training	[Phillips	LS	2001,	Salisbury	C	2006].	Clinical	inertia	is	defined	principally	in	non-communicable	
disease	 states	 such	 as	 diabetes	 and	 hypertension,	 with	 effective	 treatment	 escalation	 a	 key	
consideration.	Diagnostic	inertia	is	a	related	concept,	that	focuses	more	on	clinicians’	non-adherence	
to	clinical	guidelines	in	diagnosing	disease	[Martinez-St	John	DRJ	2015].	Whilst	all	these	concepts	are	
described	 almost	 exclusively	 in	 non-communicable	 disease	 states,	 they	 are	 of	 interest	 in	 the	
considerations	 they	give	 towards	clinicians’	attitudes	and	knowledge	towards	guidelines,	and	their	
awareness	and	perception	towards	patients’	attitudes	in	their	clinical	actions,	which	is	of	particular	
relevance	in	the	study	of	CVH	testing	activity	in	primary	care	[Martinez-St	John	DRJ	2015].	Developing	
qualitative	studies	in	primary	care	is	therefore	important	to	understand	these	factors,	and	to	assess	
the	potential	areas	to	develop	and	target	future	interventions.		
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CVH	testing	in	primary	care	
There	is	no	official	measure	of	CVH	testing	practice	or	testing	indication	in	primary	care,	and	data	that	
I	collected	from	regional	 laboratory	data	in	Surrey	,	would	suggest	that	most	CVH	requests	are	put	
forward	in	the	context	of	deranged	liver	function	tests	or	established	liver	disease,	with	1328	out	of	
3458	(38%)	testing	requests	in	“symptomatic”	cases,	compared	to	11%	(380)	of	requests	which	would	
be	in	keeping	with	conventional	case-finding	criteria	[Appendix	page	273].	This	data	is	supported	by	
studies	of	HBV	testing	for	migrant	communities	in	primary	care,	with	only	around	12%	of	an	estimated	
82,651	migrants	 receiving	 HBV	 testing	 across	 8	 GP	 practices,	with	 75%	 of	 these	 individuals	 being	
female,	and	antenatal	testing	therefore	taking	the	leading	role	in	testing	rationale	[Evlampidou	2016].	
GPs	 are	 thought	 to	 offer	 CVH	 testing	 principally	 as	 part	 of	 individual	 choice	 and	 experience,	with	
variation	in	testing	practice	that	was	demonstrated	by	Bechini	et	al.	across	European	countries,	as	well	
as	 variation	within	 nations	 [Bechini	 A	 2012].	 This	 variation	 seems	 linked	 to	 individual	 or	 regional	
experience	and	preferences,	and	the	same	study	also	demonstrates	lower	rates	of	CVH	testing	offers	
to	migrant	groups	 in	the	UK	 in	comparison	to	other	European	countries	 in	primary	care	[Bechini	A	
2012].		
Testing	activity	and	success	will	also	depend	on	the	heath	interaction	by	migrant	communities,	with	
differences	in	healthcare	engagement	practices	that	are	known	to	differ	in	some	migrant	communities	
[Kessing	L	2013],	and	with	lower	rates	of	migrant-engagement	that	have	been	demonstrated	in	study-
based	CVH	testing	interventions	in	GP	practices	in	London	[Hargreaves	S	2014].		
These	variations	are	poorly	understood,	and	heterogeneous,	and	may	be	changing	over	time.	Indeed,	
recent	analysis	by	PHE	suggest	that	HCV	testing	has	increased	in	the	South	Asian	population	by	around	
27%,	 and	 by	 52%	 in	 the	 Eastern	 European	 population	 groups	 between	 2012	 to	 2016	 [PHE	 2018].	
However,	there	is	likely	to	be	variation	based	not	only	on	the	testing	infrastructure	and	motivation,	
but	also	based	on	the	migrant	group,	with	members	of	the	Pakistani	community	well	represented	in	
testing	 initiatives	 [PHE	 2018,	 Flanagan	 S	 2019],	 perhaps	 based	 on	 familiarity	 and	 peer-support	 of	
testing	 initiatives.	 And	 it	 is	 likely	 that	 more	 isolated	 and	 vulnerable	 communities,	 including	 the	
recently	arrived	Nepali	community	may	demonstrate	lower	levels	of	agency	to	openly	engage	with	
these	initiatives	without	support,	and	will	therefore	be	strongly	influenced	by	the	support	structure	
in	place	to	offer	testing	engagement	in	local	primary	care	services.		
	
Prior	qualitative	studies	in	primary	care	have	demonstrated	gaps	in	the	knowledge	and	confidence	of	
HBV	and	HCV	management	in	primary	care.	In	the	study	by	Guirgis	et	al,	GPs	identified	difficulties	with	
interpreting	serology	results	for	HBV	and	HCV,	as	well	as	gaps	in	the	knowledge	regarding	long	term	
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risks	(including	HCC)	in	CVH,	and	the	effective	management	strategies	for	infection.	One	of	the	major	
barriers	in	migrant	testing	identified	during	this	study	was	language,	as	well	as	perceived	stigma,	with	
the	addition	of	a	specific	nurse	advocate	seen	as	positive	intervention	that	may	help	facilitate	testing	
delivery	[Guirgis	M	2012].	Primary	care	physicians	have	also	demonstrated	discomfort	in	approaching	
individuals	 for	 testing	 where	 risk	 activities	 need	 to	 be	 discussed,	 with	 concerns	 raised	 about	
discomfort	in	both	the	practitioner	and	patient	in	this	process,	and	the	same	US	study	by	Jewett	et	al.	
reports	the	perception	from	specialists	that	CVH	testing	lies	at	a	lower	priority	than	other	conventional	
testing	activity	for	cholesterol	and	similar	established	non-communicable	diseases	[Jewett	A	2015].		
Awareness	 and	 practice	 of	 CVH	 testing	 policy	 has	 been	 reported	 in	 an	 international	 and	 national	
context,	including	studies	into	the	uptake	of	previous	HCV	testing	policy	in	the	UK.	Studies	in	Australia	
among	 GPs	 and	 primary	 care	 nurses	 (n=20)	 identified	 low	 levels	 of	 awareness	 regarding	 national	
hepatitis	B	testing	policy,	and	variation	in	confidence	and	patient	communication	that	seems	strongly	
influenced	by	the	practitioners’	experiences	and	patient	demographics	served	[Richmond	J	2017].		In	
the	US,	similar	deficits	have	also	been	noted	 in	previous	surveys	of	primary	care	physicians	 (PCPs)	
towards	national	society	guidelines	[Kallman	JB	2008].		
Community	based	testing	for	viral	hepatitis	(HBV	and	HCV)	is	advocated	in	national	and	international	
guidance,	with	 testing	access	 via	primary	 care	a	 key	 facet	 in	 this	 approach	 [NICE	2012].	However,	
previous	 qualitative	 studies	 following	 the	 national	 HCV	 Action	 Plan	 in	 2004	 had	 shown	 poor	
understanding	and	awareness	of	testing	guidance	in	primary	care,	as	well	as	a	poor	uptake	of	HCV	
testing	despite	widespread	dissemination	by	 the	Department	of	Health	 [D’Souza	RF	2004].	Recent	
studies	 continue	 to	 show	 that	 most	 at-risk	 patients	 are	 untested	 in	 GP	 practices	 [Datta	 S	 2014],	
suggesting	a	continued	lack	of	engagement	in	HBV	and	HCV	testing	practice	in	primary	care.		
Little	is	known	about	the	current	awareness,	understanding	and	practice	of	viral	hepatitis	testing	for	
migrant	communities	in	GP	practices,	with	no	qualitative	studies	undertaken	in	primary	care	since	the	
introduction	of	NICE	testing	guidance;	arguably	the	most	powerful	stakeholder	in	community	based	
testing	for	viral	hepatitis	nationally.	Our	earlier	focus	group	work	with	members	of	the	local	Nepali	
community	has	also	shown	a	clear	enthusiasm	to	engage	with	primary	care	physicians,	with	further	
need	 therefore	 to	 explore	 how	 testing	 is	 understood	 in	 this	 setting,	with	 the	 aims	 to	 explore	 the	
potential	barriers	and	facilitators	towards	testing	in	primary	care,	and	to	identify	potential	leverage	
points	for	action	to	improve	community	testing	access	and	engagement.		
Understanding	the	potential	barriers	and	facilitators	to	overcome	this	gap	involves	an	exploration	of	
the	current	practice,	awareness	and	perception	in	relation	to	this	policy	in	day	to	day	practice,	which	
forms	the	basis	of	the	current	qualitative	study.	
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Research	objectives:	
The	 aim	of	 the	 current	 study	 is	 then	 to	 develop	 a	 qualitative	 strategy	 to	 identify	 these	 factors	 in	
primary	care,	with	the	following	research	objectives	to	address:	
• To	identify	current	CVH	testing	practice	in	primary	care		
• To	explore	the	awareness	and	knowledge	of	CVH	testing	policy	and	policy	objectives		
• To	identify	the	experiences	and	perception	of	viral	hepatitis	testing	in	primary	care	
• To	explore	the	perception	of	CVH	testing	in	migrant	communities		
• To	explore	potential	barriers	and	facilitators	to	testing	
	
Reflexivity:		
In	approaching	this	study,	I	was	aware	of	my	external	role	as	a	researcher	in	designing	and	conducting	
my	focus	group	study,	but	also	my	internal	role	as	a	clinical	doctor.	My	clinical	role	gives	me	both	an	
insider	status	in	view	of	my	shared	profession,	and	the	patient	care	and	interaction	that	I	commonly	
have,	but	also	as	an	outsider	to	primary	care,	representing	a	hospital	specialist,	and	one	who	may	be	
seen	as	trying	to	identify	shortcomings	in	knowledge	and	awareness	among	practitioners	not	working	
as	specialists	in	this	area.		
Ethics	application	was	 sought	 in	part	 to	 re-assure	participants	of	 the	confidential	and	professional	
research	nature	of	the	study.		The	focus	group	guide	was	designed	to	be	focused	and	impartial,	and	
to	avoid	deliberate	questions	that	may	be	viewed	as	trying	to	“catch”	individuals	out.		
During	my	moderator	role,	I	was	conscious	that	I	would	be	seen	as	both	research	moderator,	as	well	
as	 hospital	 specialist	 in	 liver	 diseases.	 This	 relationship	 is	 likely	 to	 have	 influenced	 interactions,	
although	 participants	 appeared	 to	 respond	well,	 and	 openly,	 and	may	well	 have	 led	 to	 increased	
interaction	and	discussion	with	GPs,	who	may	have	seen	me	as	a	colleague,	and	as	an	educational	
benefit.		
Participants	were	also	aware	that	there	would	be	an	educational	sessions	delivered	at	the	end	of	the	
focus	group,	which	may	have	changed	interactions,	although	one	would	hope	this	would	have	further	
supported	individuals	to	express	their	viewpoints.			
	
Focus	Group	in	Primary	Care:	Method	
To	study	these	issues,	I	developed	and	conducted	Focus	Group	sessions	with	GPs	local	to,	and	serving	
the	Nepali	community.		
The	basic	characteristics	of	focus	groups	centre	on	6	key	aspects:	(1)	the	people,	(2)	assembled	and	
interacting	 as	 a	 group,	 (3)	 all	 possessing	 certain	 characteristics,	 which	 (4)	 provide	 data	 (5)	 of	 a	
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qualitative	nature	(6)	in	a	focused	discussion	[Kruger	R	1994].		Utilising	a	focus	group	approach	I	will	
be	able	to	draw	together	a	group	of	GPs	to	explore	my	research	objectives	in	depth	relating	to	viral	
hepatitis	testing	in	real	life	practice.	Drawing	together	several	GPs,	I	hope	to	utilise	the	social	dynamic	
of	the	group	to	explore	perceptions	and	practice	in	the	group,	and	to	probe	further	into	this	through	
group	 interactions.	 	 Limitations	 of	 focus	 groups	 include	 the	 generalisability	 of	my	 findings,	which	
although	I	hope	these	will	be	in-depth,	may	be	most	representative	of	the	local	population	and	similar	
GP	practice	settings	across	the	country,	but	will	be	representative	of	the	issues	facing	the	local	Nepali	
community.		
Ethics	approval	was	obtained	through	application	to	the	University	of	Surrey	(the	study	sponsor),	with	
no	formal	Health	Research	Authority	(HRA)	ethics	approval	required	after	(formal)	enquiry	given	my	
clinical	NHS	role	and	staff	to	staff	 interaction	[[HRA	2013].	Ethics	approval	was	still	sought	through	
formal	channels	at	the	University	of	Surrey	to	provide	formal	reassurance	to	our	study	participants	of	
the	rigour	of	our	research	process,	as	well	as	with	the	aims	of	future	publications.		
Practices	around	Aldershot,	in	Hampshire	and	Surrey,	were	recruited	in	a	purposive	manner	through	
mailed	invites	to	practice	managers	and	lead	GPs,	as	well	as	promotional	presentations	delivered	to	
local	CCGs,	and	adverts	placed	through	CCG	newsletter	publications	on	a	regional	level.		
Three	practices	were	eventually	recruited	in	Aldershot,	with	the	Focus	Group	delivered	during	one	of	
the	regular	education	programme	sessions	arranged	for	these	CCG	linked	practices.	An	educational	
talk	 on	 viral	 hepatitis,	 and	 an	 update	 on	 national	 and	 international	 testing	 guidance	 and	 new	
treatment	paradigms	was	presented	to	the	same	group	after	the	FG	session.		
The	three	GP	practices	chosen	served	the	Aldershot	area	and	the	military	barracks,	and	linked	through	
a	hub	in	the	large	multi-purpose	Aldershot	for	Health	complex.	This	served	many	of	the	known	Nepali	
population	clusters	 in	and	around	Aldershot,	and	was	also	one	 the	main	GP	hubs	 for	many	of	 the	
participants	who	took	part	in	our	community	testing	study	in	central	Aldershot.		
GP	Participants	knew	each	other	from	a	work	context	at	individual	practices,	or	at	the	very	least	would	
have	met	and	interacted	at	similar	educational	forum	that	were	organised	monthly.	Trainee	GPs	would	
also	have	the	likely	added	dynamic	of	being	under	the	direction	and	assessment	of	one	of	the	senior	
GPs	on	a	day	to	day	basis,	although	this	relationship	was	not	questioned	or	explored	before	or	during	
the	session.	Identifying	GPs	who	had	not	met	or	interacted	on	a	regular	basis	was	not	deemed	feasible,	
and	not	thought	necessary	to	the	overall	aims	to	identify	our	research	objectives.	
A	focus	group	question	guide	was	developed	within	the	study	group	(researcher	and	study	supervisor)	
with	the	aims	to	understand	the	awareness,	beliefs	and	practices	relating	to	HBV	and	HCV	testing,	as	
well	as	potential	barriers	and	facilitators	to	testing,	with	close	liaison	to	NICE	testing	guidance	aims	
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(Figure	25).	 I	acted	as	the	sole	moderator	during	the	focus	group	session,	utilising	the	focus	group	
guide	to	structure	and	prompt	discussions	within	the	group.		
	
Table	15:	Focus	group	guide	in	primary	care,	and	prompts	for	the	moderator	
Formal	written	consent	was	obtained	from	participants,	with	written	information	sheets	circulated	to	
participants	before	intervention.	All	sessions	were	audio-recorded	with	written	consent.		
The	focus	group	was	conducted	over	an	afternoon	session	lasting	45	minutes	in	August	2014,	with	an	
information	sheet	that	was	disseminated	to	the	session	coordinator	from	the	3	practices	prior	to	the	
session.	The	session	was	held	at	the	Aldershot	Centre	for	Health	primary	care	seminar	room,	which	is	
a	designated	space	developed	for	meetings,	and	education	sessions	for	primary	care	staff.	The	space	
was	well	separated	from	patient	treatment/waiting	areas,	and	was	closed	off	from	any	other	staff	or	
office	space	environments.	
Questions:	
1. How	prevalent	/	relevant	do	you	think	viral	hepatitis	is	in	your	practice	population,	and	practice?	
a. Something	you	think	about/offer	patients	regulary?	
2. Which	groups	/	individuals	do	you	offer	viral	hepatitis	testing	at	present?	
a. Which	groups/individuals	do	you	think	are	at-risk?	
3. Community	testing	often	defined	as	Case-finding	–	have	you	heard	of	this	policy?	
4. Do	you	/	or	any	of	your	practices	have	such	a	policy	of	identifying	and	offering	testing	to	at-risk	
groups?	
5. Are	you	aware	of/do	you	use	any	guidelines	on	viral	hepatitis	testing?	
a. NICE/RCGP	etc	
6. How	do	you	feel	about	offering	viral	hepatitis	testing	to	asymptomatic	individuals?	
a. What	have	your	experiences	been	of	offering	testing	?	
7. How	do	you/would	you	approach	the	different	at-risk	groups?	
a. Do	you/would	you	approach	them	in	the	same	way	–	migrant	groups/sexual	risks/IVDU?	
8. Would	you	adopt	case-finding	practice	into	your	surgery?	How	do	you	feel	about	case-finding	as	a	
concept	in	primary	care?	
a. How	would	you	approach	this?		
i. Systematic	/	Opportunistic	/	New-patient	testing?	
b. How	can	primary	care	testing	be	improved		
c. DoH	Local/CCG	level,	Practice	/	Patient	level	
9. Does	anyone	have	any	other	comments/issues	they’d	like	to	raise		
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Focus	Group	data	was	analysed	using	the	Thematic	Analysis	methods	identified	earlier	by	Braun	and	
Clarke,	 working	 within	 a	 realist	 evaluation	 (RE)	 theoretical	 framework	 to	 explore	 the	 expressed	
meanings	of	participants	with	close	association	to	societal	and	contextual	factors	[Braun	V	et	al.	2006].	
Analysis	was	conducted	according	to	our	research	objectives,	utilising	the	earlier	framework	to	define	
these	objectives	within	a	Health,	Political	and	Social	context.		
Findings:	
A	total	of	9	GPs	took	part	in	the	Focus	Group	study	with	written	consent	obtained	from	all	participants.	
3	of	these	GPs	were	military	doctors,	with	the	remaining	6	who	were	civilian	GPs;	3	of	the	participants	
were	GP	registrars.		
Initial	 coding	 identified	 themes	 ordered	 around	 our	 question	 guide	 exploring:	 knowledge	 and	
awareness,	perceptions	and	priorities,	as	well	as	potential	barriers	to	testing	(fig	26).		Analysing	focus	
group	 data	 through	 a	 thematic	 analysis	 framework	 identified	 four	 overarching	 themes,	which	 are	
discussed	 in	 detail	 in	 the	 following	 sections:	 “Fear	 of	 Racism”,	 “Testing	 Causes	 Harm”,	 “We	 are	
Overwhelmed”,	and	“A	Low	Priority”.			
A	network	map	of	these	overarching	themes	is	presented	in	fig	27,	with	a	summary	that	is	presented	
in	table	15.		
Figure	25:	a	network	map	of	the	principal	candidate	themes	which	produced	the	four	higher	order	overarching	themes	in	
final	 thematic	 analysis.	 Dashed	 line	 represents	 linked	 association	 between	 the	 candidate	 theme	 “juggling	 priorities”	
between	the	two	overarching	themes	“	We	are	overwhelmed”	and	“A	low	priority”
A	Fear	of	racism:	
An	overarching	theme	that	explores	the	perception	that	testing	in	migrant	groups	may	be	viewed	
as	prejudiced.	The	fear	of	being	seen	to	act	in	a	suggested	racial	manner	is	expressed	as	a	potential	
barrier,	and	suggested	risk	to	practitioners.		
Testing	causes	harm:	
An	overarching	theme	that	explores	the	strongly	expressed	harms	that	can	be	seen	to	both	patients	
and	their	families	through	testing,	and	the	analogous	associations	expressed	towards	case-finding	
and	screening.		
We	are	overwhelmed:	
An	overarching	theme	that	explores	the	resource	pressures	that	GPs	see	themselves	under,	and	the	
potential	difficulties	that	they	associate	with	the	addition	of	a	viral	hepatitis	testing	programme.		
A	low	priority:	
An	overarching	theme	that	explores	the	lack	of	perceived	responsibility	for	viral	hepatitis	testing	in	
primary	care,	and	the	lack	of	current	awareness	and	expressed	priority	for	testing	 in	current	and	
future	practice,	as	well	as	a	low	suggested	priority	for	those	established	with	chronic	disease	in	the	
community.		
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Figure	26	–	a	network	map	of	the	principal	candidate	themes	which	produced	the	four	higher	order	overarching	themes	
in	final	thematic	analysis.	Dashed	line	represents	linked	association	between	the	candidate	theme	“juggling	priorities”	
between	the	two	overarching	themes	“	We	are	overwhelmed”	and	“A	low	priority”	
	
	
Overarching	themes	identified	in	focus	group	analysis	
Fear	of	Racism:		
This	overarching	theme	explores	participants’	expressions	that	approaching	migrant	groups	for	HBV	
and	HCV	testing	is	fraught	with	the	risks	of	appearing	or	acting	in	a	racist	manner.		
“There	has	been	a	suggestion	within	the	military	services	that	we	actually	test	everybody,	but	
there’s	 been	a	 lot	 of	 resistance	 to	 that,	 as	 it	was	perceived	as	 racially	motivated,	 because	
obviously	we	have	a	lot	of	foreign	and	commonwealth	soldiers,	and	therefore	they	are	going	
to	be	primarily	that	we	would	go	on	to	expect	to	have	infection,	although	that’s	not	completely	
true……	(Participant	4)”	
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Testing	in	military	personnel	has	clear	implications	for	work	and	deployment,	and	in	not	captured	in	
NICE	community	viral	hepatitis	testing	guidance	[NICE	2012].	However,	it	is	interesting	to	note	firstly	
the	awareness	 that	exists	 regarding	 infection	 risks	 in	different	migrant	groups,	 and	also	 the	wider	
perception	 within	 discussions	 that	 such	 Case-finding	 strategies	 could	 be	 viewed	 as	 “racially-
motivated”,	thereby	avoiding	testing	in	these	groups,	and	perceived	acts	of	discrimination.		
Other	 GP	 participants	 expand	 upon	 this	 to	 discuss	 perceived	 difficulties	 based	 upon	 cultural	 and	
language	difficulties,	as	well	as	perceptual	fears	linked	to	testing	offers:	
“there	 is	kind	of	a	bit	of	a	barrier	(nods	of	agreement	 in	room)”;	“especially	 if	you’ve	got	a	
population	with	a	cultural	or	language	barrier	already,	they	may	not	take	it	well	for	something	
unrelated,	and	it	can	cause	offense	in	some	people	as	well	(Participant	7)”	
Here,	participants’	express	concerns	that	testing	can	cause	offense	to	patients	based	upon	cultural	
perceptions	 of	 health,	 as	 well	 as	 miscommunication	 due	 to	 potential	 language	 barriers.	 The	
implication	here,	is	that	testing	is	seen	as	stigmatising	to	patients,	and	crucially	that	it	may	be	seen	as	
racially	prejudice	to	discuss	testing	with	migrant	groups.		
This	 viewpoint	 is	 mentioned	 by	 several	 participants	 of	 different	 backgrounds	 in	 the	 group,	 with	
concerns	about	how	testing	will	be	interpreted	by	those	in	migrant	communities:	
“And	also,	is	it	not	going	to	be	judged	again……,	as	being	prejudiced	against	one	racial	group,	
rather	than	everyone?”	(Participant	6)	
Against	this	widely	held	sentiment	in	the	group,	only	one	participant	offers	a	counter	narrative,	with	
analogy	drawn	towards	testing	offers	in	another	population	group	in	primary	care,	and	the	potential	
benefits	in	identifying	disease	if	present:	
“Well	it’s	like	Chlamydia	testing,	it	can	be	thought	of	as	prejudice,	but	we	still	do	it.	Naturally	
Once	you’ve	identified	a	population	group,	you	know,	its	nor,	I	don’t	think	it’s	like….	[…]	You’re	
giving	them	the	option,	and	I	think	it’s	better	to	pick	it	up	and	treat….	(Participant	3)”		
However,	 this	 sentiment	 is	 not	 echoed	 in	 the	 group,	 with	 a	 rapid	 and	 concise	 rebuttal	 to	 the	
participant	by	others	in	the	group:		
“Yes,	but	that’s	just	one	example….	(Participant	8);	But	screening	has	harms	as	well	as	benefits	
….	(Participant	5)”	
Here,	the	participant	echoes	the	earlier	expression	that	testing	offers	in	migrant	populations	raises	its	
own	perceptual	risks	towards	prejudice,	and	that	such	testing	cannot	be	seen	as	analgous	to	testing	
offers	 in	 other	 at-risk	 groups.	 Wider	 support	 for	 the	 potential	 benefits	 of	 testing,	 and	 disease	
awareness	 is	not	expressed	by	other	GPs	 in	 the	group;	 indeed,	 the	second	participants	expression	
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relating	to	the	potential	harms	of	testing	is	a	direct	response	to	this,	and	forms	a	strong	overarching	
theme	(Testing	causes	harm)	in	the	focus	group	analysis.		
	
Testing	causes	harm:		
The	potential	harms	of	testing	programmes	are	described	by	many	participants	in	the	group,	with	the	
suggestion	of	additional	responsibilities	that	GPs	have	to	identify,	and	perhaps	even	protect	patients	
from	these	risks:	
“[…]	but	screening	has	harms	as	well	as	benefit	[…]		if	we	talk	about	screening,	we’ve	got	to	
think	 about	 the	 harms,	 and	 like	 you	 say	 discussing	 what	 the	 implications	 are	 for	 family	
members,	what	the	implications	are	for	future	insurance…..	(Participant	5)’	
Case-finding	is	described	here	as	screening,	and	GPs	perceptions	regarding	testing	may	therefore	be	
influenced	by	perceptions	 towards	 large	 scale	 testing	programmes	 in	other	disease	 states	 such	as	
cancer	care,	and	the	potential	difficulties	with	false	positive	results	[Loberg	M	2015].	But	despite	this,	
there	are	specific	concerns	regarding	the	harms	that	testing	can	cause	to	the	individual	as	well	as	the	
wider	family.		
The	potential	negative	implications	of	testing	are	discussed	by	several	participants	at	various	points	
and	contexts	during	focus	group	discussions.	Whether	these	harms	are	specific	to	just	positive	test	
results	are	not	made	explicit,	but	regardless	these	potential	harms	are	strongly	expressed	by	several	
participants	in	the	group:		
“[…]	then	you’ve	got	to	talk	to	them	about	the	implications	of	having	this	test,	and	for	your	
nearest	and	dearest	and	things	like	that,	and	it	could	have	an	effect	on	their	employment	and	
things	like	that,	and	their	ability	to	get	insurance…..(Participant	3)”	
Significant	 personal	 and	 even	 familial	 harms	 are	 described	 here,	 with	 a	 responsibility	 that	 the	
practitioner	also	has	to	inform	their	patients	prior	to	testing	offers.	The	reasons	why	testing	would	
adversely	affect	the	family	is	not	expanded	upon	here;	whether	this	is	due	to	stigmatisation,	or	some	
other	 harm	 to	 internal	 or	 external	 relationships.	 There	 is	 also	 no	 recognition	 here	 of	 the	 very	
important	goals	to	 identifying	disease	 in	any	at	risk	relatives,	and	preventing	onward	transmission.	
Similarly,	the	impact	on	employment	and	insurance	is	not	made	explicit,	and	certainly	healthcare	is	
relatively	unique	in	the	close	involvement	of	occupational	health,	and	importantly	the	fact	that	there	
are	 no	 blanket	 restrictions	 on	 those	 with	 BBVs	 working	 in	 healthcare	 [DoH	 2000,	 HPS	 2008].	 On	
insurance,	the	participants’	expression	suggests	a	detriment	or	exclusion	to	being	granted	insurance	
because	of	having	viral	hepatitis,	and	perhaps	just	the	activity	of	testing	itself.	However,	this	is	contrary	
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to	guidelines	through	which	insurance	companies	practice,	with	no	requirements	to	question	clients	
regarding	previous	 testing	activity	 (presuming	negative)	outside	of	certain	 large	value	policies	 [ABI	
2010].	
Overall,	 the	 participants’	 expression	 describes	 many	 risks	 with	 testing	 across	 health,	 social	 and	
economic	aspects,	with	the	suggested	concern	that	GPs	put	across	regarding	the	potential	fear	that	
patients	may	be	exposed	to	in	taking	part	in	testing.		
	
	
We	are	overwhelmed		
The	pressures	that	GPs	face	to	meet	current	demand	is	clearly	evident	in	focus	group	discussions,	and	
is	identified	as	one	of	the	overarching	themes	in	focus	group	analysis.		
Participants	describe	the	difficulties	that	they	face	in	meeting	day	to	day	needs,	as	well	as	the	demands	
and	challenges	that	GPs	see	with	the	thought	of	any	additional	procedures,	including	viral	hepatitis	
testing:	
“[..]	 	Well	we	really	are	overwhelmed	with	workload,	and	currently	we	haven’t	got	capacity	
unless	 there	 is	 some	 money	 involved.	 […]	 Just	 from	 our	 practice,	 the	 secretaries	 are	
overwhelmed,	so	right	now,	unless	there’s	some,	something…	I	think	we’re	all…..	(Participant	
9)”;	“maxed	out	that’s	the	word	(Participant	5)”.	
The	participant	identifies	here	the	significant	pressures	that	GPs	are	under	to	meet	existing	demand,	
and	the	need	for	more	resources,	with	the	specific	mention	of	financial	input	to	even	consider	taking	
on	extra	commitments.	There	is	even	the	suggestion	of	resignation	or	perhaps	exhaustion	in	how	to	
label	and	address	these	pressures	in	primary	care.		
As	 well	 as	 these	 pressures,	 GPs	 express	 concern	 that	 viral	 hepatitis	 testing	 presents	 a	 significant	
additional	burden	to	add	on	to	day	to	day	practice:		
“[….]	 it’s	 quite	 a	 difficult	 one	 to	 just	 go…	well	 while	 you’re	 here	 whoops,	 let’s	 talk	 about	
hepatitis	B	and	c	testing,	but	also	it	is	not	a	straight-forward	thing	to	describe	to	somebody,	
and	they’ve	probably	never	heard	of	it,	then	you’ve	got	to	talk	them	about	the	implications	of	
having	this	test	[….]	and	so	it’s	not	a	small	thing,	and	you’re	going	to	say,	well	why	don’t	you	
have	a	test	whilst	you’re	here	(Participant	3)”	
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Testing	here	is	described	as	a	significant	and	likely	uncomfortable	commitment,	and	“no	small	thing”	
for	GPs	to	take	on.	It	also	suggests	a	barrier	that	exists	as	a	result	of	the	significant	information	that	
has	to	be	shared	with	patients	before	testing	can	be	adopted.		
The	potential	challenges	to	GPs	if	a	successful	testing	scheme	was	established	is	further	expanded	on	
by	others	in	the	group:		
“[…]	The	only	problem	is	 that	the	onus	 is	on	us	as	the	practitioner,	when	you’re	promoting	
screening	to	chase	up	results,	and	so	it	is	going	to	be	a	whole	new	burden.	If	you	can	educate	
people	 to	 come	 to	 you,	 then	 the	 onus	 is	 on	 them	 to	 come	 forward	 and	 get	 the	 results.		
(Participant	4)”	
Here,	the	participant	identifies	the	potential	additional	workload	that	testing	would	create,	but	also	
potential	strategies	to	facilitate	testing	that	may	be	seen	through	patient	education,	and	is	the	first	
(and	only)	among	GP	participants	to	suggest	a	role	for	patient	ownership	of	testing	through	education.		
	
A	Low	Priority	
In	addition	 to	 the	challenges	 that	a	viral	hepatitis	 testing	programme	would	pose	 to	primary	care,	
practitioners	identify	current	testing	practice,	and	responsibilities	towards	testing	that	feature	low	on	
most	practitioners’	priorities,	and	with	some	expressing	very	strong	views	to	counter	the	need	for	viral	
hepatitis	testing	in	any	form	in	primary	care:	
“I’d	 say	 that	 it	 is	a	 complete	waste	of	money,	because	 it’s	all	being	done	anyway.	And	we	
screen	all	the	antenatals	anyway	don’t	we?...	[Participant	2]”	
The	participant	here	expresses	disdain	at	the	prospect	of	ongoing	or	escalated	viral	hepatitis	testing	
practice,	that	seems	based	on	assumptions	that	testing	practice	is	engrained	elsewhere	in	the	health	
service,	including	antenatal	care,	despite	the	absence	of	routine	antenatal	HCV	testing	nationally.	On	
discussing	 the	 lack	 of	 HCV	 testing	 that	 currently	 exists	 in	 the	 antenatal	 system,	 the	 participant	
continues	to	express	a	negative	view	towards	testing	practice:	
“no,	we	don’t	do	hep	C.	I	get	all	the	results	from	our	practice,	and	they’re	just	tagged	on	to	my	
inbox,	and	I’ve	not	seen	a	positive	one,	and	they	check	it	twice,	why?	You	know,	It’s	just	one	of	
those	stupid	things	isn’t	it?....[Participant	2]”	
There	is	little	encouragement	here	regarding	the	participant’s	views	towards	testing,	and	this	seems	
closely	linked	to	a	lack	of	first-hand	experience	with	positive	cases,	as	well	as	perhaps	the	work	load	
involved	with	looking	through	these	results.	And	even	after	another	colleague	discusses	a	positive	co-
infected	maternal	case	that	they	have	encountered,	the	expressed	viewpoint	does	not	change:	
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“I	appreciate	the	HIV	patient,	but	I’ve	not	seen	it	recently	in	the	routine	screens	[Participant	
2].”	
The	responsibility	for	testing,	and	the	role	of	primary	care	in	viral	hepatitis	testing	is	also	queried	by	
several	participants:	
“one	thing	that’s	quite	tricky,	there’s	a	lack	of	communication	between	the	sexual	health	clinic	
and	us,	because	they’ve	got	all	 this	confidential	 information,	so	we	never	quite	know	what	
they	have	tested	[…]”	
“[..]	there	are	plenty	of	people	who	have	been	screened,	and	we	don’t	know	about	it	as	their	
GP,	and	they	will	get	tested	by	blood-spot	testing	in	drug-and-alcohol	clinic,	and	we	don’t	get	
told	those	results	either	[Participant	3]”	
Participants	express	 frustration	here	 that	 testing	often	occurs	 in	other	 community	 settings,	where	
information	transfer	may	be	limited,	and	responsibilities	for	testing	that	some	may	see	as	residing	in	
these	community	centres	as	a	result.		
Participants	seem	to	express	little	certainty	regarding	testing	indications,	and	in	relation	to	national	
guidance,	with	a	low	priority	that	is	associated	overall	towards	current	testing	practice:	
“NICE	has	probably	done	something…;	but	I	haven’t	read	it..	(Laughter)	[Participant	3]”	
“[…]	and	we	don’t	always	know	who	the	at-risk	groups	are,	and	we’re	not	constantly	asking	
the	 question.	 We’re	 all	 so	 busy,	 that	 to	 actually	 go	 through	 a	 whole	 load	 of	 screening	
questionnaires….	 if	 we’ve	 missed	 it	 on	 the	 new-patient	 check,	 we’ve	 probably	 missed	 it…	
[Participant	8]”	
None	of	the	participants	seem	aware	of	NICE	testing	guidance,	and	although	there	is	acceptance	that	
national	guidance	may	indeed	exist,	there	is	the	implication	that	the	subject	and	perhaps	principal	of	
multiple	guideline	documents	are	a	low	priority,	or	do	not	fit	into	their	current	working	patterns	or	
context;	akin	to	the	principals	of	the	“second	translation	gap”	identified	during	studies	of	evidence	
based	research,	and	guideline	adoption	into	clinical	practice	[Lau	R	2016].	A	lack	of	awareness	of	at-
risk	groups	and	testing	indications	seems	to	combine	with	the	perception	that	case-finding	assessment	
is	challenging,	thereby	confounding	the	likelihood	that	GPs	will	engage	in	testing	practice.	Although	
the	 latter	participant	expresses	 the	 suggestion	of	 testing	on	new-patient	 registration,	 it	 should	be	
noted	 that	none	of	 the	GPs	expressed	any	such	practice	 that	currently	exists	after	direct	question	
probes	during	focus	group	discussions.		
Further	 expression	 of	 the	 low	 priority	 in	which	 viral	 hepatitis	 testing	 is	 seen	 is	 provided	 again	 by	
Participant	2:		
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	 “In	over	25	years	as	a	GP	I	have	never	seen	a	case	of	hepatitis	B	[Participant	2]”	
This	assertion	is	queried	by	others	in	the	group,	with	the	subsequent	reply	that	raises	further	concerns	
regarding	disease	awareness	and	understanding:		
“No	it’s	never	come	way	at	all,	no	never!	Hepatitis	C	carriers	and	things	that	got	picked	up	by,	
but	not	a	hep	B	case….	And	I	worked	for	a	hepatologist,	and	I	would	be	thinking	about	that…	
[Participant	2]”	
“Do	you	mean	acute	as	opposed	to	carriers?	[Participant	6]”		
“I	mean	acute….	Yeah	[	Participant	2]”	
The	interaction	here	highlights	the	low	priority	through	which	viral	hepatitis	is	currently	seen,	as	well	
as	being	suggestive	of	misconceptions	regarding	disease	understanding	and	management.	It	is	unclear	
if	 the	 participant	 is	 referring	 to	 acute	 or	 chronic	 viral	 hepatitis,	 and	 most	 likely	 this	 relates	 to	
uncertainty	 between	 the	 two	 states.	 Regardless,	 it	wrongly	 implies	 that	 chronic	HCV	 carriage	 is	 a	
benign	 state,	 rather	 than	 one	 that	 necessitates	 referral	 and	 treatment.	Whilst	 it	may	 be	 that	 the	
practitioner	 has	 not	 encountered	 a	 chronic	 HBV	 case,	 it	 does	 raise	 the	 same	 important	 concerns	
around	the	definitions	and	understanding	of	acute	and	chronic	HBV	related	liver	disease,	and	overall	
raises	 concerns	 in	 how	 new	 migrant	 communities	 would	 be	 assessed	 and	 treated	 with	 these	
preconceptions,	given	the	likely	variance	in	disease	prevalence	to	the	background	UK	population.			
The	difficulties	that	GPs	see	though	towards	viral	hepatitis	testing,	and	in	prioritising	testing	practice	
in	their	current	constraints	is	well	illustrated	by	Participant	5:		
“Every	particular	 specialist	will	 think	 that	 they’re,	umm	area	 is	 really	 really	 important,	and	
should	be	a	priority	of	us.	And	so	we	have	to	juggle	all	of	those….	[Participant	5]”	
This	extract	highlights	the	issues	that	GPs	see	in	trying	to	“juggle”	the	demands	of	specialist,	hospital	
based	 teams	 in	 achieving	 goals	 that	 are	 presented	 as	 external,	 and	 likely	 outside	 the	 current	
responsibility	and	ownership	of	primary	care	physicians.		
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Key	findings:		
GPs	express	awareness	of	CVH	as	a	risk	for	 liver	disease	in	their	patient	cohort,	and	whilst	there	is	
knowledge	of	treatments	for	CVH,	the	overwhelming	perception	portrayed	is	that	CVH	testing	is	a	low	
priority	area,	and	one	that	may	cause	offense,	and	even	harm.		
Knowledge	of	CVH	with	regard	to	its	effects	and	complications	is	not	discussed	explicitly,	but	there	is	
the	suggestion	of	misunderstandings	in	the	relationship	between	acute	and	chronic	infection,	and	the	
need	for	monitoring,	referral	and	treatment.	Treatment	options	are	also	poorly	understood,	with	no	
reference	to	newer	agents.		
Knowledge	regarding	case	finding	and	national	guidance	is	poor,	and	whilst	some	in	the	group	express	
awareness	towards	testing	in	migrant	groups,	the	overwhelming	perception	is	that	this	will	 lead	to	
offense	and	potential	harm.	There	is	also	misunderstanding	in	the	personal	and	familial	impact	that	
CVH	 testing	 can	 have,	with	 incorrect	 beliefs	 towards	 the	work	 and	 insurance	 implications	 of	 CVH	
testing,	which	could	further	impact	case-finding	activity	in	primary	care.		
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Chapter	6:	Developing	CVH	case-finding	strategies	in	the	Nepali	community	
SUMMARY:	
At	the	heart	of	our	study	are	the	potential	risks	of	CVH	faced	by	the	newly	arrived	UK	Nepali	
community,	with	qualitative	studies	that	have	demonstrated	an	interest	to	engage	with	health	
professionals,	and	primary	care	studies	that	have	identified	testing	practice	as	a	low	priority	in	
migrant	communities.		
Developing	testing	interventions	to	successfully	reach	out	to	this	population	is	therefore	crucial	in	
assessing	this	risk,	with	difficulties	that	exist	in	comparison	to	testing	studies	in	other,	more	
established	migrant	communities,	where	religious	homogeneity,	or	established	community	meetings	
facilitate	study	promotion	and	engagement.		
Context		
Nepal	sits	between	India	and	China,	countries	with	higher	established	CVH	risks,	but	with	the	burden	
of	HBV	and	HCV	that	are	not	well	understood	in	the	unique	Nepali	population	extraction	that	now	
resides	in	the	UK.		
To	understand	this	risk	requires	a	community-based	approach	to	explore	disease	prevalence,	with	a	
testing	strategy	that	needs	to	be	developed	to	 identify	and	engage	with	members	of	this	new	and	
heterogeneous	community.		
Utilising	the	findings	from	our	qualitative	studies	in	members	of	Nepali	community,	as	well	as	local	
primary	 care	 physicians,	 there	 is	 evidence	 of	 interest	 in	 engagement	 for	 CVH,	 with	 first-hand	
experience	 of	 jaundice	 that	 is	mentioned	 by	many	 participants,	 further	 emphasising	 the	 need	 for	
study.	Our	qualitative	studies	in	primary	care	also	suggest	that	current	testing	practice	is	primary	care	
is	likely	to	be	at	a	low	level,	with	a	need	therefore	to	develop	strategies	to	engage	with	members	of	
the	local	Nepali	population	in	a	community	setting	to	assess	disease	risks.		
Community	testing	strategies	for	CVH	and	BBVs	have	been	successfully	delivered	in	several	migrant	
communities	in	the	UK,	often	targeting	common	places	of	worship,	or	pre-existing	community	groups,	
but	with	limited	studies,	and	unique	demands	that	exist	in	identifying	recruitment	and	engagement	
strategies	in	new	migrant	communities,	such	as	the	Nepali	population.		
Community	testing	strategies:	Literature	review	
Recognising	the	higher	burden	of	CVH	among	migrant	communities,	there	has	been	several	large	scale	
studies	that	have	looked	at	engaging	with	communities	for	HBV	and/or	HCV	testing,	with	engagement	
rates	 and	disease	prevalence	 rates	 that	have	differed	between	 study	 groups,	 and	 the	populations	
studied.		
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The	term	“Community”	can	be	used	in	different	contexts,	whether	as	a	descriptive	term	to	define	large	
numbers	of	a	group	and	its’	population;	but	also	may	be	considered	as	a	more	developed	unit	where	
a	shared	identity	or	belonging	can	be	utilised	to	support	and	further	develop	a	policy	objective	in	the	
community	as	a	whole	[Whitehead	T	2002].	Similarly,	community	based	interventions	(CBI),	which	is	
the	 umbrella	 term	 that	 considers	 testing	 interventions,	 can	 also	 be	 defined	 in	 several	 constructs,	
based	on	the	degree	of	involvement,	and	relationship	between	the	specialist,	or	policy	group,	and	the	
“community”	as	a	whole,	with	the	ideal	CBI	being	a	“true	partnership	between	technical	experts	and	
the	 communities	 they	 serve”	 [Robotin	 M	 2014].	 This	 model	 involves	 the	 expert	 group	 providing	
conceptual	 rigour,	 comprehensive	 study	 design	 and	 thorough	 implementation,	 with	 community	
involvement	 to	 support	 program	 incorporation	 into	 a	 sociocultural	 context	 [Robotin	 M	 2014,	
Whitehead	T	2002].		As	such,	the	development	of	community	support	is	therefore	crucial	from	this	
analysis	in	the	design	and	development	of	community	based	interventions.		
Most	 published	 studies	 focus	 on	 testing	 strategies	 in	 established	 migrant	 communities,	 typically	
utilising	lay	community	or	religious	leaders	to	facilitate	testing	recruitment	and	engagement.	There	is	
heterogeneity	 between	 studies,	 and	 the	 success	 of	 testing	 uptake	 is	 often	 not	 apparent,	 with	
difficulties	 in	 knowing	 the	 pool	 of	 eligible/invited	 individuals	 for	 testing	 (outside	 of	 mailed	 invite	
studies).	 Nevertheless,	 testing	 uptake	 can	 be	 inferred	 by	 the	 overall	 study	 size,	 and	 number	 of	
participants	and	recruiting	events	required	to	achieve	this	target.		
Multiple	strategies	have	been	trialled	 for	patient	 recruitment,	as	well	as	 testing	engagement,	with	
varied	 successes.	 Mailed	 testing	 invitations	 have	 been	 successfully	 employed	 in	 studies	 in	 the	
Netherlands,	utilising	migrant	registration	data	held	by	the	municipality	to	generate	testing	invitation.	
In	the	study	by	Veldhuijzen	et	al.	they	issued	invites	(plus	a	reminder	letter)	to	1787	Dutch-Turkish	
individuals,	achieving	a	testing	uptake	of	16%	(288/1787),	with	the	addition	of	regional	newspaper	
advert	and	website	promotion	improving	this	uptake	to	30%	[Veldhuijzen	2009].	This	uptake	is	higher	
than	that	previous	achieved	in	the	Netherlands	using	religious	and	community	leaders	alone	in	the	
same	 migrant	 population	 (around	 10%)	 [Richter	 2014],	 but	 does	 rely	 upon	 the	 coordinated	
involvement	of	regional	government	in	recording	and	writing	to	migrant	individuals	for	testing.	It	is	
perhaps	also	prudent	to	note	that	the	same	population	expressed	high	levels	of	dissatisfaction	with	
the	 Dutch	 healthcare	 system,	 and	 whilst	 this	 is	 not	 unique	 among	 migrant	 groups	 in	 Western	
healthcare	 settings,	 there	 is	 no	 exploration	 whether	 the	 involvement	 of	 local	 government	 in	 this	
process	(through	mailed	invites)	plays	a	part	in	this	dissatisfaction.		
In	 the	 review	 by	 Robotin	 et	 al.	 several	 partnership	 approaches	 are	 suggested	 in	 developing	 and	
providing	 community	 based	 interventions,	 with	 an	 outreach	 and	 partnership	 model	 (OPM)	 more	
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successful	than	other	approaches,	including	integrated	community	clinic	testing	in	primary	care;	and	
partnership	and	contract	models,	utilising	a	contracted	company	to	facilitate	testing	activity	with	the	
community	group.	In	the	OPM	approach,	community	based	interventions	continue	under	the	study	
group,	but	with	close	 involvement	of	community	advocates	 in	organising	and	 facilitating	the	study	
[Robotin	M	2014].		
In	 the	 UK,	 community-partnership	 approaches	 have	 been	 tested	 in	 the	 South	 Asian	 community,	
utilising	religious	and	community	settings	in	Mosques,	Temples	and	established	community	venues.	
Such	approaches	and	settings	seem	to	be	popular,	with	close	to	4600	individuals	tested	in	(primarily)	
religious	settings	across	the	UK	by	Uddin	et	al.	(around	29	individuals	per	session).	The	direct	support	
of	 religious	 leaders,	and	the	delivery	of	 testing	at	 the	place	of	worship	 (through	 finger-prick	blood	
tests,	or	mouth	swabs)	do	seem	to	be	important,	with	the	same	group	showing	no	uptake	in	blood	
test	requests	when	5000	invites	were	distributed	to	a	Mosque	without	local	testing	[Uddin	G	2010,	
Lewis	H	2011].	Similar	methods,	utilising	primarily	religious	settings	have	proved	successful	in	studies	
in	the	Egyptian	Coptic	community,	and	in	the	Korean	Christian	community	in	the	US,	achieving	a	high	
number	of	HBV	and	HCV	tests	in	these	populations,	with	around	a	100	individuals	tested	per	session	
in	 the	 US	 based	 Korean	 Church	 study	 [Zuure	 2013,	 Navarro	 2014].	 Similar	 studies	 in	 the	 Chinese	
community	in	the	UK	have	used	established	community	venues,	Churches	and	local	Wholesalers	to	
advertise	testing,	with	testing	uptake	 in	around	230	 individuals	 (around	15	 individuals	per	session)	
[Vedio	AB	2013].		
Behavioural	 modification	 has	 been	 attempted	 by	 researchers	 in	 the	 Netherlands,	 providing	
behavioural	and	cultural	prompts	to	link	HBV	and	HCV	tests	to	religious	(Islam)	and	cultural	beliefs	of	
healthcare,	 and	 wellness.	 Such	 methods	 have	 not	 shown	 a	 clear	 benefit	 in	 testing	 uptake,	 but	
perceptions	 towards	 health	 and	 testing	 were	 higher	 in	 those	 individuals	 receiving	 behavioural	
interventions	 with	 the	 potential	 for	 these	 strategies	 to	 have	 benefit	 over	 the	 longer	 period	 in	
healthcare	engagement	in	migrant	communities	[Van	der	Veen	2010].	
As	such	community	partnership	models	with	support	from	religious	and	community	leaders	seem	an	
effective	route	to	approach	migrant	groups	for	testing,	but	with	the	limitation	that	these	measures	
are	largely	restricted	to	those	established	migrant	groups	with	existing	community	venues,	or	religious	
homogeneity.		
The	 largest	 and	 well-funded	 community	 testing	 program	 is	 perhaps	 the	 “BfreeNYC”	 project	
undertaken	 between	 2004	 and	 2008	 in	 New	 York	 City,	 which	 tested	 8,888	 migrant	 individuals	
(principally	 of	 Chinese	 and	 Korean	 descent)	 for	 HBV.	 This	 was	 a	 large-scale	 coordinated	 testing	
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program	“championed”	by	city	councillors	in	a	top-down	approach,	and	funded	to	advertise	testing	
on	large	scale	in	major	media	outlets.	Large	scale	advertising	on	this	scale	was	successful	in	achieving	
community	awareness	in	around	10%	of	the	migrant	population.	Stigmatisation	was	not	reported	from	
the	 wider	 community	 during	 this	 advertising	 process,	 and	 importantly	 members	 of	 the	 Asian	
community	associated	less	stigma	towards	viral	hepatitis	as	a	direct	result	of	the	awareness-raising	
programme	[Pollack	2011,	Yoo	GJ	2011].		
Most	community	testing	studies	focus	on	testing	in	one	community,	with	the	Dutch	study	by	Richter	
et	al.	one	of	the	few	to	describe	testing	in	multiple	geographically-separate	migrant	communities	in	a	
single	event.	This	study	is	also	one	of	the	few	to	focus	on	just	first-generation	migrants,	although	the	
duration	 of	 residency	 in	 the	 Netherlands	 is	 not	 apparent	 from	 the	 study.	 Individuals	 were	 again	
identified	and	directly	invited	by	mail	from	the	local	municipality.	Advertising	was	delivered	in	local	
media	 sources	 (newspapers,	websites),	with	no	mention	of	 any	undue	 stigmatisation	 in	 the	wider	
community,	and	with	an	uptake	of	HBV	and	HCV	testing	in	959	out	of	3226	individuals	who	attended	
a	community	talk	delivered	by	hospital	physicians.	Individuals	attended	from	Asia,	Eastern	Europe	and	
the	Middle	East	with	marked	cultural	diversity,	but	with	 reasonable	 levels	of	engagement	 from	all	
groups.	 Rates	 of	 infection	 differed	 between	 communities,	 but	 the	 high	 levels	 of	 uptake	 in	 first-
generation	migrants	from	different	populations	is	encouraging	[Richter	2014].		
Linkage	to	care	for	positive	cases/disease	risks	is	poorly	documented	in	most	studies,	with	high	rates	
of	 individuals	 lost	 to	 follow-up	 in	 most	 studies;	 and	 even	 in	 the	 most	 comprehensive	 testing	
intervention	in	the	BFreeNYK	study,	around	57%	of	participants	were	kept	in	care	services	until	the	
end	of	the	4	year	study	[Robotin	M	2014].		
In	all	voluntary	community-based	approaches,	self-selection	bias	a	common	factor,	and	it	has	been	
suggested	that	rates	of	infection	may	indeed	be	higher	in	those	individuals	who	do	not	take	up	such	
offers,	due	to	co-morbid	disease,	or	risk-activity	that	makes	them	paradoxically	reluctant	to	attend	
[UddinG	2010].	Whilst	primary	care	testing	is	an	alternative	that	may	reach	out	to	these	individuals	
[Rein	 2011],	 recent	 studies	 in	 West	 London	 have	 shown	 poor	 attendance	 (10%)	 by	 members	 of	
migrant	communities	in	specially	prepared	new-patient	testing	sessions,	despite	an	estimated	local	
migrant	 prevalence	 of	 over	 40%	 [Hargreaves	 2014],	 and	 our	 primary	 care	 focus	 group	 work	 has	
demonstrated	 a	 low	 priority,	 and	 current	 testing	 practice	 for	 migrant	 communities,	 including	
members	of	the	newly	arrived	Nepali	population.		
177	
	
Summary:	
Overall,	 the	evidence	 from	 these	 community	endeavours	 show	 that	 successful	CVH	 testing	 can	be	
achieved	in	non-healthcare	settings,	with	several	testing	strategies	that	have	been	employed.	Media	
advertising	has	been	used	in	the	largest	of	testing	studies	in	the	BfreeNYC	project	[Pollack	H	2011],	as	
well	 as	 the	 study	 by	 Richter	 et	 al.	 with	 no	 significant	 reported	 stigma	 raised	 as	 a	 result	 of	 this	
advertising	in	either	study,	although	arguably	the	current	climate	and	sensitivities	towards	migration	
is	likely	to	be	more	acute	than	the	studies	from	2008	and	2011	[Pollack	H	2011,	Richter	C	2014].	Most	
projects	 though	have	 focused	on	utilising	 existing	 religious	 and	 cultural	 settings	 to	 reach	out	 to	 a	
migrant	community	with	religious	or	other	community	leaders	acting	as	testing	advocates	to	promote	
health	and	testing,	with	this	being	the	predominant	approach	utilised	in	the	UK.	
Rates	of	CVH	infection	identified	in	studies	also	varies,	with	heterogeneity	that	is	likely	to	exist	within	
and	 between	 individuals	 from	 the	 same	 region,	 as	 well	 as	 a	 lower	 rate	 of	 infection	 that	may	 be	
suggested	in	second	generation	migrants	[Uddin	G	2010],	but	with	many	uncertainties	that	still	exist,	
and	a	higher	prevalence	of	CVH	that	is	suggested	in	most	studies	cumulatively.		
The	optimal	 strategy	 to	engage	with,	and	 test	members	of	 the	newly	arrived	Nepali	 community	 is	
therefore	 unclear,	 with	 most	 study	 data	 available	 for	 established	 communities	 with	 an	 existing	
religious,	 or	 community	 link	 to	 disseminate	 and	 encourage	 testing	 to	 a	 population	 that	 shares	 a	
common	focus	and/or	attendance	 through	this	 religious/cultural	activity.	 It	 is	evident	 though,	 that	
community	 based	 support	 and	 advocacy	 is	 crucial	 to	 testing	 success,	 with	 the	 need	 therefore	 to	
explore	and	develop	community	links	within	the	Nepali	population	in	building	testing	sessions.	
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Research	Objectives:	
The	hypothesis	of	our	testing	study	was	that	rates	of	CVH	would	be	higher	in	the	Nepali	population,	
with	higher	rates	of	infection	that	may	be	seen	in	newly	arrived,	first-generation	migrants,	as	opposed	
to	those	Nepali	born	in	the	UK.		
The	primary	objective	of	our	study	was	to	develop	a	community	based	testing	intervention	to	explore	
HBV	and	HCV	prevalence	in	the	local	Nepali	population:	
o To	develop	and	prove	a	 successful	 health-engagement	 strategy	with	 large	numbers	of	 the	
local	community		
o To	identify	CVH	(HBV	and	HCV)	prevalence	in	the	Nepali	community	
Our	secondary	objectives	were	to	explore	potential	risk-factors	that	may	be	associated	with	past	
or	current	disease,	as	well	as	factors	that	influence	the	success	of	engagement	strategies,	onward	
linkage	strategies	to	secondary	care,	as	well	as	potential	contact	tracing	implications	of	positive	
cases.		
- To	 explore	 potential	 CVH	 risk	 factors	 associated	 with	 past	 /	 current	 infection	
including:		
§ demographic	 factors,	 geographic	 variation,	 educational	 status,	 alcohol,	
blood	borne	exposure	risks	
- To	explore	potential	barriers	and	facilitators	to	community	testing	engagement	
- Explore	linkage	to	care	in	secondary	health	services	
- Explore	potential	contact	tracing	implications	of	positive	cases	
	
Reflexivity:	
As	a	first-generation	migrant,	although	at	a	childhood	age,	I	am	conscious	that	I	am	likely	to	treat	this	
group	 differently,	 and	 feel	 comfortable	 interacting	 with	 migrant	 communities	 in	 general.	 My	
experiences	in	secondary	care	working	with	members	of	the	community	in	an	outpatient	setting	has	
shown	these	individuals	to	be	engaged,	and	nearly	always	accompanied	by	a	friend	or	member	of	the	
family	from	the	Nepali	community.		
Language	is	likely	to	be	a	significant	barrier	to	communication,	and	my	interactions	with	members	of	
the	local	community	has	demonstrated	this	in	clinical	practice,	with	the	frequent	need	for	a	translator	
in	clinic	visits.			
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Testing	a	large	number	of	Nepali	in	the	community	is	likely	to	present	a	challenge,	with	a	significant	
heterogeneity	in	religion	and	caste,	and	the	resultant	lack	of	a	common	forum	to	promote	or	engage	
with	members	of	the	community.		
	
Methods:	
Ethics:	
Formal	ethics	approval	was	obtained	through	the	National	Research	Ethics	Service	(NRES)	and	Health	
Research	 Authority	 (HRA)	 (Brighton	 and	 Sussex	 NRES	 committee;	 ref:	 12/LO/1530;	 IRAS	
114296/363341/14/402)	for	activities	relating	to	focus	group	discussions	in	the	Nepali	community,	as	
well	the	testing	activity	of	the	current	study	[Appendix	x].	The	study	sponsor	was	Frimley	Park	Hospital,	
with	original	ethics	application	submitted	by	one	of	the	research	supervisors,	Aftab	Ala	(AA).		
Study	Design:	
Community	 Leaders:	 Given	 the	 uncertainties	 that	 exist	 in	 how	 to	 approach	 and	 test	 this	 new	
community,	as	well	as	potential	sensitivities	that	may	arise,	we	first	established	a	multidisciplinary	
research	team	with	close	input	from	Nepali	community	leaders	and	community	stakeholder	groups.	
Support	was	gained	from	local	public	health	commissioners	in	Hampshire,	and	Surrey	and	Sussex	(PHE,	
formally	known	as	the	Health	Protection	Unit),	community	liaison	workers	at	Frimley	Park	Hospital,	
local	 council	 representatives,	 as	 well	 as	 the	 British	 Liver	 Trust	 patient	 charity.	 Study	 	 design	 was	
influenced	by	the	findings	of	our	qualitative	work	with	the	 local	Nepali	community,	with	the	study	
design	reviewed	by	national	Hepatology	(Clinician)	leads	prior	to	testing	activity.	
A	steering	group	was	formed	between	the	research	team	and	Nepali	community	leaders	to	coordinate	
and	deliver	testing	activity,	including	the	initial	focus	group	activities	of	this	study.	This	group	acted	to	
inform	and	direct	testing	activity,	and	also	to	act	as	peer-support	for	testing	in	the	community.	The	
core	researcher	team	was	made	up	of	myself	(SM),	Dr	Jane	Hendy	(JH),	Professor	Aftab	Ala	(AA)	and	
Mihalea	Petrova	(MP).		
Given	the	religious	heterogeneity	of	the	Nepali	community,	its	recent	arrival	and	expansion,	as	well	as	
its	 potential	 vulnerabilities	 from	 a	 social	 determinants	 model,	 we	 developed	 our	 team	 of	 Nepali	
community	 leaders	 and	 volunteers	 very	 much	 from	 its’	 infancy,	 with	 little	 in	 the	 way	 of	 existing	
healthcare	engagement	strategies	in	place.		
Initial,	 and	 key	 contributors	 to	 our	 research	 group	 included	Ramji	 Tiwari,	working	with	 Rushmoor	
Healthy	Living,	and	input	from	the	Gurkha	Welfare	Trust.	Nursing	staff	at	Frimley	Park	Hospital	also	
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contributed	as	volunteers,	and	to	direct	us	towards	other	community	volunteers.	Ramji	Tiwari	was	
identified	as	having	had	public	health	experience	 in	Nepal,	 and	was	afforded	honorary	 researcher	
status	to	act	as	our	principal	spokesperson	in	community	liaison	in	the	initial	stages	of	the	study,	and	
was	provided	financial	support	for	his	work	in	the	study.		Ex-Gurkha	veterans	were	quickly	identified	
as	community	leaders	to	engage	and	direct	activity,	with	a	strong	community	standing	given	in	view	
of	their	military	rank,	and	the	predominant	Gurkha	ranks	of	the	newly	arrived	community.		
I	became	aware	of	existing	Nepali	Diabetes	support	groups,	and	a	Macmillan	cancer	charity	support	
group	in	community	venues,	and	met	with	these	groups	to	discuss	testing	objectives	and	strategies,	
and	to	recruit	Nepali	volunteers	to	act	as	eventual	peer-advocates	in	our	testing	work.			
Council	 leaders	signposted	me	to	projects	running	through	local	churches	in	the	Farnborough	area,	
and	I	presented	our	testing	work	at	several	large	meetings,	with	the	close	support	and	peer-advocacy	
of	ex-Gurkha	veterans	who	chaired	these	sessions.	The	majority	of	Nepali	community	leaders	were	
identified	 from	 the	 Farnborough	 and	 Aldershot	 areas,	 but	 with	 smaller	 community	 groups	
subsequently	 identified	 through	 my	 travels,	 with	 involvement	 and	 recruitment	 at	 these	 areas	 in	
addition,	growing	and	recruiting	our	network	of	community	leaders.		
Our	final	network	of	Nepali	community	 leaders	was	therefore	identified	through	an	iterative,	step-
wise	approach,	relying	on	word	or	mouth,	and	signposting	to	separate	community	groups	of	different	
sizing	and	populations.	Multiple	face	to	face	presentations	were	then	made	to	promote	and	recruit	to	
our	testing	endeavours.	Gurkha	veterans	were	often	(but	not	always)	the	chairs	of	these	groups,	with	
their	support	vital	and	instructive	in	promoting	testing	uptake.		
		
Study	location:	
In	 consultation	 with	 our	 research	 steering	 group,	 the	majority	 of	 the	 local	 Nepali	 population	 are	
thought	to	live	in	clusters,	with	suggested	concentrations	in	Aldershot,	Camberley	and	Farnborough	
in	the	areas	around	Frimley	Park.		
Study	locations	were	drafted	after	consultation	with	local	community	leaders	group,	and	input	from	
our	 stakeholders.	Hospital	and	healthcare	 facilities	were	considered	 in	discussions,	but	discounted	
due	to	the	“community-testing”	aims	of	our	study,	travel	requirements,	as	well	as	capacity	issues	that	
were	thought	to	exist	in	accommodating	testing	sessions	on-top	of	existing	work	commitments.		
Testing	locations	were	strongly	influenced	by	new	escalations	in	anti-Nepali	sentiment	reported	to	us	
by	 the	 research	group,	with	Nepali	 leaders	 reporting	 intimidating	 leaflets,	 and	 concerns	of	 violent	
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encounters	with	 far-right	 groups,	 such	 as	 the	 English	 Defense	 League.	 Similar	 concerns	were	 also	
echoed	 from	 other	 stakeholders	 in	 the	 research	 group,	with	 the	 overwhelming	 aims	 therefore	 to	
deliver	testing	in	settings	close	to	Nepali	population	clusters,	and	in	locations	that	would	be	regularly	
frequented	by	members	of	the	local	community,	and	unlikely	to	draw	attention	from	the	wider	local	
community.		
Locations	were	also	suggested	in	Nepali	work	settings,	and	in	college/educational	settings	to	reach	
out	to	younger	members	of	the	community,	but	with	concerns	about	stigma	that	may	be	raised	in	the	
employer/broader	environment	through	this	activity.		
5	testing	sites	were	eventually	chosen,	serving	the	areas	of	Aldershot	(Princes	Theatre),	Farnborough	
(Samuel	Cody	School),	Camberley	 (High	Cross	Church),	Bracknell	 (Open	Learning	Centre,	Bracknell)	
and	Sandhurst	/	Owlsmoor	(Owlsmoor	Community	Centre).	All	sessions	were	held	separate	to	other	
scheduled	events	at	these	centres	(figure	28)	
	
Figure	27:	Location	of	5	testing	sites	in	Surrey	and	Hampshire:	
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Princes	Hall	Theatre,	Aldershot:		
	
	
A	large,	multi-purpose	site,	centrally	
situate	in	Aldershot,	with	
surrounding	green	spaces,	that	are	
frequent	spots	for	Nepali	
communities	to	meet	
	
	
	
High	Cross	Church,	Camberley	
	
A	central	position	in	Camberley,	
holding	local	community	events,	and	
well	known	to	members	of	the	local	
community	from	other	events.	
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Samuel	Cody	School,	Farnborough	
	
	
Well	used	hall	spaces	(outside	term	
time/school	working),	well	known	through	
(previous)	Nepali	events	held	in	these	halls.	
Away	from	the	more	commercial	
Farnborough	town	centre,	where	large	Nepali	congregations	may	seem	out	of	place.		
	
	
	
Owlsmoor	Community	Centre,	Sandhurst	
	
	
Well	positioned	in	Sandhurst,	and	known	
to	the	community	through	local	social	
enterprise	schemes	running	self-help	
groups	to	the	Nepali	community.	
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Bracknell	Opening	Learning	(community	centre)	
	
Well	known	and	attended,	with	
English-language	courses	to	the	
Nepali	community.		
	
	
Study	recruitment:	Advertising	/	participant	recruitment	
Initial	study	protocol	and	ethics	application	had	included	the	recruitment	aims	to	advertise	our	testing	
study	 to	 adult	 (>18	 years)	 members	 of	 the	 local	 community	 in	 appropriate	 sites	 frequented	 by	
members	of	the	community,	as	well	as	Nepali	TV	and	Radio.	Other	members	of	the	study	group	had	
previously	 run	 a	 successful	 testing	 study	 in	 the	 Shah	 Jahan	Mosque	 in	Woking,	 with	 widespread	
reporting,	including	on	the	local	BBC	website	[BBC	2011].		
However,	given	the	concerns	of	anti-Nepali	sentiment	at	the	time	of	our	study,	we	did	not	engage	
with	 any	 formal	 advertising	 at	 the	 outset	 of	 our	 study,	 relying	 on	 word-of-mouth	 within	 the	
community,	 as	 well	 as	 formal	 (translated)	 presentations	 in	 other	 activity	 groups,	 and	 community	
events.	As	the	study	progressed,	some	leaflets	were	distributed	in	Nepalese	only,	with	radio	adverts	
placed	at	the	final	part	of	our	study	on	the	local	(Nepali)	Gurkha	radio	networks.		
Study	 promotion	 was	 conducted	 through	 formal	 and	 informal	 presentations	 to	 existing	 Nepali	
community	groups	and	gatherings,	including	the	Nepali	Diabetic	group,	the	Nepali	World	Cup	festival	
(with	a	formal	festival	stand),	the	Madat	Samuha	Nepali	group	(St	Mark’s	Church),	and	Nepali	adult	
education	sessions	run	by	community	volunteers	in	the	local	area.	Radio	adverts	were	placed	on	the	
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2	main	Gurkha	radio	networks,	with	written	information	and	formal	discussion	of	our	study	aims,	with	
the	presenter	delivering	a	translated	version	of	these	aims.		
Participant	(study)	numbers	
Initial	study	design	hypothesised	that	individuals	at	higher	risks	of	CVH	may	have	prevalence	rates	of	
>2%,	compared	to	baseline	CVH	rates	close	to	0.5%.	Given	the	uncertainties	of	CVH	rates	in	the	newly	
arrived	 community,	 and	 engagement	 rates	 towards	 testing,	 an	 initial	 recruitment	 target	 of	 500	
individuals	was	set,	with	an	overall	aim	towards	1000	based	on	initial	feasibility	assessments.		Testing	method:	
Finger-prick	Direct	Blood	Spot	(DBS)	testing	was	chosen	to	perform	HBV	and	HCV	testing,	with	the	aim	
of	providing	practical	and	tolerable	testing	in	non-healthcare	settings.	DBS	testing	kits	were	obtained	
from	 the	 Central	Manchester	 University	 Hospitals	 virology	 laboratory,	with	 samples	 returned	 and	
processed	at	the	same	unit	(figure	28).	Mobile	sharps	bins	were	taken	to	all	sessions,	as	well	as	clinical	
waste	bags,	with	this	material	appropriately	managed	on	return	to	Frimley	Park	Hospital	in	keeping	
with	standard	procedures.		
	
	
Figure	28::	Dry	Blood	Spot	(DBS)	paper	testing	kits,	with	representation	of	the	5	“boxes”	blotted	with	blood	from	fingerpick	
assessment	
	
DBS	testing	has	been	validated	in	health	studies,	and	is	recommended	in	national	policy,	particularly	
in	 scenarios	 where	 conventional	 phlebotomy	 may	 be	 challenging,	 with	 reported	 sensitivity	 and	
specificity	rates	for	HBsAg,	HBcAb	and	HCV	Ab	reported	close	to	100%,	[Mohamed	S	2013,	Vedio	A	
2013,	PHE	2014].	Genotyping	and	HCV	RNA	testing	can	also	be	performed	on	DBS	kits,	with	high	levels	
of	concordance	reported	(100%)	to	conventional	serology	[Greenman	J	2015].		Internal	validation	data	
from	the	providing	Central	Manchester	laboratories	is	provided	in	figure	29.	
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Figure	29:	Internal	DBS	validation	data	on	HBV	and	HCV	testing	from	the	Central	Manchester	laboratory	
	Testing	activity:	
A	multidisciplinary	 team	was	 used	 to	 organise	 and	 deliver	 testing	 at	 each	 event,	made	 up	 of	 the	
researcher	(clinician),	as	well	as	research	nurses,	student	nurses,	and	members	of	the	Research	and	
Development	team	at	Frimley	Park	Hospital,	working	with	community	leaders	to	inform,	consent	and	
test	(trained	nursing	staff)	participants.		
All	patients	were	given	Patient	Information	Sheets	(PiS)	on	arrival,	with	Nepali	moderators	at	the	doors	
of	each	testing	site	to	assist	participants.	PiS’s	and	consent	forms	were	developed	in	Nepali	and	English	
detailing	 the	 study	 aims,	 as	 well	 as	 basic	 information	 on	 CVH,	 and	 the	 implications	 of	 positive	
diagnoses	(Appendix).	Participants	were	given	unique	identifier	numbers	on	entry,	which	was	linked	
to	their	samples,	and	in	follow-up	to	provide	results.		
Initial	testing	aims	were	to	separate	men	and	women	into	different	streams,	based	on	sensitivities	
seen	on	other	South	Asian	communities,	but	this	was	rapidly	adjusted	as	participants	seemed	more	
comfortable	to	attend	with	their	spouses	or	family	contacts,	and	frequently	attended	testing	sessions	
in	groups.		
	Data	collection		
Demographic	information,	as	well	as	potential	risk	factors	for	CVH	and	liver	disease	were	explored	on	
data	collection	sheets	(figure	30).	Geographic	information	on	individual	and	family	origin	sites,	as	well	
as	 educational	 status	 was	 collected,	 with	 the	 number	 of	 years	 of	 schooling	 used	 as	 a	 surrogate	
measure	of	socioeconomic	status	[Winkleby	MA	1992].		Housing	occupancy	data	was	also	collected,	
with	the	aim	of	understanding	potential	contact	tracing	needs	in	positive	cases.		
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Excess/	
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Figure	30:	Data	collection	sheet	for	participants	Participant	results	collection:	
All	patients	were	asked	to	return	at	one	week	to	the	same	venue	to	pick	up	their	results,	and	for	any	
positive	cases	to	be	discussed	with	individuals	by	the	clinician,	with	support	from	community	leaders.		
All	results	were	screened	before	sessions,	with	positive	cases	separated	and	identified	to	the	research-
clinician,	with	these	individuals	directed	to	see	the	clinician	for	discussions.	Provision	was	made	for	
individual	areas	to	discuss	with	patients	if	positive	cases	were	identified.		
Support	was	gained	from	local	CCGs,	with	patients	informed	that	any	positive	cases	(active	disease,	
HBsAg	positive,	HCV	Ab	positive)	would	be	discussed	with	their	GP	for	onward	referral	and	assessment	
with	formal	blood	test	confirmation	and	specialist	assessment.		
Funding:	
Initial	funding	for	the	study	was	obtained	through	a	grant	proposal	written	by	Professor	Aftab	Ala	(AA)	
and	 Mihaela	 Petrova	 (MP),	 with	 funding	 granted	 through	 the	 National	 Gilead	 Fellowship	 Award	
scheme	 to	 AA,	 and	 further	 support	 from	 Roche	 pharmaceuticals	 to	 assist	 with	 DBS	 testing	 kit	
purchasing.	Further	research	support	costs	were	then	delivered	through	funding	from	the	National	
Institute	for	Health	and	Research	(NIHR).	Researcher	costs	were	supplemented	additionally	through	
clinical	work	in	an	NHS	context.		
	
Results:	
Summary:		
Testing	activity	was	conducted	over	5	sites	between	March	2013	to	January	2015	with	a	total	of	1005	
individuals	tested	over	17	individual	sessions	(figure	x),	with	a	total	of	984	individuals	considered	in	
final	DBS	testing	analysis.		
Hepatitis	B	surface	antigen	(HBsAg)	was	seen	in	just	3	individuals	on	DBS	testing	(0.3%),	with	HCV	Ab	
detected	in	4	individuals	(0.41%),	and	with	hepatitis	B	core	antibody	(HBcAb)	detected	in	93	individuals	
(9.5%).	
Participant	recruitment	and	testing	activity:	
Testing	activity	was	conducted	through	the	formation	of	a	multidisciplinary	team	of	Research	Nurses	
from	 Frimley	 Park	 Hospital	 and	 Nepali	 community	 volunteers,	 and	 two	 clinical	 research	 fellows,	
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Mihaela	Petrova,	who	assisted	with	initial	testing	over	the	first	500	participants,	as	well	as	myself,	with	
the	completion	of	testing	to	1005	individuals.		
The	 number	 of	 participants	 attending	 sessions	 differed	with	 venue,	 and	over	 time,	with	 the	most	
number	of	participants	seen	in	Princes	Hall	in	Aldershot	(table	x).	The	final	session	at	Bracknell	Open	
Learning	Centre	 (Bracknell	 2),	was	purposefully	 limited	 (n=5)	 to	 capture	 those	 individuals	who	we	
could	not	fit	into	an	earlier	session	at	the	same	centre,	and	with	knowledge	that	we	had	reached	our	
target	 recruitment	 limit.	 Excluding	 this	 last	 session,	 the	median	 number	 of	 individuals	 tested	 per	
session	(16	sessions)	was	54,	with	an	IQR	of	35	to	98	(range	20-129)	(figure	32)		
After	our	first	session	where	20	people	were	tested,	the	following	sessions	had	rising	numbers,	with	
some	unpredictability,	but	staffing	requirements	that	seemed	to	require	a	minimum	of	6	members	of	
the	multidisciplinary	clinical	team,	with	2-3	qualified	research	nurses	needed	to	take	DBS	samples,	and	
a	 staffing	 range	 overall	 between	 6-9.	 This	 is	 separate	 to	 the	 additional	 requirements	 for	 Nepali	
translators,	with	a	minimum	of	6	Nepali	community	volunteers	were	needed	to	run	the	testing	session.	
Smaller	community	sessions	could	be	managed	with	4	members	of	the	multidisciplinary	team,	and	
ideally	the	same	number	of	translators.	All	studies	took	place	on	weekday	settings,	predominantly	in	
term-time	settings,	principally	in	relation	to	staffing	requirements.		
Session	 numbers	 were	 variable,	 and	 unpredictable,	 with	 large	 numbers	 arriving	 on	 occasion	 and	
sessions	lasting	from	09:00	to	15:00.	On	these	occasions,	not	all	participants	could	be	tested,	and	on	
the	last	session	in	Princes	Hall	theatre	(Aldershot	9),	many	participants	had	to	be	turned	away	from	
testing	due	to	capacity	and	timing.		
	
Figure	31:	number	of	participants	taking	part	in	testing	per	session	held	over	time	
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After	our	first	session	where	20	people	were	tested,	the	following	sessions	had	rising	numbers,	with	
some	unpredictability,	but	staffing	requirements	that	seemed	to	require	a	minimum	of	9	members	of	
the	multidisciplinary	clinical	team,	with	3	nurses	needed	to	take	DBS	samples.	This	was	in	addition	to	
requirements	for	Nepali	translators,	with	a	minimum	of	6	Nepali	community	volunteers	were	needed	
to	run	the	testing	session	(figure	33).		
	
	
	
	
	
	
	
	
Figure	32::	participant	information	and	consent	gathering	with	multidisciplinary	research	team,	and	Nepali	community	
advocates	
	
	
Smaller	community	sessions	could	be	managed	with	4	members	of	the	multidisciplinary	research	team	
for	consent	and	testing,	and	3-4	Nepali	community	advocates	to	facilitate	and	translate.		
All	studies	took	place	on	weekday	settings,	predominantly	in	term-time	settings,	principally	in	relation	
to	staffing	requirements,	with	difficulties	in	securing	staffing	and	members	of	our	community	team	to	
facilitating	testing.		
Amongst	the	majority	group	of	elderly	participants	in	the	study,	there	was	an	inability	for	most	to	read	
the	 English	 Patient	 Information	 Sheets	 (PiS),	 and	many	 required	 help	 from	our	Nepali	 community	
volunteers	 in	reading	the	Nepalese	PiS	and	Consent	 forms,	with	significant	help	required	from	our	
Nepali	volunteers.		
In	keeping	with	the	levels	of	formal	education	recorded	in	our	study,	many	of	the	elderly,	especially	
elder	women	participants	were	 unable	 to	write,	 or	 sign	 their	 own	name,	 using	 a	 “cross”	 in	 these	
situations	to	indicate	their	willingness	to	take	part	after	the	consent	process.		
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Results	delivery:	
Attendance	at	 results	 collection	 sessions	were	generally	high,	but	with	many	attending	 to	pick	up	
results	for	friends	or	relatives,	often	having	come	together	for	testing	at	the	session	before.	Around	
10-20%	did	not	attend	for	results	collection,	with	these	results	posted	to	individuals	to	their	registered	
(supplied)	address.		
Few	positive	results	were	detected	 in	our	study,	and	all	 individuals	with	suggested	active	 infection	
attended	at	results	collection	sessions.	For	those	 individuals	with	HBcAb,	and	evidence	of	previous	
exposure	 to	 HBV,	 telephone	 conversation	 was	 conducted	 using	 our	 Nepali	 study	 team	 to	 inform	
participants	if	there	was	no	representation	at	results	sessions.			
All	participants	were	made	aware	of	the	study	team	contact	details,	and	importantly	of	our	Nepali	
community	volunteers,	who	were	visible	in	the	community	given	their	role	in	formal	social	enterprise	
and	council	initiatives.		Duplicate	attendance:	
Some	individuals	(n=10)	attended	twice	for	testing	over	different	sessions,	and	this	was	despite	early	
questionnaire	modification	(with	ethics	approval)	to	try	and	minimise	duplicate	attendance.	A	further	
participant	below	18	years	was	inadvertently	entered	into	testing	(with	reporting	to	the	ethics	board	
and	 sponsor,	 and	 negative	 testing	 results),	 and	 was	 also	 subsequently	 removed	 from	 final	 data	
analysis,	leaving	a	total	of	984	individuals	considered	in	final	analysis.		
The	role	of	peer-support	in	recruitment	and	testing	activity:		
Peer	support	for	testing	was	coordinated	mostly	through	Mr	Ramji	Tiwari,	working	with	the	locally	
established	Rushmoor	Healthy	 Living	 social	 enterprise	 charity,	with	 the	 help	 of	Nepali	 community	
volunteers,	who	were	mostly	ex-Gurkha	veterans.	Our	peer-support	team	had	all	taken	part	in	testing	
activity,	with	preceding	educational	presentations	given	regarding	the	rationale	and	aims	of	the	study	
in	the	Nepali	community,	and	were	therefore	able	to	help	explain	and	promote	testing	to	the	wider	
community.		
In	view	of	the	broader	concerns	regarding	study	advertising,	word	of	mouth	alone	was	used	in	the	first	
half	of	the	testing	study	to	disseminate	awareness	of	testing	studies,	and	to	recruit	participants	to	
attend.	Face	to	face	and	telephone	based	discussions	were	conducted,	with	reminder	SMS	messaging	
/	phone	calls	placed	prior	to	testing	sessions,	with	recipients	encouraged	to	spread	word	about	these	
testing	sessions	among	fellow	Nepali	associates.		
The	peer-support	team	formed	an	integral	part	of	testing	activity,	as	well	as	study	recruitment,	being	
placed	at	key	visible	parts	of	our	testing	session	to	welcome	participants,	as	well	as	their	invaluable	
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role	 in	 supporting	 the	 consent	 and	 testing	 process.	 The	 senior	 clinician	 (clinical	 researcher/senior	
study	clinician)	was	also	prominent	at	the	reception	point	to	greet	participants,	as	well	as	throughout	
the	session,	to	provide	a	visible	clinician	focus	to	the	testing	event.		
Word-of-mouth	provided	valuable	participant	recruitment	throughout	the	study	period.	Participant	
numbers	increased	during	the	first	part	of	the	study,	with	the	most	numbers	seen	in	testing	sessions	
held	in	the	Aldershot	area,	and	one	Nepali	couple	who	attended	after	being	in	the	UK	for	less	than	a	
week.	However,	as	participant	numbers	dipped	after	the	4th	and	5th	sessions	in	Aldershot	(figure	x),	
we	utilized	 some	of	 the	ethics	approved	advertising	materials	generated	 in	our	planning	 stages.	A	
limited	number	 of	Nepali	 language	 leaflets	were	 distributed	 in	 (peer-group)	 recommended	Nepali	
shops,	as	well	as	face	to	face	presentations	at	the	very	well	attended	Nepali	World	Cup,	and	the	Madat	
Samuha	group.	We	became	aware	of	new	existing	Nepali	groups	as	our	study	progressed,	including	
the	Madat	Samuha	group,	and	the	regular,	smaller	attended	groups	in	Bracknell	and	Owlsmoor,	where	
testing	numbers	were	expectedly	low	(figure	x).	Additional	Nepali	peer	support	was	readily	obtained	
from	the	 leaders	of	 these	groups,	with	positive	encouragement,	and	testing	participation	by	 these	
individuals	in	subsequent	testing	sessions.		
Radio	advertising	was	also	utilized	at	 the	 latter	half	of	our	 study,	with	 initially	 limited	 response	 to	
advertisements	placed	in	the	local	BGWS	(British	Gurkha	Welfare	Society),	before	using	the	national	
BFBS	(British	Forces	Broadcasting	Service)	Gurkha	radio	network,	with	a	large	number,	and	eventually	
unmanaged	number	of	participants	attending	for	testing	following	this,	with	many	having	to	be	turned	
away	to	seek	GP	testing	due	to	capacity	limitations.		
Overall,	 whilst	 we	 did	 not	 collect	 formal	 data	 on	 participant	 recruitment,	 word	 of	 mouth	 in	 the	
community	seemed	the	most	powerful	driver	of	attendance,	with	positive	support	for	testing	in	those	
who	were	attending.		
	
Demographics:	
The	median	age	of	participants	was	66	years,	mean	63	years	(IQR:	60	to	70	years,	range:	19-86	years),	
with	525	female	participants	(54%).	The	majority	of	participants	were	elderly,	with	an	age	distribution	
which	was	skewed	towards	an	elderly	population	(fig	33).		
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Figure	33:	Pyramid	chart	showing	age	distribution	of	male	and	female	participants		
The	majority	of	male	participants	were	elderly,	with	 female	participants	 at	 greater	 representation	
between	45-60	years.		
Of	note,	many	of	the	participants	had	recorded	date	of	births	as	01/01	(Day,month),	with	a	lack	of	
priority	and	recall	that	 is	afforded	to	age	in	many	of	the	participants,	reducing	the	accuracy	of	age	
measures,	and	increasing	the	need	for	careful	documentation	of	personal	identifiable	details	in	the	
testing	activity	studies.	
	Geographic	origin:	
The	overwhelming	majority	of	participants	were	born	in	Nepal,	with	5	who	were	born	in	Hong	Kong,	
and	one	in	Pakistan.	No	UK	born	Nepali	born	individuals	were	identified	in	the	study.		
District	of	origin	data	was	available	on	680	individuals,	with	31	districts	identified.	A	population	map	
is	presented	in	figure	34,	table	16.	
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Figure	34:	Map	demonstrating	the	origin	points	of	testing	participants;					red	=	higher	concentration	of	participants	
(close	to	12%,	Kaski	region),	with	decreasing	frequencies:				dark	orange						=	8%,	orange						=	4%,	yellow				=	2	percent,	
green						=	1%,	blue							=	0-1%	of	participants	
	
District		 Number	of	Participants	 Percentage	
	Dolpa		 1	 0.15	
	Mustang		 1	 0.07	
	Rolpa		 1	 0.07	
	Rukum		 1	 0.07	
	Dhading		 2	 0.15	
	Parsa		 2	 0.15	
	Surkhet		 2	 0.15	
	Udayapur		 2	 0.15	
	Dhankuta		 5	 0.37	
	Morang		 4	 0.30	
	Jhapa		 7	 0.52	
	Solukhumbu		 5	 0.37	
	Ramechhap		 7	 0.53	
	Rupandehi		 7	 0.53	
	Panchthar		 8	 0.61	
	Chitwan		 12	 0.91	
	Gulmi		 12	 0.92	
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	Bhojpur		 14	 1.08	
	Ilam		 15	 1.17	
	Taplejung		 11	 0.87	
	Khotang		 17	 1.36	
	Okhaldhunga		 17	 1.37	
	Sankhuwasabha		 16	 1.31	
	Terhathum		 13	 1.08	
	Kathmandu		 24	 2.02	
	Palpa		 21	 1.78	
	Lamjung		 25	 2.17	
	Gorkha		 34	 3.00	
	Sunsari		 27	 2.44	
	Parbat		 34	 3.17	
	Baglung		 28	 2.67	
	Myagdi		 44	 4.34	
	Syanga		 39	 3.96	
	Tanahun		 71	 7.55	
	Kaski		 151	 16.74	
	Total:		 680	 		
	
Table	15:participant	distribution,	and	relative	percentage	contribution	according	to	district	Education:	years	of	formal	schooling	
The	median	number	of	years	of	schooling	reported	by	all	participants	was	0	(average	2.1	years),	with	
an	interquartile	range	of	0	to	3	years;	range	0	to	15	years.		
Looking	at	those	individuals	below	40,	the	median	number	of	years	of	schooling	across	both	males	
and	females	was	10	years.	In	those	between	40	to	50	years,	the	median	number	of	years	of	schooling	
reported	was	4	 years,	with	 a	 corresponding	median	 value	of	 10	 years	 (average	9.4	 years)	 in	male	
participants,	and	a	median	value	of	only	3	years	amongst	female	participants	in	the	same	age	group	
between	40	to	50	years.		
In	those	between	50	to	60	years,	the	median	number	of	years	of	schooling	was	0	(average	2.7	years),	
but	with	a	median	value	of	10	years	among	male	participants	(range	0	to	20,	average	8.8	years).	In	
female	participants	in	this	group,	17/19	(17%)	women	reported	some	schooling,	with	11	(11%)	of	these	
women	having	5	years	or	more	of	formal	schooling.		
This	trend	continues	in	participants	between	60	–70	years,	with	a	median	value	of	0	years	(average	
1.5	years),	and	with	and	average	range	of	schooling	of	0	years,	but	with	an	average	value	of	2.9	years	
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amongst	male	participants	(median	of	0	years).	Above	70,	few	participants	(all	male)	reported	some	
years	of	formal	schooling,	occasionally	with	training	that	they	had	received	in	neighbouring	India.		
Length	of	stay	in	UK:	
Length	of	stay	information	in	the	UK	was	available	on	930	individuals,	with	a	median	residence	of	36	
months	in	the	UK	(mean	41	months),	IQR	24	to	48	months	(range:	1	to	420	months	(36	years)).	Over	
85%	of	participants	(801/931)	included	in	the	study	had	been	in	the	UK	for	less	than	5	years,	with	18%	
(164/931)	of	the	tested	community	who	had	arrived	in	the	past	year	(figure	35).	
	
	
Figure	35:	the	majority	of	those	tested	had	been	in	the	UK	for	less	than	5	years.		
	
Potential	risk	factors:	
A	summary	of	the	potential	risk	factors	 identified	is	presented	in	table	x.	Few	(<10%)	had	received	
blood	transfusions	 in	the	past,	although	rates	of	reported	surgery	abroad	in	the	group	was	high	at	
33%.	High	proportions	of	the	group	reported	previous	vaccinations	and	dental	work	abroad,	although	
less	(8.8%)	were	aware	of	having	received	a	hepatitis	vaccine	specifically.	A	history	of	liver	disease	was	
identified	in	around	7%	of	participants,	with	a	family	history	of	liver	disease	that	was	mentioned	in	
around	9%	of	responses.		
Piercings	(outside	the	UK)	were	identified	in	90%	of	the	Nepali	participants,	with	high	representation	
among	men	and	women.	During	testing	sessions,	participants	recounted	cultural	traditions	of	most	
babies	having	their	ears	pierced	shortly	after	birth,	regardless	of	gender,	with	concerns	one	would	
envisage	from	a	sterility	perspective	in	how	these	piercings	were	delivered	in	Nepal	 in	such	a	wide	
scale,	and	over	such	a	lengthy	time	period.	Few	disclosed	recreational	drug	use,	and	given	the	busy	
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nature	of	the	sessions,	as	well	as	Nepali	advocates	working	with	the	study	team,	recreational	drug	use	
and	alcohol	use	may	have	been	more	uncomfortable	for	participants	to	discuss.	Regardless	of	this,		
alcohol	intake	above	recommended	levels	was	identified	in	17%	(166)	participants,	with	60	(34%)	of	
these	individuals’	female	(table	17).		
	
Table	16:	Potential	risk	factors	(n=total	number	of	participant	responses	available),	and	positive	findings	among	
participants		Statistical	analysis:	
All	data	collected	was	categorical,	with	analysis	conducted	on	Microsoft	Excel,	as	well	as	R	Studio,	with	
collaboration	with	the	Clinical	Informatics	Group	at	the	University	of	Surrey.		
Multiple	logistic	regression	analysis	was	chosen	to	explore	relations	between	the	variables	collected	
(figure	x),	and	 to	 reduce	 the	effects	of	possible	confounders	during	analysis.	Statistical	association	
with	each	variable	was	assessed	through	p-values,	z-values	(regression	coefficient)	and	odds	ratios.	
Further	statistical	significance	testing	was	explored	through	Chi-Square	testing	and	the	Fisher’s	Exact	
		 Total	(events	occurred)	 Male		 Female	 HBsAg	 HCV	Ab	 HBcAb	
Blood	
transfusion	
(973)	
75	(7.7%)	 42	 33	 0	 0	 6	(8%)	
Surgery	Abroad	
(979)	 327	(33%)	 127	 195	 0	 1	 29	(8.9%)	
Dental	work	
abroad	(976)	 403	(42%)	 148	 250	 1	 1	 38	(9.4%)	
Vaccination	
(973)	 698	(72%)	 318	 373	 3	 2	 67	(9.6%)	
Hepatitis	
Vaccination	
(962)	
85	(8.8%)	 40	 43	 0	 0	 6	(7%)	
Past	hx	of	
jaundice	(975)	 73	(7.5%)	 44	 28	 0	 0	 8	(11%)	
Family	history	
of	liver	disease	
(976)	
95	(9.7%)	 42	 52	 1	 0	 10	(11%)	
Body/ear	
piercing	(980)	 882	(90%)	 356	 512	 3	 4	 80	(9%)	
Recreational/illi
cit	substances	
(979)	
20	(2%)	 11	 9	 1	 1	 18	(11%)	
Alcohol	(978)	 166	(17%)	 106	 60	 1	 1	 18	(11%)	
198	
	
test,	with	particular	application	of	the	Fisher’s	Exact	test	given	the	low	absolute	numbers	of	HBsAg	
and	HCV	Ab	cases	detected	during	the	testing	study.		
Logistic	regression	analysis	provides	odds	ratios,	as	well	as	probability	assessments	of	the	relationships	
between	the	variables	collated	and	CVH	results.	However,	the	model	relies	on	the	assumptions	that	
the	variables	considered	are	linear	and	independent,	whilst	in	reality,	some	of	the	potential	risk	factors	
and	demographic	factors	may	have	some	correlation,	with	additional	modelling	errors	that	arises	from	
data	drop-out	in	the	fields	collected.		
Data	drop-out:		
All	participants	had	documented	results	for	their	HBV	and	HCV	status,	but	with	some	drop-out	of	data	
fields	 in	 most	 of	 the	 recorded	 fields	 (table	 18).	 The	 most	 affected	 field	 was	 in	 the	 recording	 of	
geographic	place	of	origin	of	participants,	with	a	loss	of	data	recording	in	304	individuals.	This	error	
originated	during	one	of	the	early	testing	sessions,	where	staff	to	participant	levels	were	low,	with	this	
field	 missed	 off	 in	 data	 recording	 over	 3	 sessions	 by	 some	 of	 the	 research	 team,	 before	 being	
subsequently	rectified	for	subsequent	sessions.		
Table	17:	data	loss	(individuals)	during	results	collection;	31%	of	District	level	data	was	not	captured 
Statistical	analysis,	and	in	particular	multiple	logistic	regression	is	likely	to	have	been	affected	by	this,	
with	multiple	logistic	regression	analysis	conducted	with	and	without	the	inclusion	of	these	data	fields	
in	the	final	analysis	of	HBcAb	status	(as	below).		
199	
	
Hepatitis	B	&	C	testing	results:	
Rates	 of	 HBsAg	 and	 HCV	 Ab	 detection	 were	 low	 across	 the	 984	 individuals	 tested.	 	 HBsAg	 was	
identified	in	3	(0.3%)	individuals	through	DBS	testing,	with	all	individuals’	male,	and	aged	between	60	
to	70	years.	HCV	Ab	was	seen	 in	4	 individuals	 (0.41%),	 in	2	males	and	2	 female	participants,	aged	
between	60	to	70	years.	
No	cases	of	dual	HBsAg	and	HCV	Ab	were	identified,	although	there	was	some	cross-over	in	chronic	
HBV	exposure,	with	one	individual	with	HCV	Ab	also	demonstrating	HBcAb	on	DBS	testing	suggesting	
previous	exposure.		
All	 identified	participants	were	offered	formal	clinic	follow-up,	with	formal	correspondence	sent	to	
the	participants	GP	(with	written,	and	verbal	consent	at	our	results	sessions)	for	onward	secondary	
care	referral.		
HBsAg	positive	participants:	
All	 3	 individuals	with	 HBsAg	 positivity	 attended	 initial	 clinic	 visits,	 with	 baseline	 characteristics	 as	
identified	in	table	19.	At	first	clinic	attendance,	the	first	individual	(B010)	had	no	detectable	DNA	on	
testing,	 indicating	 a	 low	 replicative	 state.	 The	 second	 (B372)	 had	 a	HBV	DNA	 load	of	 250iu/ml,	 in	
keeping	with	a	 low	replicative	state,	but	subsequently	 failed	to	attend	his	 follow-up	appointments	
despite	reminder	correspondence.	The	third	participant	(B610)	also	had	low	levels	of	viral	replication	
on	testing,	with	HBV	DNA	levels	of	55	iu/ml,	with	normal	Fibroscan	assessment	of	5kPa	(table	19).		
Participant	ID	 Sex	 Age	 HBsAg	 HBV	DNA	levels	/	further	assessment	
B010	 Male	 66	 HBsAg	+	 HBV	DNA	undetectable	
B372	 Male	 66	 HBsAg	+	 HBV	DNA	250	iu/ml	
B610	 Male	 70	 HBsAg	+	 HBV	DNA	55,	normal	Fibroscan		
	
Table	18:	HBsAg	positive	results,	and	demographic	information	
In	 keeping	with	 the	 low	number	 of	 positive	 cases,	 logistic	 regression	 analysis	 did	 not	 suggest	 any	
probable	relations	to	the	variables	measured,	and	Fisher’s	Exact	testing	with	these	variables	(excluding	
District	data)	also	did	not	suggest	any	associations,	with	p-values	0.3	to	1	(Appendix).		
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	HCV	Ab	positive	participants		
4	individuals	were	identified	on	DBS	with	HCV	Ab,	with	HCV	RNA	testing	that	was	performed	via	DBS	
samples.	2	individuals	were	female,	with	an	age	range	between	65	to	75	years	(table	20).		
All	samples	tested	negative	for	HCV	RNA	on	DBS	testing,	with	clinic	invitations	issued	to	all	patients	
via	their	GP,	with	formal	primary	care	referral.		
Participant	
ID	 Sex	 Age	 HCV	Ab	 HBV	status	 HCV	RNA	assessment	
B388	 Female	 67	 HCV	Ab	 HBcAb	negative	 HCV	RNA	negative		
B602	 Male	 74	 HCV	Ab	 HBcAb	negative	 HCV	RNA	negative		
B841	 Female	 66	 HCV	Ab	 HBcAb	POS	 HCV	RNA	negative		
B871	 Male	 70	 HCV	Ab	 HBcAb	negative	 HCV	RNA	negative		
	
Table	19HCV	Ab	positive	results,	and	demographic	information	
Clinic	follow-up	attendance	for	HCV	Ab	positive	patients	were	lower,	with	only	two	patients	attending	
for	 formal	 assessment,	 with	 no	 significant	 evidence	 of	 advanced	 liver	 scarring	 (fibrosis,	 portal	
hypertension),	from	bloods	and	ultrasound	assessment	on	these	individuals.	
As	expected	statistical	analysis	did	not	 suggest	 statistical	association	 through	 logistic	 regression	or	
Fisher’s	Exact	testing	(Appendix	x).		
Adults	per	household	/	Children	–	contact	tracing	implications	
Overall,	the	median	number	of	adults	per	household	in	the	Nepali	community	was	2	(average	3,	range	
1-10),	with	a	median	of	0	children	residing	per	household	(range	0	–	6).		
For	those	3	individuals	found	to	HBsAg	positive,	data	was	available	on	2	participants,	with	2	adults	
(including	the	affected	individual)	living	in	the	same	accommodation,	and	no	children	living	with	these	
individuals.	
Of	 the	 4	 individuals	 identified	 with	 HCV	 Ab	 positivity,	 2	 to	 6	 individuals	 (including	 the	 affected	
participant)	lived	in	their	home	accommodation,	with	one	individual	living	with	2	children.		
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Hepatitis	B	core	antibody	(previous	HBV	exposure):	
In	total,	HBcAb	was	identified	in	91	(9.25%)	participants,	with	HBsAg	positivity	identified	in	3	of	these	
individuals	as	discussed	above.		
The	median	age	of	these	individuals	was	68	years	(range	22-84	years,	IQR	64-72	years;	mean	67	years),	
with	58	(64%)	of	these	individuals	of	male	sex	(table	21	
Table	20:	Table:	demographics	and	characteristics	(potential	risk	factors)	of	individuals	identified	with	Hepatitis	B	core	
antibody	
Multiple	logistic	regression	analysis	was	conducted	to	look	for	possible	relations	between	a	positive	
HBcAb	 status	 and	potential	 risk	 factors	 collected,	with	 statistical	 association	 identified	with	 “male	
gender”,	and	“years	spent	at	school”.		
Logistic	regression	analysis	was	conducted	initially	with	the	inclusion	of	“district”	data,	but	with	the	
resulting	addition	of	a	significant	number	of	NA	values	to	the	modelling,	given	the	loss	of	district	level	
data	 collection	 during	 initial	 testing	 studies.	 Logistic	 analysis	 was	 therefore	 conducted	 with	 and	
without	the	addition	of	district	level	data	(table	22	A/B,)	to	assess	for	any	variance	in	the	two	models.		
Coefficients:	 		 		 		 		
		 Estimate	 Std.	Error	 z	value	 P	value	
(Intercept)	 -1.70E+00	 1.46E+00	 -1.166	 0.2438	
GenderI	 1.40E+00	 1.18E+00	 1.181	 0.2377	
Gender	Male	 1.02E+00	 3.24E-01	 3.156	 0.0016	**	
Age	 -3.72E-03	 1.70E-02	 -0.219	 0.827	
DistrictBhojpur	 2.22E-01	 1.31E+00	 0.17	 0.8651	
DistrictChitwan	 -1.65E+01	 2.47E+03	 -0.007	 0.9947	
DistrictDhading	 -1.65E+01	 4.59E+03	 -0.004	 0.9971	
DistrictDhankuta	 -1.67E+01	 6.52E+03	 -0.003	 0.998	
DistrictDolpa	 -1.64E+01	 6.52E+03	 -0.003	 0.998	
DistrictGorkha	 -1.45E+00	 1.21E+00	 -1.194	 0.2325	
DistrictGulmi	 -1.64E+01	 1.96E+03	 -0.008	 0.9933	
DistrictIlam	 -1.65E+01	 1.62E+03	 -0.01	 0.9919	
DistrictIlam	 -1.70E+01	 4.57E+03	 -0.004	 0.997	
DistrictJhapa	 -1.63E+01	 2.57E+03	 -0.006	 0.9949	
DistrictKaski	 -2.33E-01	 7.45E-01	 -0.313	 0.754	
DistrictKaski	 -1.74E+01	 6.52E+03	 -0.003	 0.9979	
202	
	
DistrictKathmandu	 -7.71E-01	 1.31E+00	 -0.589	 0.5558	
DistrictKhotang	 4.32E-01	 1.06E+00	 0.408	 0.6835	
DistrictLamjung	 3.96E-01	 9.24E-01	 0.429	 0.6683	
DistrictMorang	 -1.61E+01	 3.05E+03	 -0.005	 0.9958	
DistrictMustang	 -1.73E+01	 6.52E+03	 -0.003	 0.9979	
District	Myagdi	 1.37E+00	 7.80E-01	 1.763	 0.0779	.	
Districtn/a	 2.20E-01	 6.89E-01	 0.32	 0.749	
DistrictOkhaldhunga	 -1.65E+01	 1.72E+03	 -0.01	 0.9923	
DistrictPalpa	 -4.55E-01	 1.27E+00	 -0.358	 0.7203	
DistrictPanchtar	 -1.65E+01	 6.52E+03	 -0.003	 0.998	
DistrictPanchthar	 -1.63E+01	 2.60E+03	 -0.006	 0.995	
DistrictParbat	 -4.19E-01	 1.00E+00	 -0.418	 0.676	
DistrictParbat	 -1.65E+01	 6.52E+03	 -0.003	 0.998	
DistrictParsa	 -1.75E+01	 6.52E+03	 -0.003	 0.9979	
DistrictRamechhap	 -1.67E+01	 2.64E+03	 -0.006	 0.9949	
DistrictRukum	 -1.55E+01	 6.52E+03	 -0.002	 0.9981	
DistrictRupandehi	 -1.59E+01	 2.45E+03	 -0.006	 0.9948	
DistrictSankhuwasabha	 -1.69E+01	 1.89E+03	 -0.009	 0.9929	
DistrictSunsari	 -6.53E-01	 1.26E+00	 -0.519	 0.6041	
DistrictSurkhet	 -1.63E+01	 4.61E+03	 -0.004	 0.9972	
DistrictSyanga	 -1.48E+00	 1.23E+00	 -1.207	 0.2273	
DistrictTanahun	 -6.78E-01	 8.96E-01	 -0.757	 0.449	
DistrictTaplejung	 -1.65E+01	 2.26E+03	 -0.007	 0.9942	
DistrictTerhathum	 6.85E-02	 1.33E+00	 0.052	 0.9589	
DistrictUdayapur	 -1.56E+01	 6.52E+03	 -0.002	 0.9981	
Months.in.UK	 4.07E-03	 5.34E-03	 0.761	 0.4464	
Adults.in.household	 -1.02E-01	 9.29E-02	 -1.1	 0.2712	
Children	 -1.61E-01	 2.25E-01	 -0.716	 0.4741	
Years.spent.in.school	 -1.26E-01	 5.60E-02	 -2.24	 0.0251	*	
Blood.transfusion	 -4.48E-02	 5.44E-01	 -0.082	 0.9344	
Surgery.abroad	 -1.65E-01	 2.97E-01	 -0.557	 0.5777	
Dental.work	 2.70E-01	 2.82E-01	 0.957	 0.3386	
Vaccinationy	 -2.81E-01	 3.33E-01	 -0.843	 0.399	
Hep.vacciney	 -1.50E-01	 5.50E-01	 -0.272	 0.7857	
PHx.of.jaundice	 1.38E-01	 5.41E-01	 0.254	 0.7993	
FHx.of.jaundice.LD	 6.97E-02	 4.26E-01	 0.164	 0.8701	
Body.ear.piercing	 -2.16E-01	 5.11E-01	 -0.423	 0.6723	
drugs	 9.83E-01	 7.71E-01	 1.274	 0.2025	
alcohol	 6.85E-02	 3.92E-01	 0.174	 0.8615	
	
Table	21	A		:	Logistic	regression	analysis	with	the	inclusion	(A)	and	exclusion	(B)	of	District	level	data	
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Coefficients:	 		 		 		 		
		 Estimate	 Std.	Error	 z	value	 P	value		
(Intercept)	 -1.801819	 1.201755	 -1.499	 0.13379	
GenderI	 0.889918	 1.11072	 0.801	 0.42301	
GenderM	 0.954461	 0.308318	 3.096	 0.00196	**	
Age	 -0.006964	 0.016649	 -0.418	 0.67574	
Months.in.UK	 0.002371	 0.004739	 0.5	 0.61688	
Adults.in.household	 -0.091073	 0.088982	 -1.023	 0.30607	
Children	 -0.19525	 0.213116	 -0.916	 0.35958	
Years.spent.in.school	 -0.1254	 0.05465	 -2.295	 0.02176	*	
Blood.transfusion	 -0.103508	 0.51566	 -0.201	 0.84091	
Surgery.abroad	 -0.047528	 0.280544	 -0.169	 0.86547	
Dental.work	 0.154459	 0.264726	 0.583	 0.55958	
Vaccination	 -0.03777	 0.307957	 -0.123	 0.90239	
Hep.vaccine	 -0.268196	 0.508622	 -0.527	 0.59799	
PHx.of.jaundice	 0.044834	 0.510651	 0.088	 0.93004	
Body.ear.piercing	 -0.077951	 0.453025	 -0.172	 0.86338	
drugs	 0.84116	 0.681712	 1.234	 0.21724	
alcohol	 -0.067874	 0.335341	 -0.202	 0.8396	
Table	22B:	Logistic	regression	analysis	with	the	exclusion	of	District	level	data	
	
Logistic	 regression	 analysis	 with	 and	 without	 this	 (district	 level)	 data	 identified	 two	 statistically	
significant	associations	between	HBcAb	status	and	male	gender,	as	well	as	the	number	of	years	spent	
at	school.		For	male	gender,	a	positive	correlation	towards	HBcAb	status	was	suggested,	with	a	p-value	
of	0.0016,	a	z-value	of	3.16	(table	21),	and	an	Odds	ratio	(OR)	of	2.60	(confidence	interval	(CI)	1.42	–	
4.78);	with	the	OR	calculated	with	the	exclusion	of	district	level	data.		
For	the	number	of	years	spent	in	school,	a	negative	correlation	was	suggested,	with	a	p-value	of	0.025,	
a	z-value	of	-2.30,	and	an	OR	0.88	(CI	0.78-0.97),	with	fewer	years	of	schooling	seemingly	associated	
with	HBcAb	status	(figure	37).		
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Although	the	initial	district	level	regression	analysis	suggested	that	there	may	be	some	association	
between	HBcAb	status	and	participants	from	the	Myagdi	region	(table	22A),	this	did	not	reach	
statistical	significance	(p=0.0779),	and	with	a	loss	in	data	fields.			
	
Key	Outcomes:	
We	developed	a	 successful	 strategy	 to	engage	with	 close	 to	1000	 individual	members	of	 the	 local	
Nepali	community.	We	utilized	the	help	and	integral	support	of	community	advocates	in	the	Nepali	
community	to	achieve	testing	in	large	numbers,	with	close	ties	formed	with	key	respected	members	
of	the	Nepali	community.		
Nepali	community	advocates	provided	peer	support	for	testing,	disseminating	awareness	of	the	study,	
as	well	as	the	rationale	and	health	benefits	to	the	community	through	taking	part.	Despite	limitations	
that	we	faced	in	advertising,	word	of	mouth	proved	a	strong	medium	to	disseminate	information,	and	
to	achieve	a	good	attendance	at	testing	sessions,	with	all	participants	happy	to	take	part	in	the	study	
on	attendance.	Within	the	limited	advertising	strategies	assessed,	radio	adverts	placed	on	the	national	
BFBS	Gurka	network	achieved	a	high	uptake	of	participants,	with	many	participants	having	to	be	sign-
posted	 to	GP	 services	 due	 to	 the	 overwhelming	 attendance.	 Stall-based	 presentations	 to	 a	mixed	
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HBcAb	status	and	Years	spent	in	School	
Figure	36:	HBcAb	positivity	(represented	as	a	percentage;	with	0	years	taken	as	reference),	and	the	number	of	
reported	Years	spent	in	formal	schooling		
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Nepali	crowd	at	the	large	Nepali	World	Cup	was	received	with	interest	from	other	community	groups	
in	the	Nepali	community,	but	with	little	suggestion	of	direct	impact	anecdotally.	My	presentations	and	
discussion	 at	 Nepali	 community	 groups,	 with	 direct	 translation	 and	 support	 from	 senior	 Nepali	
members	of	each	group	was	met	with	positive	support,	with	many	individuals	seen	shortly	after	 in	
testing	sessions	as	a	result.	
The	majority	of	the	group	were	unable	to	read	and	write	in	English,	with	many	of	the	elderly,	especially	
Nepali	women	demonstrating	a	functional	illiteracy	in	Nepalese	as	well.		Language	remained	a	barrier	
through	the	study	process,	but	with	good	levels	of	engagement,	attention	and	interest	given	towards	
healthcare	staff	during	presentations	and	discussions	which	were	translated	in	real	time.		
The	Nepali	community	is	heterogeneous,	with	multiple	community	based	sessions	that	can	provide	
access	 to	meet	with	 different	 groups	 of	 the	 local	 population,	 but	with	 no	 central	 organisation,	 or	
oversight	 of	 these	 activities,	 and	 no	 universal	 route	 to	 access.	 Testing	 sessions	 were	 developed	
iteratively,	with	new	groups	and	 locations	 identified	during	our	study	through	the	enquiries	of	our	
Nepali	advocates,	as	well	as	the	research	team.		
DBS	 testing	 was	 well	 received,	 with	 no	 practical	 difficulties	 encountered	 with	 delivering	 this	 in	
community	 settings,	 and	no	 concerns	 raised	 from	 the	organisers	 of	 the	multi-purpose	 community	
centres	used.		
Absolute	rates	of	active	CVH	for	HBsAg	(0.3%)	and	HCV	Ab	(0.41%)	was	low,	and	comparable	to	the	
rates	seen	in	the	background	UK	population	(HBsAg	0.3%	(UK),	HCV	0.4%	(England)	[PHE	2013]).	On	
initial	assessment,	rates	of	viral	replication	were	low	in	HBV,	and	with	no	RNA	detected	on	HCV	Ab	
testing,	suggesting	previous,	cleared	HCV	infection.		
Rates	of	HBcAb	exposure	however	are	high,	at	9.25%;	suggesting	HBV	exposure	in	Nepal,	and	raising	
the	concern	for	any	additional	cases	of	HBsAg	that	may	have	been	missed	in	the	community	in	those	
who	did	not	take	part	in	testing	studies.		
Multiple	logistic	regression	analysis	suggests	a	statistical	association	between	male	gender,	and	lower	
education	 status	 with	 HBcAb	 positivity,	 and	 it	 may	 be	 that	 there	 is	 some	 geographic	 variation	
associated	towards	HBcAb	status,	although	without	reaching	formal	statistical	analysis	cut-offs,	and	
with	significant	data	gaps	in	the	collated	geographic	district	data	from	many	patients.		
Nearly	 all	 participants	were	 exposed	 to	 presumed	 non-sterile	 piercings	 at	 a	 young	 age,	with	 high	
proportions	also	exposed	to	surgical	and	dental	procedures,	but	without	a	noted	association	to	HBcAb	
or	CVH,	and	with	low	absolute	levels	of	active	disease.	Alcohol	was	mentioned	as	a	risk	factor	in	17%	
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of	participants,	with	a	third	of	these	being	women.	Given	the	communal	nature	through	which	this	
information	was	gathered,	it	may	be	that	this	is	an	underrepresentation,	with	concerns	over	alcohol	
risk	modification	long	term.			
Initial	clinic	uptake	for	follow-up	of	patients	identified	with	HBV	was	high,	but	with	subsequent	missed	
hospital	appointments,	and	with	a	lower	attendance	among	patients	identified	with	HCV	Ab	profiles.		
	
Chapter	Summary:		
We	 developed	 a	 successful	 engagement	 strategy	 with	 members	 of	 the	 recently	 arrived	 Nepal	
community.	Community	volunteers	and	peer	support	were	instrumental	in	the	implementation	of	CVH	
testing,	with	 a	 dedicate	multi-disciplinary	 research	 team	 leading	 CVH	 testing	 in	 community	 based	
settings.		
There	was	clear	evidence	of	racial	tension	in	the	local	community	through	the	publicity	of	far-right	
groups	during	our	 testing	 study.	 This	 had	 impact	 on	our	 study	 recruitment,	 but	more	 importantly	
raises	 fears	 of	 social	 exclusion	 in	 the	 recently	 arrived	 Nepali	 community.	 Despite	 this,	 the	 local	
community	were	keen	to	engage	in	testing	activity,	and	in	learning	more	about	liver	disease	in	keeping	
with	focus	group	findings.		
Active	CVH	rates	are	very	low	in	the	tested	cohort,	but	with	significantly	elevated	rates	of	previous	
HBV	exposure	that	raise	the	need	for	ongoing	study	to	understand	this	risk,	and	possible	higher	HBV	
risks	in	the	Nepali	community.		
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Chapter	7	Discussion	and	Conclusions:	
Introduction:		
The	 aims	 of	 this	 study	were	 to	 understand	 the	 CVH	 risks	 that	 exist	 in	 the	 recently	 arrived	Nepali	
community,	and	the	barriers	that	exist	towards	CVH	testing	in	migrant	communities	across	the	health	
system.		
The	following	chapter	presents	an	overview	of	the	key	arguments	raised	and	identified	through	the	
narrative	 of	 this	 thesis,	 and	 its	 principal	 findings.	 The	 implications	 of	 these	 findings,	 and	 their	
grounding	in	existing	literatures	is	also	presented,	with	a	summary	of	the	key	limitations	of	the	study,	
and	areas	to	explore	in	future	studies	to	further	develop	CVH	testing	access	and	provision	to	migrant	
communities.		
Principal	findings:	
The	political,	social	and	health	impact	on	migration	and	the	recently	arrived	Nepali	
community:		
Politically,	migration	 continues	 to	 feature	 at	 the	 highest	 level,	with	 contribution	 to	 the	 recent	 EU	
referendum	and	to	UK	elections	during	the	timespan	of	this	thesis	[Independent	June	2017].	Rising	
nationalism	and	anti-migrant	 sentiment	 is	being	 seen	across	Europe,	 coupled	with	unprecedented	
rates	 of	migration	 that	 continue	worldwide	 due	 to	 complex	 political,	military,	 environmental	 and	
economic	pressures.	 Socially,	migrants	may	 face	anti-migrant	 sentiment	within	 their	 environment,	
with	these	challenges	clearly	demonstrated	during	our	work	with	the	Nepali	community.	And	despite	
the	high	profile	public	 support	 for	UK	settlement	 rights	 for	 the	Gurkha	community,	 they	now	face	
many	 of	 these	 challenges	 here	 in	 the	UK	 after	 their	 arrival	 [Telegraph	 February	 2011],	with	 clear	
evidence	of	anti-Nepali	sentiment	expressed	during	our	time	with	the	community.			
As	such,	migrant	communities	may	face	many	negative	determinants	of	health	across	socioeconomic	
and	environmental	conditions,	with	impacts	on	social	and	community	networks	that	may	negatively	
impact	health	access	and	engagement	[WHO	2010];	with	these	concerns	evident	in	the	newly	arrived	
Nepali	community.	
Chronic	Viral	Hepatitis	(CVH)	risks	globally	are	substantial,	with	more	deaths	attributable	to	CVH	than	
that	seen	due	to	HIV,	and	comparable	to	that	seen	with	tuberculosis	[WHA	September	2017,	Lancet	
September	2017],	with	risks	that	are	largely	unknown	in	the	newly	arrived	Nepali	community.		
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Developing	 an	 intervention	 to	 understand	 the	 CVH	 risks	 in	 the	 Nepali	 community	 is	 therefore	
important,	with	the	need	for	direct	assessment	of	this	risk,	as	well	as	understanding	of	the	barriers	
that	exist	more	broadly	in	migrant	communities.		
Policy	(macro-level)	analysis	of	NICE	CVH	testing	recommendations	–	achieving	policy	
priority	
NICE	CVH	recommendations	provide	comprehensive	guidance	on	at-risk	groups	to	be	offered	testing,	
with	Primary	Care	the	principal	group	charged	with	delivering	these	community	testing	interventions,	
particularly	in	migrant	communities.	These	recommendations	feed	into	the	global	targets	established	
during	the	development	of	this	thesis,	with	the	WHO	published	goals	of	CVH	eradication	by	2030,	for	
which	 effective	 policy	 implementation	 towards	 CVH	 case-finding	 is	 crucial.	 Effective	 policy	
implementation	would	 provide	 an	 effective	method	 to	 achieve	widespread	 CVH	 testing,	 including	
testing	access	in	the	newly	arrived	Nepali	community.	
The	history	of	CVH	testing	uptake	is	however	poor,	despite	previous	national	policy	endeavours	in	the	
UK,	with	 particular	 concerns	 of	 policy	 awareness	 and	 uptake	 in	 primary	 care.	 	 Utilising	 the	 Policy	
Prioritisation	Framework	as	developed	by	Shiffman	and	Smith,	and	as	adapted	by	Walt	and	Gilson,	
several	gaps	are	apparent	that	are	likely	to	affect	policy	uptake	and	implementation	across	several	
levels:	
• Actor	Power:	The	actors	involved	in	policy	development	are	supportive	of	its’	objectives	and	
implementation,	 but	 without	 clear	 leadership	 that	 is	 identified,	 and	 with	 policy	 that	 was	
designed	 largely	 in	 a	 top-down	 approach,	with	 little	 evidence	 of	 community	 involvement,	
incentive	or	dedication	towards	testing	practice.	
• Ideas:	there	are	uncertainties	that	exist	in	our	understanding	of	CVH	risks,	and	how	to	best	
achieve	 testing.	 The	 internal	 community	 remains	 committed	 to	 endeavours	 to	 improve	
current	activity,	but	the	view	and	commitment	at	the	primary	care	(ground)	level	is	unclear.	
At	 the	 external	 frame,	 the	 public	 are	 likely	more	 aware	 of	 CVH	 through	 recent	 (positive)	
initiatives	and	developments,	but	concerns	of	stigmatisation	remain,	particularly	in	migrant	
communities.		
• Context:	 CVH	 testing	 policy	was	 developed	with	 high-level	 political	 support,	with	 national	
oversight	 that	 was	 developed	 at	 the	 same	 time	 through	 the	 National	 Liver	 Strategy.	 The	
introduction	of	the	Health	and	Social	Care	Act	does	not	appear	to	have	not	been	predicted,	or	
factored	into	CVH	policy,	with	the	subsequent	loss	of	the	National	Liver	Strategy.	The	recent	
introduction	 of	 the	 ODNs,	 and	 central	 role	 played	 by	 NHS	 England	 may	 provide	 greater	
coordination	and	oversight	of	CVH	case-finding	and	treatment	going	forward.	
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• Issue	Characteristics:	there	is	ongoing	uncertainty	in	the	measures	used	to	currently	monitor	
CVH	testing,	with	no	established	oversight	(coordination)	of	testing	activity.		The	severity	of	
CVH	can	be	assessed	through	surrogate	markers	in	hospital	statistics,	but	there	remains	gaps	
in	 our	 understanding	 of	 the	 effective	 (practical)	 routes	 to	 achieve	 testing	 uptake	 in	
heterogeneous	 at-risk	 groups,	 including	 migrant	 communities.	 Previous	 (positive)	 cost-
effectiveness	assessments	of	CVH	testing	are	likely	to	be	improved	in	consideration	of	the	vast	
improvement	in	treatment	options	and	treatment	uptake.	
• Outcome:	Whilst	there	are	clear	recommendations	to	primary	care	and	community	groups	to	
action	testing	in	migrant	groups	and	other	at-risk	groups,	there	is	little	in	the	way	of	practical	
direction	as	to	how	this	can	be	achieved,	reducing	the	authoritative	decisiveness	of	policy.	
Dedicated	resources	to	facilitate	testing	are	difficult	to	find,	with	a	lack	of	financial	and	human	
resources	that	are	additional	or	identified	from	policy.	The	development	of	the	newly	formed	
ODNs,	 and	 recent	drives	 in	 the	wake	of	DAA	 successes	may	however	 act	 as	 a	 resource	 to	
facilitate	policy	objectives.		
Focus	Group	studies	in	the	Nepali	community:	the	awareness,	knowledge	and	perception	of	
liver	disease:	
Common	themes	are	identified	across	the	four	Nepali	focus	groups,	as	well	as	conflicting	views	that	
are	seen	within	and	between	groups.		
Awareness	of	disease:	Awareness	of	liver	disease	is	high	across	all	4	focus	groups,	and	is	synonymous	
with	the	clinical	manifestation	of	jaundice	in	the	vast	majority	of	participant	discussions.	Uncertainties	
and	conflict	though	exist	towards	the	cause	of	liver	disease;	why	it	occurs,	and	how	one	can	protect	
oneself	from	the	onset	of	disease:		
“In	my	opinion	anybody	can	get	it.	It	might	get	for	children.	I	have	seen	young	friends	also	did	
get	liver	disease.	If	you	do	not	care,	it	get	to	everybody.	It	goes	beyond	gender	and	age	and	
reach	everybody	(participant	1);	Taking	care	with	food	matters	long	term,	even	if	jaundice	has	
happened	before….is	this	true?	(participant	6)	[Male	FG	<30]”	
Awareness	of	disease	is	frequently	presented	in	personal	or	first-hand	reflection,	and	this	may	relate	
to	prior	experiences	with	hepatitis	A	as	a	transient	illness	in	Nepal.		
Knowledge	of	specific	aetiologies	is	limited,	and	whilst	viral	hepatitis	is	mentioned	a	specific	agent	by	
some	participants,	it	is	mentioned	infrequently,	and	often	with	a	plurality	of	beliefs	that	place	a	viral	
pathogen	alongside	possible	food	and	water	pollutants,	which	remain	the	principal	agent	associated	
with	liver	disease	across	all	focus	groups.	There	is	considerable	uncertainty	among	participants	though	
how	 to	 define	 liver	 disease,	 and	 the	 potential	 agents	 responsible	 for	 disease.	 Despite	 the	
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heterogeneity	in	viewpoints,	there	is	equally	a	degree	of	certainty	expressed	in	defining	these	often	
opposing	views.	
	Intrinsic	 and	 extrinsic	 factors	 are	 listed	 as	 potential	 causes	 of	 disease,	 with	 self-control	 and	
responsibility	that	are	expressed	as	controlling	factors	to	protect	against,	and	manage	disease:		
“	[..]	It	is	necessary	to	take	care	on	food.	It	is	caused	by	negligence	(participant	1);	“[…]	Because	
of	not	taking	care	in	their	food	habit	it	occurs	(participant	2)	[Male	FG<30]”.	
“When	we	see	the	jaundice	from	a	Nepalese	perspective,	it	is	transmitted	through	stool,	urine	
and	food	(Participant	3)	[Male	FG>30]”.	
Spiritual	associations	feature	in	discussion	alongside	dietary	exposure	and	a	loss	of	traditional	cooking	
or	 eating	 practices	 as	 causes	 of	 disease,	with	 the	 additional	 role	 of	 self-control	 and	 responsibility	
placed	as	factors	that	may	promote	or	limit	disease:		
“	[..]	It	is	necessary	to	take	care	on	food.	It	is	caused	by	negligence	(participant	1);	“[…]	Because	
of	not	taking	care	in	their	food	habit	it	occurs	(participant	2)	[Male	FG<30]”.	
“When	we	see	the	jaundice	from	a	Nepalese	perspective,	it	is	transmitted	through	stool,	urine	
and	food	(Participant	3)	[Male	FG>30]”.	
Knowledge	of	potential	treatment	strategies	is	limited	in	the	group,	and	there	is	the	strong	suggestion	
that	many	view	herbal	and	traditional	strategies	as	a	trusted	“first-source”	of	therapy,	with	particularly	
negative	perspective	portrayed	from	their	experiences	in	Nepal.		
Perceptions	towards	the	severity	of	liver	disease,	and	the	concern	of	liver	disease	in	the	community	
suggests	this	to	be	a	feared	disease,	with	particular	futility	presented	by	some	of	the	older	female	
participants	once	liver	disease	was	diagnosed,	often	at	a	late	stage.		
In	addition,	many	express	concern	in	trying	to	understand	how	to	protect	themselves	from	this	severe	
illness,	with	uncertainties	that	exist	within	the	heterogeneous	range	of	aetiologies	and	risks	presented	
in	the	four	focus	groups.	As	such,	liver	disease	is	expressed	as	a	disease	area	of	concern,	and	an	area	
to	engage	in	for	education	and	management.		
Perceptions	towards	stigma	are	raised	by	individuals	 in	each	focus	group,	but	with	younger	female	
participants	expressing	particular	concerns	towards	the	role	of	alcohol	and	prostitutes	in	liver	disease.	
Many	of	the	factors	that	suggest	stigma	are	likely	to	be	external	factors	that	are	prevalent	in	society	
at	large,	but	there	is	likely	to	be	a	degree	of	internalisation	of	these	stigmatising	factors	in	how	CVH	is	
viewed,	with	 some	 of	 the	 younger	 female	 participants	 identifying	 differences	 in	 how	 the	 English,	
Chinese	and	Nepali	interact	and	view	one	another:		
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“I	think	more	English	and	Chinese	people	have	it	than	Nepali.		They	use	more	perfume	and	take	
less	 shower.	 They	 smell	 badly.	 They	 point	 to	 us	 but	 I	 say	we	 are	more	 healthy	 then	 them	
(Participant	2)	[FemaleFG<30].		
Despite	 this,	 and	 the	 alliance	 towards	 traditional	 therapies,	 the	 community	 seem	 engaged	 with	
learning	 more	 about	 liver	 disease,	 and	 interacting	 with	 primary	 care	 in	 particular.	 There	 is	 also	
understanding,	particularly	 in	the	older	female	group	that	modern	medicine	and	 life	 in	the	UK	can	
offer	many	new	and	modified	therapy	approaches	that	would	not	be	available	to	them	in	Nepal.		
Qualitative	studies	in	primary	care:	the	awareness,	perception	and	practice	of	CVH	testing:		
Qualitative	studies	 in	primary	care	suggest	a	 low	priority	currently	afforded	to	CVH	testing	overall,	
with	particular	deficits	in	testing	in	migrant	populations.		
Most	GPs	reported	awareness	of	CVH	testing	activity	in	relation	to	clinically	driven	scenarios,	and	as	
reactive	testing	activity	to	jaundice,	or	deranged	liver	function	tests.	Awareness	of	testing	in	antenatal	
settings	seems	well	adopted,	but	with	the	simultaneous	identification	that	most	of	this	testing	activity	
is	performed	by	associated	midwives.		
The	main	group	considered	to	approach	for	CVH	testing	are	those	with	an	injecting	drug	use	history;	
but	with	difficulties	that	practitioners	report	in	engaging	with	these	individuals	for	testing,	as	well	as	
perceived	blurring	of	responsibilities	and	communication	between	primary	care	services	and	drug	and	
alcohol	services	who	may	also	interact	with	these	individuals.	
There	is	lack	of	any	systematic	or	structured	approaches	to	identify	at-risk	groups	in	practices,	with	
resource	pressures	cited	as	one	of	the	reasons	behind	this:		
“And	we	don’t	always	know	who	the	at-risk	groups	are,	and	we’re	not	constantly	asking	the	
question.	 We’re	 all	 so	 busy,	 that	 to	 actually	 go	 through	 a	 whole	 load	 of	 screening	
questionnaires.	(pause)	If	we’ve	missed	it	on	the	new-patient	check,	we’ve	probably	missed	
it…	(Participant	8)”.	
Knowledge	of	formal	CVH	testing	policy	seems	limited	and	likely	absent	from	focus	group	discussions.	
This	may	 relate	 to	 the	broader	work	 and	 resource	pressures	 that	GPs	 feel,	 but	more	 likely	 seems	
related	to	the	low	priority	and	resistance	that	is	presented	towards	CVH	testing	activity	overall.		
Chronic	CVH	is	portrayed	as	poorly,	or	incorrectly	misunderstood,	particularly	in	reference	to	acute	
and	chronic	CVH,	and	the	casual	way	in	which	CVH	is	identified	for	patients,	with	no	corresponding	
reference	during	discussions	as	to	the	 linkage	of	care	that	 is	required	for	these	 individuals	to	have	
been	treated.		
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CVH	is	therefore	framed	principally	as	a	benign	condition,	with	 little	mention	of	the	morbidity	and	
mortality	complications	that	CVH	can	lead	to,	particularly	in	view	of	cirrhosis	and	HCC.	None	of	the	
GPs	across	the	three	GP	practices	had	any	current	system	of	CVH	case-finding.		
Perceptions	towards	CVH	testing	was	principally	discussed	with	reference	to	the	harm	that	 testing	
could	have	on	patients	and	their	immediate	family,	as	well	as	the	difficulties	that	CVH	testing	poses	to	
GPs	who	may	be	unfamiliar	with	this	activity,	and	who	appear	fearful	of	raising	issues	of	prejudice	and	
racism	in	specific	reference	to	testing	in	migrant	communities:		
“there	is	kind	of	a	bit	of	a	barrier”	(nods	of	agreement	in	room);	“especially	if	you’ve	got	a	
population	with	a	cultural	or	language	barrier	already,	they	may	not	take	it	well	for	something	
unrelated,	and	it	can	cause	offense	[…]	(Participant	7)”.	
“is	it	not	going	to	be	judged	again……,	as	being	prejudiced	against	one	racial	group	(Participant	
6)”.		
Only	amongst	the	military	practitioners	was	the	concept	of	testing	in	migrant	groups	mentioned,	but	
with	the	stated	abandonment	of	this	testing	activity	due	to	concerns	of	acting	in,	or	being	seen	in	a	
prejudice	manner.		
Capacity	and	resource	pressures	are	a	significant	 issue	and	concern	among	all	participants,	but	the	
overwhelming	expression	as	a	group	is	to	place	CVH	testing	as	poorly	understood,	and	a	low	priority	
to	engage	with	in	primary	care:		
“I’d	say	 that	 it	 is	a	complete	waste	of	money,	because	 it’s	all	being	done	anyway.	And	we	
screen	all	the	antenatals	anyway	don’t	we?”;	“You	know,	It’s	just	one	of	those	stupid	things	
isn’t	it?	(Participant	2)”	
Developing	a	community-based	intervention	to	assess	CVH	risks	in	the	Nepali	population:		
We	developed	a	successful	community-based	CVH	testing	initiative	in	close	to	1000	members	of	the	
local	 Nepali	 population,	 with	 the	 integral	 help	 and	 involvement	 of	 a	 specially	 developed	 Nepali	
research	committee,	as	well	as	close	multidisciplinary	working	across	multiple	specialities.		
• A	 comprehensive	multidisciplinary	 team	was	 established	with	 specialist	 input	 from	 expert	
clinicians	 with	 special	 interest	 and	 proven	 record	 in	 community	 testing	 interventions,	
academics,	 local	 PHE	 representatives,	 hospital	 community	 liaison	 teams,	 research	 and	
governance	teams	and	local	council	representatives.		
• This	research	team	was	completed	with	the	help	of	a	newly	(specifically)	developed	Nepali	
research	 committee,	with	 the	 inclusion	of	 a	 nominated	member	of	 the	Nepali	 community	
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acting	as	a	formal	appointed	member	of	the	Research	team,	with	formal	accreditation	and	
status.		
• 5	community	venues	were	chosen	for	their	established	familiarity	and	ease	of	access	to	known	
Nepali	population	clusters,	with	testing	delivered	by	DBS	testing	kits	between	March	2013	to	
January	2015	over	17	individual	sessions.	
• 984	individuals	took	part	in	testing,	of	whom	54%	were	female,	and	with	a	median	age	of	66	
years.	
• The	median	residence	period	in	the	UK	was	36	months,	with	85%	of	the	Nepali	community	
resident	for	<	5	years,	and	close	20%	who	had	arrived	in	the	past	year.	
• Advertising	for	testing	activity	was	 limited	and	modified	 in	the	face	of	 far-right	groups	and	
anti-migrant	sentiments	expressed	in	the	local	community,	and	given	the	fears	of	our	Nepali	
research	committee.		
• Word-of-mouth	was	 the	 principal	 route	 to	 disseminate	 interest	 and	 attendance	 at	 testing	
sessions,	with	radio	advertising	on	national	Nepali	military	service	networks	that	is	likely	to	be	
a	powerful	tool	that	can	be	utilised	in	further,	or	future	health	promotion	initiatives.		
• Engagement	with	members	 of	 the	 research	 team	was	 positive	 during	 study	 presentations	
delivered	to	Nepali	groups,	and	in	interactions	during	organised	testing	sessions.		
• The	median	number	of	individuals	per	household	in	tested	community	was	2.		
• The	median	number	of	years	of	schooling	by	all	participants	was	0,	with	a	transition	that	is	
evident	 in	 participants	 above	40	 years,	 and	with	 lower	 levels	 of	 schooling	 in	 older	 female	
participants	 as	 well.	 Literacy	 in	 English	 was	 low	 in	 older	 participants,	 with	 a	 degree	 of	
functional	illiteracy	towards	Nepalese	seen	in	elderly	participants	as	well.		
• The	 prevalence	 of	 active	 HBV	 and	 HCV	 was	 low	 in	 the	 984	 unique	 individuals	 tested.	 3	
individuals	had	evidence	of	HBsAg	positivity	(0.3%),	and	4	individuals	had	detected	HCV	Ab,	
but	with	RNA	that	was	then	undetectable	on	subsequent	DBS	sample	testing	in	all	4	of	these	
individuals.	
• HBcAb	positivity	was	high,	with	HBcAb	identified	in	91	individuals	(9.25%).	
• Potential	risk	factors:	Over	70%	of	the	population	had	received	vaccines	abroad,	with	a	1/3rd	
with	a	history	of	surgery	abroad,	and	over	90%	who	had	a	history	of	piercings	abroad,	with	
the	majority	 of	 these	 piercings	 as	 infants.	 Alcohol	 intake	 above	 recommended	 levels	 was	
suggested	 in	 17%,	 with	 34%	 of	 these	 individuals	 being	 female.	 None	 of	 these	 factors	
demonstrated	correlation	to	HBcAb	status	in	subsequent	analysis.	
• Multiple	logistic	regression	analysis	identified	male	gender	(OR	2.6,	p=0.016)	and	years	spent	
at	school	(OR	0.88,	p=0.025)	as	possible	associations	towards	HBcAb	positivity.		
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• Variation	 in	 HBcAb	 status	was	 also	 seen	 according	 to	 district	 of	 origin,	 with	 a	 correlation	
suggested	towards	those	originating	from	the	Myagdi	district,	but	without	reaching	statistical	
significance,	and	data	drop	out	that	is	likely	to	be	significant	in	overall	analysis.		
	
Implications	of	findings:		
Political,	Social	and	Health	impact	on	CVH	testing	in	migrant	communities:		Politically	in	the	UK,	as	
with	 much	 of	 Europe,	 there	 is	 an	 overwhelming	 desire	 to	 reduce	 migration,	 with	 anti-migrant	
sentiment	 that	appears	on	 the	 rise	 in	many	political	parties	across	Europe,	and	 in	mainstream	UK	
politics	[Telegraph	April	2017,	Guardian	June	2016,	BBC	October	2017].		BBVs	such	as	HIV	have	been	
used	in	negative	public	debates	about	migrant	communities	by	mainstream	right-wing	groups	such	as	
UKIP	[Telegraph	April	2015],	and	the	political	will	and	ability	to	address	disease	risks	in	migrant	groups,	
particularly	other	BBVs	such	as	CVH	would	seem	limited	in	the	current	political	climate.	The	comments	
of	local	political	leaders	in	Aldershot	are	likely	to	inflame	and	drive	anti-migrant	sentiment	that	already	
exists	 in	 the	 community,	 and	 importantly	 are	 likely	 to	 adversely	 affect	 the	 Nepali	 community’s	
integration,	and	perception	of	belonging.		
The	anti-migrant	sentiment	that	arose	during	our	testing	study	is	evidence	of	the	pressures	that	the	
Nepali	community	is	facing	at	the	society	level,	and	council	members	involved	in	our	research	group	
expressed	significant	concerns	informally	about	the	risks	of	inflaming	tensions	in	the	local	community	
in	trying	in	to	understand	CVH	disease	risks	in	the	community.		
These	political	and	social	factors	would	be	expected	to	negatively	impact	on	the	social	determinants	
of	health,	effecting	social	and	community	networks,	as	well	the	agency	of	individuals,	with	negative	
expectations	on	healthcare	engagement	in	CVH,	and	other	health	conditions	[Dahlgren	and	Whitehall	
1992].	In	addition,	the	findings	from	our	testing	study	demonstrate	low	levels	of	education	and	literacy	
in	the	vast	majority	of	participants,	which	is	likely	to	further	impact	conventional	health	engagement	
strategies,	 and	 suggests	 a	 greater	 need	 for	 resources	 to	 support	 and	 build	 health	 engagement	
strategies	in	CVH	and	beyond.		
CVH	testing	policy:	The	historic	context	of	CVH	policy	in	the	UK	suggests	there	are	established	deficits	
in	awareness	and	understanding	or	CVH,	as	well	as	gaps	in	the	integration	and	coordination	between	
specialist	 and	 primary	 and	 community	 (e.g.	 Drug	 and	 Alcohol	 services).	 NICE	 CVH	 testing	 policy	
provides	 a	 comprehensive	 list	 of	 groups	who	 should	 be	 approached	 for	 testing,	 and	 primary	 care	
services	would	be	principal	agent	to	deliver	these	initiatives,	given	the	existing	provision	and	access	
opportunities,	as	well	as	the	high	levels	of	trust	the	service	holds	with	the	community,	and	of	course	
the	potential	access	 for	migrant	groups	at	 the	national	 level.	Whilst	policy	 recommendations	have	
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many	uncertainties,	there	is	internal	consensus	in	the	policy	development	group	on	the	need	to	better	
understand	CVH	risks,	and	to	reduce	the	rising	morbidity	and	mortality	risks	seen	with	liver	disease	
and	CVH.		
However,	the	Political	Prioritisation	Framework	demonstrates	gaps	that	exist	 in	policy	reaching	the	
agenda	setting	process,	and	how	policy	can	be	achieved;	with	a	lack	of	leadership	and	oversight	that	
is	most	evident,	as	well	as	a	gap	between	the	macro	level	policy	development	stakeholders,	and	the	
meso	and	micro-levels	where	policy	is	coordinated	and	actioned.	Policy	actions	(recommendations)	
demonstrate	a	lack	of	authority,	with	the	need	for	clear	practical	recommendations	for	community	
practitioners	 to	 follow,	 and	 greater	 detail	 and	 simplicity	 in	 actions	 and	 referral	 pathways	 for	
community	practitioners	to	follow.		The	lack	of	resources	identified	or	allocated	towards	policy	is	also	
a	significant	weakness,	and	the	provision	of	simple	practical	forms,	or	procedures	for	GPs	to	follow	
would	go	some	way	to	alleviate	the	resource	hurdles	that	disparate	GP	practices	face.		
NICE	CVH	testing	policy	development	started	before	the	introduction	of	the	Health	and	Social	Care	
Act,	with	a	significantly	negative	impact	that	policy	is	likely	to	have	suffered	as	result,	most	notably	
with	 its	 contribution	 to	 the	 loss	of	 the	National	 Liver	 Strategy,	 and	 the	 central	 oversight	 that	one	
presumes	would	otherwise	have	helped	coordinate	testing	activity.	Testing	policy	was	also	not	able	to	
predict	the	paradigm	shift	brought	on	with	the	development	of	DAA	based	therapies,	and	the	current	
commissioning	role	of	NHSE,	which	would	significant	 (positive)	 impact	on	the	cost-effectiveness	of	
CVH	testing	interventions,	and	take	away	CVH	treatment	commissioning	needs	from	primary	care	and	
CCGs;	 both	which	would	 be	 presumed	 to	work	 favourably	 towards	 improved	 testing	 efficacy	 and	
uptake.			
Qualitative	studies	between	Primary	care	and	the	Nepali	community:		Participants	in	the	Nepali	focus	
groups	 demonstrated	 a	 high	 level	 of	 awareness	 towards	 liver	 disease,	 and	 although	 disease	 is	
principally	 identified	as	 jaundice,	 it	 is	 also	 seen	as	 a	 serious	 condition,	with	 fear	 that	 is	 expressed	
through	personal	reflections	of	mortality	in	close	relatives.		
Considerable	uncertainty	exists	in	how	to	explain	liver	disease,	or	its	causes,	and	particularly	how	to	
protect	 from	 illness,	with	 a	 keenness	 to	 engage	 and	 understand	more	 about	 disease	 from	 health	
professionals.		
Multiple	potential	causes	and	treatments	of	disease	are	discussed,	with	a	plurality	between	internal	
and	 external	 causes	 of	 disease;	 including	 spiritual	 causes	 as	 well	 as	 food	 and	 water	 pollutants.	
Negative	perceptions	and	 stigma	are	expressed,	most	notably	 in	 younger	 female	participants	who	
have	not	had	any	first	hand	contact	with	liver	disease	patients/relatives.	However,	overall,	despite	the	
predominant	negative	perceptions	to	cooking	practices	or	food	hygiene,	there	is	an	expressed	desire	
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to	support	members	of	the	community	who	may	be	effected	by	CVH,	and	a	recognition	by	all	that	liver	
disease	is	something	that	can	affect	anyone.		
Low	levels	of	 literacy	to	English,	and	a	functional	 illiteracy	in	Nepalese	is	again	demonstrated,	with	
considerations	 that	 need	 to	 be	 borne	 into	 the	 development	 of	 health	 education	 and	 intervention	
initiatives.		
Looking	at	the	focus	group	findings	between	the	local	Nepali	community	and	the	GPs	who	serve	them,	
there	is	a	keen	expression	in	Nepali	focus	groups	to	learn	more	about	liver	disease	and	to	engage	with	
health	professionals	and	GPs	in	particular.	However,	looking	at	our	qualitative	study	in	local	primary	
care	 it	 is	apparent	 that	 testing	 is	viewed	not	only	as	a	 low	priority,	but	as	a	 subject	 that	 is	 largely	
avoided	with	the	perception	that	migrants	would	not	be	aware	of	liver	disease,	or	want	to	engage	in	
discussions	regarding	this.		
Indeed,	concerns	of	prejudice	are	strongly	expressed	in	GPs,	and	whilst	stigma	is	identified	in	Nepali	
discussions,	there	is	no	suggestion	overall	of	negative	perceptions	to	testing,	and	an	overwhelming	
desire	 to	 gain	 better	 self-control	 and	understanding	 of	 disease	 risks,	which	 remains	 supportive	 of	
community	based	testing	offers.		
Testing	 activity	 is	 however	 a	 low	priority	 in	 primary	 care,	with	no	expressed	 awareness	of	 testing	
policy,	or	policy	recommendations	to	offer	testing	to	migrant	groups.	Strong	negative	views	are	put	
forward	regarding	the	merits	of	CVH	testing,	with	misunderstanding	that	seems	evident	 in	disease	
awareness,	 and	with	 the	 risks	 that	 existing	 chronic	 CVH	patients	 are	 under-prioritised	 for	 onward	
referral,	coupled	with	testing	activity	that	remains	largely	non-existent.		
The	negative	views	of	testing	in	primary	care	are	expressed	principally	by	senior	members	of	the	team,	
and	whilst	others	in	the	group	may	hold	opposing,	or	more	informed	views,	these	are	not	expressed,	
and	the	controlling	current	testing	activity	seems	to	be	run	by	these	individuals.	Of	note,	the	negative	
perceptions	 of	 offense	 and	 racial	 profiling	were	 not	 apparent	 in	 discussions	 and	 presentations	 to	
Nepali	community	groups	as	part	of	our	study	promotion,	or	during	testing	activity.	
Modifiable	factors	to	improve	testing	seem	principally	resource	based	from	focus	group	discussions,	
but	overarching	to	this	is	the	need	to	improve	the	awareness	of	CVH,	the	morbidity	and	mortality	toll	
that	 it	 holds,	 and	 the	 revolutionary	 cost-effective	 treatments	 that	 can	 be	 delivered	 if	 disease	 is	
identified	at	the	right-time.		
At	the	personal	level,	the	richness	of	the	qualitative	data	from	the	Nepali	community	was	illuminating	
in	understanding	the	 importance	of	awareness	and	perception	 in	how	we	design	and	reach	out	 to	
migrant	 populations,	 and	 has	 changed	 my	 perspective	 in	 how	 I	 approach	 and	 appreciate	 the	
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complexities	of	patient	care.	The	richness	and	openness	of	the	primary	care	data	was	also	illuminating	
in	unexpected	ways,	identifying	perspectives	that	I	had	not	appreciated,	and	that	create	challenges	
and	opportunities	to	manage	going	forward.		
	
Community	CVH	testing	study:				
Study	 design:	 Our	 multidisciplinary	 team	 worked	 well	 together	 under	 the	 leadership	 of	 the	 core	
research	 team	 to	explore	CVH	 risks	 in	 the	Nepali	 community.	 The	Nepali	 research	 committee	was	
invaluable	 in	 identifying	 testing	 locations,	 and	 in	 participant	 recruitment	 and	 in	 facilitating	 testing	
activity.	Embedding	key	Nepali	community	leaders	into	the	research	team	through	formal	links	helped	
provide	authority	and	 inclusiveness	 to	our	Nepali	 colleagues,	as	well	as	motivation	 to	act	as	peer-
support	mentors	for	testing	promotion.		
Given	the	heterogeneous	nature	of	the	Nepali	population,	divide	across	multiple	castes	and	religions;	
involvement	of	the	Nepali	research	committee	was	crucial	in	identifying	potential	testing	sites	around	
(otherwise	unknown,	or	conjectured)	population	clusters,	as	well	as	study	advertisement.		
Advertising:	Word	of	mouth	proved	a	powerful	media	 to	 recruit	 participants,	 presumably	building	
upon	strong	national	ties	that	exist	in	the	newly	arrived	community,	as	well	as	the	underlying	socially-
minded	nature	of	the	community,	who	are	often	seen	together	in	groups	in	the	local	community,	and	
who	attended	CVH	testing	sessions	as	groups,	rather	than	individuals.	Although	we	were	limited	in	
our	ability	to	utilise	written	leaflets,	invites	of	posters	in	the	general	community,	it	is	likely	that	word	
of	mouth,	and	spoken	or	visual	medial	is	the	preferred	tool	to	reach	out	to	members	of	the	community	
to	promote	health	engagement,	with	corresponding	findings	that	are	of	course	evident	from	our	focus	
group	work,	as	well	as	the	low	levels	of	formal	education	identified	during	the	course	of	our	testing	
study.	 Indeed,	 the	 late	 addition	 of	 radio-advertising	 (following	 a	 formal	 telephone	 interview)	
promotion	on	national	Gurkha	breakfast	radio	seemed	to	produce	a	powerful	uptake	in	participant	
numbers,	many	who	we	could	not	accommodate	for	testing.		
Testing	activity	and	engagement:	Informally,	the	Nepali	participants	expressed	satisfaction	with	the	
community	testing	sites,	and	we	concentrated	our	testing	activity	to	the	busiest	and	centrally	located	
centre	in	Aldershot.	DBS	(dry	blood	spot)	testing	was	well	tolerated,	and	easy	to	deliver,	with	only	a	
few	samples	that	required	repeating	(due	to	a	small	amount	of	blood	on	the	first	finger	prick).	Whilst	
research	nurses	delivered	this	testing	as	part	of	our	research	study,	there	would	seem	no	preclusion	
to	this	being	delivered	by	non-healthcare	trained	professionals,	provided	the	correct	training	facilities	
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were	in	place;	with	a	role	for	these	kits	also	in	primary	care,	and	self-testing	kits	that	remain	a	potential	
mailed	testing	route	as	trialled	in	HIV	testing	initiatives	[PHE	Dec	2016].		
Community	testing	did	though	require	a	reasonable	staff	provision	per	testing	activity	(6-9),	in	addition	
to	the	needs	for	4-6	members	of	the	Nepali	community	to	help	with	patient	information,	consent	and	
testing.		
Demographics:	The	majority	of	testing	participants	were	elderly	(median	age	of	66	years),	and	whilst	
this	age	distribution	is	skewed	to	an	older	age	in	comparison	to	earlier	reports	from	2008,	this	may	
also	be	a	reflection	of	the	older	ex-servicemen	and	their	dependents	who	have	since	arrived	in	the	
UK.	These	older	 individuals	may	also	provide	a	representation	of	cumulative	risks	 that	would	have	
developed	with	undiagnosed	CVH	over	this	period.		
All	participants	were	first-generation	migrants,	with	the	majority	(>85%)	who	had	been	in	the	UK	for	
less	than	5	years,	supporting	the	concept	of	a	new	migrant	community	in	the	local	Nepali	population.	
And,	whilst	 there	was	 a	wide	 variation	 in	 the	 district	 level	 origin	 of	 these	 individuals,	 the	 overall	
distribution	is	similar	to	earlier	estimates	by	CNSUK,	in	keeping	with	a	select	extraction	of	the	Nepali	
population	who	are	now	resident	in	the	UK.		
CVH	prevalence:	The	absolute	numbers	of	active	infection	suggested	through	our	study	is	very	low	in	
the	 Nepali	 community,	 with	 HBsAg	 positivity	 (0.3%)	 which	 is	 on	 par	 with	 those	 identified	 in	 the	
background	UK	population	(0.3%	[PHE	2013]).	Whilst	2	of	the	4	participants	with	HCV	Ab	detected	on	
DBS	did	not	attend	subsequent	clinic	follow-up,	all	4	were	RNA	negative	on	further	DBS	sub-testing,	
and	 therefore	 one	 presumes	 that	 no	 cases	 of	 active	 HCV	 were	 detected,	 with	 prevalence	 rates	
therefore	for	HCV	that	are	between	0	to	0.41%.		
CVH	prevalence:	The	absolute	numbers	of	active	CVH	infection	suggested	through	our	study	is	very	
low	in	the	Nepali	community,	with	HBsAg	positivity	(0.3%)	that	is	on	part	with	those	in	the	background	
UK	population	(0.3%	[PHE	2013]).	Rates	for	HCV	infection	seem	to	be	lower;	between	0	to	0.4%,	with	
all	4	participants	who	were	RNA	negative	at	subsequent	DBS	testing,	but	with	2	patients	who	did	not	
attend	clinic	follow-up	to	confirm	HCV	RNA	negativity.		
As	 such	active	 infection,	and	 immediate	 risks	and	needs	 for	 treatment	and	contact	 tracing	activity	
appear	low	based	on	this	information.		
However,	this	is	contrasted	with	high	levels	of	(previous)	HBV	exposure,	with	9.25%	of	the	population	
(91/984)	identified	as	HBcAb	positive.	Looking	at	the	internal	validation	data	for	the	DBS	testing	kits	
used	in	this	study	(table	x),	the	reported	specificity	is	100%	for	HBcAb	detection,	suggesting	that	this	
is	an	accurate	representation.	Logistic	regression	analysis	identifies	male	gender	and	lower	education	
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as	possible	associated	factors	with	HBcAb	exposure,	and	there	does	not	appear	to	be	an	alternate	
(overt)	risk	factor	identified	in	our	study	to	account	for	HBV	exposure.	Therefore,	one	would	presume	
a	 vertical	 transmission	 route,	 or	 childhood	 exposure	 in	 these	 individuals,	 with	 the	 corresponding	
expectation	that	80-90%	of	these	infants	will	develop	chronic	active	HBV,	and	30-50%	of	children	if	
infected	before	the	age	of	6	years.	As	such,	the	risks	of	active	HBV	in	other	members	of	the	community	
who	may	have	the	same	exposure	risks	seems	to	remain,	with	the	need	for	ongoing	investigation.		
Risk	factors	for	CVH:		Male	gender	and	lower	levels	of	education	were	the	only	statistically	significant	
risks	factors	in	relation	to	HBcAb	status,	with	district	level	origins	that	suggest	some	association,	but	
without	reaching	significance.		
Formal	 education	 is	 generally	 low	 in	 the	 study	population,	with	particular	deficit	 in	 those	over	50	
years.	 Nevertheless,	 age	 does	 not	 appear	 as	 a	 statistically	 significant	 variant	 in	 analysis,	 and	
educational	 status	 may	 reflect	 broader	 socioeconomic	 relations	 that	 positively	 influence	 health	
outcomes	as	noted	in	other	health	settings	[Feinstein	L	2006].		
It	 is	 of	 interest	 that	 despite	 relatively	 higher	 rates	 of	 exposure	 to	 invasive	 iatrogenic	 procedures	
abroad,	 as	well	 as	 almost	 universal	 piercings	 at	 birth	 in	 presumably	 rural	 areas,	 rates	 of	 infection	
remain	low,	and	without	statistical	significance	towards	HBcAb	positivity.		
	
Comparison	in	Literature:		
Policy	analysis:		
Formal	policy	level	analyses	are	not	apparent	for	previous	CVH	testing	initiatives,	and	remain	absent	
in	many	conventional	chronic	disease	states.	The	Priority	Setting	Framework	developed	by	Shiffman	
and	Smith	was	constructed	based	on	policy	applied	to	low	and	middle	income	countries,	but	with	a	
heterogeneous	and	inclusive	analysis	provided	in	the	following	review	by	Walt	and	Gilson,	including	
its	application	into	HBV	vaccination	uptake	rates	[Walt	G	2014].		
Policy	analysis	is	seen	to	be	both	intuitive	and	complex,	with	findings	that	may	only	become	apparent	
during	the	analysis	process.	CVH	testing	policy	is	seen	to	have	been	developed	in	a	top-down	fashion,	
with	a	loss	of	oversight	and	coordination	brought	on	through	the	loss	of	the	National	Liver	Strategy,	
as	well	as	demonstrating	a	lack	of	authority	in	policy	objectives,	disparities	between	the	internal	and	
external	frames	in	how	policy	 is	viewed,	and	in	the	resources	that	can	be	utilised	to	achieve	policy	
objectives.		
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HIV	policy	is	perhaps	a	good	policy	comparator,	albeit	in	the	context	of	disease	with	far	greater	reach	
in	terms	of	its	recognition,	funding	and	impact	at	a	societal	level,	and	with	strong	community	actors	
who	are	well	recognised	in	the	public	and	internal	arena.		
Similar	 to	CVH,	HIV	has	 received	 renewed	motivation	 to	 improve	 testing	and	 treatment	as	part	of	
global	initiatives	to	drive	up	testing,	identification	and	linkage	to	care	to	try	and	control	and	eliminate	
disease	by	2030	[PHE	December	2016].	Updated	guidance	to	increase	HIV	testing	uptake	have	also	
been	released	by	NICE	in	2016	[NICE	December	2016].		
At	the	Actor	 level,	although	the	same	stakeholders	and	relations	underpin	HIV	testing	and	onward	
care,	 there	 is	a	greater	 role	 for	Local	Authorities	 through	sexual	health	clinics,	and	 the	position	of	
actors	such	as	PHE	is	far	stronger.	PHE	runs	dedicated	internet	awareness	raising	pages,	and	promotes	
testing,	even	with	the	provision	and	funding	of	home	DBS	testing	kits,	with	mailed	results	that	are	sent	
to	participants	[PHE	December	2016].	As	well	as	this	there	is	a	stronger	role	for	community	interaction,	
and	community-based	groups	to	encourage	HIV	testing,	with	PHE	funded	initiatives	to	identify	(and	
fund)	new	testing	and	linkage	initiatives.	Grassroots	support	is	more	vocal	and	varied,	with	wide	scale	
public	promotional	testing	adverts	distributed	across	the	country;	without	fear	of	stigma,	issued	with	
celebrity	support	from	leading	figures.		
The	internal	and	external	frames	of	HIV	testing	is	well	defined,	and	despite	falling	numbers	of	cases,	
there	 remains	 a	 strong	 impetus	 to	 improve	 testing,	 with	 the	 stated	 call	 in	 policy	 documents	 to	
“normalise	testing”,	thereby	aiming	to	adapt	testing	perception	and	behaviours	[PHE	December	2016].	
HIV	policy	is	of	course	shaped	by	the	AIDS	epidemic,	and	how	this	has	been	portrayed	and	perceived,	
and	whilst	treatments	have	progressed	hugely	over	the	past	decade,	there	has	not	been	a	contextual	
revolution	in	treatment	as	seen	in	HCV	over	the	same	period,	with	a	policy	window	that	one	could	
argue	for	more	strongly	in	HCV	and	CVH	testing	drives.		
Considering	the	Issue	Characteristics	in	HIV	policy,	there	is	greater	clarity	in	the	need	for	treatment	in	
patients	who	are	identified,	with	severity	measures	that	are	well	defined	in	clinical	practice.	But	there	
are	also	similarities	with	CVH	testing,	with	uncertainties	that	exist	in	prevalence	rates,	and	the	groups	
to	target.		
Considering	 the	 Outcome	 category	 in	 the	 policy	 prioritisation	 framework	 model,	 the	 resources	
allocated	HIV	testing	are	similar	on	some	levels,	with	commissioning	that	is	coordinated	between	Local	
Authorities	and	CCGs	in	a	similar	fashion	to	CVH,	but	with	greater	acceptance	and	standardisation	at	
the	Local	Authority	level	due	to	its	commissioning	role	in	Sexual	Health	services.	Technical	resources	
appear	in	newer	HIV	policy,	with	easy	to	access	prevalence	assessments	for	practitioners,	which	may	
of	course	represent	technological	advances	rather	than	any	other	variance.	Testing	recommendations	
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for	HIV	do	appear	more	authoritative,	with	practical	testing	strategies	given	to	GPs	with	New	Patient	
testing,	 Opportunistic	 testing,	 although	 there	 is	 flexibility	 in	 the	 decisiveness	 of	 some	 of	 these	
recommendations,	presumably	in	relation	to	the	sensitivities	perceived	of	HIV	testing	offers.		
Overall,	 it	can	be	seen	that	HIV	testing	policy	has	many	similarities	to	CVH	care,	but	with	advances	
that	are	clearly	evident	in	HIV	policy.	The	Actors	involved	in	testing	activity	appear	more	supported	
from	 PHE,	 and	 likely	 also	 from	 Local	 Health	 Authorities,	 with	 the	 involvement	 of	 voluntary	
organisations,	who	have	a	stronger	community	presence,	and	external	frame	in	view	of	the	greater	
awareness	 and	 recognition	 of	 HIV.	 The	 public	 recognition	 and	 support	 for	 HIV	 is	 far	 higher,	 with	
celebrity	support	for	testing,	as	well	as	widespread	media	advertising	for	testing	uptake	with	the	aims	
to	normalise	testing.		
These	testing	endeavours	and	successes	are	despite	the	stigma	associated	with	HIV,	and	suggest	that	
greater	 coordination	 and	 involvement	 of	 actors	 in	 the	 testing	 process,	 as	well	 as	 improved	public	
awareness	 can	 modify	 current	 misperceptions	 if	 these	 exist,	 and	 should	 act	 to	 re-assure	 other	
providers	and	actors	 to	support	wide-scale	CVH	testing	uptake	 in	keeping	with	official	CVH	testing	
policy.		
Focus	Group	analysis	in	Migrant	groups	and	Primary	Care:		
At	the	community	level,	Nepali	participants	expressed	high	levels	of	awareness	towards	liver	disease,	
with	jaundice	used	as	the	principal	reference	in	discussing	and	defining	disease,	in	keeping	with	the	
findings	 of	 previous	 qualitative	 studies	 in	migrant	 groups	 [Burke	 N	 2011].	 	 Nepali	 participants	 do	
however	reference	liver	disease	more	strongly	than	that	noted	in	most	other	qualitative	studies,	with	
first-hand	accounts	of	disease	given	by	all	groups,	except	in	younger	female	participants.		
Spiritual	causes	of	disease,	and	the	role	of	Witch	Doctors	as	external	agents	responsible	for	disease	
and	 cure	 are	mentioned	 in	 all	 four	 focus	 groups,	with	 a	 role	 for	 Spirits	mentioned	 in	 some	other	
community	 studies	 in	 the	 US	 Cambodian	 community	 [Uehara	 ES	 2001],	 and	 in	 elderly	 Turkish	
participants	[Van	der	Veen	YJ	2009],	but	without	strong	mention	of	this	association	in	other	migrant	
studies.	It	should	be	noted	though,	that	the	perceived	role	of	Spirits	and	Witch	doctors	in	the	current	
focus	 groups	 seems	 low	 across	 the	 focus	 group	 studies,	 and	 is	 principally	 mentioned	 on	 specific	
exploration	by	the	moderator.	In	addition,	there	is	no	mention	of	any	particular	religious	paradigms	
associated	 with	 disease,	 or	 cure,	 which	 may	 reflect	 the	 religious	 heterogeneity	 of	 the	 Nepali	
population.	
Whilst	food	and	water	pollutants	are	strongly	expressed	as	potential	causes	of	disease,	there	is	also	
wide	range	of	aetiologies,	 including	viral	hepatitis	 that	are	mentioned.	The	understanding	of	these	
medical	terms	is	though	unclear,	and	it	may	be	that	these	terms	are	understood	differently,	and	in	
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“linear”	 learned	forms	of	hepatitis	A,	B	and	C,	as	 identified	by	n	other	qualitative	studies	[Burke	N	
2011].		
Stigma	is	a	feature	in	focus	group	studies,	but	without	a	clear	negative	effect	on	testing	likelihood,	
with	 corresponding	 studies	 among	 community	 healthcare	 providers	 suggesting	 a	 lack	 of	 disease	
awareness	as	a	more	potent	factor	to	impact	testing	uptake	[Seedat	F	2014].	Alcohol	is	well	recognised	
in	focus	group	discussions	in	the	Nepali	community,	and	it	is	described	principally	as	a	risk	in	those	
perhaps	back	in	Nepal,	and	has	negative	implications.	However,	it	is	often	referenced	as	a	co-factor,	
and	it	is	not	expressed	as	often,	or	strongly	as	water	and	food	pollutants	as	a	driver	of	liver	disease.	
Additionally,	 it	may	be	 that	 liver	disease	and	CVH	 is	viewed	 in	a	different	 fashion	 for	 those	Nepali	
participants	 now	 resident	 in	 the	UK	 compared	 to	 those	 in	Nepal,	 as	 suggested	 by	 Drazic	 et	 al.	 in	
qualitative	studies	into	the	South	Asian	community	in	Australia	[Drazic	NY	2013].		
Overall,	the	Nepali	community	seem	supportive	and	keen	to	engage	with	health	teams	to	learn	more	
about	 liver	 disease,	 with	 engagement	 that	 seems	 more	 positive	 than	 that	 identified	 in	 other	
community	studies.		
At	the	primary	care	level,	the	low	levels	of	awareness	in	CVH	testing	seems	in	keeping	with	previous	
findings	 following	 the	 2004	 HCV	 Action	 Plan	 [D’Souza	 RF	 2004],	 and	 the	 findings	 of	more	 recent	
studies,	with	the	majority	of	at-risk	individuals	that	remain	untested	for	CVH	in	UK	primary	care	[Datta	
S	2014].		
There	is	a	lack	of	awareness	towards	CVH	testing	policy	expressed	during	the	focus	group,	and	whilst	
there	may	be	some	(tacit)	underlying	knowledge	of	testing	needs	in	migrant	populations	(as	suggested	
by	military	affiliated	GPs);	the	lack	of	any	expressed	policy-knowledge	makes	it	difficult	to	associate	
concepts	of	a	second	translation	gap,	or	to	associate	the	lack	of	testing	activity	as	a	true	measure	of	
clinical	or	diagnostic	 inertia.	 It	 is	the	case	though,	that	many	of	the	aspects	of	a	Clinical/Diagnostic	
Inertia	 are	 otherwise	 present;	with	 “soft”	 reasons	 provided	 not	 to	 proceed,	 an	 overestimation	 of	
current	levels	of	testing,	and	a	lack	of	education	and	training	that	is	likely	to	be	evident	[Phillips	LS	
2001,	Salisbury	C	2006].		
Gaps	in	CVH	knowledge,	as	suggested	in	the	classification	and	importance	afforded	to	chronic	CVH	are	
well	 documented	 in	 primary	 care	 [Bechini	 A	 2012],	 as	 are	 gaps	 in	 knowledge	 relating	 to	 serology	
results,	 and	 in	 the	 long	 term	 risks	of	 CVH,	 including	HCC	 [Guirgis	M	2012],	with	 common	 findings	
therefore	to	the	current	focus	group	study.		
The	negative	opinions	taken	towards	CVH	testing	in	migrant	groups	is	though	more	strongly	expressed	
than	in	prior	studies	in	primary	care.	Indeed,	whilst	practitioners	express	discomfort	in	approaching	
testing	due	to	potentially	awkward	discussions	on	risk-activity,	there	is	no	specific	mention	of	race,	or	
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fears	of	prejudice/racism	as	a	barrier	 to	 testing	activity	 [Jewett	A	2015].	Similarly,	 the	concerns	of	
“causing	harm”	as	 reflected	 in	our	 current	 focus	group	 is	not	 reflected	 in	earlier	 studies,	with	 the	
raised	concerns	on	insurance,	and	the	“harm	to	loved	ones”	not	mentioned	in	prior	qualitative	studies	
in	primary	care.		
The	 findings	 from	 our	 current	 focus	 group	 study	 therefore	 paint	 the	 picture	 of	 a	 more	 negative	
attitude	towards	CVH	testing	and	a	 lower	priority	 to	CVH	testing	 in	migrant	groups.	This	may	be	a	
reflection	of	primary	care	views	outside	of	the	major	city	centres,	with	most	research	studies	affiliated	
to	urban	centres.	But	it	remains	reflective	of	the	real-life	views	of	GPs	who	would	traditionally	have	
managed	 a	 more	 homogenous	 population,	 but	 are	 now	 faced	 with	 the	 arrival	 of	 a	 new	migrant	
community,	with	 focus	 group	 data	 that	 suggests	 an	 ongoing	mismatch	 in	 perception,	 and	 gaps	 in	
knowledge	relating	to	CVH,	as	well	as	an	absence	of,	and	lack	of	priority	afforded	to	testing	activity.		
Community	CVH	testing	strategy:		
The	 Nepali	 community	 is	 a	 heterogeneous	 population	 with	 regard	 to	 religion	 and	 caste,	 with	
difficulties	 in	accessing	and	promoting	testing	through	a	single	source,	such	as	religious	settings	or	
faith	leaders,	as	have	been	successfully	utilised	in	other	research	studies	[Uddin	G	2010,	Lewis	H	2011,	
Zuure	2013].		
Despite	this,	we	were	able	to	develop	a	successful	CVH	community	testing	study	to	test	close	to	a	1000	
members	of	the	local	Nepali	community	over	17	testing	sessions,	with	recruitment	(testing)	numbers	
that	appear	 in	the	medium	range	 in	comparison	to	other	 large	scale	testing	 interventions	(table	x)		
with	the	largest,	and	highest	profile	BFreeNYC	project	achieving	CVH	testing	in	close	to	9000,	mostly	
Chinese	origin	American	individuals	over	a	4-year	period;	with	an	estimated	700,000	ethnic	Chinese	
individuals	resident	in	NYC	[Pollock	H	2011,	Wikipedia	NYC].		
We	were	 restricted	our	advertising	 strategies	 for	participant	 recruitment,	with	word-of-mouth	 the	
predominant	route	for	recruitment.	Most	community	testing	endeavours	utilise	a	range	of	strategies,	
with	national	media,	and	internet	based	advertising	used	widely	in	studies	in	migrant	communities,	
without	significant	stigma	that	was	reported	as	a	result	[Pollock	H	2011,	Richter	2014].	Word	of	mouth	
though	is	supported	as	a	recruitment	tool	in	most	community	studies,	although	its	effect	is	difficult	to	
qualify	among	the	multiple	strategies	often	employed.		
Nepali	community	volunteers	formed	an	integral	part	of	testing	activity,	and	played	a	formal	role	in	
directing	testing	activity	and	locations	through	the	dedicated	Nepali	research	committee.	Community	
support	is	well-established	in	testing,	providing	grassroots	support	and	access	to	community	networks	
and	language	support.	In	the	review	by	Robotin	and	George	the	“ideal”	community-based	intervention	
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is	suggested	to	be	a	“true	partnership”	between	technical	experts	and	these	community	advocates,	
providing	support	in	a	socio-cultural	context	to	promote	and	develop	testing	ideals	[Robotin	M	2014].		
We	 sought	 to	 enhance	 this	 position	 with	 our	 Nepali	 community	 volunteers,	 through	 formal	
recognition	and	 inclusion	 into	 the	research	 team	for	select	community	 leaders.	The	success	of	 the	
study	was	due	in	large	part	to	the	active	participation	and	peer-support	given	by	a	large	number	of	
community	 volunteers.	Members	 of	 the	 community	were	 very	 keen	 to	help	 and	engage	 in	 health	
interventions,	 and	 it	 may	 be	 that	 this	 volunteer	 action	 relates	 to	 the	 broader	 acumen	 in	 health	
engagement	and	volunteering	seen	through	the	female	community	health	volunteers	in	Nepal,	who	
are	widely	credited	with	having	brought	down	rates	of	maternal	mortality	[Panday	S	2017].		
The	absolute	numbers	of	active	CVH	detected	in	the	tested	Nepali	community	is	very	low,	with	rates	
comparable	 to	or	 lower	 to	 that	 seen	 in	 the	UK	population,	 but	with	higher	 rates	of	 previous	HBV	
exposure	 that	 is	 suggested.	 These	 findings	do	 correspond	 to	prevalence	 rates	 suggested	 from	 the	
limited	studies	available	in	Nepal,	with	HCV	Ab	rates	of	0.6%	detected	in	healthy	volunteer	studies	in	
1998,	and	with	similar	prevalence	rates	(0.66%)	in	blood	donor	testing	in	2008	[Shrestha	SM	1998,	
Shrestha	A	2016].	For	HBV,	 testing	data	 in	healthy	volunteers	 from	the	early	1990s	suggest	HBsAg	
prevalence	rates	of	0.9%,	with	high	levels	of	HBcAb	positivity	detected	at	close	to	44%	[Shreshtha	SM	
1990].	More	recent	publications	on	Nepali	viral	hepatitis	risks	mention	the	same	prevalence	for	HBV	
at	 0.9%,	 but	 use	 data	 from	 the	 early	 1990s	 to	 evidence	 this	 [Shrestha	 A	 2015,	 Shrestha	 A	 2016].	
Antenatal	studies	in	Nepal	from	2012	have	also	shown	low	level	of	detected	HBsAg	(0.5%),	and	higher	
rates	of	HBcAb	positivity	(28.5%)	that	are	again	seen.	Ethnic	and	likely	geographical	variation	is	also	
suggested	in	the	same	2012	review,	with	HBsAg	prevalence	rates	of	6.6%	noted	in	participants	from	
the	Surkhet	valley	in	a	dedicated	testing	study	in	Nepal;	but	with	low	levels	of	representation	from	
individuals	in	the	Sukhet	valley	in	our	testing	study	[Shreshtha	SM	2012].	
As	such,	the	low	levels	of	HBsAg	positivity	detected	in	our	current	study	seem	comparable	to	the	data	
from	previous	research-based	studies	in	Nepal,	but	with	the	primary	data	set	for	HBV	that	is	from	an	
individual	study	in	1990.	Higher	rates	of	HBcAb	exposure	seem	reported	across	several	studies,	and	
whilst	the	reasons	for	this	are	not	clear,	low	levels	of	documented	infection	in	those	under	5	years,	
and	 amongst	 tested	 pregnant	 women	 have	 led	 to	 suggestions	 that	 self-limited	 infection	 in	 older	
children	may	be	a	possible	reason	for	this	trend;	but	with	no	formal	assessment	of	this	finding,	or	any	
possible	implications	[Shreshtha	SM	2012].		
The	CVH	risks	 identified	in	our	testing	study	of	the	Nepali	population	fall	below	the	2%	prevalence	
rates	 suggested	as	 the	 threshold	 for	case-finding	 in	 testing	policy	 [NICE	2012],	particularly	 in	HCV,	
highlighting	 the	 heterogeneity	 that	 exists	 in	migrant	 communities.	 However,	 given	 the	 significant	
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HBcAb	risks	identified	in	the	tested	population,	and	the	nature	of	the	elderly	self-selected	population	
selected	for	testing,	it	becomes	difficult	to	ignore	these	risks	in	the	onward	support	for	CVH	testing	in	
this	community.	
Limitations:	
Focus	group	studies	in	the	Nepali	community	were	conducted	in	Nepalese,	and	whilst	this	preserves	
the	 richness	 of	 language	 and	 expressions	 during	 focus	 groups,	 it	 did	 require	 individual	 session	
translation	by	a	single	Nepali	volunteer	(overseen	by	R	Tiwari),	with	data	losses	that	would	occur	in	
this	process.	Whilst	 future	qualitative	studies	 in	 the	Nepali	 community	are	 likely	 to	 require	similar	
Nepalese	mediated	 sessions,	 one	 could	 endeavour	 to	 have	 greater	 effort	 through	 synchronous	 or	
collaborative	translation	of	extracts.	
There	were	significant	data	losses	in	the	first	part	of	our	CVH	testing	study	towards	the	place	of	origin	
of	 over	 300	 participants.	 This	 would	 have	 impacted	 the	 outcome	 and	 any	 possible	 statistical	
association	that	may	exist	between	geographic	origin	and	HBcAb	risks.	The	population	demographics	
of	our	testing	study	identified	an	older	Nepali	population,	and	whilst	this	may	be	representative	of	
many	in	the	newly	arrived	community,	our	sessions	were	limited	to	weekday	daytime	sessions;	driven	
principally	 by	 the	 needs	 and	 availability	 of	 our	 (large)	 research	 team	 of	 nurses	 and	 community	
volunteers.	Whilst	targeted	recruitment	to	younger	Nepali	individuals	at	college	campuses,	and	work	
settings	 were	 considered,	 these	 were	 all	 felt	 to	 offer	 too	 high	 a	 risk	 of	 stigmatisation	 to	 our	
participants	and	were	not	explored.		
The	effects	 and	 limitations	of	 anti-migrant	 sentiment	 in	 the	 local	 community	 is	 also	 likely	 to	have	
effected	 recruitment,	and	one	presumes	 that	posters	or	 leaflets	 in	health	 settings,	and	communal	
access	points	would	have	improved	community	awareness	and	uptake.		
The	purposive	nature	of	recruitment	to	our	focus	groups,	and	the	nature	of	community	based	testing	
interventions	is	likely	to	produce	a	self-selection	bias,	and	may	therefore	miss	those	participants	who	
choose	 not	 to	 engage	 with	 these	 measures,	 but	 who	 may	 be	 at	 greater	 CVH	 risk	 due	 to	 other	
underlying	 factors	 [Uddin	G	2010].	And	whilst	other	testing	strategies	such	as	“opportunistic”	CVH	
testing	in	primary	care	may	provide	an	alternative	route	to	reach	these	individuals,	our	primary	care	
work	 suggests	 that	 current	CVH	 testing	 in	migrant	 communities	 in	an	opportunistic	manner	 is	not	
feasible.		
Finally,	 in	 the	original	design	of	 this	 thesis,	 I	had	hoped	to	undertake	a	whole-system	approach	to	
provide	an	analysis	of	the	gaps	that	exist	in	testing	across	the	macro,	meso	and	micro	levels	of	the	
health	system.	However,	the	current	policy	does	not	formally	examine	current	meso-level	actors	such	
as	CCGs	or	Local	Authorities,	nor	patient	advocacy	groups;	and	this	relates	to	the	time	pressures	of	
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arranging	these	formal	semi-structured	interviews.	At	the	same	time	though,	my	own	presentations	
to	local	CCG	representatives	as	part	of	my	study	recruitment	in	primary	care,		as	well	as	in	local	Clinical	
Reference	Groups	(CRGs)	all	suggested	low	levels	of	awareness	of	CVH	testing	guidance	in	its	current	
form,	and	it	is	likely	that	CVH	testing	would	have	been	identified	as	a	low	priority;	in	keeping	with	the	
findings	of	other	studies	in	Local	Authorities	[HCV	Action	2014].	Boundary	spanning	activities	that	I	
conducted	working	with	the	British	Liver	Trust	as	part	of	the	“Love	Your	Liver”	campaign	during	the	
time	of	this	thesis,	did	highlight	strong	levels	of	engagement	with	groups	that	we	would	not	usually	
meet	to	discuss	and	explore	liver	disease;	providing	(confidential)	outreach	drop-in	visits	in	community	
settings,	including	work	settings	(Appendix).		
Further	research:		
Looking	again	at	the	overview	of	commissioning	responsibilities	and	the	principal	actors	involved	in	
CVH	testing	(figure	37),	there	are	multiple	agents	and	complex	relations	that	are	integral	in	the	optimal	
provision	of	CVH	case-finding	activity.		
The	current	study	has	focused	on	the	macro,	policy-level	actions	on	CVH	testing,	with	principal	focus	
in	primary	care,	as	well	as	micro-level	work	with	local	primary	care	physicians	and	members	of	the	
local	Nepali	community.		
A	more	comprehensive	approach	would	be	to	involve	multiple	levels	across	this	system,	adopting	a	
whole-system	approach,	looking	at	the	complex	relations	that	often	govern	outcomes	in	healthcare	
across	these	levels,	which	may	achieve	a	relative	positive	or	negative	impact	on	testing	activity	[Litaker	
2006].	A	 system-wide	approach	across	macro,	meso	and	micro	 levels,	may	also	help	 in	 identifying	
principal	leverage	points	for	action	that	may	otherwise	be	missed	Dattee	2010,	Chysanthaki	2013].			
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Figure	 37	 	 Overview	 of	 commissioning	 responsibilities	 in	 CVH	 (Chronic	 Viral	 Hepatitis)	 testing;	 (PHE	 =	 Public	 Health	
England,	 CCG	 =	 Clinical	 Commissioning	 Group/Local	 Health	 Provider,	 HCC	 =	 hepatocellular	 carcinoma,	 GUM	 =	
Genitourinary	medicine)	
	
		
Figure	38:	An	overview	of	the	complex	relations	and	agents	involved	in	CVH	testing	activity	across	Macro	
(red),	Meso	(orange)	and	Micro	(green)	levels.		
Further	work	at	 the	patient	 level,	also	needs	 to	 look	at	how	CVH	testing	uptake	can	be	 improved,	
adopting	 strategies	 used	 in	 other	 BBVs;	 namely	HIV.	HIV	 testing	 adverts	 are	widespread	 in	 public	
spaces	without	reports	of	significant	stigmatisation.	HIV	testing	enjoys	high-profile	support,	with	even	
Prince	Harry	 taking	part	 in	 live	HIV	testing	through	social	medial	 [Independent	 July	2016]	with	 the	
support	 of	 the	 Terence	Higgins	 Trust.	Whilst	 the	 history	 and	 context	 of	HIV	 is	 different,	 it	will	 be	
Providers:	 PRIMARY	CARE
Secondary	Care
Community	testing	
(DAAT,	GUM)
Government	/	DoH
NHS	England
CCGs
PHE	+	Local	Authority
Health	&	Wellbeing	
Boards	
Interest	Groups:
Patient	charity	(HCV	Trust,	HCV	
Action,	British	Liver	Trust)
APPHG
RCGP
BSG/BASL
Economic	(Pharmaceutical)
MICRO-level
MACRO-level
MESO-level
MESO-level
230	
	
important	to	look	at	how	similar	public	campaigns	outside	of	specific	at-risk	groups	can	be	employed	
in	CVH,	as	this	would	facilitate	greater	priority	for	CVH	testing	with	community	practitioners,	but	also	
importantly	should	promote	and	support	agency	in	at-risk	groups	coming	forward	for	testing.		
At	the	primary	care	(micro)	level,	one	of	the	findings	from	our	focus	group	study	is	the	absence	of	any	
structured	activity	to	identify	and	offer	testing	to	patients.	Whilst	some	practitioners	seem	aware	of	
new-patient	 testing	 opportunities,	 there	 is	 no	 established	 action	 to	 support	 this,	 and	 resource	
difficulties	that	may	exist	if	this	activity	is	to	be	widely	employed.	Another	strategy	is	to	identify	at-
risk	 groups	 according	 to	 electronic	 coding	 data,	 with	 the	 development	 of	 MIQUEST	 (Morbidity	
Information	Query	and	Export	Syntax)	codes	that	I	have	undertaken	and	utilised	as	part	of	a	separate	
CRN	 (Clinical	 Research	 Network)	 registered	 study	 (CRN	 17297),	 looking	 at	 testing	 invites	 through	
mailed	 invites,	 opportunistic	 testing	 and	 new-patient	 registrations.	 	 A	 summary	 of	 these	 codes	 is	
presented	 in	 the	appendix,	with	 the	need	to	explore	methods	to	 identify	at-risk	groups	 in	primary	
care,	and	methods	to	offer	testing	in	the	context	of	primary	care	services	which	are	overstretched.		
	
Conclusion:		
We	developed	a	successful	engagement	strategy	to	assess	chronic	viral	hepatitis	 (CVH)	risks	 in	the	
newly	arrived	Nepali	community,	with	a	comprehensive	study	of	the	barriers	that	exist	towards	CVH	
testing	across	the	health	system.		
The	findings	of	this	study	suggest	 low	levels	of	active	Hepatitis	B	and	C	(HBV	and	HCV)	 in	the	 local	
Nepali	community,	but	with	high	levels	of	previous	HBV	exposure	that	require	further	investigation	
and	testing;	and	demonstrates	a	heterogeneous	risk	profile	in	migrant	groups.	
Migrant	 groups,	 including	 the	 newly	 arrived	 Nepali	 community	 face	 significant	 challenges	 from	
political	 and	 social	 determinants	 that	may	 negatively	 impact	 health	 access	 and	 engagement,	with	
active	anti-migrant	sentiments	expressed	during	our	study.	Broad	testing	recommendations	exist	in	
migrant	groups	through	NICE	guidance,	but	there	are	gaps	in	the	decisiveness	and	leadership	of	policy	
delivery,	as	well	as	the	resources	allocated	to	implementation;	with	the	need	for	improved	oversight	
and	coordination.			
In	primary	care,	there	is	a	lack	of	awareness	and	priority	afforded	to	CVH	testing,	and	a	reluctance	to	
engage	with	migrant	communities	in	testing	activity;	but	with	high	levels	of	awareness	of	liver	disease	
in	the	local	Nepali	community,	and	a	desire	to	engage	with	health	professionals,	particularly	GPs	in	
health	awareness	and	testing	activity;	evidenced	by	the	high	levels	of	engagement	demonstrated	in	
our	community-based	interventions.		
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As	such	there	are	barriers	that	exist	in	CVH	testing	at	the	macro	(policy)	level,	and	at	the	micro	level	
with	the	delivery	of	CVH	testing	to	migrant	groups	in	primary	care.	These	factors	are	likely	to	impact	
the	 access	 and	 provision	 of	 CVH	 testing	 to	 migrant	 groups,	 with	 additional	 challenges	 to	 health	
engagement	in	migrant	communities	given	the	rising	political	and	social	pressures	seen	nationally	and	
internationally.		
Multidisciplinary	interventions	over	macro,	meso	and	micro	levels	are	required	to	improve	CVH	testing	
provision,	with	interventions	to	provide	leadership	and	coordination	between	CCGs,	Local	Authorities	
and	NHS	England	that	should	facilitate	greater	adoption	and	 integration	of	testing	 in	primary	care.	
Agents,	such	as	the	Operational	Delivery	Networks	(ODNs)	may	be	able	to	provide	such	coordination,	
with	 resource	 and	 educational	 support	 to	 guide	 and	 drive	 community	 testing	 practice.	 The	
involvement	of	patient	advocacy	groups	will	be	crucial	to	improve	public	awareness,	with	the	aim	of	
normalising	and	supporting	public-testing	activity.			
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Appendix	
	
	
Contents:	
Ethics	Approvals		
Consent	Forms		
- Nepali	Focus	Group	and	Testing	Study	
- GP	Focus	Group	study	
Nepali	Testing	study	
- Odds	Ratio	tables	
Additional	Research	Activity	/	Future	Studies:		
Micro	level	activity	–	Local	Primary	Care	CVH	testing	activity	
Boundary	Spanning	Activity	–	working	with	the	British	Liver	Trust			
Primary	care	case-finding	–	developing	electronic	coding	strategies	to	identify	at-risk	
groups	–	CAG	approval	
Primary	care	case-finding	–	developing	electronic	coding	strategies	to	identify	at-risk	
groups	–	MIQUEST	Coding	(tested	in	regional	GP	practices	in	KSS	
PRESENTATIONS	(National	&	International):		
Nepali	Focus	Group	study	–	BSG	POSTER	2014	PRESENTATION	JUNE	2014	(Manchester	
UK)	
AASLD/EASL	HCV	conference	presentation	–	New	York	2014	
EASL,	ILC	2015,	Vienna,	Austria	–	Focus	Group	Comparator	between	the	newly	arrived	
Nepali	community	and	Primary	care	Physcians	who	serve	the.	
Digestive	 Disorders	 Federation	 (DDF),	 June	 2015:	 Household	 contact-tracing	 for	
Hepatitis	B,	London,	UK;	published	in	Gut:	PWE-118,	Volume	64,	Issue	Supplement	1	
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Nepali	Focus	Group	and	Intervention	study	–	Ethics	approval:	
Ethics	approval	for	focus	group	studies	in	the	Nepali	community,	and	the	development	of	a	
testing	intervention	were	developed	and	submitted	together.		
	
	
Nepali	Focus	Group	&	Testing	study:	ETHICS	APPROVAL			
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Nepali	Focus	Group	&	Testing	study:	ETHICS	APPROVAL			
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Nepali	Focus	Group	&	Testing	study:	ETHICS	APPROVAL			
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Nepali	Focus	Group	Consent	Form	
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GP	Case-Finding	Study:	UNIVERSITY	ETHICS	APPROVAL		
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GP	Case-Finding	Study:	UNIVERSITY	ETHICS	APPROVAL		
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GP	Focus	Group	study	–	Participant	Information	Sheet		
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GP	Focus	Group	study	–	Participant	Information	Sheet		
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GP	Focus	Group	study	–	Participant	Information	Sheet		
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Nepali	Testing	Study	–	Patient	Information	Sheet		
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Nepali	Testing	Study	–	Patient	Information	Sheet		
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Nepali	Testing	Study	–	Patient	Information	Sheet		
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Nepali	Testing	Study	–	Consent	Form	(Nepalese)	
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Nepali	Testing	Study	–	Consent	Form		
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With	 District	 level	 data	 included,	 significant	 numbers	 of	 NAs	 enter,	 which	 may	 affect	 model	
performance.		
	
	
Table	3:	Odds	ratios,	with	District	level	data	removed:	
  OR	 2.50%	 97.50%	
(Intercept) 0.1649984	 0.0145332	 1.6459629	
GenderI 2.4349292	 0.1247615	 15.3487466	
GenderM 2.5972712	 1.4237929	 4.784868	
Age 0.9930603	 0.96203	 1.0272233	
Months.in.UK 1.0023737	 0.9926432	 1.0113265	
Adults.in.household 0.9129508	 0.7589348	 1.0774791	
Children 0.8226292	 0.524449	 1.2181124	
Years.spent.in.school 0.8821438	 0.7865766	 0.9759679	
Blood.transfusiony 0.9016691	 0.2916659	 2.2882823	
Surgery.abroady 0.953584	 0.5422141	 1.6360678	
Dental.worky 1.1670261	 0.6919	 1.95999	
Vaccinationy 0.9629342	 0.5359541	 1.8043675	
Hep.vacciney 0.7647578	 0.2500315	 1.9081172	
PHx.of.jaundicey 1.0458542	 0.3409839	 2.6240732	
Body.ear.piercingy 0.9250094	 0.4003907	 2.4217032	
drugs 2.3190547	 0.501001	 7.9218049	
alcohol 0.9343778	 0.4677277	 1.7558643	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Nepali	Testing	Study	–	Odds	Ratio	table	
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Regional	HBV	and	HCV	testing	data	in	Surrey	2013:		
I	used	anonymised	testing	data	from	regional	laboratory	data	to	identify	testing	practice	for	
HBV	 and	 HCV	 in	 primary	 care	 across	 Surrey.	 Approximately	 14%	 of	 requests	 could	 be	
categorised	into	one	of	the	conventional	case-finding	indications	(figure	1).		
	
	
Figure	1:	Analysis	of	primary	care	requests	for	HBV	and	HCV	in	2013.		
	
	
Household	contact-tracing	for	Hepatitis	B		
I	have	also	looked	at	rates	of	household-contact	tracing	for	HBV,	which	is	an	important	target	
in	hepatitis	B,	and	driven	by	primary	care	testing	requests.	 I	collected	data	on	HBV	testing	
over	the	past	ten	years,	looking	at	over	110,000	HBV	testing	requests.	Where	postcode	and	
address	data	could	be	effectively	identified,	there	was	no	evidence	of	household	testing	in	
over	70%	of	HBV	positive	individuals.	This	work	has	been	accepted	to	present	at	the	upcoming	
Digestive	Diseases	Federation	meeting	in	June	2015.		
	
	
	
	
	
	
	
	
Micro	level	activity	–	Local	Primary	Care	CVH	testing	activity		
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Boundary-spanning	activity	working	with	the	British	Liver	Trust	
We	collaborated	with	the	British	Liver	Trust	to	build	upon	their	national	“Love	Your	Liver”	
campaign,	 providing	 work-based	 questionnaires	 to	 all	 employees	 identifying	 the	 key	 risk	
factors	for	liver	disease:	alcohol	excess,	obesity	and	viral	hepatitis.	Working	with	Siemens,	I	
undertook	an	in-house	clinic	offering	counselling	and	a	dedicated	liver	USS	and	elastography	
(non-invasive	assessment	of	fibrosis)	to	all	employees	who	wished	to	attend	during	the	day.		
9	 slots	were	granted	 to	 staff	members	during	 the	day,	and	we	were	not	able	 to	 fulfil	 the	
number	 of	 review	 requests.	 The	 event	was	 publicised	 through	 the	 British	 Liver	 Trust	 and	
Siemens,	with	a	publicity	video	where	I	discuss	the	burden	of	liver	disease	in	the	UK:		
http://www.siemens.co.uk/en/insights/liver_disease.htm	
	
Figure	1:	screenshot	of	boundary	spanning	activities	taken	from	the	Siemens	Love	Your	Liver	day	
The	 session	 was	 successful	 in	 identifying	 a	 high	 level	 of	 interest	 among	 employees,	 and	
utilised	the	support	of	the	employer	to	promote	questionnaire	uptake.	Working	with	a	patient	
charity	group	also	afforded	a	large	amount	of	publicity	and	volunteer	support	to	increase	the	
profile	of	the	session,	with	designated	“liver	champions”	that	were	on	hand	to	spread	the	
message	of	liver	disease	and	the	importance	of	risk-modification.	Employers	are	perhaps	also	
more	 likely	 to	 participate	with	 patient	 charity	 groups,	 as	 this	may	 tap	 into	 dimensions	 of	
corporate	social	responsibility	and	the	direct	and	indirect	benefits	of	“employee	wellbeing”.		
Boundary	Spanning	Activity	–	working	with	the	British	Liver	Trust			
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Staff	participating	in	the	study	were	given	designated	leave	periods	to	come	and	see	me	for	
a	confidential	discussion	of	any	concerns,	and	for	a	designated	liver	scan.	Out	of	9	“clinic”	
discussions	(held	in	a	makeshift	room),	we	identified	2	people	with	possible	liver	fibrosis	on	
imaging,	 and	 who	 had	 clear	 risk	 factors	 from	 the	 associated	 questionnaire.	 Alcohol	 and	
obesity	were	 the	 likely	 risk-factor	 in	 these	 individuals,	 but	 despite	 clear	 risk	 profiles,	 this	
session	 was	 the	 first	 time	 that	 these	 risks	 were	 discussed,	 and	 that	 liver	 disease	 was	
mentioned	to	these	individuals.		
Whilst	some	individuals	may	be	reluctant	to	engage	with	health	discussions	in	the	work	place,	
this	multidisciplinary	approach	represents	a	successful	and	potential	approach	to	reaching	
some	groups	of	the	population.		
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Primary	care	case-finding	–	developing	electronic	coding	strategies	to	identify	at-risk	groups	–	
CAG	approval	
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ASIA Africa	
Ethnic	category	2001	census File
Indian	or	British	Indian 9i7.. 04ETCNAS African 9iC..
Pakistani	or	British	Pakistani 9i8.. Somali 9iD0.
Bangladeshi	or	British	Bangladeshi 9i9.. Nigerian 9iD1.
Chinese 9iE.. North	African 9iFA.
Vietnamese 9iF0. Moroccan 9iFF.
Japanese 9iF1.
Mauritian/Seychellois/Maldivian/St	
Helena 9iFJ.
Filipino 9iF2.
Malaysian 9iF3.
non-census	coded
South	East	Asian 9T1B. 08ETNC
Indian		 9T1D.
Chinese 9T1C.
Nepali 9T9..
"born-in"	
Born	in	Pakistan 13eW. 09ETBIAS Born	in	Egypt 13gE.
Born	in	Afghanistan 13e0. Born	in	Algeria 13g0.
Born	in	Bangladesh 13e3. Born	in	Ethiopia 13gG.
Born	in	China 13e8. Born	in	Ghana 13gJ.
Born	in	India 13eD. Born	in	Kenya 13gN.
Born	in	Indonesia 13eE. Born	in	Malawi 13gS.
Born	in	Malaysia 13eP. Born	in	Morocco 13gV.
Born	in	Nepal 13eT. Born	in	Nigeria 13gZ.
Born	in	Philippines 13eY. Born	in	Somalia 13ge.
Born	in	South	Korea 13ee. Born	in	South	Africa 13gf.
Primary	care	case-finding	–	developing	electronic	coding	strategies	to	identify	at-risk	groups	–	
MIQUEST	Coding	(tested	in	regional	GP	practices	in	KSS)	
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BACKGRO
U
N
D 
RESU
LTS 
The U
K N
epali com
m
unity is a new
 and unique m
igrant group, 
w
hich has grow
n by over 900%
 since the granting of settlem
ent 
rights to ex-Gurkha servicem
en and their dependants. 
Rates of viral hepatitis B &
 C (HBV, HCV) are unknow
n in this U
K 
com
m
unity, w
ith higher rates of disease seen in the bordering 
countries of India &
 China 
Testing in m
igrant com
m
unities is recom
m
ended in N
ICE guidance, 
but w
ith m
any first generation m
igrants representing a hard-to-
reach population, - w
ith higher rates of disease prevalence and 
com
plications seen in this group 
Little is know
n about health perception in this com
m
unity, or how
 
to engage w
ith and offer testing to this population, w
hich has 
m
ultiple faith and caste denom
inations  
•  W
e therefore undertook a large-scale study to understand the 
perceptions of liver disease in this population, and to develop a 
com
m
unity engagem
ent strategy to identify the HBV and HCV 
prevalence in this new
 m
igrant group 
M
ATERIALS &
 M
ETHO
DS 
          
STU
DY PO
PU
LATIO
N
  
•1005 N
epali individuals w
ere tested over 17 sessions from
 M
arch 2013- January 2015 
•  973 individuals w
ere included in the final analysis 
     •  O
nly 1.8%
 (18 individuals had been in the U
K > 10 years) 
 Age (m
ean) 
63 yrs (19-86) 
Blood transfusions 
8%
 
M
ales 
45%
 
Surgery Abroad 
34%
 
M
onths in U
K 
36 m
nths (M
edian) 
Piercings  
91%
 
• VIRAL M
ARKERS  
     •  Low
 rates of HBsAg &
 HCV Ab prevalence  
•  Higher rates of HBcAb prevlance 
HB s Ag  + 
 3 / 973 (0.31 %
) 
HCV Ab  + 
 4 / 973 (0.41 %
)  
HB core Antibody  
93 / 973 (9.6 %
)  
HBV DN
A < 300 iu/m
l 
HCV RN
A N
egative  
N
o evidence of sig. Fibrosis/Cirrhosis (U
SS, Fibroscan) 
• Hospital Clinic F/up (via GP referral)  - 5 / 7 patients   
Regression Analysis (HBsAg, HCV Ab) 
•  N
o statistically significant risk-factor associations in 
those (few
) patients identified w
ith HBsAg / HCV Ab 
HB core Antibody –  regression analysis:  
-Variation by Districts, w
ith som
e reaching significance 
(p=0.053) 
- M
ale Gender  p = 0.016 
- Yrs at school   p = 0.025 
  
Box Plot – inverse association 
w
ith low
er years of schooling 
and HBcAb presence 
Years in School – HBcAb+ 
Age distribution  
D
istrict of O
rigin in N
epal (w
eighted) 
Discussion 
 •  Focus group sessions w
ere held  first; using N
epali m
oderators  
to help understand disease perception, and to develop culturally-
appropriate com
m
unity testing strategies. 
•  Com
m
unity venues w
ere chosen central to know
n population 
clusters, w
ith peer-advocate support, and N
epali language 
advertising on local radio netw
orks.  
•  DBS finger-prick blood testing w
as utilised for:                                    
-  HBsAg, HB core Antibody and HCV Antibody  
•  Risk-questionnaires w
ere assessed w
ith each participant 
 
•
R
ates of active H
B
V
 and H
C
V
 infection are low
 in the study population 
•
B
ut rates of previous H
B
V
 exposure (H
B
cA
b) are high, w
ith low
er years of schooling and m
ale gender statistically associated w
ith this. 
•
Variation in H
B
cA
b positiviity is seen according to district of origin, but w
ithout reaching statistical significance 
•
The N
epali com
m
unity has m
ultiple castes and religious groups, and has encountered significant stigm
a from
 right w
ing groups and local m
edia sources in keeping w
ith m
any 
new
 m
igrant com
m
unities in the current clim
ate 
•
W
orking w
ith peer-advocates and com
m
unity leaders w
e have developed a successful m
odel of engagem
ent to build strong links w
ith this large diverse com
m
unity, w
ith 
strategies that can be adopted to other m
igrant com
m
unities and health settings.  
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